{"Title": ["Tuesday Sector Leaders: Healthcare, Services", "Why the Coming Year Will Make or Break Biogen's Stock", "Meet the Pharma Company That Just Had a Bigger IPO Than Moderna's", "Better Buy: Biogen vs. Bristol Myers Squibb", "Nasdaq 100 Movers: BIIB, LBTYA", "S&P 500 Movers: BIIB, VIAC", "FDA Nod For EPZM, RARE, Court Rules In MYL's Favor, Ocuphire To Hop Onto Nasdaq, ALPN Soars", "Oversold Conditions For Biogen (BIIB)", "Tuesday Sector Leaders: Healthcare, Services", "S&P 500 closes nominally higher amid COVID-19 spikes, muted data", "Health Care Sector Update for 06/18/2020: BBI,REXN,HCM,BIIB,MYL", "S&P 500 closes nominally higher amid COVID-19 spikes, muted data", "Wall Street oscillates amid COVID-19 spikes, muted data", "Health Care Sector Update for 06/18/2020: BIIB,REXN,HCM", "S&P 500 muted as virus cases rise, jobless claims weigh", "BUZZ-U.S. STOCKS ON THE MOVE-Spotify, First Solar, JanOne, Designer Brands", "Biogen Loses Patent Case Over Its Best-Selling Drug", "Stock Alert: Biogen Tanks 6%", "U.S. court rules in favor of Mylan over Biogen's key MS drug patent", "BUZZ-U.S. STOCKS ON THE MOVE-Quicklogic, Fox Factory, Francesca's Holdings", "U.S. district court rules for Mylan in MS drug patent battle with Biogen", "Better Buy: Gilead Sciences vs. Biogen", "Stock Market Today: Stocks Mixed on Disappointing Jobless Claims", "As Biogen Stock Struggles, Look Elsewhere for Biotech Exposure", "S&P 500, Dow muted as virus cases rise, jobless claims weigh", "Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics", "IBB, VRTX, BIIB, ILMN: Large Outflows Detected at ETF", "BIIB Makes Notable Cross Below Critical Moving Average", "Should You Sell Biogen Stock?", "Biogen: New Results From NURTURE Study Reveals Sustained Benefit Of SPINRAZA", "Japan's Fujifilm to spend $928 mln to double capacity of Danish drug facility", "7 of the Best Blue-Chip Stocks to Buy", "Implied MOAT Analyst Target Price: $58", "Despite Recent Speed Bumps, Biogen's Stock Will Soon Grow Again", "Vir Biotechnology Is Bucking The Biotech COVID-19 Trends, And Stands To Win", "Got $3,000? Here Are 3 Great Biotech Stocks to Buy Right Now", "Better Buy: Biogen vs. Axsome Therapeutics", "Noteworthy ETF Outflows: IVE, IBM, FIS, BIIB", "7 Top-Rated Biotech Stocks to Buy on the Hunt for a Vaccine", "Nothing Will Stop Biogen Stock From Moving Higher", "iShares Nasdaq Biotechnology ETF Experiences Big Inflow", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 5/17/2020", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 5/17/2020", "Noteworthy ETF Outflows: MTUM, AMD, BIIB, HUM", "5 Stocks Buffett Probably Bought in the First Quarter", "The All-Important Question Buffett Will Answer This Week", "BUZZ-U.S. STOCKS ON THE MOVE-GM, Axcella, Beyond Meat, SmileDirect", "Apple Sells $8.5 Billion in Bonds to Fuel Share Buybacks", "Validea's Top Five Healthcare Stocks Based On Joel Greenblatt - 5/17/2020", "Health Care Sector Update for 05/04/2020: EGRX,VIR,RARE,TEVA,BIIB", "Health Care Sector Update for 05/04/2020: VIR,RARE,TEVA,BIIB", "Why Biogen Shares Fell 6.18% in April", "Has Biogen Found the Answer to Treating Alzheimer's?", "IBB, GILD, VRTX, BIIB: ETF Inflow Alert", "Better Buy: Cara Therapeutics vs. Sangamo Therapeutics", "At least 14 borrowers rush into US high-grade primary", "Apple borrows on the cheap to fund buybacks, dividends", "Japanese shares snap 3-day losing streak as battered stocks bought back", "Biogen Reports First-Quarter Results, Shares Plunge 9.4%", "Biogen Inc (BIIB) Q1 2020 Earnings Call Transcript", "Health Care Sector Update for 04/22/2020: BIIB,IMMU,PRTA,VBIV", "Noteworthy Wednesday Option Activity: CNNE, BIIB, SFNC", "Johnson & Johnson and AbbVie Earn a New FDA Approval for Imbruvica", "Analysts Forecast 13% Upside For The Holdings of TOK", "Why Biogen Stock Is Sinking Today", "Noteworthy ETF Inflows: IBB, VRTX, BIIB, REGN", "Nasdaq 100 Movers: BIIB, LRCX", "S&P 500 Movers: BIIB, EXPE", "Health Care Sector Update for 04/22/2020: BNTX, PFE, TMO, BIIB, XLV, IBB, VHT, IYH", "BUZZ-U.S. STOCKS ON THE MOVE-SAExploration Holdings, Unit Corp, Expedia Group", "Biogen delays Alzheimer's drug filing plans, shares fall", "BUZZ-U.S. STOCKS ON THE MOVE-Snap, Peck Company, VBI Vaccines", "Biogen posts marginal rise in first-quarter sales", "Biogen Q1 20 Earnings Conference Call At 8:00 AM ET", "BUZZ-U.S. STOCKS ON THE MOVE-Co-Diagnostics, Xeris Pharma, Cyclacel Pharma", "BUZZ-U.S. STOCKS ON THE MOVE-DuPont, Occidental Petroleum, Safe-T Group", "BUZZ-U.S. STOCKS ON THE MOVE-Safe-T Group, Ford Motor, Facebook", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 4/19/2020", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 4/19/2020", "Biogen Q1 Results Top Estimates - Quick Facts", "Biogen Reaches Analyst Target Price", "Biogen Is Building a COVID-19 Biobank With the Broad Institute", "Biogen joins consortium for building COVID-19 'biobank'", "Biogen joins consortium for building COVID-19 'biobank'", "Better Buy: Alnylam Pharmaceuticals vs. Vir Biotechnology", "Should Investors Take a Chance on Biogen?", "BIIB May 29th Options Begin Trading", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 4/19/2020", "Biogen Reaches Analyst Target Price", "GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln", "GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln", "GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln", "3 Warren Buffett Stocks I Absolutely, Positively Wouldn't Buy Right Now", "Why Gilead Sciences Is the Hottest Stock to Buy Today", "3 Big Stock Charts for Thursday: Goldman Sachs, FedEx, and Biogen", "Better Buy: Gilead Sciences vs. Biogen", "Why Biogen Shares Rose 2.59% in March", "So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature", "IBB, VRTX, BIIB, ILMN: ETF Outflow Alert", "4 Reasons Drug Stocks Are a Buy Right Now", "First Week of BIIB May 15th Options Trading", "Bristol Myers Squibb's Multiple Sclerosis Drug, a Potential Blockbuster, Wins FDA Approval", "Investors Are Wondering: Where\u2019s Warren Buffett?", "Better Buy: Gilead Sciences vs. Biogen", "Why Biogen Shares Rose 2.59% in March", "iShares Nasdaq Biotechnology ETF Experiences Big Inflow", "Are These Warren Buffett Stocks a Buy at Beaten-Down Prices?", "Berkshire\u2019s Recent Purchases Show Why Value Investing Still Works", "Why Biogen, GW Pharmaceuticals, and Vertex Pharmaceuticals Stocks Jumped Today", "7 Biotech Stocks to Buy and Hold in 2020", "4 Reasons Biotech Stocks Are a Buy Right Now", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 3/15/2020", "Validea's Top Five Healthcare Stocks Based On Joel Greenblatt - 3/15/2020", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 3/15/2020", "Better Buy: Biogen vs. Amgen", "Why These Drug Stocks Soared Today", "3 Ways Coronavirus Lockdowns Put Biotech and Big Pharma on Hold", "Biogen and Vir Biotechnology to Collaborate to Find a Treatment for the Coronavirus", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 3/15/2020", "Health Care Sector Update for 03/12/2020: VIR,BIIB,CEMI,AZN", "IBB, GILD, VRTX, BIIB: Large Outflows Detected at ETF", "Coronavirus Concerns Have Big Pharma Working From Home", "Is iShares Nasdaq Biotechnology Index Fund a Buy?", "Why Biogen Stock Rose 14.7% in February", "Former Biogen CEO to Become Biotech's New Coronavirus Czar", "Investors Endure Wild Ride in This Biotech Taking on COVID-19", "Health Care Sector Update for 03/12/2020: POAI,VIR,BIIB,CEMI,AZN", "Biogen Could Score a Major Win if Alzheimer's Drug Gets the Green Light", "Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%", "Biogen, Sangamo Sign Deal To Develop Gene Therapies For Neurological Diseases", "Ionis Pharmaceuticals' Revenues Rose 85% in 2019", "Noteworthy ETF Inflows: IBB, GILD, VRTX, BIIB", "Warren Buffett Is Buying This Stock Faster Than Any Other", "3 Top Stocks You Should Watch to Invest Like Berkshire Hathaway", "Here's Why Sangamo Therapeutics Jumped Higher Today", "Warren Buffett's 2 Pure-Play Pharma Picks Are Real Head-Scratchers", "Top Stocks Warren Buffett Just Bought", "Warren Buffett's Big Biotech Bet Is 1 of His Riskiest Wagers Ever", "IBB, GILD, VRTX, BIIB: ETF Outflow Alert", "16 Stocks Warren Buffett Is Buying and Selling", "Stock Alert: Warren Buffett's Berkshire Hathaway Reveals Stake In Kroger, Biogen", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 2/16/2020", "Why Did Warren Buffett Buy These 6 Stocks in Q4?", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 2/16/2020", "Validea's Top Five Healthcare Stocks Based On David Dreman - 2/16/2020", "Validea's Top Five Healthcare Stocks Based On Joel Greenblatt - 2/16/2020", "Better Buy: Biogen vs. Bristol-Myers Squibb", "Warren Buffett's Berkshire Hathaway Dives Into Biotechnology", "3 Biotech Stocks That Made Early Shareholders Millionaires", "Tuesday Sector Laggards: Consumer Products, Healthcare", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 2/16/2020", "A Double Failure of Alzheimer's Drugs", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "3 Biotech Companies Analyzed", "Roche Presents Spinal Muscular Atrophy Drug Data", "Is This Under-the-Radar Stock Set to Succeed in Alzheimer's Disease?", "Why Amgen Stock Dropped 10.4% in January", "Biogen Surges After Winning Crucial Multiple Sclerosis Drug Patent", "Will Biogen\u2019s Big Patent Victory Ease Investor Worries About Its Alzheimer\u2019s Drug?", "Why Biogen Shares Soared Today", "Look Under The Hood: IWX Has 11% Upside", "Pfizer's Biosimilar Ruxience Gets EU Regulatory Backing", "Pfizer's Biosimilar Ruxience Gets EU Regulatory Backing", "Biogen is Now Oversold (BIIB)", "Amgen Revenue Slipped 1% in the Fourth Quarter", "Biogen Inc (BIIB) Q4 2019 Earnings Call Transcript", "Here's Why Alkermes Jumped Almost 11% Today", "Is Biogen Stock a Buy?", "Is Eli Lilly Stock Overvalued?", "Biogen Guides FY20 In Line With Estimates - Quick Facts", "Biogen Inc. Q4 adjusted earnings Beat Estimates", "Noteworthy ETF Outflows: IBB, GILD, VRTX, BIIB", "2 of the Best Healthcare Stocks to Buy Today", "Nasdaq 100 Movers: AAL, BIIB", "Biogen's Earnings Per Share Jumped 19% in Fourth Quarter", "Notable Friday Option Activity: BIIB, CASA, XRX", "Roche's Spinal Muscular Atrophy Drug Meets Primary Endpoint in Infants", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "2 Reasons to be Optimistic About Biogen\u2019s Alzheimer\u2019s Drug", "Validea's Top Five Healthcare Stocks Based On Joel Greenblatt - 1/19/2020", "Validea's Top Five Healthcare Stocks Based On David Dreman - 1/19/2020", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 1/19/2020", "Is Biogen Stock a Buy?", "Noteworthy Friday Option Activity: CME, BIIB, PM", "Thursday Sector Laggards: Healthcare, Energy", "Why Biogen Stock Slumped Last Year", "5 Reasons 2020 Will Be a Big Year for Ionis Pharmaceuticals", "3 Big Stock Charts for Wednesday: Biogen, Cooper Companies, and Maxim", "New Research Shows Probiotics Can Help Prevent Parkinson's", "Biogen Buys Azheimer's and Parkinson's Drug From Pfizer", "Validea's Top Five Healthcare Stocks Based On John Neff - 1/19/2020", "Biogen To Acquire Clinical Stage PF-05251749 From Pfizer - Quick Facts", "Better Buy: Biogen vs. Gilead Sciences", "Biogen Reaches Analyst Target Price", "Notable Thursday Option Activity: BLK, WHR, BIIB", "Better Buy: AbbVie vs. Biogen", "Better Buy: Gilead Sciences vs. Biogen", "IBB, GILD, VRTX, BIIB: ETF Outflow Alert", "IBB, GILD, VRTX, BIIB: Large Inflows Detected at ETF", "2 Biotech Stocks Poised to Soar in 2020", "Make the Shift Toward Value Stocks With These 5 Picks", "Why Longer-Term Investors Should Buy Amarin Stock on Weakness", "7 Biotech Stocks to Buy and Hold in 2020", "Validea's Top Five Healthcare Stocks Based On Joel Greenblatt - 12/15/2019", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 12/15/2019", "Validea's Top Five Healthcare Stocks Based On John Neff - 12/15/2019", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Is Biogen Too Cheap to Ignore?", "Biogen Stops Development Of Gosuranemab For Progressive Supranuclear Palsy", "Should Investors Be Worried About Biogen's Alzheimer's Drug?", "Commit To Buy Biogen At $230, Earn 9.7% Using Options", "Why Shares of PDL BioPharma Are Soaring Today", "Better Buy: Biogen vs. Amgen", "Why Biogen\u2019s Alzheimer\u2019s Drug Presentation Left Investors Uninspired", "Validea's Top Five Healthcare Stocks Based On David Dreman - 12/15/2019", "5 Top Stock Trades for Friday: RH, DG, KR, BIIB", "Why AbbVie Is a Dividend Growth Stock That's Too Cheap to Ignore", "Why Biogen's Recent Rebound May Not Last -- at Least for Now", "Biogen's Data Shows Improved Gastrointestinal Tolerability With Vumerity", "MOAT, STT, BIIB, BMY: Large Inflows Detected at ETF", "Thursday Sector Laggards: Consumer Products, Healthcare", "7 Biotech Stocks to Buy With Plenty of Power in the Pipeline", "PJP, MDCO, LLY, BIIB: ETF Inflow Alert", "5 Top Stock Trades for Friday: RH, DG, KR, BIIB", "2 Biotech Stocks Fighting Alzheimer\u2019s Disease to Own Now", "Biogen's Alzheimer's Drug Goes From Bust to Boon, Plus Why Walgreens Is Shuttering 200 Healthcare Clinics", "Noteworthy ETF Inflows: MOAT, STT, BIIB, BMY", "Is There Still Room to Profit From Biogen?", "Earningspalooza 2019: Round 4", "Noteworthy Tuesday Option Activity: ROK, CPB, BIIB", "What Should Investors Think of Biogen's Alzheimer's Drug Candidate?", "How The Aducanumab Surprise Helped Biogen Stock", "2 Biotech Stocks That Soared Last Week", "5 Top Healthcare ETFs", "First Trust NYSE Arca Biotechnology Index Fund Experiences Big Outflow", "Validea Warren Buffett Strategy Daily Upgrade Report - 10/24/2019", "Biogen CEO Confident Its Alzheimer's Drug Will Get FDA Approval", "Massive News in Alzheimer's Drugs", "Biogen's Stock Could More Than Quadruple in Value in 5 Years", "Here's Why Biogen's Big Gain Won't Last Long", "Is Biogen a Buy After the Biggest Biotech Bombshell in Years?", "2 Stocks That Flew High on Tuesday", "What Happened in the Stock Market Today", "Health Care Sector Update for 10/22/2019: OBLN,NLNK,BIIB,ARWR", "Tuesday Sector Leaders: Energy, Healthcare", "Biogen Reaches Analyst Target Price", "Biogen's Stock Could More Than Quadruple in Value in 5 Years", "Biogen Inc (BIIB) Q3 2019 Earnings Call Transcript", "Nasdaq 100 Movers: HAS, BIIB", "S&P 500 Movers: HAS, BIIB", "Health Care Sector Update for 10/22/2019: BIIB, CNC, NVS, JNJ, PFE, ABT, MRK, AMGN", "Why Biogen Stock Is on Fire Today", "Biogen Q3 Profit Tops Estimates; Revenue Up 5% - Quick Facts", "Health Care Sector Update for 10/22/2019: NLNK,BIIB,ARWR", "Notable Friday Option Activity: WGO, BIIB, AXTA", "Why Did the Market Whack This IPO?", "Better Buy: Biogen vs. Gilead Sciences", "Noteworthy Wednesday Option Activity: LNN, BIIB, UAA", "Insiders Buy the Holdings of VHT ETF", "Implied MOAT Analyst Target Price: $56", "Biogen Canada Reports Positive Results On Spinal Muscular Atrophy Study", "Biogen Plans To Submit BLA For Aducanumab In Alzheimer's Disease; Shares Jump", "Notable Friday Option Activity: WGO, BIIB, AXTA", "Biogen Appoints Alfred Sandrock As EVP, Research And Development", "2 Biotechs Tackling the Challenge of Lou Gehrig\u2019s Disease", "Better Buy: Biogen vs. Amgen", "Notable Tuesday Option Activity: ISRG, BIIB, COF", "Noteworthy Monday Option Activity: BIIB, MRO, WDAY", "3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector", "Notable Wednesday Option Activity: BIIB, CLX, MAC", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Noteworthy Monday Option Activity: BIIB, CAT, MKTX", "Insiders Buy the Holdings of MOAT ETF", "Better Buy: Gilead Sciences vs. Biogen", "Noteworthy Friday Option Activity: CI, ITW, BIIB", "Better Buy: Biogen vs. Celgene", "Health Care Sector Update for 08/21/2019: NVTA,BIIB,ALT,PFE,ALC", "Eisai, Biogen To Discontinue Elenbecestat Phase III Studies - Quick Facts", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Noteworthy Monday Option Activity: BIIB, CAT, MKTX", "Insiders Buy the Holdings of MOAT ETF", "Better Buy: Gilead Sciences vs. Biogen", "Noteworthy Friday Option Activity: CI, ITW, BIIB", "Better Buy: Biogen vs. Celgene", "Health Care Sector Update for 08/21/2019: NVTA,BIIB,ALT,PFE,ALC", "Eisai, Biogen To Discontinue Elenbecestat Phase III Studies - Quick Facts", "Notable Tuesday Option Activity: BIIB, CWEN, GS", "Biogen Inc (BIIB) Q2 2019 Earnings Call Transcript", "Biogen Earnings: BIIB Stock Surges on Big Q2 Earnings Beat", "Insiders Buy the Holdings of MOAT ETF", "Biogen Q2 Profit Rises; Lifts 2019 Outlook", "MS Franchise, Spinraza Likely to Be Key Catalysts for Biogen Stock", "Notable Earnings To Watch On July 23 - AN, JBLU, BIIB, CMG, KO, HOG, HAS, TXN", "Biogen Raises Guidance as It Looks to the Pipeline for Growth", "The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On", "Notable Tuesday Option Activity: COST, BIIB, ULTA", "Notable Monday Option Activity: MED, EPAM, BIIB", "Why Biogen Stock Has Plummeted in 2019", "Why Amicus Therapeutics' Stock Perked Up in June", "3 Top Biotech Stocks to Add to Your Watchlist", "3 Top Biotech Stocks to Buy Right Now", "8 More Big Pharma Events in 2019 You Don't Want to Miss", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "The 10 Biggest Biotech Stocks", "Nasdaq 100 Movers: NTES, BIIB", "3 Large-Cap Biotech Stocks to Buy for Massive Gains", "3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal", "Notable ETF Outflow Detected - IBB, GILD, BIIB, VRTX", "Insiders Buy the Holdings of JKD ETF", "Nasdaq Today: Hard to Keep Track of the Losers", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Pain, Pain Go Away - The Suicide Disease Drug Pipeline", "Better Buy: Biogen vs. Amgen", "Analysts Anticipate 17% Upside For The Holdings of JKD", "Can Novartis Convince Insurers a $2.1 Million Gene Therapy Is a Great Deal?", "Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio", "Notable Thursday Option Activity: REGN, BIIB, GRMN", "IBB, GILD, CELG, BIIB: ETF Outflow Alert", "Ionis Pharmaceuticals Is 40% of the Way There", "Notable Thursday Option Activity: BIIB, FRO, FDX", "Stock Buybacks Surge", "IBB, BIIB, VRTX, ILMN: Large Outflows Detected at ETF", "Monday 5/6 Insider Buying Report: BIIB, UNH", "Noteworthy Thursday Option Activity: ABMD, BIIB, OXY", "Notable ETF Outflow Detected - FXH, BRKR, MD, BIIB", "IBB, GILD, CELG, BIIB: ETF Outflow Alert", "Ionis Pharmaceuticals Is 40% of the Way There", "Notable Thursday Option Activity: BIIB, FRO, FDX", "Stock Buybacks Surge", "Biogen Inc (BIIB) Q1 2019 Earnings Call Transcript", "Biogen Earnings: BIIB Stock Slips Despite Q1 Beat", "Earnings Reaction History: Biogen Idec, 36.4% Follow-Through Indicator, 2.8% Sensitive", "Sum Up The Pieces: QQXT Could Be Worth $59", "Notable Tuesday Option Activity: HIIQ, BIIB, EA", "Better Buy: Biogen vs. AbbVie", "Here's Why Ionis Pharmaceuticals Slumped Today", "2 Beaten Down Bluechips: Are They Buys?", "2 Beaten-Down Blue Chips: Are They Buys?", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Here's Why Ionis Pharmaceuticals Slumped Today", "Biogen Inc. Q1 adjusted earnings Beat Estimates", "2 Beaten Down Bluechips: Are They Buys?", "Relative Strength Alert For Biogen", "Relative Strength Alert For Biogen", "Better Buy: Gilead Sciences vs. Biogen", "Health Care Sector Update for 04/12/2019: BHVN,VIVE,XFOR,TCON", "Notable Thursday Option Activity: SRPT, UNM, BIIB", "Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock", "2 Beaten-Down Blue Chips: Are They Buys?", "Biogen (BIIB) Dips More Than Broader Markets: What You Should Know", "Should Biogen Investors Be Extra Nervous Right Now?", "Should Biogen Investors Be Extra Nervous Right Now?", "1 Biotech That Biogen Should Buy ... but Probably Won't", "MGK, BIIB, CL, SCHW: Large Outflows Detected at ETF", "Why Biogen Stock Tanked in March", "1 Biotech That Biogen Should Buy ... but Probably Won't", "Notable Thursday Option Activity: SRPT, UNM, BIIB", "Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group", "3 Healthcare Stocks to Trade Now", "Celgene Gets Positive CHMP Nod for Revlimid Label Expansion", "2 Blockbuster Gene Therapy Programs to Watch in 2019", "3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop", "Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks?", "Why Biogen's Alzheimer's Drug Failure May Have a Silver Lining", "Why Nightstar Therapeutics Stock Skyrocketed 71% in March", "Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks?", "Novartis (NVS) Receives FDA Approval for MS Drug Mayzent", "AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan", "Biogen's Bad News for Everyone", "Celgene (CELG) Submits NDA for MS Drug to FDA for Review", "Market Close Report: NASDAQ Composite index closes at 7,691.52 up 53.98 points", "Why Viacom, Ferroglobe, and Biogen Jumped Today", "Analysts Predict 12% Upside For DIVB", "Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks?", "Novartis (NVS) Receives FDA Approval for MS Drug Mayzent", "AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan", "Notable Monday Option Activity: NWSA, BIIB, JPM", "Is It Safe to Buy Biogen Stock Right Now?", "2 Biotech Takeout Targets Perfect for Biogen", "Sustainable Business Practices, Transparency Land Nasdaq Companies at Top of 2017\u2019s \u201c100 Best Corporate Citizens\u201d Ranking", "Nasdaq 100 Movers: TSLA, ORLY", "iShares Nasdaq Biotechnology ETF Experiences Big Inflow", "Biogen Stock Fell Too Far on Unfortunate News", "Company News For Mar 22, 2019", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 3/22/2019", "Mid-Afternoon Market Update: Dow Surges 250 Points; Micron Shares Gain On Upbeat Earnings", "Mid-Day Market Update: Superconductor Technologies Rises After Q4 Results; Staffing 360 Solutions Shares Slide", "Mid-Day Market Update: Superconductor Technologies Rises After Q4 Results; Staffing 360 Solutions Shares Slide", "Biogen Stock Crashes on Termination of Alzheimer's Studies", "Biogen News: BIIB Stock Plummets on Alzheimer\u2019s Drug Failure", "Biogen Becomes Oversold (BIIB)", "Biogen\u2019s Big Bet in Alzheimer\u2019s Disease Is a Bust", "Jobless Claims Dip, Philly Fed Swings, Biogen (BIIB) Plummets", "Stock Market News: Biogen Bombs, but Micron Moves Higher", "Why Biogen Stock Is Crashing Today", "Nasdaq 100 Movers: BIIB, MU", "What's Next for Biogen After Its Alzheimer's Disease Drug Flop?", "S&P 500 Movers: BIIB, CAG", "Initial Jobless Claims Decline", "Mid-Morning Market Update: Markets Open Higher; Conagra Earnings Top Expectations", "Mid-Morning Market Update: Markets Open Higher; Conagra Earnings Top Expectations", "Jobless Claims Dip, Philly Fed Swings, Biogen (BIIB) Plummets", "Alkermes Focuses on Pipeline, Depends on Partners for Funds", "Health Care Sector Update for 03/21/2019: BIIB, OGEN, NVCN, JNJ, PFE, ABT, MRK, AMGN", "Assessing Impact Of Biogen (BIIB) News", "Pre-Market Most Active for Mar 21, 2019 : BIIB, MU, SQQQ, QQQ, NOK, EQH, OPK, ERIC, CHL, LYG, CAG, ACB", "US Futures Drop on Dovish Fed, White House US-China Trade Talk", "Stock Market Today: Biogen Crushed After Failure of Alzheimer's Drug", "Is Biogen a Bad-News Buy Now?", "NASDAQ Composite Index closes up 5.02 points for the week, rising for the 5th straight day", "Close Update: Technology Sector Rally Sends US Stocks Higher as Nasdaq Leads Major Indexes", "Health Care Sector Update for 03/21/2019: LIFE,OGEN,NVCN,NVCN.TO,BIIB", "Wall Street Tips Lower Ahead of Opening Bell on Dovish Fed, White House US-China Trade Talk", "Pre-Market Most Active for Mar 21, 2019 : BIIB, MU, SQQQ, QQQ, NOK, EQH, OPK, ERIC, CHL, LYG, CAG, ACB", "US Futures Drop on Dovish Fed, White House US-China Trade Talk", "Stock Market Today: Biogen Crushed After Failure of Alzheimer's Drug", "Is Biogen a Bad-News Buy Now?", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for March 14, 2019", "Celgene (CELG) Submits Application for MS Drug in Europe", "Mid-Afternoon Market Update: Dow Surges 250 Points; Micron Shares Gain On Upbeat Earnings", "Health Care Sector Update for 03/21/2019: OGEN,NVCN,BIIB", "US Stocks Push Higher After Dovish Federal Reserve Signals Goldilocks to Markets; Pound Slips on Brexit Chaos", "PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y", "IBB, CELG, BIIB, GILD: Large Inflows Detected at ETF", "The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for March 14, 2019", "Celgene (CELG) Submits Application for MS Drug in Europe", "Mid-Afternoon Market Update: Dow Surges 250 Points; Micron Shares Gain On Upbeat Earnings", "Why Nightstar Therapeutics Stock Is Soaring Today", "Health Care Sector Update for 03/04/2019: NITE, BIIB, ASND, AVXL, JNJ, PFE, MRK, ABT, AMGN", "Stock Market Today: Biogen Buys Gene Therapy Company Nightstar Therapeutics", "US Stock Indexes Kick Off Week With Slump as Dow Leads Key Gauges Lower", "Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs", "Health Care Sector Update for 03/04/2019: ASND,CSII,NTRI,TVTY,NITE,INO", "Mid-Afternoon Market Update: Nightstar Therapeutics Surges On Acquisition News; Evoke Pharma Shares Plunge", "AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab", "Biogen to buy Nightstar Therapeutics for about $800 mln", "Health Care Sector Update for 03/04/2019: CSII,NTRI,TVTY,NITE,INO", "Here's Why Ionis Pharmaceuticals Jumped Higher Today", "Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA", "2 More Gene Therapy Stocks on Big Pharma's Buyout Radar", "Novartis In-Licenses Rights to Heart Candidate From Ionis", "Surprising Analyst 12-Month Target For OEW", "Biogen to buy Nightstar Therapeutics in $800 mln cash deal", "Novartis gene therapy is cost effective at up to $900,000 -U.S. group", "Biogen Takes Over #114 Spot From Vulcan Materials", "Nasdaq 100 Movers: NTES, HSIC", "AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review", "Alkermes Breaks $1 Billion", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 2/17/2019", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 2/17/2019", "Novartis gene therapy would be cost effective up to $900,000 -U.S. group", "Notable ETF Outflow Detected - IBB, BIIB, ILMN, REGN", "Should You Buy Viking Therapeutics After Gilead Drug Failure?", "Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 14, 2019", "The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T", "Top Research Reports for Visa, Charter Communications & Biogen", "BIIB Crosses Below Key Moving Average Level", "Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates", "Notable ETF Outflow Detected - IBB, BIIB, ILMN, REGN", "Should You Buy Viking Therapeutics After Gilead Drug Failure?", "6 Biotech Stocks to Watch Now", "Biogen Looks to 2020", "Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y", "Biogen beats estimates on multiple sclerosis drugs sales", "Market Close Report: NASDAQ Composite index closes at 7,288.35 down -86.93 points", "Biogen (BIIB) Beats Revenues and Earnings Estimates in Q4", "Biogen beats estimates on Spinraza, Tecfidera strength", "Biogen Q4 Results Top Estimates; Sees 2019 Results In Line With View", "Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?", "Drugmaker Biogen's fourth-quarter revenue rises 6.6 pct", "Earnings Reaction History: Biogen Idec, 45.5% Follow-Through Indicator, 3.1% Sensitive", "Health Care Sector Update for 01/29/2019: JNJ,CGC,WEED.TO,BIIB,AGN", "March 2020 Options Now Available For Biogen (BIIB)", "Biogen (BIIB) Beats Revenues and Earnings Estimates in Q4", "Pre-Market Earnings Report for January 29, 2019 : PFE, VZ, MMM, LMT, DHR, BIIB, AGN, HCA, GLW, PCAR, ROK, NUE", "Noteworthy Monday Option Activity: DISH, ALGN, BIIB", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 1/26/2019", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips", "Biogen (BIIB) Q4 Earnings Coming Up: What's in the Cards?", "Health Care Sector Update for 01/29/2019: CGC,WEED.TO,BIIB,AGN", "Biogen Inc (BIIB) Q4 2018 Earnings Conference Call Transcript", "Pre-Market Earnings Report for January 29, 2019 : PFE, VZ, MMM, LMT, DHR, BIIB, AGN, HCA, GLW, PCAR, ROK, NUE", "Noteworthy Monday Option Activity: DISH, ALGN, BIIB", "7 Pharmaceutical Stocks That Just Raised Prices This Year", "Value Added: 7 Top Stocks for 2019", "Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus", "Best Health-Care Stocks to Buy for 2019", "Better Buy: Biogen vs. Gilead Sciences", "All the Pre-JPM News Healthcare Investors Need to Know", "Biogen, Skyhawk Announce Collaboration - Quick Facts", "Biogen Begins Improved Dosing Regimen on Tysabri in Phase III", "Perrigo Stock Up as Appeal Date for Irish Tax Bill Nears", "Perrigo Plunges on $1.9B Tax Bill From Irish Government", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Why Shares of Perrigo Are Plunging Today", "Biogen Inks Two Deals to Make Drugs for Neurological Diseases", "Health Care Sector Update for 12/21/2018: APVO,JAZZ,RCKT,PRGO", "AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib", "Health Care Sector Update for 12/21/2018: JAZZ,RCKT,PRGO", "U.S body says gene therapy may be more cost effective for spinal muscular atrophy", "Nasdaq 100 Movers: BIIB, NXPI", "S&P 500 Movers: BIIB, BA", "Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug", "Health Care Sector Update for 12/21/2018: PRGO, PTI, RCKT, JNJ, PFE, ABT, MRK, AMGN", "Market Close Report: NASDAQ Composite index closes at 6,783.91 up 30.18 points", "Noteworthy Tuesday Option Activity: BA, BIIB, BHF", "Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU", "Validea's Top Five Healthcare Stocks Based On John Neff - 12/16/2018", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 12/16/2018", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 12/16/2018", "Better Buy: Biogen vs. Amgen", "Surprising Analyst 12-Month Target For QUS", "Market Close Report: NASDAQ Composite index closes at 6,783.91 up 30.18 points", "Noteworthy Tuesday Option Activity: BA, BIIB, BHF", "Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU", "The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen", "4 Biotech Stocks Investors Can Add to Their Portfolio in 2019", "iShares Nasdaq Biotechnology ETF Experiences Big Inflow", "Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis", "The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis", "AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018", "Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma", "Why Is Biogen (BIIB) Up 4.5% Since Last Earnings Report?", "BIIB January 2019 Options Begin Trading", "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 11/18/2018", "Validea's Top Five Healthcare Stocks Based On John Neff - 11/18/2018", "FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101", "Implied MOAT Analyst Target Price: $51", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 15, 2018", "Ionis Pharmaceuticals Collects Royalties -- and Spends It All", "Noteworthy ETF Inflows: IYH, BIIB, DHR, ESRX", "6 Pharmaceutical Stocks to Buy After the Midterms", "PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up", "5 Top Stocks to Make the Most of a Divided Congress", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 11/18/2018", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "What's in the Cards for AbbVie (ABBV) This Earnings Season?", "Noteworthy Friday Option Activity: BIIB, Z, AKS", "Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod", "Biogen Becomes Oversold (BIIB)", "Biogen Rides the Spinraza Wave to Double-Digit Growth", "Alkermes Makes Financial Progress as Its Pipeline Moves Forward", "Biogen Stock Rebounds After Impressive Q3 Earnings", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "What's in the Cards for AbbVie (ABBV) This Earnings Season?", "Noteworthy Friday Option Activity: BIIB, Z, AKS", "Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod", "Biogen Becomes Oversold (BIIB)", "Biogen Inc (BIIB) Q3 2018 Earnings Conference Call Transcript", "Biogen Breaks Below 200-Day Moving Average - Notable for BIIB", "Biogen Earnings: 10 Highlights From BIIB\u2019s Q3", "BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?", "Pre-Market Earnings Report for October 23, 2018 : VZ, MCD, MMM, UTX, LMT, NEE, CAT, BIIB, CNC, GLW, PCAR, RF", "Better Buy: Biogen Inc. vs. Amgen Inc.", "Nasdaq 100 Movers: EBAY, PYPL", "Alkermes Boasts Strong Portfolio and Impressive Pipeline", "Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?", "Corium's (CORI) Shares Surge on Merger Agreement With Gurnet", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?", "Pre-Market Earnings Report for October 23, 2018 : VZ, MCD, MMM, UTX, LMT, NEE, CAT, BIIB, CNC, GLW, PCAR, RF", "Better Buy: Biogen Inc. vs. Amgen Inc.", "Nasdaq 100 Movers: EBAY, PYPL", "Alkermes Boasts Strong Portfolio and Impressive Pipeline", "Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status", "Commit To Buy Biogen At $250, Earn 6.3% Using Options", "The Implied Analyst 12-Month Target For RYH", "Notable ETF Outflow Detected - IBB, GILD, BIIB, CELG", "Roche (RHHBY) Presents Encouraging Data on SMA Drug Risdiplam", "Notable Tuesday Option Activity: BIIB, EPAY, TREE", "3 Biotech Stocks With Rising Estimates in the Past Month", "IBB, BIIB, GILD, CELG: ETF Inflow Alert", "3 Drug/Biotech Stocks in Focus on World Alzheimer's Day", "The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works", "Novartis' Applications for MS Drug Accepted by FDA & EMA", "Top Research Reports for Wells Fargo, Schlumberger & Biogen", "Better Buy: Celgene Corp. vs. Biogen", "Noteworthy Monday Option Activity: BIIB, EGOV, ANAB", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 9/16/2018", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 9/16/2018", "IBB, BIIB, GILD, CELG: Large Outflows Detected at ETF", "Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija", "Is iShares Nasdaq Biotechnology ETF a Buy?", "Better Buy: Gilead Sciences, Inc. vs. Biogen", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for September 13, 2018", "Look Under The Hood: EQWL Has 10% Upside", "Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo", "Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down", "Noteworthy Monday Option Activity: AKAM, JBHT, BIIB", "PBE, ILMN, BIIB, VRTX: ETF Inflow Alert", "3 Biotech Stocks Analysts Say Are Market Winners", "Biotech Fund Flows, Including ETF Activity, Remain a Driver to Watch", "Notable Friday Option Activity: GRUB, COOL, BIIB", "Nasdaq 100 Movers: DLTR, BIIB", "Can Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. Recover?", "Notable ETF Outflow Detected - IBB, BIIB, GILD, CELG", "Gene Editing is a Major Technology to Watch", "Notable Friday Option Activity: PVH, PYPL, BIIB", "Biogen Begins Phase III Study on Ischemic Stroke Candidate", "3 Terrible Stocks for Retirees", "Lilly (LLY) Hits 52-Week High, Can the Run Continue?", "Is Biogen (BIIB) Outperforming Other Medical Stocks This Year?", "Has Biogen (BIIB) Outpaced Other Medical Stocks This Year?", "Pain Therapeutics' Shares Rally on Alzheimer's Study Grant", "Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 16, 2018", "Biogen (BIIB) Down 10.1% Since Last Earnings Report: Can It Rebound?", "Why Biogen's Stock Ripped Higher in July", "PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "S&P 500 Posts 5th Straight Weekly Gain: 5 Great Picks", "5 Stocks That Should Start Paying Dividends", "Interesting BIIB Put And Call Options For June 2020", "Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM", "Ionis Pharmaceuticals' Royalties Rise, but So Do Expenses", "5 Cheap PEG Stocks Suitable for GARP Investors", "Is a Beat in Store for Ionis (IONS) This Earnings Season?", "Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit", "The Zacks Analyst Blog Highlights: Comcast, United Technologies, Biogen, Mondelez and Valero", "Wednesday Sector Leaders: Healthcare, Financial", "Better Buy: Biogen Inc. vs. Gilead Sciences, Inc.", "Collaborations Help Alkermes Flip to Profitability", "Avoid Treating Biogen Like a Speculative Drug Stock", "Nasdaq 100 Movers: FB, XLNX", "Why Biogen's Stock Is Slumping Today", "Thursday's ETF with Unusual Volume: FBT", "Thursday Sector Laggards: Healthcare, Materials", "Why Every Investor Should Hold Shares of Biogen Stock", "Company News For Jul 25, 2018", "Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug", "iShares Nasdaq Biotechnology ETF Experiences Big Inflow", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 7/25/2018", "Biogen Posts Solid Earnings as the Biotech Waits for Clinical Trial Data", "Wall Street Rises After Strong Earnings From Tech, Health Care Sectors", "US Stocks Trend Higher After Strong Earnings from Tech, Health Care Sectors", "Biogen (BIIB) Q2 Earnings & Sales Beat Estimates, Shares Up", "Nasdaq 100 Movers: HAS, BIIB", "Morning Movers: Biogen, Alphabet, Verizon Soar as Earnings Lift the Dow", "Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions", "Earnings Reaction History: Biogen Idec, 45.5% Follow-Through Indicator, 3.1% Sensitive", "Market Close Report: NASDAQ Composite index closes at 7,840.77 down -1.10 points", "Health Care Sector Update for 07/24/2018: BMY,BIIB,IMRN,LLY", "Health Care Sector Update for 07/24/2018: BIIB,IMRN,LLY", "BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions", "5 Top Stock Trades for Tuesday \u2014 Buy, Sell or Hold Tesla?", "5 Surprising Things You Probably Didn't Know About Alzheimer's Drug Pipelines", "Biogen (BIIB) Q2 Earnings Beat, Shares Up", "Earnings Reaction History: Biogen Idec, 45.5% Follow-Through Indicator, 3.1% Sensitive", "Market Close Report: NASDAQ Composite index closes at 7,840.77 down -1.10 points", "Health Care Sector Update for 07/24/2018: BMY,BIIB,IMRN,LLY", "AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.", "New Drugs and Expected Growth Could Trigger a Recovery for Celgene Stock", "The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 7/15/2018", "Pre-Market Earnings Report for July 24, 2018 : VZ, MMM, UTX, LLY, LMT, BIIB, SHW, KMB, CNC, IQV, PCAR, AGR", "Validea's Top Five Healthcare Stocks Based On John Neff - 7/15/2018", "Better Buy: Biogen Inc. vs. Amgen", "Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom", "Better Know Biotech: Regenxbio Inc.", "Noteworthy Friday Option Activity: WYNN, FDX, BIIB", "Are We on the Cusp of a Big Alzheimer's Disease Breakthrough?", "Dopamine and the Weather, Part 2", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 7/15/2018", "Is Ionis Pharmaceuticals, Inc. a Buy?", "Noteworthy ETF Inflows: IBB, GILD, AMGN, BIIB", "Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More", "The Sad Truth: This Biotech Investing Strategy Almost Always Works", "Nasdaq 100 Movers: CERN, IDXX", "CTI BioPharma Falls After Failure of Pivotal Lymphoma Study", "Morning Movers: Pepsi Jumps, Celgene Climbs, Chipotle Slides", "AbbVie's Imbruvica Fails in Phase III Blood Cancer Study", "Is Ionis Pharmaceuticals, Inc. a Buy?", "Why CTI BioPharma Corp. Is Sinking Today", "Nasdaq 100 Movers: TTWO, BIDU", "Stock Market News For Jul 9, 2018", "Biogen Reaches Analyst Target Price", "5 Top Stock Trades for Monday", "Biogen Is the Right Alzheimer\u2019s Stock \u2026 At the Wrong Time", "Why Biogen Inc. Stock Soared 15.2% Today", "BIIB Makes Bullish Cross Above Critical Moving Average", "Mid-Day Market Update: Crude Oil Up Over 1%; Black Box Shares Spike Higher", "Mid-Day Market Update: Crude Oil Up Over 1%; Black Box Shares Spike Higher", "Biogen Inc Stock Shoots Higher on Alzheimer\u2019s Drug Trial", "S&P 500 Movers: QRVO, BIIB", "Nasdaq 100 Movers: LRCX, BIIB", "3 Biotech Stocks That Soared This Week: Are They Buys?", "Mid-Morning Market Update: Markets Mostly Higher; U.S. Adds 213,000 Jobs For June", "Biogen's Alzheimer Disease Candidate Succeeds in Phase II", "Morning Movers: Dow Erases Losses as Payrolls Shine, Biogen Soars, Costco Dips", "Health Care Sector Update for 07/06/2018: BIIB,CELG,RGLS", "Pre-Market Most Active for Jul 6, 2018 : ANW, DB, SHV, IQ, BIIB, SNY, QQQ, SQQQ, TVIX, NOK, BABA, BP", "What Happened in the Stock Market Today", "Market Close Report: NASDAQ Composite index closes at 7,688.39 up 101.96 points", "Mid-Morning Market Update: Markets Mostly Higher; U.S. Adds 213,000 Jobs For June", "Health Care Sector Update for 07/06/2018: CELG,TGTX,BIIB,RGLS", "Why Biotech Stocks Rallied on Biogen's Alzheimer's Test", "Friday's ETF Movers: IBB, GDX", "Mid-Day Update: US Shares Rise for Second Day, Boosted by Positive Data", "Health Care Sector Update for 07/06/2018: TGTX,BIIB,CELG,RGLS", "Notable Friday Option Activity: AMZN, BIIB, GOOGL", "IBB, GILD, AMGN, BIIB: Large Outflows Detected at ETF", "Close Update: Wall Street Ends on High Note After Jobs Data Beats Expectations", "Health Care Sector Update for 07/06/2018: CELG,TGTX,BIIB,RGLS", "Why Biotech Stocks Rallied on Biogen's Alzheimer's Test", "IBB, GILD, BIIB, CELG: ETF Inflow Alert", "First Week of August 17th Options Trading For Biogen (BIIB)", "Don't Get Too Excited About PTC Therapeutics (Yet)", "Commit To Purchase Biogen At $195, Earn 3.4% Using Options", "PTC Therapeutics' Spinal Muscular Atrophy Study Successful", "Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion", "Market Close Report: NASDAQ Composite index closes at 7,747.03 up .65 points", "Why Biogen, Baytex Energy, and Catalyst Biosciences Slumped Today", "Monday Sector Laggards: Consumer Products, Healthcare", "Monday's ETF with Unusual Volume: IXJ", "Notable Monday Option Activity: FB, BIIB, GWW", "Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 6/17/2018", "Nasdaq 100 Movers: BIIB, JD", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 6/17/2018", "Noteworthy ETF Outflows: IBB, BIIB, GILD, CELG", "Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant", "Roche Announces Positive Data on Gazyva and MS Drug Ocrevus", "Analysts Anticipate OEW Will Reach $37", "Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for June 14, 2018", "Validea's Top Five Healthcare Stocks Based On John Neff - 6/17/2018", "Gilead Sciences a Top Socially Responsible Dividend Stock With 3.2% Yield (GILD)", "Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset", "Roche Rituxan Label Expanded by FDA for Pemphigus Vulgaris", "Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus", "iShares Nasdaq Biotechnology ETF Experiences Big Inflow", "Health Care Sector Update for 06/06/2018: ENTA,ITCI,CLRB,ALKS,BIIB", "Health Care Sector Update for 06/06/2018: ITCI,CLRB,ALKS,BIIB", "Drug Stocks: The Next Hot Industry or Value Traps?", "Biogen Inc Stock Got an Upgrade, but Should You Listen?", "Better Buy: Biogen Inc. vs. Celgene", "Validea John Neff Strategy Daily Upgrade Report - 5/30/2018", "3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More", "3 Big Pharma Stocks with Huge Future Growth Potential", "Why is Biogen (BIIB) Up 6.7% Since Its Last Earnings Report?", "10 Top Health-Care Stocks That Never Break a Sweat", "3 Top Biotech Stocks to Buy in June", "Better Buy: Acadia Pharmaceuticals vs. Biogen", "S&P 500 Analyst Moves: BIIB", "Sangamo Therapeutics Stock History", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 16, 2018", "Better Buy: Amgen Inc. vs. Biogen Inc.", "Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents", "MOAT's Holdings Could Mean 14% Gain Potential", "IBB, BIIB, CELG, VRTX: ETF Outflow Alert", "Noteworthy Friday Option Activity: ADBE, CELG, BIIB", "IBB, CELG, BIIB, VRTX: ETF Inflow Alert", "3 Stocks That Turned $10,000 Into $1 Million", "Ionis Pharmaceuticals Prepares for Launch", "IBB, CELG, BIIB, VRTX: ETF Outflow Alert", "What's in the Cards for Ionis (IONS) This Earnings Season?", "Better Buy: Biogen Inc. vs. Gilead Sciences Inc.", "Nasdaq 100 Movers: SYMC, REGN", "The Good and the Bad News With Biogen Inc Earnings Results", "Is Biogen Inc. a Buy?", "Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1", "Here\u2019s Why 275% in Biogen Inc Stock Looks Realistic", "A Promising Step for Medical Marijuana", "After a Bumpy Ride, Alkermes Confirms That It's Back on Track", "Nasdaq 100 Movers: CHKP, BIIB", "Biogen's $1 Billion Bet on Ionis", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 4/25/2018", "Biogen Posts Double-Digit Profits, Has Cash to Burn", "Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down", "Health Care Sector Update for 04/24/2018: LLY, INCY, BIIB, CNC", "Biogen (BIIB) Q1 Earnings Beat, Sales Miss", "Earnings Reaction History: Biogen Idec, 54.5% Follow-Through Indicator, 5.0% Sensitive", "Why Ionis Pharmaceuticals Crashed Today", "Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales", "Eli Lilly And Co Produced a Monstrous Q1 Beat, But Is It Enough?", "Health Care Sector Update for 04/24/2018: INCY, BIIB,CNC", "Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN", "Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus", "Why Is Biogen Inc. Giving Ionis Another $1 Billion?", "Pre-Market Earnings Report for April 24, 2018 : VZ, KO, MMM, LMT, UTX, CAT, LLY, NEE, BIIB, TRV, SHW, FCX", "Novartis (NVS) Reports Encouraging Data on MS Candidate", "Health Care Sector Update for 04/24/2018: ENZ,HOLX,BIIB,CNC,INCY", "Health Care Sector Update for 04/20/2018: IONS, BIIB, RIGL, CMTA, VXRT", "Health Care Sector Update for 04/20/2018: VXRT,CMIA,IONS,BIIB,RIGL,NABI", "Health Care Sector Update for 04/20/2018: CMIA,IONS,BIIB,RIGL", "Big Biotech ETF Can Bounce Back", "Is It Time to Give Up on Alkermes?", "Validea's Top Five Healthcare Stocks Based On John Neff - 4/15/2018", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 4/15/2018", "What's in Store for Biogen (BIIB) This Earnings Season?", "Health Care Sector Update for 04/20/2018: IONS, BIIB, RIGL, CMTA, VXRT", "The Zacks Analyst Blog Highlights: NextEra, Danaher, Biogen, Facebook and Apple", "Why One Drug Flop Tanked Incyte's Stock", "Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar", "Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis", "Top Research Reports for NextEra, Danaher & Biogen", "Novartis' Acquisition of Avexis: Bad News for Biogen?", "IBB, GILD, BIIB, VRTX: ETF Outflow Alert", "Notable Tuesday Option Activity: IDCC, DAL, BIIB", "Novartis' Acquisition of AveXis Takes Aim at Biogen", "Why AveXis, Inc. Stock Is Soaring Today", "Novartis Inks $8.7 Billion Gene Therapy Deal to Buy AveXis", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 4/7/2018", "Biogen Cracks the Case With AbbVie for Humira Biosimilar", "Expect the Chaos to Continue With Today\u2019s Jobs Report", "AbbVie's RA Candidate Meets Primary Endpoints in Phase III", "Notable ETF Outflow Detected - IBB, BIIB, VRTX, ILMN", "Better Buy: Biogen Inc. vs. Amgen Inc.", "Better Buy: Gilead Sciences, Inc. vs. Biogen Inc.", "Is Ionis Pharmaceuticals, Inc. a Buy?", "Better Buy: Celgene Corporation vs. Biogen Inc.", "Noteworthy ETF Outflows: OEF, CHTR, DHR, BIIB", "Buy the Bottom in Biogen Inc. Stock for a 100% Return", "Nasdaq 100 Movers: MU, FB", "Despite Struggles Celgene Corporation Stock Is Still A Buy", "Validea's Top Five Healthcare Stocks Based On John Neff - 3/18/2018", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 3/18/2018", "Why Multiple Sclerosis is a Promising but Risky Space?", "Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for March 15, 2018", "Bull of the Day: Regeneron (REGN)", "The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene", "Why Biogen Stock Slumped in February", "Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer", "Notable ETF Outflow Detected - BBH, CELG, BIIB, VRTX", "Market Close Report: NASDAQ Composite index closes at 7,511.01 down -77.31 points", "Biogen is Now Oversold (BIIB)", "Health Care Sector Update for 03/12/2018: SRPT,BIIB,PFE,SVRA,ALNY,SNY", "PDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y", "Is Biogen Inc. a Buy?", "More Commercial Revenue on Its Way for Ionis Pharmaceuticals", "Biogen (BIIB) Down 17.2% Since Earnings Report: Can It Rebound?", "Notable Monday Option Activity: LGIH, BIIB, KHC", "Better Buy: Biogen Inc. vs. Celgene Corporation", "What's in the Cards for Ionis (IONS) This Earnings Season?", "Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M", "Agree To Purchase Biogen At $270, Earn 9.1% Annualized Using Options", "Are Alzheimer's-Focused Stocks Set for a Financial Windfall?", "Buy Biogen Stock on the Dip?", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 2/18/2018", "3 Biotech Stocks That Soared This Week: Are They Buys?", "Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat", "FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments", "Biogen is Now Oversold", "Notable Friday Option Activity: COHU, BIIB, FDX", "IBB, BIIB, CELG, REGN: ETF Inflow Alert", "Buy Biogen Stock on the Dip?", "Validea's Top Five Healthcare Stocks Based On Warren Buffett - 2/18/2018", "3 Biotech Stocks That Soared This Week: Are They Buys?", "NASDAQ Composite Index closes up 31.55 points for the week, rising for the 4th straight day", "Why Biogen, Groupon, and Omeros Slumped Today", "BIIB Makes Notable Cross Below Critical Moving Average", "Here's Why Alkermes Spiked Today", "Validea Warren Buffett Strategy Daily Upgrade Report - 2/15/2018", "3 Biotech Stocks That Soared This Week: Are They Buys?", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 2/10/2018", "The Zacks Analyst Blog Highlights: Novartis, BP and Biogen", "Notable Friday Option Activity: PWR, BIIB, ITW", "Biogen Halts Tysabri Development in Stroke as Study Fails", "Analysts Expect MGK To Hit $128", "3 Top Obesity-Drug Stocks to Consider Buying Now", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 14, 2018", "Indexes Edge Lower: Dr. Pepper Surges, Goldman Leads Dow", "Sanofi Will Buy Ablynx For $4.8 Billion On Heels Of $11.6 Billion Bioverativ Deal", "Biogen Inc. Caps Off a Solid 2017, Waits on Aducanumab", "Biogen Inc Is Beckoning to the Bulls", "Why Insurers Haven't \u2014 And Won't \u2014 Push Back On Rare Disease Drugs", "5 Biotech and Pharmaceutical Stocks Going Bonkers", "Biogen Earns Relative Strength Rating Upgrade; Hits Key Threshold", "Could Sanofi's Ablynx Deal Spur A Biopharma Buying Spree?", "Noteworthy ETF Outflows: XLV, TMO, BIIB, ANTM", "Biogen (BIIB) Q4 Earnings Miss, Sales Top, 2018 View Upbeat", "Health Care Sector Update for 01/25/2018: JNJ, PFE, ABT, MRK, AMGN, VAR, XLNX, KPTI, OCUL, SMMT, SN", "Biogen (BIIB) Q4 Earnings Miss, Sales Top, Stock Up", "Nasdaq Rebounds As Intel, Boeing Lift Dow; Varian Nails Breakout", "Biogen Revenue Tops As Spinraza, MS Drugs Deliver Upside", "Earnings Reaction History: Biogen Idec, 50.0% Follow-Through Indicator, 5.1% Sensitive", "Biogen Sees Its Composite Rating Rise To 98", "Noteworthy ETF Outflows: XLV, TMO, BIIB, ANTM", "Biogen (BIIB) Q4 Earnings Miss, Sales Top, 2018 View Upbeat", "Health Care Sector Update for 01/25/2018: JNJ, PFE, ABT, MRK, AMGN, VAR, XLNX, KPTI, OCUL, SMMT, SN", "Noteworthy Wednesday Option Activity: LVS, HLF, BIIB", "Intel, Starbucks, Biotechs Lead Earnings Rush: Investing Action Plan", "3 Pharma and Biotech Stocks to Watch Out for in 2018", "First Trust Mega Cap AlphaDEX Fund -- Insider Buying Index Registering 10.9%", "Health Care Sector Update for 01/25/2018: OCUL,KPTI,BIIB,SNN,XLNX", "Health Care Sector Update for 01/25/2018: KPTI,BIIB,SNN,XLNX", "Will Sanofi's Big Hemophilia Deal Pay Off?", "Why 2017 Was a Year to Remember for Ionis Pharmaceuticals, Inc.", "Celgene Will Buy Juno Therapeutics For $9 Billion; Sanofi Acquires Bioverativ", "What's in the Cards for Biogen (BIIB) This Earnings Season?", "Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips", "Why Bioverativ Inc. Stock Is Soaring Today", "Biotech M&A Off to a Strong Start in 2018: More Deals to Follow?", "Insiders Were Right: BIIB Makes New 52-Week High", "Is Sanofi\u2019s Bioverative Inc Buyout Just the Start?", "Here's Why Acorda Therapeutics Inc. Stock Is Surging Today", "Correction: Futures Reverse Early Gains As Focus Shifts to Washington", "Futures Reverse Early Gains As Focus Shifts to Washington", "Stocks With Rising Relative Strength: Biogen", "Notable Wednesday Option Activity: PSX, BIIB, JCI", "Bioverativ Inc Stock Gets 64% Premium in Acquisition by Sanofi", "Roche MS Drug Ocrevus Gets Marketing Authorization in Europe", "Will 2018 Be Biogen Inc.'s Best Year Yet?", "Will 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet?", "Biogen Trying To Close In On Key Technical Measure", "Notable Tuesday Option Activity: MCK, ABBV, BIIB", "Nasdaq 100 Movers: SHPG, STX", "Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs", "3 Pharma and Biotech Stocks to Watch Out for in 2018", "Biogen Unlikely To See Spinraza Rival In 2018 As AveXis Delayed", "IWF, NVDA, LOW, BIIB: ETF Outflow Alert", "Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer", "Stocks Generating Improved Relative Strength: Biogen", "Generalists On Biotech Sidelines As Tax Reform Sweeps The U.S.", "Tuesday Sector Leaders: Healthcare, Services", "Best Stocks Of 2017: Biotechs Shined, Despite Lack Of Profits", "Monday Sector Laggards: Healthcare, Services", "Noteworthy ETF Outflows: XLV, GILD, LLY, BIIB", "Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo", "Biogen's Alzheimer's Drug Misses Goal in Interim Analysis", "The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum", "Biogen Shares Drop After Alzheimer's Drug Misses In Testing", "Nasdaq 100 Movers: PAYX, NTES", "The Top 8 Market-Moving Healthcare Stories of 2017", "Another Reason 2018 Might Not Be A Banner Year For Biotech Mergers", "Stocks Inch Higher as Shutdown Threat Looms", "Top Research Reports for Pfizer, FedEx & Abbott", "Notable Thursday Option Activity: KMX, BIIB, ALGN", "3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2018", "Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies", "Orbimed Advisors Llc Buys Clementia Pharmaceuticals Inc, Aetna Inc, Universal Health Services ...", "Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy", "Celgene Whacked After Blood-Drug Regimen Fails In Phase 3 Trial", "This Stock Leads Oil Plays Up; Apple Fine; How Far Will This Bitcoin ETF Fall?", "Stocks Close Lower; Oracle Falls After Earnings", "Biogen, Ionis Sink As Competitor Plans Rival Drug To Spinraza", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for December 14, 2017", "5 Biotech Buyout Candidates for 2018", "Biogen Sees RS Rating Rise To 72", "These 5 Top Stocks Are Near Buys In This Bullish Pattern: Action Plan", "Indexes Dip; Tax Reform Gets Done As Bullish Sentiment Rises", "Looking for Top Stocks in the Strongest Performing Sectors", "Noteworthy ETF Outflows: IYH, TMO, BIIB, AET", "S&P 500 Analyst Moves: BIIB", "Here's What's Unusual About Regeneron Pharmaceuticals' Latest Deal", "Thursday 11/30 Insider Buying Report: BIIB, MDCO", "The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt", "Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data", "Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal", "Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)", "Top Research Reports for Amazon, AbbVie & Biogen", "Biogen Acquires Worldwide License for Alkermes' MS Candidate", "Sphera Funds Management Ltd. Buys Cellcom Israel, Allergan PLC, Teva Pharmaceutical Industries, ...", "Is Biogen's Multiple Sclerosis Franchise Getting A New Lease On Life?", "Zacks Value Trader Highlights: General Electric, Macy's, Biogen, Chipotle and Exxon Mobil", "No. 1-Ranked Medical Stock Tests Support In New Base", "Noteworthy Monday Option Activity: BIIB, TSN, ILMN", "Should You Buy the Beaten Down Blue-Chip Stocks?", "Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks", "Bet on Biogen Inc for Easy Profits Into the New Year", "IBD Rating Upgrades: Biogen Shows Improved Price Strength", "Better Buy: Biogen Inc. vs. Gilead Sciences", "Why It\u2019s Time to Put Pfizer Inc. Stock on Your Watchlist", "Biogen Inc. Buys Its Way Out of Competition", "Noteworthy Monday Option Activity: BIIB, TSN, ILMN", "Should You Buy the Beaten Down Blue-Chip Stocks?", "Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks", "Bet on Biogen Inc for Easy Profits Into the New Year", "IBD Rating Upgrades: Biogen Shows Improved Price Strength", "Better Buy: Biogen Inc. vs. Gilead Sciences", "Why It\u2019s Time to Put Pfizer Inc. Stock on Your Watchlist", "Biogen Inc. Buys Its Way Out of Competition", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 16, 2017", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 11/15/2017", "Ionis Pharmaceuticals Inc. Sets Itself Up for Growth", "Can Marijuana Cure Alzheimer's Disease?", "Better Buy: Acadia Pharmaceuticals vs. Biogen", "Ionis Pharmaceuticals' Earnings Results Fuel Volatility", "Sphera Funds Management Ltd. Buys Cellcom Israel, Allergan PLC, Teva Pharmaceutical Industries, ...", "Americafirst Capital Management, Llc Buys Sysco Corp, Exelon Corp, Thermo Fisher Scientific ...", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 16, 2017", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 11/15/2017", "Ionis Pharmaceuticals Inc. Sets Itself Up for Growth", "Can Marijuana Cure Alzheimer's Disease?", "Better Buy: Acadia Pharmaceuticals vs. Biogen", "Ionis Pharmaceuticals' Earnings Results Fuel Volatility", "Sphera Funds Management Ltd. Buys Cellcom Israel, Allergan PLC, Teva Pharmaceutical Industries, ...", "Americafirst Capital Management, Llc Buys Sysco Corp, Exelon Corp, Thermo Fisher Scientific ...", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 16, 2017", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 11/15/2017", "Ionis Pharmaceuticals Inc. Sets Itself Up for Growth", "Can Marijuana Cure Alzheimer's Disease?", "Better Buy: Acadia Pharmaceuticals vs. Biogen", "Ionis Pharmaceuticals' Earnings Results Fuel Volatility", "Sphera Funds Management Ltd. Buys Cellcom Israel, Allergan PLC, Teva Pharmaceutical Industries, ...", "Americafirst Capital Management, Llc Buys Sysco Corp, Exelon Corp, Thermo Fisher Scientific ...", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 16, 2017", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 11/15/2017", "Ionis Pharmaceuticals Inc. Sets Itself Up for Growth", "Can Marijuana Cure Alzheimer's Disease?", "Better Buy: Acadia Pharmaceuticals vs. Biogen", "Ionis Pharmaceuticals' Earnings Results Fuel Volatility", "Sphera Funds Management Ltd. Buys Cellcom Israel, Allergan PLC, Teva Pharmaceutical Industries, ...", "Americafirst Capital Management, Llc Buys Sysco Corp, Exelon Corp, Thermo Fisher Scientific ...", "Biogen Shows Rising Relative Strength; Still Shy Of Key Threshold", "PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y", "Lipe & Dalton Buys Citigroup Inc, Synchrony Financial, McKesson Corp, Sells American ...", "WestEnd Advisors, LLC Buys Bank of America Corporation, SPDR Portfolio Short Term Corporate ...", "Biogen Sees IBD RS Rating Climb To 73", "Stoneridge Investment Partners Llc Buys Altria Group Inc, Mondelez International Inc, Merck ...", "Is a Beat in Store for Ionis (IONS) This Earnings Season?", "What's Biogen's Big Risk?", "IBD's No. 1 Group Under Pressure; These 6 Key Earnings Loom; S&P 500 Futures", "Pre-Market Earnings Report for October 24, 2017 : MCD, MMM, UTX, LLY, LMT, CAT, BIIB, GM, SHW, NVS, GLW, PCAR", "Noteworthy Monday Option Activity: BIIB, INTC, FCX", "iShares U.S. Healthcare ETF Experiences Big Inflow", "Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna", "BIIB Crosses Above Average Analyst Target", "IBD Biotech Innovator Awards", "Stock Indexes Up Slightly; Trump Threatens Drug Firms", "Biogen Biomarkers Mark Way To Alzheimer's, Parkinson's Treatments", "Trump Likely To Sign Executive Order On Drug Pricing 'Any Day'", "Noteworthy Monday Option Activity: FCX, BMY, BIIB", "Why These Biotech Players Look Poised To Crush Earnings Views", "This No. 1-Ranked Medical Stock Is Breaking Out With Q3 Earnings Due", "Better Buy: Biogen Inc. vs. Celgene", "Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit", "6 Top Biotech Companies In Innovation Earn Recognition In New Awards", "No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock", "Notable Friday Option Activity: GDOT, BIIB, CRM", "ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status", "Catabasis' DMD Candidate Slows Disease Progression, Stock Up", "Ligand (LGND) Signs Deal to Acquire Crystal Bioscience", "Nasdaq 100 Movers: CELG, NCLH", "11.7% of OVLC Holdings Seeing Recent Insider Buys", "Intercept Dives Along With Ocaliva Prescriptions On FDA Warning", "No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock", "Notable Friday Option Activity: GDOT, BIIB, CRM", "Emergent Completes Acquisition of Anthrax Drug Raxibacumab", "Notable ETF Outflow Detected - VHT, AGN, TMO, BIIB", "Nasdaq 100 Movers: JD, MYL", "Allergan's Botox Gets FDA Nod for Forehead Line Treatment", "Morning Movers: Constellation Brands Jumps, Biogen Bounces, Celgene Slips", "Zacks.com featured highlights include article Texas Instruments, Applied Materials, Pepsico, CBRE Group and Biogen", "Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy", "After Intepirdine Flunked in Alzheimer\u2019s Disease, Is Axovant Sciences a Buy?", "Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA", "3 Top-Ranked Big Biotech Stocks to Buy Now", "5 Top ROE Stocks to Buy as Markets Snub Geopolitical Threats", "The Zacks Analyst Blog Highlights: Procter & Gamble, PetroChina, Biogen, Accenture and Norfolk Southern", "Amgen Enters Into an Immuno-Oncology Partnership With CytomX", "Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up", "AveXis Flies, But PTC Sinks On Spinal Muscular Atrophy Data", "Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults", "Lilly (LLY) Makes Leadership Changes to Executive Positions", "Top Stock Reports for Procter & Gamble, PetroChina & Biogen", "Top Stock Reports for Procter & Gamble, PetroChina & Biogen", "4 Biotech Stocks (and 1 ETF) to Buy As They Bolt Higher", "Why PTC Therapeutics, Inc. Dropped Today", "Biotechs Beating The Market, But Are They In Buy Range?", "Why Amgen's Drug Win Sent AbbVie Stock Into The Stratosphere", "MOAT, OILU: Big ETF Outflows", "Is Biogen Inc. (BIIB) a Great Stock for Value Investors?", "Sorry Qualcomm, Inc. (QCOM) Stock Bears, It Has Bottomed!", "Play the Support Test in VanEck Vectors Gold Miners ETF (GDX)", "Think Before You Chase Nvidia Corporation (NVDA) Stock\u2019s Momentum", "Notable Friday Option Activity: BIIB, RJF, TSN", "Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?", "IBB, BIIB, REGN, ALXN: ETF Inflow Alert", "4 Biotech Stocks for the Long-Term", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for September 14, 2017", "BIIB January 2020 Options Begin Trading", "Why Biogen Stock Raced Higher In August", "Biogen Reaches Analyst Target Price", "Profit From the Biogen Inc (BIIB) Stock Dip!", "Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study", "Thursday Sector Leaders: Healthcare, Energy", "5 Biotech Stocks That Are Breaking Higher", "Biogen Alzheimer's Drug Shows Promise in Long-Term Study", "Company News For August 29, 2017", "Trade of the Day: Biogen Inc (BIIB) Stock Is Coiling", "Vanguard Russell 1000 ETF -- Insider Buying Index Registering 11.9%", "AbbVie Submits NDA for Endometriosis Candidate to the FDA", "Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study", "Thursday Sector Leaders: Healthcare, Energy", "5 Biotech Stocks That Are Breaking Higher", "Biogen Alzheimer's Drug Shows Promise in Long-Term Study", "Company News For August 29, 2017", "Orbimed Advisors Llc Buys Cigna Corp, Clovis Oncology Inc, Gilead Sciences Inc, Sells Centene ...", "Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why", "Monday Sector Leaders: Healthcare, Technology & Communications", "Orbimed Advisors Llc Buys Cigna Corp, Clovis Oncology Inc, Gilead Sciences Inc, Sells Centene ...", "Notable Thursday Option Activity: DE, NVDA, BIIB", "Noteworthy ETF Inflows: TQQQ, GOOG, AMGN, BIIB", "What You See, and What You Get: The Neurology of Perception", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 15, 2017", "Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs", "The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix", "We Did The Math OEF Can Go To $119", "Top Analyst Reports for Biogen, Activision & Cigna", "These 3 Biotechs Just Crushed Analyst Expectations", "PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y", "See Which Of The Latest 13F Filers Holds Biogen", "Is a Beat in Store for Ionis (IONS) This Earnings Season?", "7 Explosive Healthcare Stocks to Buy Now", "Notable ETF Inflow Detected - VHT, LLY, TMO, BIIB", "Noteworthy ETF Inflows: VHT, TMO, BIIB, AET", "Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 6,422.75.", "Biogen Inc Wants to Be the \"Fastest-Growing Large-Cap Biotech Company\"", "Validea Warren Buffett Strategy Daily Upgrade Report", "Lgt Capital Partners Ltd. Buys Dr Pepper Snapple Group Inc, UnitedHealth Group Inc, Starbucks ...", "Notable Tuesday Option Activity: CTRN, PCRX, BIIB", "Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed", "Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line", "Wal-Mart Stores Inc (WMT) Stock Is Perking Up!", "3 Stocks to Watch on Tuesday: Alphabet Inc (GOOGL), Biogen Inc (BIIB) and Michael Kors Holdings Ltd (KORS)", "Earnings Reaction History: Biogen Idec, 58.3% Follow-Through Indicator, 5.3% Sensitive", "Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up", "Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN", "Pre-Market Earnings Report for July 25, 2017 : MMM, MCD, UTX, LLY, DD, CAT, BIIB, GM, KMB, HCA, PCAR, TROW", "These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet", "Biogen (BIIB) Tops Q2 Earnings and Revenue", "Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?", "Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs", "Agree To Purchase Biogen At $200, Earn 4% Using Options", "Insiders Buy the Holdings of BBH ETF", "AveXis Inc.: Buy at the High?", "Biogen Breaks Above 200-Day Moving Average - Bullish for BIIB", "Noteworthy Monday Option Activity: VHC, AGN, BIIB", "ITOT, TMO, COST, BIIB: ETF Inflow Alert", "Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?", "The Math Shows BBH Can Go To $140", "Amgen, Inc. (AMGN) Stock Is the Cure for Ailing Portfolios", "BIB, BIIB, REGN, VRTX: ETF Outflow Alert", "3 Hot Biotech Stocks Ready for the Sector\u2019s Next Breakout", "Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More", "Better Buy: Biogen Inc. vs. Celgene Corporation", "Top Stock Reports for Boeing, AbbVie & U.S. Bancorp", "How Biogen Inc. Makes Most of Its Money", "4 Reasons the AveXis Inc. Rally Could Continue", "Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod", "Noteworthy ETF Outflows: JKD, MO, BIIB, ANTM", "Update: Wall Street Weighed Down By Oil Declines as Health Stocks Lift Nasdaq", "5 Biotech Stocks That Are Roaring Back to Life", "3 Reasons Sizzling-Hot Bioverativ Stock Can Go Even Higher", "7 Healthcare Stocks to Buy Now", "Monday Sector Leaders: Healthcare, Technology & Communications", "Bear of the Day: Bioverativ (BIVV)", "Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why", "Will These Cutting-Edge Cancer Killers Reignite The Biotech Rally?", "Don\u2019t Be Scared of Biogen Inc (BIIB) Stock", "Biogen Loses Top Executive Again, CFO Clancy to Join Alexion", "Noteworthy Wednesday Option Activity: CMG, BIIB, AAPL", "7 Healthcare Stocks to Buy Now", "Monday Sector Leaders: Healthcare, Technology & Communications", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for June 14, 2017", "Insiders Buy the Holdings of VONE ETF", "2 Reasons Why Biogen's Shares Slumped in May", "3 Stocks That Could Be Life-Changers", "Nasdaq 100 Movers: BIIB, ALXN", "3 Stocks to Watch on Wednesday: Ford Motor Company (F), Alexion Pharmaceuticals, Inc. (ALXN) and H & R Block Inc (HRB)", "Biotech ETF Experiences Big Outflow", "Biogen/Ionis Spinraza Granted Marketing Authorization in EU", "Notable Friday Option Activity: LEN, BIIB, RRC", "5 Drug Stocks in Focus on World MS Day", "The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture", "Celgene's Stock May Be Incredibly Overvalued Right Now -- Here's Why", "Why Ionis Pharmaceuticals Inc. Swooned 6% in May", "Biogen Inc (BIIB) Stock Can Help You Earn Income From Thin Air", "Biotech ETF Experiences Big Outflow", "Biogen/Ionis Spinraza Granted Marketing Authorization in EU", "Notable Friday Option Activity: LEN, BIIB, RRC", "Stock Exchange: Time to reconsider health care?", "Biogen (BIIB) Down 9.5% Since Earnings Report: Can It Rebound?", "Biogen's Fampyra Conditional Approval Converted to Standard", "Better Buy: Biogen Inc. vs. Gilead Sciences Inc.", "Notable Wednesday Option Activity: JNJ, C, BIIB", "Why Long-Term Investors Should Prefer Celgene Over Biogen", "Noteworthy ETF Outflows: VV, BIIB, PYPL, DHR", "Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal", "Want to Get in on Biotech? Check Out These 3 Stocks", "Biogen (BIIB) Buys Stroke Candidate Cirara for $120M", "Notable Monday Option Activity: RTN, BIIB, MON", "Jeff Ubben Buys 1, Sells 1 in 1st Quarter", "Biogen Enters Oversold Territory (BIIB)", "Ionis Pharmaceuticals Inc.'s First Royalties Roll In", "iShares Russell 1000 Growth ETF Experiences Big Outflow", "IYH's Underlying Holdings Could Mean 10% Gain Potential", "Why Biogen Inc. Shareholders Have Something to Worry About", "The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson", "Friday Sector Laggards: Healthcare, Financial", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 15, 2017", "What's in the Cards for Ionis (IONS) this Earnings Season?", "What's Behind Ionis Pharmaceuticals' 20% Rally In April", "Top Research Reports for May 4, 2017", "Morningstar Wide Moat ETF -- Insider Buying Index Registering 12.0%", "Notable ETF Outflow Detected - BIB, BIIB, REGN, ILMN", "Tuesday 5/2 Insider Buying Report: BIIB, WWD", "Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss", "Notable Friday Option Activity: BIIB, NWL, NKE", "Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY", "Better Buy: Amgen Inc. vs. Biogen", "Biogen Inc. Earnings: New Drug Sparks Life", "Biogen Inc (BIIB) Stock Pops on Strong Q1 Earnings", "Nasdaq 100 Movers: ESRX, BIIB", "Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down", "Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong", "Better Buy: Ionis Pharmaceuticals, Inc. vs. bluebird bio", "Health Care Sector Update for 04/25/2017: BIIB, ESRX, JNJ, PFE, ABT, MRK, AMGN", "Earnings Reaction History: Biogen Idec, 58.3% Follow-Through Indicator, 5.0% Sensitive", "Spinraza's Fast Start Puts Ionis on a Path to Profit", "Biogen and Alzheimer\u2019s: There\u2019s a Fundamental Problem Here", "Monday\u2019s Vital Data: Apple Inc. (AAPL), Visa Inc (V) and Micron Technology, Inc (MU)", "3 Key Factors to Look Out for in Biogen's Q1 Results", "Make Biogen Inc (BIIB) Stock Pay You, Even With No Dividend", "Biogen (BIIB) Beats on Q1 Earnings and Revenue", "Pre-Market Earnings Report for April 25, 2017 : KO, MMM, MCD, LLY, LMT, DD, BIIB, CAT, SPGI, VLO, GLW, BHI", "Noteworthy Monday Option Activity: AAPL, ISRG, BIIB", "3 Stocks That Growth Investors Should Love", "Marijuana Stocks: A 4/20 Special", "What's in Store for Biogen (BIIB) this Earnings Season?", "Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed", "Bristol-Myers and Nordic Ink Biomarker Collaboration Deal", "Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS", "Commit To Buy Biogen At $140, Earn 2.6% Using Options", "Biogen to License Alzheimer Candidate from Bristol-Myers", "AbbVie's Elagolix Meets Primary Endpoint in Phase II Study", "Roche Just Scored One of the Biggest Pharma Wins of 2017", "3 Big Stock Charts for Friday: Biogen Inc (BIIB), American Airlines Group Inc (AAL) and Cisco Systems, Inc. (CSCO)", "Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline", "Peek Under The Hood: BBH Has 14% Upside", "The 7 Most Expensive Prescription Drugs in the World", "3 Biotech Trades for the Faux Doomsday Scenario", "Acorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge", "Why Acorda Therapeutics Inc and Forward Pharma A/S Got Crushed Today", "Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher", "Noteworthy Friday Option Activity: PX, BIIB, EXPE", "Nasdaq 100 Movers: BIIB, VRTX", "Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis", "Wednesday Sector Laggards: Utilities, Healthcare", "Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results", "3 Biotech Stocks That Are Broker Favorites", "Health Care Sector Update for 03/21/2017: BIIB,PTIE,AXSM", "Billionaires' Best Healthcare Stock Picks of 2017 (So Far)", "AveXis Inc Stock Is Spiking Again Today -- Here's Why", "Stock Market News for March 17, 2017", "Alkermes Starts Phase III Study to Treat Multiple Sclerosis", "Biotech ETFs Defy Trump Tweets To Rally, But What Can Send Them Higher?", "BIIB Crosses Below Key Moving Average Level", "Noteworthy ETF Outflows: IBB, BIIB, REGN, INCY", "Nasdaq 100 Movers: BIIB, QVCA", "S&P 500 Movers: BIIB, ORCL", "Biogen Inc (BIIB): Profit From the BIIB Stock Bears", "Market Close Report: NASDAQ Composite index closes at 5,900.76 up .71 points", "Thursday Sector Laggards: Healthcare, Utilities", "Mid-Day Market Update: U.S. Stocks Turn Negative; GoPro Shares Spike Higher", "Thursday's ETF Movers: ITB, BBH", "Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for March 14, 2017", "Biogen Spinoff Takes Flight With Focus On Hemophilia Drugs", "AbbVie Stock Upgraded: What You Need to Know", "Why Ionis Pharmaceuticals Rallied 12% in February", "Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal", "Noteworthy Thursday Option Activity: MPC, BIIB, HUM", "Repros (RPRX) Q4 Earnings: What's in Store for the Stock?", "Is This the Right Time to Invest in Biotech Stocks?", "5 Things Biogen's CEO Just Said That You Don't Want to Miss", "Inovio (INO): What's in the Cards this Earnings Season?", "BioDelivery (BDSI): What's in Store this Earnings Season?", "4 Things Alkermes Wants Investors to Know", "New Features: Individual Portfolio Tracker and Value Screens Tracker", "Notable ETF Inflow Detected - IYH, GILD, AGN, BIIB", "The Zacks Analyst Blog Highlights: AT&T, Visa, Biogen, Tesla and PG&E", "Ionis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' Money", "Get in Biogen Inc (BIIB) Stock Before It Breaks Out", "Perrigo to Sell Tysabri Royalties; Issues Tepid 2017 View", "QUAL, KMB, PEG, BIIB: ETF Inflow Alert", "Better Buy: Biogen Inc. vs. Gilead Sciences Inc.", "Here's Why Celgene's Latest Drug Is So Exciting", "Why Celgene's Shares Rallied Higher in February", "The Zacks Analyst Blog Highlights: AT&T, Visa, Biogen, Tesla and PG&E", "Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?", "3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter", "Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?", "Why Ionis Pharmaceuticals (IONS) Looks Worth the Risk", "Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next?", "BIB, BIIB, REGN, ILMN: Large Outflows Detected at ETF", "Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences", "A Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's Disease", "Is Biogen a Risky Stock?", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 13, 2017", "How Biogen Inc (BIIB) Stock Could Gain Another 25%", "What's Behind Bioverativ's Spin-Out, and Should You Buy?", "Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib", "In an Ironic Twist, Generics Take Aim at Teva Pharmaceutical", "PRIMECAP Management Buys AstraZeneca PLC, Alkermes PLC, Whirlpool, Sells Union Pacific, ...", "A Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's Disease", "Why Forward Pharma A/S Stock Surged 107% in January", "It\u2019s a Scratch, Not a Ding for Biogen Inc (BIIB) Stock", "QUAL, KMB, PEG, BIIB: ETF Outflow Alert", "5 Drugmakers Battle Over the $10 Billion Hemophilia Market", "Nasdaq 100 Movers: BIIB, TSCO", "Implied RYH Analyst Target Price: $172", "3 Healthcare Tickers That Will Return Profits in 3 Months", "Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data", "The Zacks Analyst Blog Highlights: AT&T, Biogen, Qualcomm, Facebook and Royal Caribbean", "Biogen Inc Makes Up for Lackluster Revenue Growth", "How to Trade Biogen Inc (BIIB) Stock After Its Q4 Beat", "Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft", "The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb", "Biogen (BIIB) Beats on Q4 Earnings; Misses Sales", "What Could Make Biogen Crash?", "Earnings Reaction History: Biogen Idec, 50.0% Follow-Through Indicator, 4.5% Sensitive", "Notable Thursday Option Activity: PYPL, BIIB, MJN", "Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA", "Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY", "Pre-Market Earnings Report for January 26, 2017 : CMCSA, CELG, BMY, DOW, BIIB, CAT, F, RTN, NOC, PX, AEP, LUV", "Better Buy: Biogen Inc. vs. Gilead Sciences Inc.", "Biogen Inc (BIIB) Stock Enters Uncharted Waters", "3 Top Biotech Stocks You Can Still Buy With the Dow at 20,000", "Nektar Therapeutics: An Undervalued Biopharmaceuticals Company With Plenty In The Pipeline", "Noteworthy Thursday Option Activity: NANO, BIIB, SWKS", "Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?", "Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug", "The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway", "Why Forward Pharma A/S Stock Gained 48.2% on Tuesday", "Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit", "5 Drugs That Are Way Cheaper in Canada", "Mid-Day Market Update: Clayton Williams Energy Surges On Acquisition News; Christopher & Banks Shares Slide", "Agree To Buy Biogen At $180, Earn 5.3% Using Options", "Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Tops Q4 Estimates", "Why Netflix, Inc. (NFLX) Stock Could Pop After Q4 Earnings", "3 Stocks to Watch on Tuesday: Chipotle Mexican Grill, Inc. (CMG), Noble Energy, Inc. (NBL) and Wells Fargo & Co (WFC)", "Biogen Inc (BIIB) Will Win a Battle, But Could Lose the War", "Why Clayton Williams Energy, Forward Pharma, and Luxottica Jumped Today", "Midday Update: Stocks Pressured By Trump's Dollar Warning, Earnings and Inauguration Sell-0ff", "Mid-Day Market Update: Clayton Williams Energy Surges On Acquisition News; Christopher & Banks Shares Slide", "Close Update: Wall Street Braces For \"Sell-The-Fact\" Reaction After Inauguration", "The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal", "Biogen (BIIB) Presents Positive Phase III Data on Spinraza", "Is Biogen's Stock Ready to Heat Up After a Forgettable 2016?", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 5,574.12.", "Top Research Reports for Alibaba, Costco & Walgreens", "Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?", "Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017", "Close Update: Wall Street Braces For \"Sell-The-Fact\" Reaction After Inauguration", "The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal", "Notable Wednesday Option Activity: BIIB, MRK, AMGN", "Stock Market News for January 10, 2017", "3 Big Reasons (and 8 Smaller Ones) to Buy Ionis Pharmaceuticals Stock", "Energous Corp Shines Brightly as the Next Fortune-Building Company (WATT)", "This Could Very Well Be the Greatest Drug Advancement in a Decade", "Biogen Licenses Amunix's XTEN Technology for Factor IX Drug", "Biotech Investing: 3 Bold Predictions for 2017", "Biogen's New CEO: Lots of Questions, Few Answers", "Noteworthy ETF Outflows: IYH, CELG, BIIB, AET", "Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data", "5 Slides Every Ionis Pharmaceuticals Inc Investor Needs to See", "Top Stocks to Buy Now That the 21st Century Cures Act Has Passed", "Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation", "Is Biogen Playing With Fire?", "My Worst Predictions for Biotech in 2016", "AbbVie's Humira and Imbruvica Drive Performance in 2016", "iShares Edge MSCI USA Quality Factor ETF Experiences Big Outflow", "Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold", "Why Twilio, Northern Dynasty Minerals, and Ionis Pharmaceuticals Slumped Today", "Did Biogen Just Throw in the Towel to Celgene?", "Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation", "Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy", "The 3 Biggest Risks for Pfizer in 2017", "Health Care Sector Update for 12/27/2016: IONS,BIIB,CAPN,ENGX", "3 Biggest Risks for AbbVie in 2017", "Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug", "2016's Worst Clinical Failures", "Will Spinraza Supercharge Biogen's Top Line Next Year?", "Health Care Sector Update for 12/27/2016: SGEN, IONS, JNJ, PFE, ABT, MRK, AMGN", "Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy", "Biogen Names Commercial Officer as New CEO, Shares Fall", "3 Reasons Biogen Inc. Stock Is Set to Soar in 2017", "3 Low-Volatility Biotech Stocks to Buy", "OEF, WBA, TWX, BIIB: ETF Outflow Alert", "The Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & ChemicalThe Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & Chemical", "Biogen (BIIB) Board Okays Hemophilia Business Spin-off", "Top Research Reports for Barclays, Netflix and Nike", "Trade Valeant Pharmaceuticals Intl Inc (VRX) Stock for Free Profits", "3 Top Biotech Stocks to Buy on Sale", "Biogen Presents Positive Early Data from Alzheimer's Study", "Lilly/AstraZeneca Expand Alzheimer Disease Collaboration", "The 3 Most Profit-Friendly Biotech Stocks", "Better Buy: Amgen Inc. vs. Biogen", "Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data", "Does New Alzheimer's Data Make Biogen Stock a Buy Now?", "Stock Market News for December 09, 2016", "Nasdaq 100 Movers: LRCX, BIIB", "Should You Buy Drug Stocks on Their Post-Election Drop?", "S&P 500 Movers: GRMN, BIIB", "Health Care Sector Update for 12/09/2016: BIIB", "Pre-Market Most Active for Dec 9, 2016 : SWC, MGM, BAC, TLK, LVS, MPEL, WYNN, VOD, VALE, SQQQ, BIIB, TVIX", "Is Biogen's Aducanumab a Game-Changing Alzheimer's Drug?", "Stock Market News for December 08, 2016", "The 3 Best Biotech Stocks for 2017", "Biogen Breaks Below 200-Day Moving Average - Notable for BIIB", "3 Top Healthcare Stocks", "Can Biogen Beat the Broader Markets in 2017?", "How Can Value Screener Record Trends Explain Market Valuations?", "Stock Exchange: Model Picks Teach Us To Manage Risk", "Biogen Inc (BIIB) Stock Trade Showcases the \u2018Art of the Steal\u2019", "3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline", "Better Buy: Biogen Inc. vs. Amgen", "Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno", "Charles Payne on Biotech: Biogen Inc (BIIB), Intercept Pharmaceuticals Inc (ICPT)", "Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?", "Lilly's Alzheimer Drug Fails Phase III Study, Stock Down", "Eli Lilly and Co (LLY) Drug Failure Doesn\u2019t Answer the Bigger Question", "GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?", "Nasdaq 100 Movers: BIIB, EA", "Pre-Market Most Active for Nov 23, 2016 : LLY, NVO, TGT, MT, BAC, DE, JUNO, BIIB, ERIC, QQQ, XIV, TVIX", "Pre-Market Most Active for Nov 23, 2016 : LLY, DE, RDY, NVO, BIIB, ERIC, MT, SNY, JUNO, QQQ, XIV, TVIX", "Eli Lilly's Alzheimer's Drug Is a Bust", "Market Close Report: NASDAQ Composite index closes at 5,380.68 down -5.67 points", "3 Potentially Huge Catalysts for Ionis Pharmaceuticals, Inc. in 2017", "Why Biogen Shareholders Lost $3 Billion Today", "Instant Analysis: Eli Lilly Drops Pre-holiday Alzheimer's Bomb", "Acorda Stops Post-Stroke Development Program on Ampyra", "5 Biotech Stocks George Soros Is Buying", "3 Biotechs That Don't Pay Dividends -- but Could", "$13 Billion Opportunity: 5 Companies That Could Dominate the Alzheimer's Disease Market", "3 Irrefutable Reasons to Sell Johnson & Johnson Stock", "The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties", "3 Beaten-Down Biotech Stocks to Buy for Huge Gains", "Are Biogen and Gilead Sciences in Denial?", "Acorda Stops Post-Stroke Development Program on Ampyra", "5 Biotech Stocks George Soros Is Buying", "XLV, JNJ, GILD, BIIB: ETF Inflow Alert", "3 Biotech Stocks You MUST Buy for Donald Trump\u2019s Presidency", "Perrigo (PRGO) Beats on Q3 Earnings, Revenues; View Intact", "Peek Into Drug Stocks' Q3 Earnings on Nov 11: XBIT & REPH", "Better Buy: Biogen Inc. vs. Celgene Corporation", "Why Biogen Inc. Stock Lost 10.5% of Its Value In October", "Why Ionis Pharma Is Rocketing 25% Higher Today", "Biogen's Growth Is Far Weaker Than You May Think", "Company News for November 08, 2016", "See Which Of The Latest 13F Filers Holds Biogen", "Spinal Muscular Atrophy in Focus as Biogen, IONS Shoot Up on Data", "Drug Stock Earnings to Watch on Nov 9: MYL, IONS & More", "How a Donald Trump Presidency Could Affect Biotech Stocks", "Midday Update: Wall Street's Appetite For Risk Returns After Clinton Cleared by FBI", "Mid-Day Market Update: Dow Gains Over 300 Points; Concordia International Shares Drop Following Disappointing Earnings", "Nasdaq 100 Movers: LVNTA, BIIB", "Mid-Morning Market Update: Markets Open Higher; LendingClub Posts Narrower-Than-Expected Loss", "3 Mid-Cap Stocks to Buy in November", "Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals", "Close Update: Stocks Soar As FBI Clears Potential Path For Clinton on Election Day", "Why Ionis Pharmaceuticals Inc. Skyrocketed Higher Today", "Midday Update: Wall Street's Appetite For Risk Returns After Clinton Cleared by FBI", "Mid-Day Market Update: Dow Gains Over 300 Points; Concordia International Shares Drop Following Disappointing Earnings", "Nasdaq 100 Movers: LVNTA, BIIB", "Mid-Morning Market Update: Markets Open Higher; LendingClub Posts Narrower-Than-Expected Loss", "Noteworthy ETF Outflows: QUAL, PEG, COST, BIIB", "5 Reasons Ionis Pharmaceuticals Is a Top Stock to Buy Now", "The Zacks Analyst Blog Highlights: Biogen, Merck, Eli Lilly, AbbVie and ImmunoGen", "BIIB Crosses Below Key Moving Average Level", "Here's Why Biogen Should Buy Ionis Pharmaceuticals", "Bioverativ Could Be Why Investors Should Buy Biogen", "Key Takeaways from Biogen's Q3 Call: Tecfidera, Pipeline, Biosimilars", "Peek Into Drug Stocks' Earnings on Oct 28: ABBV & IMGN", "Biogen Inc. Working With What It's Got as It Looks to Diversify", "Midday Update: Stocks Trim Losses on Supply-Related Bounce in Oil", "Nasdaq 100 Movers: AAPL, AKAM", "Acorda (ACOR) Reports Wider Q3 Loss, Revenues Down Y/Y", "Biogen (BIIB) Beats on Q3 Earnings; Tecfidera Propels Sales", "Biogen (BIIB) Beats on Q3 Earnings and Sales", "Biogen Inc (BIIB) Stock Rises on Better-Than-Expected Quarter", "Drug Stock Earnings to Watch on Oct 26: BIIB, MDCO & More", "Pre-Market Earnings Report for October 26, 2016 : KO, CMCSA, BA, MDLZ, BIIB, SPG, GD, NOC, BSX, STT, WM, NSC", "Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry", "Can Biogen (BIIB) Keep the Earnings Streak Alive in Q3?", "Biotech Stock Roundup: Clinical Holds Hit Inovio & Aduro, Vertex Q3 Results Miss Estimates", "Biotech Stock Roundup: ARIAD Down on Drug Pricing Tweet, Regeneron Study on Clinical Hold", "3 Stocks That Will Be Bought Out Before Twitter", "Better Buy: Biogen Inc. vs. Gilead Sciences, Inc.", "Commit To Buy Biogen At $180, Earn 5% Using Options", "Alzheimer's Remains a Top Priority for Big Pharma", "BioMarin Issues Encouraging Update on Hemophilia A Drug", "Is AveXis a Major Threat to Ionis Pharmaceuticals?", "iShares Edge MSCI USA Quality Factor ETF Experiences Big Outflow", "Biotech Stock Roundup: ARIAD Down on Drug Pricing Tweet, Regeneron Study on Clinical Hold", "Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO", "3 Biotechs Most Likely to Be Acquired", "3 Top Biotech Stocks to Buy Right Now", "Better Buy: Biogen vs. Celgene", "6 Healthcare Stocks Investors Can't Miss in Q3 Earnings", "Noteworthy Friday Option Activity: NLNK, SRPT, BIIB", "Why This Top Columbia Fund Loads Up On Facebook, Other Stock Leaders", "Biotech Stock Roundup: Summit Soars on Sarepta Deal, Regeneron Presents Data", "Better Buy: Anavex Life Sciences Corp. vs. Ionis Pharmaceuticals, Inc.", "Instant Analysis: Biogen's Agreement With Anavex Life Sciences", "Will Celgene Depose Biogen to Become Top Dog In Multiple Sclerosis?", "Health Care Sector Update for 09/28/2016: ATHX, AVXL, BIIB, GALT", "Anavex Life Sciences Corp. (AVXL) Scores Big on Biogen Test", "Why Anavex Life Sciences Corp. Rocketed Higher Today", "The Key Reason Ionis Pharmaceuticals, Inc. Gained Another 24% in September", "Biotech Stock Roundup: Summit Soars on Sarepta Deal, Regeneron Presents Data", "Better Buy: Anavex Life Sciences Corp. vs. Ionis Pharmaceuticals, Inc.", "The Implied Analyst 12-Month Target For IWL", "Stock Market News for September 21, 2016", "Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug", "Trade of the Day: iShares Nasdaq Biotechnology Index (ETF) (IBB) Is Turning Things Around", "3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition", "Health Care Sector Update for 09/28/2016: VSAR,AVXL,BIIB,GALT", "Marijuana Could Be the Answer to Curing Alzheimer's Disease, Study Shows", "Is This New Market the Biggest Investment Idea of the Decade?", "3 Stocks to Trade Now for New Year\u2019s Profits", "SPDR S&P Biotech (ETF) (XBI): The Bears Got Nothin\u2019 on Biotech Stocks", "Stock Market News for September 15, 2016", "Biotech Stock Roundup: Horizon-Raptor Acquisition Deal, Geron Down on Pipeline News", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for September 14, 2016", "Could This Alzheimer\u2019s Disease Drug Really Be Worth $20 Billion?", "Why Applied Genetic Technologies Corp. Is Tanking Today", "How the Tides Are Turning in Alzheimer's Research", "Nasdaq 100 Movers: SWKS, STX", "IXJ, MDT, LLY, BIIB: Large Outflows Detected at ETF", "Better Buy: Biogen Inc. vs. Gilead Sciences", "Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled", "GW Pharmaceuticals PLC- ADR (GWPH) Boards the Buyout Rumor Mill", "Perrigo Up as Starboard Reveals Stake, Changes Proposed", "Why Applied Genetic Technologies Corp. Is Tanking Today", "How the Tides Are Turning in Alzheimer's Research", "Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.", "Health Care Sector Update for 09/02/2016: BIIB,ATEC,GMED,ELTP", "Tesla Motors Inc (TSLA) Needs More Cash for Gigafactory, Model 3", "Health Care Sector Update for 08/31/2016: BIIB,VEEV,ATOS", "SPDR Gold Trust (ETF) (GLD) Is Ready to Rally", "Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review", "Notable ETF Outflow Detected - QLD, TXN, CHTR, BIIB", "Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data", "Sarah Ketterer Takes 3 Positions in 2nd Quarter", "Another Endorsement for Biotech ETFs", "Ionis Pharmaceuticals Inc Begins to Shift Focus", "Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline", "Analysts Anticipate 12% Gains Ahead For RYH", "The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 15, 2016", "Biogen Inc: BIIB Stock Is a Biotech Standout", "Perrigo (PRGO) Misses Q2 Earnings Estimates, Cuts '16 View", "Ionis (IONS) Q2 Loss Narrower than Expected, Issues Outlook", "QUAL, PEG, BIIB, NKE: Large Outflows Detected at ETF", "The Zacks Analyst Blog Highlights: Intel, Align Technology, Qorvo and Biogen", "Top 3 Research Reports for August 15, 2016", "The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 15, 2016", "Biogen Inc: BIIB Stock Is a Biotech Standout", "Allergan Plc: Will the Downtrend Continue for AGN Stock?", "Stop Dreaming: Biogen Isn't for Sale", "5 Best PEG Stocks for a Lucrative Value Investing", "Ionis Pharmaceuticals (IONS) Q2 Earnings: Stock to Beat?", "Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss", "How Shows Like Grey's Anatomy Influence Patient Perceptions of Healthcare", "Does Biogen's Latest Win Make Its Shares a Buy?", "Zacks.com featured highlights: AngloGold Ashanti, Biogen, QUALCOMM, Tallgrass Energy GP and Steel Dynamics", "Allergan Plc: Will the Downtrend Continue for AGN Stock?", "Stop Dreaming: Biogen Isn't for Sale", "Why Avon Products, Inc. (AVP), Biogen Inc (BIIB) and Sodastream International Ltd (SODA) Are 3 of Today\u2019s Best Stocks", "Market Close Report: NASDAQ Composite index closes at 5,137.73 down -46.47 points", "Why Sangamo Biosciences, Inc. Fell 29% Today", "Biogen (BIIB) Stock Surges 8% on Takeover Rumors", "2 Biotech Funds Leading Nascent Bull Market: Which Is Right For You?", "Midday Update: Stocks Return to Session Lows as Oil Tumbles Towards $40/Barrel", "Why Biogen Inc (BIIB) Stock Is Soaring Today", "Why Ionis Pharmaceuticals Inc Skyrocked Higher Today", "QQQ ETF Posts 52-Week High; Energy Stocks Sag As Oil Drops To $40", "Nasdaq 100 Movers: CTXS, BIIB", "Biogen Inc (BIIB) Tacks on $7B in Market Value on Buyout Talk", "Mid-Morning Market Update: Markets Mostly Higher; Tesla To Acquire SolarCity", "U.S. Equity Futures Slightly Higher As Mergers Provide A Boost", "Why Ionis Pharmaceuticals Inc (IONS), Newell Brands Inc (NWL) and Trina Solar Limited (ADR) (TSL) Are 3 of Today\u2019s Best Stocks", "These Legendary CEO's Could Catch Lightning in a Bottle -- Again.", "Health Care Sector Update for 08/01/2016: EYEG,IONS,KERX,BIIB", "Mid-Afternoon Market Update: Trina Solar Gains Following Go-Private Deal; Insperity Shares Drop", "Ionis Pharmaceuticals (IONS) Stock Surges 36% on Clinical Trial Success", "S&P 500 Movers: RIG, BIIB", "Noteworthy ETF Outflows: BIB, AMGN, CELG, BIIB", "UCB (UCBJF) Posts 1H16 Results, Reaffirms 2016 Guidance", "The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene", "Amgen (AMGN) Tops Q2 Earnings & Revenues, Raises View", "Vertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short", "2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK", "5 Undervalued Growth Stocks to Buy Today", "Health Care Sector Update for 08/01/2016: ITEK,IONS,KERX,BIIB", "What's in Store for these 5 Drug Stocks in Q2 Earnings?", "This Week Could Decide Whether Biotech ETFs' Rally Sizzles Or Fizzles", "Biogen Inc: How Double-Digit Growth Got Trumped", "SPY ETF Posts Fourth Weekly Gain As Chip And Biotech Giants Surge", "BIIB Makes Bullish Cross Above Critical Moving Average", "Noteworthy ETF Outflows: BIB, BIIB, REGN, MYL", "E*Trade Financial Corp: ETFC Stock Stepping Into the Spotlight", "Zacks Industry Outlook Highlights: Bristol-Myers, Pfizer, Sanofi, Amgen and Biogen", "The Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen", "Futures Trade Lower Amid Data, Earnings Deluge", "Thursday\u2019s Vital Data: Microsoft Corporation (MSFT), Intel Corporation (INTC) and Facebook Inc (FB)", "Biogen (BIIB) Beats on Q2 Earnings by a Huge Margin", "Biogen Inc (BIIB) Stock: Q2 Earnings End a Year of Misery", "Earnings Reaction History: Biogen Idec, 33.3% Follow-Through Indicator, 3.8% Sensitive", "BIIB Stock: What to Know About Biogen Inc Before Thursday Morning", "Biogen (BIIB) Stock Up on Q2 Earnings Beat, Raised Outlook", "Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug", "Medical Stocks to Post Earnings This Week: ABT, BIIB, ALIOF", "4 Rock-Solid, Cheap Biotech Stocks", "Agree To Buy Biogen At $135, Earn 3.5% Using Options", "Nasdaq 100 Movers: NCLH, INCY", "Biogen (BIIB) Q2 Earnings: Will the Stock Disappoint?", "Does Biogen's Lower P/E Ratio Make It a Better Buy Than Celgene?", "Pre-Market Earnings Report for July 21, 2016 : SLB, UNP, BIIB, GM, BK, TRV, PPG, BBT, SHW, JCI, LUV, NUE", "Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug", "Medical Stocks to Post Earnings This Week: ABT, BIIB, ALIOF", "Juno (JUNO) Suffers Setback, Pivotal Study on Clinical Hold", "Why Biogen Inc. Stock Dropped 15.7% in June", "Stock Market News for July 07, 2016", "3 Reasons To Buy Biogen", "How Much Do Stock Prices Matter in Biotech?", "Better Buy: NantKwest, Inc. vs. Ionis Pharmaceuticals", "3 Reasons Anavex Stock Could Rise", "The iShares NASDAQ Biotechnology Index (IBB): Biotech Stocks Are Pushing for Recovery", "3 Stocks That Can and Should Start Paying Dividends", "2 Biotech Stocks That Won't Pay a Dividend Anytime Soon, and 1 That Should", "Better Buy: Biogen Inc. vs. Celgene Corporation", "3 Biotech Stocks to Buy Now: CELG, REGN and BIIB", "These 3 Biotechs Are Down More Than 36% This Year, and They're Bargains", "Why Biogen Inc. Is Down 22.5% In 2016", "Stock Market News for June 16, 2016", "The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for June 14, 2016", "Is Biogen a Buy After its Clinical Failure?", "Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure", "4 Stocks That Crushed the Biotechnology ETF (IBB) This Week", "These 5 Biotech Stocks Are Ridiculously Cheap", "BBH's Holdings Imply 25% Gain Potential", "Better Buy: Anavex Life Sciences Corp. vs. Biogen", "Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead", "Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus", "Mid-Day Market Update: LDR Rises On Acquisition News; DryShips Shares Drop", "Instant Analysis: Biogen's Anti-Lingo-1 Flunks Game-Changing Study In MS", "IBB: The iShares NASDAQ Biotechnology Index (ETF) Is Still a Buy", "The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics", "Nasdaq 100 Movers: BIIB, WDC", "S&P 500 Movers: BIIB, WDC", "Mid-Morning Market Update: Markets Mostly Higher; Valeant Earnings Miss Views", "Why Biogen, LendingClub, and Valeant Pharmaceuticals Slumped Today", "These Drug Stocks Just Disappointed Investors -- Are They Buys?", "Why Biogen Inc (BIIB), LendingClub Corp (LC) and Valeant Pharmaceuticals Intl Inc (VRX) Are Three of Today\u2019s Worst Stocks", "Why is Biogen (BIIB) Stock Plunging Today?", "Noteworthy Tuesday Option Activity: CYTR, BIIB, Z", "Mid-Afternoon Market Update: Navistar Climbs Following Earnings Beat; Biogen Shares Tumble", "Biogen Inc: BIIB Loses $8B on Drug Failure, But Upside Remains", "Tuesday's ETF Movers: XOP, IBB", "Why Biogen Inc's Shares Couldn't Find SYNERGY Today", "The New $17 Billion Market You've Probably Never Heard of (and 3 Stocks Poised to Profit)", "Joel Greenblatt Bets on eBay, Intel, Biogen", "3 Reasons AbbVie's and Biogen's Latest MS Drug Might Flop", "Tuesday Sector Laggards: Healthcare, Utilities", "The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis", "Kite (KITE) and Biogen's Drugs Included in PRIME Initiative", "Las Vegas Sands Corp.: Ride the Bull Without the Risk (LVS)", "Biogen Inc: Run With the Bulls for Triple-Digit Profits (BIIB)", "Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News", "Nasdaq 100 Movers: CHTR, BIIB", "Roche's Subcutaneous Formulation of MabThera Gets EU Nod", "10 Great Stocks That Will Make a Splash This Summer", "Biogen & AbbVie's Multiple Sclerosis Drug Gets FDA Nod", "Last Week's Best Healthcare ETF", "Bullish Two Hundred Day Moving Average Cross - BIIB", "The Best Buys in Biopharma Today", "Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals Inc.", "Noteworthy ETF Outflows: IVW, MO, PCLN, BIIB", "Noteworthy Thursday Option Activity: AHP, WDAY, BIIB", "10 Biotech Stocks With Symptoms of Strong Growth", "See Which Of The Latest 13F Filers Holds Biogen", "Perrigo (PRGO) Tops Q1 Earnings, 2016 Earnings View Intact", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 13, 2016", "Notable ETF Outflow Detected - IWB, LLY, TWX, BIIB", "Stock Market News for May 10, 2016", "Ionis Incurs Wider-than-Expected Loss in Q1, Stock Down", "The Zacks Analyst Blog Highlights: Amgen, Gilead, Celgene, Medivation and Biogen", "Biogen Inc (BIIB) Spinout: A Graceful Exit for the Hemophilia Biz", "See Which Of The Latest 13F Filers Holds Biogen", "Perrigo (PRGO) Tops Q1 Earnings, 2016 Earnings View Intact", "Biotech ETFs Sink on Mixed Q1 Results", "IBB, BIIB, CELG, REGN: ETF Inflow Alert", "Acorda (ACOR) Q1 Earnings Decline Y/Y, Ampyra in Focus", "3 Drug Stocks Reporting Early Next Week: PFE, MYL, MNK", "Alkermes (ALKS) Reports Narrower-than-Expected Q1 Loss", "Better Buy: Gilead Sciences vs. Biogen", "The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead", "The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Novartis, Baxalta Incorporated and Shire", "Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN", "Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News", "Biogen Inc: Market Takes the Bull by the Horns Despite Sales Miss (BIIB)", "Biogen Inc Earnings Explode Higher, Revenue Not So Much", "Dow Jones Holds 18,000 Despite Weak Tech Earnings", "Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA", "The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead", "The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Novartis, Baxalta Incorporated and Shire", "Alibaba Group Holding Ltd: BABA Goes BOOM and Bulls Take Note", "Biogen (BIIB) Tops on Q1 Earnings, Slight Revenue Miss", "Biogen Inc (BIIB): Embrace the \u201cDrug Trade\u201d", "Health Care Sector Update for 04/21/2016: NVS, BIIB", "6 Mega-Cap Tech Stocks at the Brink of Imploding", "7 A-Rated Stocks With Rock-Solid Foundations", "Key Morning Earnings for April 21: BIIB, GM, UA, VZ", "Energy Select Sector SPDR (ETF): Get Paid to Gas Up on XLE", "Alibaba Group Holding Ltd: BABA Goes BOOM and Bulls Take Note", "Health Care Select Sector SPDR Fund Experiences Big Outflow", "Biogen Inc.: Bet on BIIB for Healthy Profits", "Health Care Sector Update for 04/18/2016: MDVN, BIIB, AMGN, MRK, ABT, PFE, JNJ", "Biogen (BIIB) Beats on 1Q Earnings by a Wide Margin", "Thursday Sector Leaders: Healthcare, Services", "Health Care Sector Update for 04/21/2016: BIIB,CBAY,TRXC", "Pre-Market Earnings Report for April 21, 2016 : VZ, UNP, DHR, BIIB, GM, BK, TRV, PPG, LUV, ERIC, SHW, BBT", "Commit To Buy Biogen At $150, Earn 5.2% Using Options", "Ionis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study", "Surprising Analyst 12-Month Target For SPXT", "Biotech Stock Roundup: Gilead's HIV Drug Approved, Regeneron Up on Positive Data", "Will MS Franchise Sales Boost Biogen's (BIIB) 1Q Earnings?", "Will Perrigo (PRGO) Surprise Earnings Estimates in Q1?", "ClubCorp Holdings, Inc.: Countering The Bulls", "AstraZeneca/Eli Lilly Alzheimer's Disease Drug in Phase III", "Commit To Buy Biogen At $150, Earn 5.2% Using Options", "Ionis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study", "Surprising Analyst 12-Month Target For SPXT", "Biotech Stock Roundup: Gilead's HIV Drug Approved, Regeneron Up on Positive Data", "Will MS Franchise Sales Boost Biogen's (BIIB) 1Q Earnings?", "Better Buy: Gilead Sciences Inc. vs. Biogen Inc.", "The Zacks Analyst Blog Highlights: Gilead, Amgen, Regeneron, Ionis and Biogen", "9 Things You Need to Know About Biosimilar Drugs", "Better To Short Biotech ETF Or To Invest In Inverse Counterpart?", "How to Ride the Next Wave of Potential Alzheimer's Drugs", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for March 14, 2016", "Zacks Industry Outlook Highlights: Valeant, Pfizer, Amgen and Biogen", "iShares S&P 500 Growth ETF Experiences Big Outflow", "Stock Market News for March 16, 2016", "Eli Lilly Down, Alters Primary Endpoint of Solanezumab", "John Buckingham Trades in ETFs in 4th Quarter", "Better To Short Biotech ETF Or To Invest In Inverse Counterpart?", "What Does Trump's Healthcare Plan Mean for Investors?", "Ionis Incurs Wider-than-Expected Loss in Q4, Shares Down", "Biogen Inc: Regenerate Profits in a Bear-Trapped BIIB", "Better Buy: Amgen Inc. vs. Biogen", "Better Big Biotech Stock: Biogen vs. Celgene", "VUG, ABBV, UPS, BIIB: Large Outflows Detected at ETF", "Perrigo Lags on Q4 Earnings and Revenues, Updates View", "3 Biotechs that Could Snap Back and Soar Even Higher", "Noteworthy ETF Outflows: IYH, JNJ, BIIB, TMO", "Alkermes Q4 Loss Narrower than Expected, Updates Pipeline", "Why Biogen Inc.'s Stock Sank in January", "See Which Of The Latest 13F Filers Holds Biogen", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 11, 2016", "The Agony of High Returns", "Biotech ETFs Slide as Stocks Report Mixed Q4 Results", "Biogen Inc. Takes Aim at Johnson & Johnson", "Notable Friday Option Activity: BIIB, EIGI, ALLY", "Acorda Q4 Earnings Decline Y/Y, Ampyra & Pipeline in Focus", "The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Intrexon and NewLink", "Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention", "Start the New Year off Right with 3 Best Biotech Stocks", "4 Top-Ranked Biotech Stocks on Sale", "Biogen Inc. Slows (But Let's Keep This in Perspective)", "Financial Sector Update for 02/02/2016: PDLI,BIIB,ACC,CACC", "Biotech ETF (IBB) Hits New 52-Week Low", "FBT, TECH, QGEN, BIIB: Large Outflows Detected at ETF", "Nasdaq 100 Movers: AAPL, BIIB", "S&P 500 Movers: TSS, COF", "Biogen (BIIB) Beats on 4Q Earnings & Revenues", "US Stocks Eye Lower Open Ahead Of Fed Announcement; Oil Weighs on Commodities Stocks", "US Equities Futures Slip Amid Weaker Oil Prices, Apple Disappointment; Fed Decision on Tap", "Why Biogen, Freeport-McMoRan, and Hawaiian Holdings Jumped Today", "Biogen (BIIB) Looks Good: Stock Adds 5.2% in Session", "Celgene (CELG) to Report Q4 Earnings: What to Expect?", "Pre-Market Earnings Report for January 27, 2016 : BA, UTX, BIIB, EMC, GD, ANTM, ITW, ERIC, STT, NSC, PGR, STJ", "Will Biogen (BIIB) Beat 4Q Earnings on MS Franchise Sales?", "Will Bristol-Myers (BMY) Beat Q4 Earnings Expectations?", "The Weekly Play: Sell Calls on This Sector (IBB)", "Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie", "The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Cytokinetics and Bristol-Myers Squibb", "3 Healthcare Stocks You Don't Have to Babysit", "AbbVie's Management Just Made Some Pretty Bold Predictions", "4 Biotech Stocks Looking Good this Earnings Season", "Biogen's CEO Sums Up Everything You Need to Know About the Company in 1 Comment", "7 Battered Biotech Stocks: Bargains or Busts?", "Was Celgene Corporation's Bad News Really That Bad?", "Agree To Buy Biogen At $160, Earn 6.1% Using Options", "Is This a Potential $7 Billion Waste for Celgene Corporation?", "Biogen's (BIIB) Biosimilar of Amgen's Enbrel Gets EU Nod", "The Biggest Healthcare M&A News of 2015", "Great News: This Government Agency Just Received a Big Raise", "Biotech Industry Could Offer Early Profit in 2016", "Top Biotech Stocks to Buy in 2016", "Alkermes Hits 52 Week High on Pipeline Update & Aristada", "Health Care Sector Update for 12/16/2015: MRNS, BIIB, ALKS", "Biotech Stock Roundup: Amgen Hikes First Quarter Dividend, ARIAD Lowers Iclusig Outlook", "Jean Hynes Finds Her Pot of Gold", "The Biggest Healthcare M&A News of 2015", "Great News: This Government Agency Just Received a Big Raise", "Biotech Industry Could Offer Early Profit in 2016", "Positive Clinical Data Sends Isis Pharmaceuticals, Inc. Soaring in November", "Novartis??? Biosimilar for Pfizer???s Enbrel Accepted in the EU", "Do Eli Lilly and Biogen Have Alzheimer's All Wrong? Anavex Life Sciences Thinks So.", "Isis/Biogen Initiate Amyotrophic Lateral Sclerosis Study", "Insight Into Eli Lilly's Alzheimer's Drugs Is Coming Soon", "Noteworthy ETF Outflows: IBB, REGN, BIIB, ALXN", "PDL BioPharma Receives $133.7 Million in Cash Payments", "Is Anavex LIfe Sciences Corp. a Stock Worth Buying?", "Biotech Stock Roundup: Repros Tanks on CRL, AbbVie Multiple Myeloma Drug Approved", "The World's Largest Investing Firm Bought These 2 Biotech Stocks: Should You?", "There's a 0.0000000000028% Chance This Drug Doesn't Work", "The 3 Most Important Drugs in Isis Pharmaceuticals' Pipeline", "Bristol-Myers' Cancer Drug Opdivo Gets CRL from the FDA", "The Zacks Analyst Blog Highlights: BioMarin, Amgen, Vertex, Gilead, Biogen and Repros", "Biotech Stock Roundup: KaloBios Soars as Shkreli Steps In, FDA Panel Not Convinced about BioMarin Drug", "Bristol-Myers' Opdivo Gets FDA Nod for Another Indication", "BioMarin's (BMRN) Kyndrisa Fails to Impress FDA Panel", "Gilead's (GILD) Cocktail HIV Drug Genvoya Approved in EU", "Health Care Sector Update for 11/24/2015: SYN, NVS, BIIB", "A $26 Billion Hedge Fund Just Bought 9 Million Shares of This Stock: Should You Follow?", "Biogen's (BIIB) Biosimilar of Pfizer's Enbrel Gets CHMP Nod", "Amgen's Repatha Is Too Bloody Pricey for the U.K.", "Biotech Stock Roundup: Clovis Plunges, Label Expansion for Gilead's Harvoni", "Why Sangamo BioSciences Shares Rose 26% in October", "PRIMECAP Sells Stake in Technology Company", "These Biotech Stocks May Start Paying Dividends in 2016", "A Pro Forma Profit for ISIS Pharmaceuticals, Inc.", "Bristol-Myers' Opdivo Label Now Includes Renal Cell Cancer", "Nasdaq 100 Movers: GMCR, BIIB", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 12, 2015", "Biogen Among Murray Stahl's Holdings With Growing Earnings", "What Does 2016 Hold for This Closely-Watched Biotech ETF?", "$5.9 Billion Buyout: 1 Number Underpins Shire's Huge Dyax Bet", "Biotech Sees Better-than-Expected Earnings: ETFs in Focus", "Gilead and 2 Biotech Picks Value Investors Will Love", "VUG, MA, UPS, BIIB: Large Inflows Detected at ETF", "Biotech Stock Roundup: AbbVie's Humira Remains Strong, Shire to Buy Dyax", "Is This Drug Going to Be a Big Threat to Biogen and Novartis Next Year?", "Big Changes Ahead for Biogen", "12 Companies Who Have Cut Jobs in 2015", "After Hours Most Active for Oct 30, 2015 : BAC, HPQ, MKTX, CYN, NYCB, FOXA, QQQ, HCBK, GE, PFE, MSFT, BIIB", "Biotech Stock Roundup: Biogen Tops Estimates, FDA Approves Alexion's Strensiq", "Biogen director buys 310,000 shares", "Will Isis Pharmaceuticals (ISIS) Surprise in Q3 Earnings?", "Specialty Drug Classes That Are Costing Consumers an Arm and a Leg", "Acorda Up on Q3 Earnings & Revenue Beat, Ampyra in Focus", "Battle Royale: Amgen Inc. vs. Biogen Inc.", "3 Earnings Reports That Surprised Us", "Perrigo Beats on Q3 Earnings, Misses Revenues, Cuts Jobs", "Biogen's Beat, Raise, and Yawn", "Biogen To Cut 11% of Its Workforce As Part Of Restructuring Plan", "Tuesday 10/27 Insider Buying Report: BIIB, DKL", "Specialty Drug Classes That Are Costing Consumers an Arm and a Leg", "Acorda Up on Q3 Earnings & Revenue Beat, Ampyra in Focus", "Battle Royale: Amgen Inc. vs. Biogen Inc.", "3 Earnings Reports That Surprised Us", "Perrigo Beats on Q3 Earnings, Misses Revenues, Cuts Jobs", "Biogen's Beat, Raise, and Yawn", "Biogen To Cut 11% of Its Workforce As Part Of Restructuring Plan", "Tuesday 10/27 Insider Buying Report: BIIB, DKL", "Commit To Buy Biogen At $180, Earn 5.3% Using Options", "Biogen Tops Q3 Earnings, Announces Job Cuts, Ups View", "Stock Market News for October 21, 2015", "Biogen (BIIB) Beats on 3Q Earnings & Revenues", "Earnings Reaction History: Biogen Idec, 45.5% Follow-Through Indicator, 3.8% Sensitive", "Stock Market News for October 20, 2015", "Did Roche Unleash Biogen's Worst Nightmare?", "BBH, CELG, BIIB, BXLT: Large Outflows Detected at ETF", "Pre-Market Earnings Report for October 21, 2015 : KO, BA, BIIB, ABT, EMC, GM, TMO, KMB, ITW, BHI, STJ, NLSN", "Will Tecfidera Slowdown Hit Biogen (BIIB) Earnings in Q3?", "3 Blue-Chip Biotech Stocks Worth Buying for the Long Haul", "Can These Repurposed Antibodies Reshape the Multiple Sclerosis Market?", "Frank Sands' Undervalued Holdings With Growing EPS", "Biogen, Roche & Novartis Present Data on MS Drugs in Spain", "Stock Market News for October 08, 2015", "Isis (ISIS) Begins Extension Study SHINE on ISIS-SMNRx", "Stock Market News for October 07, 2015", "3 Large-Cap Biotech Stocks Whose Valuations Should Make You Skeptical", "Biotech Stock Roundup: PBM Lists Both Amgen & Regeneron PCSK9 Inhibitors, FOLD Plunges on NDA Delay", "Acorda Soars, Settles Ampyra Patent Dispute with Allergan", "3 Biotech Bargains to Buy", "VUG, MA, UNP, BIIB: Large Inflows Detected at ETF", "The Coming Clash of Big Biotechs: Biogen vs. Celgene", "Sanofi Unveils New Positive Data on Lemtrada and Aubagio", "The Best-Selling Drugs in the World By 2020", "Stock Market News for September 25, 2015", "Health Care Sector Update for 09/25/2015: NAVB, BIIB, AMGN", "Biotech Stock Roundup: Clinton's Tweet Shakes Biotech Stocks, Amgen In Pipeline-Boosting Deals", "5 Biotech Stocks Hit Hard by Hillary Clinton's Tweet", "The Undervalued Stocks Among Richard Snow's Recent Buys", "Is Beaten-Down Biogen Stock a Bargain?", "The Zacks Analyst Blog Highlights: Regeneron, Vertex, Gilead, Biogen and Celgene", "Merck KGaA Intends to File for Approval of MS Drug in EU", "Better Buy: Biogen vs. Gilead Sciences", "4 Ways to Protect Yourself From a Biotech Meltdown", "Noteworthy ETF Outflows: IYH, ABBV, MDT, BIIB", "Roche's Hemophilia A Drug Gets Breakthrough Status in U.S.", "3 Biotech Stocks to Buy in the Middle of a Turbulent Market", "Biotech Stock Roundup: Amgen in the News, ARIAD a Takeover Target?", "Nasdaq 100 Movers: WYNN, LILA", "We Believe Healthcare's Next Biotech Buyout Target Is\u2026", "IVW, NKE, BIIB, KMI: Large Outflows Detected at ETF", "Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data", "Biogen (BIIB) Crumbles: Stock Falls by 5.9%", "Acorda (ACOR) Gets Favorable Outcome in Ampyra IPR Issue", "Bull Or Bear? Biotech's Post-Earnings Buys and Sells", "Using ETFs To Run Your Own Hedge Fund", "Applied Genetic Meets Enrolment Milestone in XLRS Study", "We Believe Healthcare's Next Biotech Buyout Target Is\u2026", "IVW, NKE, BIIB, KMI: Large Outflows Detected at ETF", "Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data", "Biogen (BIIB) Crumbles: Stock Falls by 5.9%", "Nasdaq 100 Movers: TSLA, NVDA", "Emergent BioSolutions Tops on Q2 Earnings, Plans Spin-Off - Analyst Blog", "Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data", "Noteworthy Thursday Option Activity: TSO, JPM, BIIB", "Perrigo Beats on Q2 Earnings, Revenues In Line, Keeps View - Analyst Blog", "Here's Why Biogen Lost $20 Billion in Market Value in July", "What Company Will Be Fastest Growing Big-Cap Biotech?", "Notable ETF Inflow Detected - VUG, ORCL, V, BIIB", "Mixed Biotech Earnings put These ETFs in Focus - ETF News And Commentary", "Will Isis Pharmaceuticals (ISIS) Beat Q2 Earnings Estimates? - Analyst Blog", "3 Crashing Healthcare Stocks That You Can Buy", "Acorda 2Q Earnings & Revenues Top, Ampyra in Focus - Analyst Blog", "Attention New Biotech Investors: Biogen Inc's Recent Weakness Is Your Opportunity", "The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases", "Tuesday 7/28 Insider Buying Report: BIIB, MJN", "The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases", "3 Big Biotech Buybacks That Investors Should Love", "Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog", "The Blockbuster Potential of Biogen Inc's Pipeline", "S&P 500 Movers: MYL, BIIB", "Nasdaq 100 Movers: MYL, BIIB", "Stock Market News for July 27, 2015 - Market News", "A Look Ahead: Biotech And Energy ETFs To Watch This Week", "5 Things Biogen's Management Wants You to Know", "A Big Day For Biotech And It's Not Going So Well", "Biogen Enters Oversold Territory (BIIB)", "3 Signs That the Healthcare Stock Bubble Might Have Just Popped", "S&P 500 Movers: MYL, BIIB", "Nasdaq 100 Movers: BIIB, AMZN", "S&P 500 Movers: BIIB, AMZN", "3 Alzheimer's Drugs Investors Should Be Watching", "Health Care Sector Update for 07/24/2015: CGIX, REPH, BIIB", "Pre-Market Most Active for Jul 24, 2015 : EXEL, T, AMZN, BIIB, ITEK, FB, STM, QQQ, NOK, UN, ALU, CI", "Biogen (BIIB) Beats on 2Q Earnings, Misses on Revenues - Tale of the Tape", "BIIB Crosses Below Key Moving Average Level", "Biogen's Terrible, Horrible, No Good, Very Bad Week", "Biogen (BIIB) Stock Plummets on Weak Guidance - Stocks in the News", "Notable Friday Option Activity: BIIB, GT, XOM", "September 4th Options Now Available For Biogen (BIIB)", "Will Biogen (BIIB) Surprise in 2Q Despite Tecfidera Issues? - Analyst Blog", "Pre-Market Earnings Report for July 24, 2015 : ABBV, BIIB, SPG, STT, VFC, JCI, AAL, MCO, VTR, DTE, XRX, COL", "Eli Lilly, Biogen Present Data at Alzheimer's Association - Analyst Blog", "Earnings Reaction History: Biogen Idec, 40.0% Follow-Through Indicator, 2.1% Sensitive", "Biogen's Terrible, Horrible, No Good, Very Bad Week", "Biogen (BIIB) Stock Plummets on Weak Guidance - Stocks in the News", "Notable Friday Option Activity: BIIB, GT, XOM", "September 4th Options Now Available For Biogen (BIIB)", "Big Week for Biogen", "Celgene Buys Receptos. Is Arena Pharmaceuticals Next?", "Notable Friday Option Activity: MAT, SNDK, BIIB", "Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog", "The Zacks Analyst Blog Highlights: Eli Lilly, Valeant Pharmaceuticals International, Biogen and Medicines Company - Press Releases", "Isis Pharmaceuticals Up on Milestone Payment from Biogen - Analyst Blog", "Stock Market News for July 14, 2015 - Market News", "Health Care Sector Update for 07/14/2015: BIIB, CAH, CPXX", "4 Health Care Stocks to Watch Out for this Earnings Season - Earnings ESP", "Biogen (BIIB) Slips 2.8%, Lead R&D Executive Set to Leave - Analyst Blog", "$1.5 Trillion Reasons to Invest in These Companies", "S&P 500 Analyst Moves: BIIB", "The Zacks Analyst Blog Highlights: Eli Lilly, Valeant Pharmaceuticals International, Biogen and Medicines Company - Press Releases", "Noteworthy Friday Option Activity: GOOGL, BIIB, KO", "The Zacks Analyst Blog Highlights: Vertex, Biogen, Applied Genetic, Gilead and Alexion - Press Releases", "Vanguard Growth ETF Experiences Big Outflow", "Biotech Stock Roundup: Vertex CF Drug Approved, Biogen Strikes Deal for Gene Therapy - Analyst Blog", "Are Biotechs In A Bubble?", "S&P 500 Movers: BIIB, GCI", "Forget Biogen (BIIB), Buy These 3 Biotechnology Stocks Instead - Stocks in the News", "Applied Genetic Up on Biogen Deal for Eye Disease Drugs - Analyst Blog", "Why Applied Genetic Technologies Corporation Stock Jumped Today", "Mid-Day Market Update: US Stocks Down; Xoom Shares Jump On Acquisition News", "Midday Update: Stocks Surrender Opening Gains After Technical Resistances Holds", "Mid-Morning Market Update: Markets Edge Higher; Centene To Acquire Health Net For $6.3B", "Futures Build on Early Gains With June Payroll Report", "Biogen Sees Promise in Gene Therapy", "Forget Biogen (BIIB), Buy These 3 Biotechnology Stocks Instead - Stocks in the News", "Applied Genetic Up on Biogen Deal for Eye Disease Drugs - Analyst Blog", "Why Applied Genetic Technologies Corporation Stock Jumped Today", "Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress - Analyst Blog", "Stock Market News for July 01, 2015 - Market News", "Bayer Files Hemophilia A Drug Marketing Application in Japan - Analyst Blog", "VUG, ORCL, V, BIIB: Large Outflows Detected at ETF", "Close Update: Stocks Give Back Early Gains With Greece Uncertainty Escalating", "Biogen/Sobi's Hemophilia B Drug Alprolix under EU Review - Analyst Blog", "Transition Therapeutics Tanks on Alzheimer's Disease Data - Analyst Blog", "Stock Market News for June 23, 2015 - Market News", "Isis Pharmaceuticals Up on Spinal Muscular Atrophy Data - Analyst Blog", "Stock Market News for June 19, 2015 - Market News", "3 Big Healthcare Trends Wall Street Is Overlooking", "Isis Pharmaceuticals Up on Positive Data on ISIS-SMNRx - Analyst Blog", "3 Stocks to Buy if Biotech Crashes", "Biogen/Sobi's Hemophilia B Drug Alprolix under EU Review - Analyst Blog", "Transition Therapeutics Tanks on Alzheimer's Disease Data - Analyst Blog", "Stock Market News for June 23, 2015 - Market News", "Why Isis Pharmaceuticals, Inc. Exploded Higher By 19% in May", "Nasdaq 100 Movers: VRTX, WYNN", "Investing for Beginners: How to Start in Biotech", "OEF, ABBV, BA, BIIB: ETF Outflow Alert", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for June 12, 2015", "Healthcare Investment Opportunities for the Long Term", "Stock Market News for May 21, 2015 - Market News", "Is Gilead Sciences Its Own Worst Enemy?", "Why Shares of Sangamo Biosciences Fell Today", "Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 12, 2015", "Here's Why Biotech Blue Chip Stock Biogen Inc. Lost 11% in April", "Pop! 3 To Buy If Biotech Stocks Burst", "Healthcare Investment Opportunities for the Long Term", "Stock Market News for May 21, 2015 - Market News", "Is Gilead Sciences Its Own Worst Enemy?", "Why Shares of Sangamo Biosciences Fell Today", "Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 12, 2015", "Here's Why Biotech Blue Chip Stock Biogen Inc. Lost 11% in April", "Pop! 3 To Buy If Biotech Stocks Burst", "Healthcare Investment Opportunities for the Long Term", "Stock Market News for May 21, 2015 - Market News", "Is Gilead Sciences Its Own Worst Enemy?", "Frothy China Or No, World Mutual Funds Topped In April", "Zoetis Beats on Q1 Earnings, Revenue Guidance Lowered - Analyst Blog", "Incyte Posts Wider-than-Expected Q1 Loss, Jakafi Grows - Analyst Blog", "Integra LifeSciences Tops Q1 Earnings, Revenues; View Up - Analyst Blog", "Isis Pharmaceuticals' Q1 Loss Narrower than Expected - Analyst Blog", "Mylan Q1 Earnings Meet Expectations, 2015 Guidance Upheld - Analyst Blog", "10 Most Profitable Businesses in Boston", "Is This Why the Street Keeps Doubting Gilead Sciences, Inc.?", "Frothy China Or No, World Mutual Funds Topped In April", "Zoetis Beats on Q1 Earnings, Revenue Guidance Lowered - Analyst Blog", "Incyte Posts Wider-than-Expected Q1 Loss, Jakafi Grows - Analyst Blog", "Integra LifeSciences Tops Q1 Earnings, Revenues; View Up - Analyst Blog", "Isis Pharmaceuticals' Q1 Loss Narrower than Expected - Analyst Blog", "Mylan Q1 Earnings Meet Expectations, 2015 Guidance Upheld - Analyst Blog", "10 Most Profitable Businesses in Boston", "Is This Why the Street Keeps Doubting Gilead Sciences, Inc.?", "Frothy China Or No, World Mutual Funds Topped In April", "Zoetis Beats on Q1 Earnings, Revenue Guidance Lowered - Analyst Blog", "Incyte Posts Wider-than-Expected Q1 Loss, Jakafi Grows - Analyst Blog", "Integra LifeSciences Tops Q1 Earnings, Revenues; View Up - Analyst Blog", "Isis Pharmaceuticals' Q1 Loss Narrower than Expected - Analyst Blog", "Mylan Q1 Earnings Meet Expectations, 2015 Guidance Upheld - Analyst Blog", "10 Most Profitable Businesses in Boston", "Is This Why the Street Keeps Doubting Gilead Sciences, Inc.?", "Frothy China Or No, World Mutual Funds Topped In April", "Zoetis Beats on Q1 Earnings, Revenue Guidance Lowered - Analyst Blog", "Incyte Posts Wider-than-Expected Q1 Loss, Jakafi Grows - Analyst Blog", "Integra LifeSciences Tops Q1 Earnings, Revenues; View Up - Analyst Blog", "Isis Pharmaceuticals' Q1 Loss Narrower than Expected - Analyst Blog", "QLT (QLTI) Reports Wider-than-Expected Loss in Q1 - Analyst Blog", "Acorda Posts 1Q Loss, Ampyra Generic Challenges in Focus - Analyst Blog", "The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Biogen, Actelion and Horizon Pharma - Press Releases", "Biotech's Blue Chip Stocks", "Kythera's (KYTH) Double Chin Drug Kybella Gets FDA Nod - Analyst Blog", "Will Isis Pharmaceuticals (ISIS) Disappoint in Q1 Earnings? - Analyst Blog", "Alkermes' Q1 Loss Narrower than Expected, Maintains View - Analyst Blog", "Pharmacyclics Beats on Q1 Earnings, Misses Revenues - Analyst Blog", "Synageva Q1 Loss Narrower-than-Expected, Pipeline in Focus - Analyst Blog", "The Zacks Analyst Blog Highlights: Amgen, Celladon, Biogen, Celgene and Gilead - Press Releases", "Vertex Posts Wider 1Q Loss, Affirms Kalydeco Outlook - Analyst Blog", "Celgene Beats on Q1 Earnings, Misses Revenues, Keeps View - Analyst Blog", "Stock Market News for April 28, 2015 - Market News", "Pfizer Beats on Q1 Earnings, Cuts View on Currency Woes - Analyst Blog", "Fidelity Contrafund: Beating the Market the Old-Fashioned Way", "Will Teva's (TEVA) Earnings Streak Continue in Q1? - Analyst Blog", "Isis Pharmaceuticals' ISIS-TTR Effective in Extension Study - Analyst Blog", "Acorda Reports Encouraging Data on MS Drug - Analyst Blog", "Emergent BioSolutions Resumes BioThrax Manufacturing - Analyst Blog", "Gilead (GILD) Announces Encouraging Data on its HCV Drugs - Analyst Blog", "Capricor's CAP-1002 Gets Orphan Drug Status in the U.S. - Analyst Blog", "Baxter International Inc.: Where a Decline Is a Win", "Eli Lilly Beats on 1Q Earnings by Wide Margin, Affirms View - Analyst Blog", "Ultragenyx Announces Positive Data from Triheptanoin Study - Analyst Blog", "Pre-Market Earnings Report for April 24, 2015 : BIIB, SPG, LYB, AAL, STT, VTR, TYC, DTE, XRX, COG, IMS, LEA", "ETF Preview: Broad Market ETFs Mixed With Earnings in Spotlight", "Illumina (ILMN) Tops Q1 Earnings, Revenues; EPS View Up - Analyst Blog", "Actelion (ALIOF) Beats Q1 Earnings & Revenue Expectations - Analyst Blog", "The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera Pharmaceuticals - Press Releases", "Amgen Beats on Q1 Earnings & Revenues, Ups Earnings View - Analyst Blog", "Will Biogen's (BIIB) Earnings Streak Continue in 1Q? - Analyst Blog", "Pfizer's Cancer Drug Meets First Primary Endpoint in Phase III - Analyst Blog", "Immunomedics (IMMU) Provides Update on Lead ADC Candidate - Analyst Blog", "Will Agenus (AGEN) Disappoint in Q1 Earning Season? - Analyst Blog", "Alnylam Reports Positive Patisiran Results, Shares Up - Analyst Blog", "Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog", "Will Edwards Lifesciences (EW) Top Q1 Earnings Estimates? - Analyst Blog", "Can Healthways (HWAY) Pull a Surprise this Earnings? - Analyst Blog", "Perrigo Beats on Q3 Earnings, Gives View, Rejects Mylan Bid - Analyst Blog", "Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog", "Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog", "Pharmacyclics Announces Positive Results on Imbruvica - Analyst Blog", "C. R. Bard (BCR) Q1 Earnings: Lutonix DCB Holds the Key - Analyst Blog", "Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog", "Actavis' Botox Upper Limb Spasticity Label Expanded by FDA - Analyst Blog", "Is AbbVie (ABBV) Set to Top 1Q Earnings on Humira & HCV? - Analyst Blog", "Fate Therapeutics (FATE) Jumps: Stock Moves 12.4% Higher - Tale of the Tape", "Will Novartis' (NVS) Earnings Disappoint This Quarter? - Analyst Blog", "Will Baxter's (BAX) Earnings Disappoint Estimates in Q1? - Analyst Blog", "Will Mead Johnson's (MJN) Q1 Earnings Surprise Estimates? - Analyst Blog", "ResMed (RMD) Poised to Outshine Q3 Earnings Estimates - Analyst Blog", "Clovis Oncology (CLVS) Falls: Stock Goes Down 5.3% - Tale of the Tape", "Athersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst Blog", "Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog", "Will Eli Lilly (LLY) Beat Earnings in 1Q Despite Generics? - Analyst Blog", "Will CONMED (CNMD) Disappoint Earnings Estimates in Q1? - Analyst Blog", "Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog", "3 Biotech Stocks That Could Be Developing Billion Dollar Drugs", "Biotech Investors Shouldn't Miss These Stocks This Earnings - Earnings ESP", "Will Intuitive Surgical (ISRG) Surprise Earnings in Q1? - Analyst Blog", "Can Illumina (ILMN) Keep the Earnings Streak Alive in Q1? - Analyst Blog", "Amgen Gets FDA Nod for Chronic Heart Failure Drug Corlanor - Analyst Blog", "Will Amgen (AMGN) Keep Earnings Streak Alive in 1Q? - Analyst Blog", "AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog", "Biogen Reports New Data from Acute Optic Neuritis Study - Analyst Blog", "Bayer to Expand Copanlisib Program by Three New Studies - Analyst Blog", "Biotech Stock Roundup: Favorable Briefing Documents for MDCO's Kengreal, Alexion Soliris Label Update - Analyst Blog", "J&J Beats on Q1 Earnings, Cuts View on Currency Woes - Analyst Blog", "Alnylam Reports Publication of New Data on Hemophilia Drug - Analyst Blog", "Aeterna Zentaris to Advance Hormone Drug to Phase III Study - Analyst Blog", "VIVUS Responds to Teva's Filing for Qsymia Generics - Analyst Blog", "AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog", "Biogen Reports New Data from Acute Optic Neuritis Study - Analyst Blog", "Bayer to Expand Copanlisib Program by Three New Studies - Analyst Blog", "Biotech Stock Roundup: Favorable Briefing Documents for MDCO's Kengreal, Alexion Soliris Label Update - Analyst Blog", "J&J Beats on Q1 Earnings, Cuts View on Currency Woes - Analyst Blog", "Why Smart Money Loves This Biotech Stock", "Will Pharmaceutical Sales Drive J&J (JNJ) Earnings Again? - Analyst Blog", "Has the Biotech Bubble Already Popped?", "The Safest Biotech Bet on the Market", "Notable ETF Outflow Detected - IWF, ACT, BIIB, CELG", "The Zacks Analyst Blog Highlights: Horizon Pharma, Hyperion Therapeutics, Conatus, Amgen and Biogen - Press Releases", "Stock Market News for April 01, 2015 - Market News", "Why Receptos, Inc. Shares Soared Higher Today", "Biotech Stock Roundup: Horizon to Buy Hyperion, Conatus Up on Liver Disease Data - Analyst Blog", "The Truly Staggering Cost of Alzheimer's Disease", "Stock Market News for March 30, 2015 - Market News", "Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog", "Based on This Study, an Alzheimer's Disease Cure Could Be Around the Corner", "Could These Experimental Drugs Eclipse Harvoni's Historic Launch?", "The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases", "Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst Blog", "The Zacks Analyst Blog Highlights: HSBC Holdings, Goldman Sachs, Acorda Therapeutics, Biogen Idec and Ross Stores - Press Releases", "Biogen's Biosimilar Version of Remicade Under EU Review - Analyst Blog", "Stock Market News for March 30, 2015 - Market News", "Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog", "Biogen Idec (BIIB) Worth Watching: Stock Rises 9.8% - Tale of the Tape", "Biogen Gains on Positive Alzheimer's Drug Interim Results - Analyst Blog", "3 Biotech Stocks to Buy If the Sector Crashes", "Financial Sector Update for 03/23/2015: GNW,BIIB,OCN,BRX,BX", "1 Biotech Stock You Can Buy and Hold for the Next 20 Years", "This Tiny Biotech Offers Up New Hope for Parkinson's Disease Patients", "Biogen Idec Inc.'s Stock Bursts Higher On Alzheimer\u2019s News: Here's Why", "Notable ETF Inflow Detected - XLV, AMGN, BIIB, CELG", "Nasdaq 100 Movers: DISH, BIIB", "S&P 500 Movers: MAC, BIIB", "U.S. Stock Futures Follow European Markets Higher on Hopes for Greece Deal", "Pre-Market Most Active for Mar 20, 2015 : MAC, BIIB, CTRP, NOK, QQQ, BAC, FB, AAPL, PRTA, NKE, KBH, HSEB", "U.S. Stock Futures Point Higher After Weak Thursday Session; Germany Sees Hope for Greece Deal", "Midday Update: First Day of Spring Brings Green on Wall Street; Nasdaq Hits 15-Yr High", "Health Care Sector Update for 03/20/2015: BIIB,PRTA,THRX", "Can This Biotech Stock Go from Good to Great?", "New Biotech ETFs Highlight Evolving Growth Opportunities", "Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases", "Should Gilead Sciences Inc.\u2019s Slowing Growth Concern Investors?", "3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary", "S&P 500 Analyst Moves: BIIB", "Closing Update: Session-Long Surge Lifts, Market Gauges to Big Weekly Advance; Nasdaq Composite Index Again Tops 5,000", "Health Care Sector Update for 03/20/2015: BIIB,PRTA,THRX", "Can This Biotech Stock Go from Good to Great?", "New Biotech ETFs Highlight Evolving Growth Opportunities", "Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases", "Should Gilead Sciences Inc.\u2019s Slowing Growth Concern Investors?", "3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary", "S&P 500 Analyst Moves: BIIB", "Closing Update: Session-Long Surge Lifts, Market Gauges to Big Weekly Advance; Nasdaq Composite Index Again Tops 5,000", "Merck KGaA to Pay $3M to Opexa for Tcelna Study - Analyst Blog", "Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst Blog", "Could This Study Help Lead to a Cure for Select Multiple Sclerosis Patients?", "2 Tiny Biotechs That Could Have Blockbuster Opportunity", "Health Care Sector Update for 03/06/2015: CALA, ISIS, HZNP", "Top Funds Buying Rackspace, Allergan, Biogen Idec, Apple", "Isis Pharmaceuticals Up on Q4 Earnings and Revenues Beat - Analyst Blog", "Notable ETF Outflow Detected - XLV, MDT, BIIB, CELG", "Merck KGaA to Pay $3M to Opexa for Tcelna Study - Analyst Blog", "Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst Blog", "Could This Study Help Lead to a Cure for Select Multiple Sclerosis Patients?", "2 Tiny Biotechs That Could Have Blockbuster Opportunity", "Health Care Sector Update for 03/06/2015: CALA, ISIS, HZNP", "Top Funds Buying Rackspace, Allergan, Biogen Idec, Apple", "Isis Pharmaceuticals Up on Q4 Earnings and Revenues Beat - Analyst Blog", "Notable ETF Outflow Detected - XLV, MDT, BIIB, CELG", "3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year", "Why Don't These Winning Stocks Pay Dividends?", "iShares S&P 500 Growth ETF Experiences Big Outflow", "5 Things Biogen Idec Inc's Management Wants You to Know", "3 Biotech Stocks I'd Love to Stash Away in My Portfolio Forever", "Sucampo, Par Pharmaceuticals Enter License Agreement - Analyst Blog", "Why Sangamo Biosciences Inc. Shares Rocketed Higher Today", "3 Stocks That Were Huge Winners Last Week", "Isis Pharma to Get $5M from Biogen - Analyst Blog", "How to Profit from Elon Musk's \"Space Internet\"", "Orexigen Gives Positive Updates on its Weight Loss Drug - Analyst Blog", "Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog", "Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 10, 2015", "Will Sangamo (SGMO) Disappoint This Earnings Season? - Analyst Blog", "Charles River (CRL) Beats on Q4 Earnings and Revenues - Analyst Blog", "3 Biotech Stocks We've Fallen For", "These Common Medications May Put You At a Greater Risk of Developing Dementia", "3 Blockbuster Drugs That May Be Obsolete in 5 Years", "Sanofi Misses on Q4 Earnings, Maintains Diabetes Guidance - Analyst Blog", "Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs - ETF News And Commentary", "Perrigo Beats on Earnings, FY15 Guidance In Line - Analyst Blog", "Allergan Beats Earnings Yet Again on Strong Revenues - Analyst Blog", "3 Medical Advancements You May Be Missing Out On", "IUSG, VZ, BIIB, HON: ETF Outflow Alert", "Biogen Tops Q4 Earnings, Provides Strong Outlook for 2015 - Analyst Blog", "Nasdaq 100 Movers: PCAR, AMZN", "S&P 500 Movers: PCAR, BIIB", "Why Biogen Idec's Shares Skyrocketed Higher", "Vertex Posts Wider 4Q Loss, Affirms Kalydeco Outlook - Analyst Blog", "This Could Be Game-Changing News in the Battle Against Multiple Sclerosis", "Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog", "Pre-Market Earnings Report for January 28, 2015 : BA, BIIB, EMC, GD, PX, AEP, TEL, IP, TROW, HES, ABC, STJ", "Commit To Purchase Biogen Idec At $240, Earn 6.7% Using Options", "How Will M&A ETFs Perform In 2015? Many Deals Lined Up", "Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, CytRx Partial Clinical Hold Lifted - Analyst Blog", "State of the Union Address Investing Idea: Precision Medicine", "Biogen Idec Inc Earnings: Worth the Wait", "Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst Blog", "Health Care Sector Update for 01/14/2015: AZN, ISIS, VICL", "Biogen to Acquire Convergence, Expand Pain Pipeline - Analyst Blog", "Seattle Genetics, Bristol-Myers to Study Adcetris-Opdivo - Analyst Blog", "Which Big Biotech Will Soar in 2015?", "Better Healthcare Buy: Big or Little Biotechs", "IYH, BIIB, MDT, ACT: ETF Inflow Alert", "AbbVie Inc.'s Insights at the JP Morgan Healthcare Conference", "Diving Deeper into Biogen's Lingo Results", "Biogen Reveals Positive Data from Acute Optic Neuritis Study - Analyst Blog", "Nasdaq 100 Movers: BIIB, TSCO", "3 Biotech Stocks That Could Trounce Gilead Sciences, Inc. in 2015", "Why Isis Pharmaceuticals, Inc. Stock Surged 19% in December", "Nasdaq 100 Movers: NXPI, BIIB", "Why Biogen Idec Inc. Stock Catapulted 10% Higher in December", "Isis Pharmaceuticals Improves 2014 Outlook, Shares Up - Analyst Blog", "Diving Deeper into Biogen's Lingo Results", "Vertex Pharmaceuticals' Kalydeco Label Expanded in the U.S. - Analyst Blog", "Ignyta's Lead Oncology Candidate Gets Orphan Drug Status - Analyst Blog", "Devon Energy Achieves #107 Analyst Rank, Surpassing Biogen Idec", "Stock Market News for December 26, 2014 - Market News", "After Gilead Sciences, Is it Time to Sell Biotech Stocks? - Analyst Blog", "Vanda Gains Fanapt Rights from Novartis for the U.S. Region - Analyst Blog", "Isis Pharmaceuticals Up on Collaboration with J&J - Analyst Blog", "3 Drugmakers Facing a Pivotal 2015", "Puma Biotechnology (PBYI) Jumps: Stock Moves 6.1% Up - Tale of the Tape", "Prothena Corp. (PRTA) Looks Good: Stock Moves Up 5.7% - Tale of the Tape", "Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog", "Genomic Health (GHDX) Shines on Prospective Cancer Tests - Analyst Blog", "Roche to Acquire Austrian Biotechnology Company Dutalys - Analyst Blog", "Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst Blog", "XLV, BIIB, ACT, AGN: Large Inflows Detected at ETF", "Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - Analyst Blog", "3 Large Cap Biotech Stocks That Could Surprise Investors in 2015", "Seattle Genetics Initiates Phase Ib Study on Leukemia Drug - Analyst Blog", "3 Pharma Giants Growing Significantly Faster Than Pfizer, Inc.", "Agenus Jumps on Positive Data from Shingles Candidate - Analyst Blog", "Integra Lifesciences Up on Launch of Bilayer Skin Product - Analyst Blog", "Bruker Unveils bioAFM System for High Resolution Imaging - Analyst Blog", "Novo Nordisk's Tresiba Favored by CHMP for Expanded Use - Analyst Blog", "Which Biotech Will Become the Next Gilead Sciences, Inc.?", "BioDelivery Sciences (BDSI) in Focus: Stock Tanks 11% - Tale of the Tape", "Trevena (TRVN) in Focus: Stock Rallies 7.5% - Tale of the Tape", "Alkermes Starts Phase I Study on Schizophrenia Candidate - Analyst Blog", "Acorda's Ampyra in Phase III for Post-Stroke Walking Deficit - Analyst Blog", "Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst Blog", "OPKO Up on Announcing Global Partnership with Pfizer - Analyst Blog", "OvaScience Slumps: OVAS Tanks 12.3% in Session - Tale of the Tape", "Strength Seen in GTX Inc (GTXI): Stock Rises 10.6% - Tale of the Tape", "Alder Biopharmaceuticals Slumps: ALDR Falls 5.5% in Session - Tale of the Tape", "Alexion's Soliris Receives Orphan Drug Status in Japan - Analyst Blog", "Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - Analyst Blog", "Sangamo Biosciences (SGMO) Jumps: Stock Rises 7.2% - Tale of the Tape", "Alder Biopharmaceuticals Inc. (ALDR) in Focus: Stock Soars 31.9% - Tale of the Tape", "Celladon Corporation (CLDN) Falls: Stock Goes Down 8.6% - Tale of the Tape", "Genomic Health's Breast Cancer Test Yields Positive Results - Analyst Blog", "Strength Seen in GTX Inc (GTXI): Stock Rises 10.6% - Tale of the Tape", "Alder Biopharmaceuticals Slumps: ALDR Falls 5.5% in Session - Tale of the Tape", "Alexion's Soliris Receives Orphan Drug Status in Japan - Analyst Blog", "Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - Analyst Blog", "Sangamo Biosciences (SGMO) Jumps: Stock Rises 7.2% - Tale of the Tape", "Alder Biopharmaceuticals Inc. (ALDR) in Focus: Stock Soars 31.9% - Tale of the Tape", "Celladon Corporation (CLDN) Falls: Stock Goes Down 8.6% - Tale of the Tape", "Genomic Health's Breast Cancer Test Yields Positive Results - Analyst Blog", "Incyte (INCY) Gains on Positive Baricitinib Study Results - Analyst Blog", "JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 - Analyst Blog", "Myriad Genetics Unveils Positive Cancer Study Results - Analyst Blog", "Rexahn Pharmaceuticals, Inc. (RNN) Rises: Stock Up 8.6% - Tale of the Tape", "Acceleron Pharma, Inc. (XLRN) in Focus: Stock Soars 13.6% - Tale of the Tape", "bluebird bio (BLUE) in Focus: Stock Surges 9.4% - Tale of the Tape", "ISIS Jumps on Positive Results for Venous Thrombosis Drug - Analyst Blog", "Avalanche Biotechnologies (AAVL) Jumps: Stock Adds 6.1% in Session - Tale of the Tape", "Incyte (INCY) Gains on Positive Baricitinib Study Results - Analyst Blog", "JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 - Analyst Blog", "Myriad Genetics Unveils Positive Cancer Study Results - Analyst Blog", "Rexahn Pharmaceuticals, Inc. (RNN) Rises: Stock Up 8.6% - Tale of the Tape", "Compugen (CGEN) Worth Watching: Stock Moves 8.8% Higher - Tale of the Tape", "Kindred Biosciences, Inc. (KIN) in Focus: Stock Soars 10.6% - Tale of the Tape", "Amgen Unveils Positive Results from Blood Cancer Studies - Analyst Blog", "Dynavax & AstraZeneca Alter Agreement for Asthma Product - Analyst Blog", "Alnylam Reports Positive Initial Phase I Data on ALN-AT3 - Analyst Blog", "Pharmacyclics Presents Imbruvica Data at the ASH Meeting - Analyst Blog", "Amgen Successfully Expands Xgeva Label in the U.S. - Analyst Blog", "Cara Therapeutics (CARA) in Focus: Stock Rises 6.1% - Tale of the Tape", "Compugen (CGEN) Worth Watching: Stock Moves 8.8% Higher - Tale of the Tape", "Bayer Files Hemophilia A Drug Marketing Application in EU - Analyst Blog", "Array BioPharma, Inc. (ARRY) in Focus: Stock Soars 14.3% - Tale of the Tape", "Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog", "Agios (AGIO) Reports Encouraging Data on Leukemia Drug - Analyst Blog", "Seattle Genetics-Takeda's Adcetris Shows Long-Term Effect - Analyst Blog", "AbbVie Reveals Phase II Data on Blood Cancer Drug at ASH - Analyst Blog", "Sequenom Inc. (SQNM) in Focus: Stock Surges 23.6% - Tale of the Tape", "Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning - Analyst Blog", "ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog", "Synageva Completes BLA Submission for Sebelipase Alfa - Analyst Blog", "Walgreens (WAG) Up on 4.9% Y/Y Rise in November Sales - Analyst Blog", "Celldex's Glembatumumab Vedotin in Phase II for Melanoma - Analyst Blog", "Incyte's Jakafi Gets FDA Approval for Polycythemia Vera - Analyst Blog", "Why Isis Pharmaceuticals, Inc. Stock Leaped 12% in November", "Sequenom Inc. (SQNM) in Focus: Stock Surges 23.6% - Tale of the Tape", "Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning - Analyst Blog", "Actelion Submits Marketing Application for Uptravi in EU - Analyst Blog", "Biogen Up on Encouraging Interim Data on Alzheimer's Drug - Analyst Blog", "Array BioPharma Regains Binimetinib Rights from Novartis - Analyst Blog", "Midday Update: Stocks Positive on Construction Spending, Auto Sales", "S&P 500 Movers: NEM, BIIB", "Nasdaq 100 Movers: NXPI, BIIB", "Stocks Resume Advance, Buoyed by Construction Spending", "Noteworthy ETF Outflows: MTUM, MU, ACT, BIIB", "Intra-Cellular Therapies (ITCI) Jumps: Stock Rises 6.8% - Tale of the Tape", "MediciNova (MNOV) Looks Good: Stock Soars 19.3% - Tale of the Tape", "Myriad Genetics' Prolaris: A Pocket-Friendly Cancer Test - Analyst Blog", "Midday Update: Stocks Positive on Construction Spending, Auto Sales", "S&P 500 Movers: NEM, BIIB", "Nasdaq 100 Movers: NXPI, BIIB", "Health Care Sector Update for 12/02/2014: BIIB, IMNP, QDEL, PFE, GSK", "Dynavax Regains TLR 7/9 Inhibitor DV1179 Rights from Glaxo - Analyst Blog", "Vertex Pharmaceuticals' 52-Week High Driven by Kalydeco - Analyst Blog", "Pharmacyclics, J&J Seek Imbruvica Label Expansion in EU - Analyst Blog", "Alexion's Soliris Gets Final Positive NICE Recommendation - Analyst Blog", "Avanir's Migraine Drug Gets Complete Response Letter - Analyst Blog", "Strength Seen in Kythera (KYTH): Stock Moves 5.5% Higher - Tale of the Tape", "Alexion's (ALXN) Soliris Gets Orphan Drug Status in Japan - Analyst Blog", "Isis Pharmaceuticals Earns Milestone on Study Initiation - Analyst Blog", "Intra-Cellular Commences Phase III Schizophrenia Study - Analyst Blog", "Coronado Biosciences (CNDO) Jumps: Stock Rises 8.5% - Tale of the Tape", "Oncothyreon Inc. (ONTY) in Focus: Stock Surges 10.1% - Tale of the Tape", "Amgen Ends Gastric Cancer Drug Studies on Safety Review - Analyst Blog", "SPY, BA, COP, BIIB: ETF Outflow Alert", "Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4% - Tale of the Tape", "Enzo Biochem (ENZ) in Focus: Stock Moves 6.9% Higher - Tale of the Tape", "AbbVie's HCV Cocktail Treatment Closer to EU Approval - Analyst Blog", "Immunomedics' Veltuzumab Receives Orphan Drug Status - Analyst Blog", "XOMA Corp Worth Watching: Stock Moves 10.3% Higher - Tale of the Tape", "Prosensa Soars on $680M Buyout Offer from BioMarin - Analyst Blog", "Amgen Ends Gastric Cancer Drug Studies on Safety Review - Analyst Blog", "SPY, BA, COP, BIIB: ETF Outflow Alert", "Novavax Gains on Fast Track Designation for RSV F Vaccine - Analyst Blog", "Epizyme Gains on Positive Phase I Data on EPZ-6438 - Analyst Blog", "Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst Blog", "Amgen and AbbVie Strengthen Manufacturing Facilities in Asia - Analyst Blog", "Agios (AGIO) Shares Up on Positive AG-120 Study Data - Analyst Blog", "EPIRUS Biopharmaceuticals (EPRS) Jumps: Stock Up 15.9% - Tale of the Tape", "Compugen (CGEN) Worth Watching: Stock Adds 6% in Session - Tale of the Tape", "This High-Yield Dividend Stock Screams Danger", "Novavax Gains on Fast Track Designation for RSV F Vaccine - Analyst Blog", "Epizyme Gains on Positive Phase I Data on EPZ-6438 - Analyst Blog", "Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst Blog", "Alnylam Reports Positive Initial Phase II Data on Revusiran - Analyst Blog", "Is Mallinckrodt (MNK) Poised to Beat Q4 Earnings Estimates? - Analyst Blog", "Mallinckrodt Q4 Earnings Boosted by Acquisitions, Sales Beat - Analyst Blog", "Puma Biotechnology Falls on Disappointing Neratinib Data - Analyst Blog", "Biotech: And Yet We've Just Begun...", "Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog", "Geron Collaborates with J&J for Imetelstat - Analyst Blog", "Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog", "Notable Two Hundred Day Moving Average Cross - BIIB", "Aegerion to Acquire Myalept, Boost Portfolio - Shares Up - Analyst Blog", "Sanofi's Lemtrada Gets U.S. Approval, Carries Boxed Warning - Analyst Blog", "Puma Biotechnology Falls on Disappointing Neratinib Data - Analyst Blog", "Biotech: And Yet We've Just Begun...", "Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog", "Geron Collaborates with J&J for Imetelstat - Analyst Blog", "Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog", "Intercept Pharmaceuticals' Shares Crash on FLINT Results - Analyst Blog", "5 Prescription Drugs Selling Like Hot Cakes", "Orexigen (OREX) Worth Watching: Stock Soars 33.3% - Tale of the Tape", "Salix Q3 Earnings Marred by Inventory Issues, Cuts View - Analyst Blog", "Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 10, 2014", "Isis Pharmaceuticals Inc. Strikes Out on Its Own", "5 Things Biogen Idec Inc's Management Wants You to Know", "Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog", "Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog", "Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog", "Salix Q3 Earnings Marred by Inventory Issues, Cuts View - Analyst Blog", "Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape", "Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance - Analyst Blog", "MannKind Falls on Missing Q3 Estimates Yet Cuts Loss Y/Y - Analyst Blog", "Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog", "AMAG Up on Q3 Earnings Beat, Revenues Up - Analyst Blog", "Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape", "Vertex Pharmaceuticals Seeks Approval for CF Combination - Analyst Blog", "Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y - Analyst Blog", "Affymetrix Beats Q3 Earnings & Revenues; Raises '14 View - Analyst Blog", "Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog", "Acorda (ACOR) Beats on Q3 Earnings, Ups Ampyra Outlook - Analyst Blog", "Oncolytics Biotech (ONCY) Looks Good: Stock Soars 26% - Tale of the Tape", "Buy These Top Ranked ETFs on Solid Biotech Stock Earnings - ETF News And Commentary", "The Medicines Company (MDCO) Jumps: Stock Gains 16.5% - Tale of the Tape", "BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape", "Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y - Analyst Blog", "Vertex Pharmaceuticals Posts Narrower-than-Expected Loss - Analyst Blog", "Gilead (GILD) Posts Weak Earnings; Stock Falls 4% After-Hours - Stocks in the News", "Amgen Beats on Q3 Earnings & Revenues, Ups View Again - Analyst Blog", "Sarepta Slumps: SRPT Plunges 32.5% in Session - Tale of the Tape", "Pfizer Q3 Earnings Top Estimates Despite Generic Pressure - Analyst Blog", "Sarepta Slumps as Eteplirsen NDA Submission Gets Delayed - Analyst Blog", "Amgen Up on Strategic Initiatives and 2015 Guidance - Analyst Blog", "A safe route into the biotech sector", "Allergan Beats on Earnings, Revenues; Valeant Raises Offer - Analyst Blog", "Is Biogen Idec Inc. in Trouble?", "3 Biotech Stocks Growing Faster Than Gilead Sciences Inc.", "Biogen Falls on Concerns Regarding Tecfidera Sales and PML Case - Analyst Blog", "Notable ETF Inflow Detected - IWF, V, UNP, BIIB", "Why Biogen Idec Stock Shares Are Getting Pummeled Today", "Merck Tops on Q3 Earnings, Patent Expiries Hit Revenues - Analyst Blog", "Wednesday's ETF with Unusual Volume: PWB", "S&P 500 Movers: BIIB, BRCM", "Nasdaq 100 Movers: BIIB, BRCM", "Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog", "Pre-Market Earnings Report for October 22, 2014 : BA, BIIB, USB, ABT, DOW, EMC, SPG, TMO, GD, NSC, NOC, BSX", "3 Stocks That Could Surprise This Earnings Season", "Will Sangamo (SGMO) Incur Wider-than-Expected Q3 Loss? - Analyst Blog", "Biogen Idec inc Earnings Were Great. Here's Why the Stock Tumbled Anyway", "This Drug Could Outsell Medical Marijuana", "US IPO Weekly Recap: 5 IPOs achieve moderate gains during the market slide and a biotech rejection", "Sustainability Pays: 3 Green Companies Making Money", "Forward Pharma goes backward: year's largest biotech drops 17% on IPO", "Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx - Analyst Blog", "1 Huge Risk Facing This Marijuana Stock", "Notable Two Hundred Day Moving Average Cross - BIIB", "Will Biogen Idec (BIIB) Pull a Surprise this Earnings Season? - Analyst Blog", "This Drug Could Outsell Medical Marijuana", "The Next Blue-Chip Stocks: Biogen Idec", "Perrigo Sells Some Assets to Imago Pharmaceuticals - Analyst Blog", "These Companies Are Saving Money and Sticking You With a Tax Bill", "ETF Outlook: S&P Health Care Select SPDR ETF (XLV)", "Isis Pharmaceuticals Up on $4M Milestone Payment - Analyst Blog", "Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer - Analyst Blog", "XLV, AMGN, BMY, BIIB: ETF Inflow Alert", "5 States Expected to See the Biggest Increase in Alzheimer's Disease", "The Next Blue-Chip Stocks: Biogen Idec", "Perrigo Sells Some Assets to Imago Pharmaceuticals - Analyst Blog", "Repros Therapeutics (RPRX) Crumbles: Stock Falls by 10.5% - Tale of the Tape", "Integra Poised on Impressive Duraseal Product Line, Solid Q2 - Analyst Blog", "Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog", "Alnylam (ALNY) to File Clinical Trial Application for ALN-CC5 - Analyst Blog", "Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% - Tale of the Tape", "Is Merck KGaA on Track with its \"Fit for 2018\" Program? - Analyst Blog", "3 Biotechs Investors Should Watch", "Zacks Rank #1 Additions for Tuesday - Tale of the Tape", "Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog", "Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog", "Why Biogen Idec Inc's Stock is Up 17% in 2014", "Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada - Analyst Blog", "Noteworthy ETF Inflows: VUG, BIIB, UPS, EBAY", "Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog", "Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog", "Why Receptos Inc. Shares Rocketed Higher", "5 Things Biogen Idec Inc's Management Wants You to Know", "IBB, CELG, BIIB, ALXN: ETF Outflow Alert", "Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog", "What Investors Gain from Large, Mid & Small-Cap Growth Funds - Mutual Fund Commentary", "Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog", "Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog", "Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog", "Why Receptos Inc. Shares Rocketed Higher", "5 Things Biogen Idec Inc's Management Wants You to Know", "IBB, CELG, BIIB, ALXN: ETF Outflow Alert", "Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog", "What Investors Gain from Large, Mid & Small-Cap Growth Funds - Mutual Fund Commentary", "Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog", "Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog", "Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog", "Why Receptos Inc. Shares Rocketed Higher", "5 Things Biogen Idec Inc's Management Wants You to Know", "IBB, CELG, BIIB, ALXN: ETF Outflow Alert", "Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog", "What Investors Gain from Large, Mid & Small-Cap Growth Funds - Mutual Fund Commentary", "Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog", "Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog", "Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog", "Why Receptos Inc. Shares Rocketed Higher", "5 Things Biogen Idec Inc's Management Wants You to Know", "IBB, CELG, BIIB, ALXN: ETF Outflow Alert", "Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog", "AbbVie Q2 Earnings Top on Humira Sales, Shire In Focus - Analyst Blog", "Noteworthy ETF Outflows: IYH, AMGN, BIIB, CELG", "Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog", "Perrigo Beats on Q4 Earnings and Sales, Provides Guidance - Analyst Blog", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 12, 2014", "S&P 500 Analyst Moves: BIIB", "Increased Earnings Estimates Seen for Biogen Idec (BIIB): Can It Move Higher? - Tale of the Tape", "Biotech ETF Price Swings May Signal Need For Caution", "AbbVie Q2 Earnings Top on Humira Sales, Shire In Focus - Analyst Blog", "Noteworthy ETF Outflows: IYH, AMGN, BIIB, CELG", "Celsion (CLSN) in Focus: Stock Adds 5.3% in Session - Tale of the Tape", "Agenus Inc. (AGEN) Looks Strong as Stock Surges 11.15% - Tale of the Tape", "Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog", "Illumina (ILMN) Tops Q2 Earnings & Revenues, Ups Guidance - Analyst Blog", "IYH, PFE, ABBV, BIIB: Large Outflows Detected at ETF", "Stock Market News for July 24, 2014 - Market News", "Gilead Crushes Q2 Earnings Estimates as Sovaldi Sales Soar - Analyst Blog", "Exelixis (EXEL) Jumps: Stock Adds 11.4% in Session - Tale of the Tape", "Celsion (CLSN) in Focus: Stock Adds 5.3% in Session - Tale of the Tape", "Agenus Inc. (AGEN) Looks Strong as Stock Surges 11.15% - Tale of the Tape", "Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog", "Illumina (ILMN) Tops Q2 Earnings & Revenues, Ups Guidance - Analyst Blog", "IYH, PFE, ABBV, BIIB: Large Outflows Detected at ETF", "Stock Market News for July 24, 2014 - Market News", "Gilead Crushes Q2 Earnings Estimates as Sovaldi Sales Soar - Analyst Blog", "Exelixis (EXEL) Jumps: Stock Adds 11.4% in Session - Tale of the Tape", "The Medicines Co.'s (MDCO) Q2 Earnings Decline Y/Y - Analyst Blog", "Array BioPharma, Inc. (ARRY) Jumps: Stock Surges 10.7% Higher - Tale of the Tape", "Biogen Idec (BIIB) Soars: Stock Adds 11.2% in Session - Tale of the Tape", "UCB's Brivaracetam Positive in Phase III Epilepsy Study - Analyst Blog", "Alexion Pharmaceuticals Q2 Earnings In Line; Revises View - Analyst Blog", "Actelion Beats on Q2 Earnings and Sales, Revises View - Analyst Blog", "Midday Update: Stocks Mixed with Techs, Biotechs Buoying Nasdaq, But Geo-Political Tensions Dogging Dow", "Zacks Rank #1 Additions for Thursday - Tale of the Tape", "Nasdaq 100 Movers: XLNX, ISRG", "Markets Mixed; PepsiCo Q2 Earnings Beat Street View", "Healthcare Spending Uptrend: 3 Medical Stocks for Strong Growth - Analyst Blog", "Avanir to Conduct Phase II Study on AVP-786 for Depression - Analyst Blog", "Closing Update: Blue Chips Decline But Broader Indices Extend Gains On Mostly Positive Earnings Results", "Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential Buyout Target", "Alkermes' Pipeline Development Impresses, Key Updates Ahead - Analyst Blog", "Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines - Analyst Blog", "Bristol-Myers to Seek U.S. Approval for Immuno-Oncology Drug - Analyst Blog", "Oncolytics Up on Patient Enrolment Completion - Analyst Blog", "Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog", "Lexicon (LXRX) Jumps: Stock Moves 7.6% Higher - Tale of the Tape", "Regado's REGULATE-PCI Study Under Clinical Hold - Analyst Blog", "BIND Therapeutics (BIND) in Focus: Stock Tumbles 10.0% - Tale of the Tape", "UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog", "Bristol-Myers Gains Japanese Approval for HCV Combo Drug - Analyst Blog", "BioDelivery Sciences International (BDSI) Rises: Stock Jumps 8.9% - Tale of the Tape", "Oncolytics Biotech Inc. (ONCY) in Focus: Stock Rises 9.5% - Tale of the Tape", "Sanofi's Basal Insulin Candidate Under FDA Review - Analyst Blog", "Regeneron Shares Jump as Sanofi Increases Stake - Analyst Blog", "Strength Seen in Amicus Therapeutics, Inc. (FOLD) as Stock Rallies 19.46% - Tale of the Tape", "Vertex Pharmaceuticals Up on Kalydeco sNDA Submission - Analyst Blog", "Amgen Gets Breakthrough Therapy Status for Leukemia Drug - Analyst Blog", "Integra Upbeat on DuraSeal Acquisition despite Tepid Q1 - Analyst Blog", "AVEO Pharmaceuticals (AVEO) Jumps: Stock Rises 6.4% - Tale of the Tape", "Illumina Expands in Europe on 3 NIPT Deals - Analyst Blog", "Synageva's Sebelipase Alfa Meets Primary Endpoint in ARISE - Analyst Blog", "UCB's Vimpat Positive for Partial-Onset Seizures - Analyst Blog", "Discovery Laboratories Inc. (DSCO) in Focus: Stock Rises 7.83% - Tale of the Tape", "Integra Lifesciences Down to Sell - Analyst Blog", "Eli Lilly & Boehringer's Insulin Copy Gets Positive EU Opinion - Analyst Blog", "NPS Pharmaceuticals' Gattex Gets Updated Label - Analyst Blog", "BioDelivery Progresses with Clonidine Late-Stage Study - Analyst Blog", "Bristol-Myers Up on Nivolumab News - Analyst Blog", "Prothena Corporation (PRTA) Falls: Stock Goes Down 5.3% - Tale of the Tape", "Auxilium/Sobi's Xiapex Filed for Label Expansion - Analyst Blog", "Isis Pharma Gets $1M Milestone Payment from Glaxo - Analyst Blog", "Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors - Analyst Blog", "XenoPort's XP23829 in Phase II Study - Analyst Blog", "Coronado Falls on TSO Study Results - Analyst Blog", "Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog", "Merck KGaA-Ono Pharma Deal Ends - Analyst Blog", "Biogen/AbbVie Presents Positive Data on Daclizumab - Analyst Blog", "Sector Update: Share Higher Pre-Market; GW Pharmaceuticals Rallies 6% on Results from Study on Epilepsy Treatment", "Sector Update: Healthcare Healthcare", "Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted - Analyst Blog", "Isis Pharma Earns Milestone Payment on Study Initiation - Analyst Blog", "Stocks with Upgraded Broker Ratings - Screen of the Week", "Nasdaq 100 Movers: BIIB, ADSK", "Stock Market News for June 05, 2014 - Market News", "S&P 500 Movers: KORS, TSN", "Nasdaq 100 Movers: GMCR, BIIB", "Array BioPharma Collaborates with Biogen - Analyst Blog", "Nasdaq 100 Movers: TSLA, MU", "CHMP Still Negative on Teva/Active Biotech's Nerventra - Analyst Blog", "Biogen's Eloctate Approved in the U.S. - Analyst Blog", "Celgene Gains Slightly on Management Changes - Analyst Blog", "iShares Russell 1000 ETF Experiences Big Inflow", "Narrower-than-Expected Loss at AVEO - Analyst Blog", "Infinity Pharma Down on Wider-than-Expected Loss - Analyst Blog", "Isis Pharma's Q1 Loss Widens - Analyst Blog", "Perrigo Misses on Earnings and Sales, Outlook Slashed - Analyst Blog", "Is Perrigo (PRGO) Poised to Beat Earnings Estimates? - Analyst Blog", "Nasdaq 100 Plays Catch-Up - Real Time Insight", "Acorda Down on Plumiaz CRL - Analyst Blog", "3 Biotech Beats this Earnings Season - Earnings ESP", "eBay Now #57 Largest Company, Surpassing Biogen Idec", "S&P 500 Movers: XLNX, ZMH", "Stock Market News for April 24, 2014 - Market News", "Spectrum Pharma Candidate Gets Positive Data - Analyst Blog", "Amgen's Q1 Earnings Decline Y/Y - Analyst Blog", "Nasdaq 100 Movers: WYNN, GILD", "Sector Update: Healthcare Shares Flat in Pre-Market; Biogen up on Q1 Results, FY 2014 Guidance", "Sector Update: Healthcare", "Healthcare Stocks Snap Recent Winning Streak; Biogen Idec Slips Underwater Late After EPS Miss", "Sector Update: Healthcare", "Biogen's Q1 Earnings Soar Y/Y on Tecfidera Sales - Analyst Blog", "Keep an Eye on these 3 Biotech Stocks - Earnings ESP", "Alexion Likely to Keep Earnings Streak Alive - Analyst Blog", "Revance Therapeutics (RVNC) Soars: Stock Up 25.8% - Tale of the Tape", "Zacks Rank #1 Additions for Tuesday - Tale of the Tape", "Ken Fisher's Top Increases of the First Quarter", "Is Biogen (BIIB) Poised to Beat Earnings Estimates? - Analyst Blog", "Sarepta Soars on Eteplirsen Submission Plans - Analyst Blog", "Pre-Market Earnings Report for April 23, 2014 : PG, BA, BIIB, DOW, EMC, TMO, ERIC, PX, GD, NSC, JCI, RAI", "Will Gilead (GILD) Beat Q1 Earnings? - Analyst Blog", "Will Amgen (AMGN) Miss This Earnings Season? - Analyst Blog", "Cytokinetics, Incorporated (CYTK) Jumps: Stock Up 13.5% - Tale of the Tape", "Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog", "Will Abbott Labs (ABT) Disappoint This Quarter? - Analyst Blog", "Gilead Bucks Biotech Trend Thanks to Sovaldi News - Analyst Blog", "Will Johnson & Johnson (JNJ) Miss This Earnings Season? - Analyst Blog", "Positive Data on Biogen/Sobi's Eloctate - Analyst Blog", "Next Chapter In The Acorda Story Will Be A Page Turner", "3 Top-Ranked Biotech Stocks on the Rebound - Analyst Blog", "AbbVie Candidate in Pivotal Study - Analyst Blog", "Noteworthy ETF Inflows: IBB, AMGN, BIIB, ALXN", "Stock Market News for March 31, 2014 - Market News", "FDA Nod for Biogen's Alprolix - Analyst Blog", "IBB, BIIB, AMGN, REGN: ETF Outflow Alert", "Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog", "Stock Market News for March 24, 2014 - Market News", "Biogen's Alprolix Approved in Canada - Analyst Blog", "Momentum Slide to Continue for Netflix, Facebook? - Analyst Blog", "AVEO Regains AV-203 Rights from Biogen - Analyst Blog", "Healthcare Stocks Mixed at Mid-Day; Endocyte Nearly Doubles In Price On Chemotherapy Test Results", "Sector Update: Healthcare", "Biogen Entry to S&P 100 Puts OEF in Focus - ETF News And Commentary", "Stock Market News for March 19, 2014 - Market News", "Biogen Faces Delay in FDA Action Date - Analyst Blog", "Biotech Stock Roundup: Biogen Up for S&P100, Geron Plunges on Clinical Hold - Analyst Blog", "3 ETFs Tumble Most on Biotech Sell-off - ETF News And Commentary", "AVEO Regains AV-203 Rights from Biogen - Analyst Blog", "Healthcare Stocks Mixed at Mid-Day; Endocyte Nearly Doubles In Price On Chemotherapy Test Results", "Sector Update: Healthcare", "Biogen Entry to S&P 100 Puts OEF in Focus - ETF News And Commentary", "Stock Market News for March 19, 2014 - Market News", "Biogen Faces Delay in FDA Action Date - Analyst Blog", "Biotech Stock Roundup: Biogen Up for S&P100, Geron Plunges on Clinical Hold - Analyst Blog", "Sector Update: Healthcare Shares Flat Pre-Market; Novogen Soars 19% on Positive Outlook for Anti-Cancer Drug", "Sector Update: Healthcare", "Biogen to be added to S&P100 - Analyst Blog", "Nasdaq 100 Movers: ILMN, YHOO", "Monday's ETF Movers: FBT, GDX", "S&P 500 Movers: VRSN, BIIB", "AVEO Q4 Loss Narrower than Expected - Analyst Blog", "MultiStem Overshadows Q4 Loss at Athersys - Analyst Blog", "Sector Update: Healthcare Shares Flat Pre-Market; Novogen Soars 19% on Positive Outlook for Anti-Cancer Drug", "Wider Q4 Loss at Keryx - Analyst Blog", "Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog", "Myriad Genetics Down on Court Ruling - Analyst Blog", "Alexion Lifts 2014 View, Shares Up - Analyst Blog", "Biogen Upgraded to Strong Buy - Analyst Blog", "IBB, BIIB, AMGN, REGN: ETF Outflow Alert", "Aegerion Pharmaceuticals (AEGR) Soars: Stock Rises 10.6% - Tale of the Tape", "Fate Therapeutics' Prohema in Phase II Study - Analyst Blog", "Emergent Beats on Earnings & Revenues, Shares Up - Analyst Blog", "InterMune Rises on Takeover Rumor - Analyst Blog", "Nasdaq 100 Movers: BIIB, INTU", "Sangamo Soars on Positive Data - Analyst Blog", "Spectrum Pharma Posts Lower Y/Y Q4 Earnings - Analyst Blog", "Zacks Rank #1 Additions for Wednesday - Tale of the Tape", "Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher - Tale of the Tape", "Nasdaq 100 Movers: SPLS, BIDU", "Oncothyreon (ONTY) Jumps: Stock Moves 9.9% Higher - Tale of the Tape", "Biogen-Eisai Ink Alzheimer's Deal - Analyst Blog", "Update on Alexion's Soliris - Analyst Blog", "Dynavax Receives Milestone Payments from AstraZeneca - Analyst Blog", "Pipeline Setback Overshadows XOMA's Q4 - Analyst Blog", "Zacks Rank #1 Additions for Wednesday - Tale of the Tape", "Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher - Tale of the Tape", "Nasdaq 100 Movers: SPLS, BIDU", "Isis Pharmaceuticals, Inc. (ISIS) in Focus: Stock up 8.9% - Tale of the Tape", "Promising Data on Merck Allergy Drug - Analyst Blog", "Profit from Orphan Drugs: 3 Choices - Analyst Blog", "Dendreon Corp. (DNDN) Soars: Stock Rises 14.9% - Tale of the Tape", "Top Mutual Funds Add To Health Care, Leisure And Banks", "Myriad Genetics Up on Prolaris Data; Aims Reimbursement - Analyst Blog", "Transition Therapeutics (TTHI) Jumps: Stock Moves 7.6% Higher - Tale of the Tape", "OvaScience (OVAS) in Focus: Stock Tanks 9.5% - Analyst Blog", "Biogen Keeps Momentum Going With MS Drug Tecfidera", "Noteworthy ETF Inflows: IBB, BIIB, GILD, AMGN", "Medivation Swings to Earnings in Q4 - Analyst Blog", "Zacks Rank #1 Additions for Friday - Tale of the Tape", "Halozyme's Q4 Loss Wider-Than-Expected - Analyst Blog", "Standard Review for Merck's V503 - Analyst Blog", "Orphan Drug Status for XOMA's Gevokizumab - Analyst Blog", "Shares Fall as Aegerion Posts Wider-than-Expected Loss - Analyst Blog", "Oncothyreon Inc. (ONTY) in Focus: Stock up 9.3% - Tale of the Tape", "InterMune Soars on Positive Esbriet Data - Analyst Blog", "Enter Biosimilars: 3 Stock Picks - Analyst Blog", "Endocyte's Q4 Loss Narrower than Expected - Analyst Blog", "Synta Pharmaceuticals (SNTA) Catches Eye: Stock Rises 8.9% - Tale of the Tape", "Isis Pharma Soars on Positive Data - Analyst Blog", "XenoPort's 4Q Loss Narrower-Than-Expected - Analyst Blog", "Progenics to Raise Funds - Analyst Blog", "Can The Uptrend Continue for Biogen Idec (BIIB)? - Tale of the Tape", "Stemline Therapeutics (STML) Worth Watching: Stock Rises 8.1% - Tale of the Tape", "ACADIA Pharmaceuticals (ACAD) Jumps: Stock Rises 17.3% - Tale of the Tape", "Pipeline Progress at Pluristem - Analyst Blog", "Discovery Laboratories (DSCO) Soars: Stock Rises 8.9% - Tale of the Tape", "CHTP's Northera Gains FDA Approval - Analyst Blog", "OncoMed Commences Study on OMP-54F28 - Analyst Blog", "Positive Opinion on Isis Pharma's ISIS-TTRRx - Analyst Blog", "Vanda Reports Wider-than-Expected Loss - Analyst Blog", "Acorda Up After Q4 Earnings - Analyst Blog", "Chelsea Therapeutics (CHTP) in Focus: Stock Tumbles 7.5% - Tale of the Tape", "Positive News for Regado's REG2 - Analyst Blog", "Additional Data on Omeros' OMS824 - Analyst Blog", "Vical Q4 Loss Narrows - Analyst Blog", "Myriad Genetics Unveils Prolaris Data - Analyst Blog", "IBB, GILD, BIIB, AMGN: Large Inflows Detected at ETF", "NewLink Genetics (NLNK) Jumps: Stock Rises 8.3% - Tale of the Tape", "Sunesis Pharmaceuticals (SNSS) Falls: Stock Goes Down 5.4% - Tale of the Tape", "Data on Repros' Androxal - Analyst Blog", "Three ETFs To Buy On The Pullback (PJP, SKYY, SPY)", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 11, 2014", "Why You Need to Pay Attention to Cambrex Corporation. (CBM) Stock? - Tale of the Tape", "What Makes Genomic Health (GHDX) a Strong Sell? - Tale of the Tape", "Affymetrix Slips to Hold - Analyst Blog", "Teva Beats on Q4 Earnings & Revs, Affirms View - Analyst Blog", "FDA to Review Spectrum Pharma' Beleodaq - Analyst Blog", "Affymetrix Sees Turnaround Quarter but Earnings Miss - Analyst Blog", "Acquisition and Earnings Beat Lift Myriad Shares - Analyst Blog", "Medicines Co. Awarded BARDA Contract - Analyst Blog", "Pernix Appoints New CEO, Shares Up - Analyst Blog", "Puma Biotech Surges on Favorable Patent Ruling - Analyst Blog", "Affymetrix Slips to Hold - Analyst Blog", "Teva Beats on Q4 Earnings & Revs, Affirms View - Analyst Blog", "Study on Pluristem's Placental Cells - Analyst Blog", "Is Perrigo (PRGO) Poised to Beat Earnings Estimates? - Analyst Blog", "Safely playing the biotech sector", "Biogen Idec is a winner, even if everyone knows it", "InterMune (ITMN) in Focus: Stock Tumbles 17.9% - Tale of the Tape", "Earnings Beat at Perrigo, Guides Up - Analyst Blog", "3 Reasons For Biotech Stock Advance To Continue", "Zacks Rank #1 Additions for Friday - Tale of the Tape", "Sector Update: Healthcare Shares Flat Pre-Market; Teva Pharmaceuticals up 4% on FDA Approval for Copaxone", "Sector Update: Healthcare", "FDA Nod for New Formulation of Teva's Copaxone - Analyst Blog", "Will Affymetrix (AFFX) Surprise This Earnings Season? - Analyst Blog", "Biogen Beats, Tecfidera Continues to Shine - Analyst Blog", "Guidance Update From Actavis - Analyst Blog", "Will Celgene (CELG) Miss This Earnings Season? - Analyst Blog", "Pfizer Tops on Earnings & Revs, Guides In-Line - Analyst Blog", "Pre-Market Earnings Report for January 29, 2014 : BA, BIIB, DOW, EMC, PSX, PX, SO, VLO, HES, MPC, WLP, NVS", "Is Biogen (BIIB) Poised to Beat Earnings Estimates? - Analyst Blog", "Will Amgen (AMGN) Miss This Earnings Season? - Analyst Blog", "Teva Falls on Negative CHMP Opinion - Analyst Blog", "Will Pfizer (PFE) Miss This Earnings Season? - Analyst Blog", "Will Alexion's (ALXN) Earnings Streak End? - Analyst Blog", "Will Celgene (CELG) Miss This Earnings Season? - Analyst Blog", "Generic Unit at Perrigo Looks Promising - Analyst Blog", "ACOR Preliminary Q4 Revs Look Good - Analyst Blog", "Can Biotech Repeat in 2014?", "Sangamo and Biogen Tie Up - Analyst Blog", "Biogen Idec director sells 15,000 shares", "A New CEO for Teva - Analyst Blog", "Will Bristol-Myers (BMY) Beat Q4 Earnings? - Analyst Blog", "Can JNJ Keep the Earnings Streak Alive? - Analyst Blog", "Perrigo Maintained at Neutral - Analyst Blog", "Never Ever Sell These Stocks", "Positive Data on Infinity Pharma Candidate - Analyst Blog", "Biogen Idec Inc. (BIIB): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "Biotech Stock Roundup: CBST Hits 52-Week High, OREX Lights Up - Analyst Blog", "Biogen's Hemophilia B Drug Approval Delayed - Analyst Blog", "Mid-Day Market Update: U.S. Stocks Turn Red; Bed Bath & Beyond Shares Decline On Weak Q3 Earnings", "Notice of Allowance Received by Alkermes - Analyst Blog", "Perrigo Maintained at Neutral - Analyst Blog", "Never Ever Sell These Stocks", "Cubist Hoists Biotech ETFs To Nose-Bleed Levels", "MIDDAY UPDATE: Stocks Holding Slim Gains; Intel Drops on Downbeat 2014 Sales Forecast", "Dow Consolidating Above 16,000,Fighting To Extend Gains for Seventh Straight Week", "A safe way to win with biotech growth", "QIAGEN, Eli Lilly Expand Partnership - Analyst Blog", "Isis Pharma Posts Lower Q3 Loss - Analyst Blog", "Acorda Down on Q3 Earnings - Analyst Blog", "Teva's Earnings Overshadowed by CEO Exit - Analyst Blog", "Perrigo Beats Both on Earnings and Revs - Analyst Blog", "Teva Slumps on CEO Departure - Analyst Blog", "Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day", "Biotech Stock Roundup: Vanda Soars, Sarepta Slumps - Analyst Blog", "Stock Downgrades: Crocs Takes a Walk on the Wild Side", "#PreMarket Primer: Monday, October 28: All Eyes On Apple", "Earnings & Revs Beat from Biogen, Ups View Again - Analyst Blog", "Elan Narrows Q3 Loss - Analyst Blog", "Is Biogen (BIIB) Poised to Beat Earnings Estimates? - Analyst Blog", "Trading Radar: Backlogged Economic Data Catches Up to Market; Apple, Facebook Earnings on the Way", "Benzinga Weekly Preview: FOMC Meeting Closely Watched", "Company news for October 29, 2013 - Corporate Summary", "Is McKesson Corporation (MCK) Poised to Beat Earnings? - Analyst Blog", "FDA Approves Novo Nordisk's NovoEight - Analyst Blog", "Another Milestone for Isis Pharma - Analyst Blog", "Acorda's Label Expansion Efforts - Analyst Blog", "Earnings Preview: Will Abbott Labs (ABT) Disappoint in Q3? - Analyst Blog", "Can Johnson & Johnson (JNJ) Keep the Earnings Streak Alive? - Analyst Blog", "Update on Sanofi's Aubagio - Analyst Blog", "Pre-Market Earnings Report for October 28, 2013 : MRK, BIIB, L, ROP, CNA, EW, BWP, BKW, KEX, AHGP, AWI, TEN", "Is McKesson Corporation (MCK) Poised to Beat Earnings? - Analyst Blog", "FDA Approves Novo Nordisk's NovoEight - Analyst Blog", "Another Milestone for Isis Pharma - Analyst Blog", "Acorda's Label Expansion Efforts - Analyst Blog", "Earnings Preview: Will Abbott Labs (ABT) Disappoint in Q3? - Analyst Blog", "Can Johnson & Johnson (JNJ) Keep the Earnings Streak Alive? - Analyst Blog", "Update on Sanofi's Aubagio - Analyst Blog", "Biotech ETFs Plummeting (XBI, IBB, BBH)", "Milestone Payment for Isis Pharma - Analyst Blog", "Encouraging Data on Novartis' Gilenya - Analyst Blog", "Top Biotechnology ETF in Focus: PBE - ETF News And Commentary", "Pipeline Progress at BioMarin - Analyst Blog", "Good News for Perrigo's Generic Unit - Analyst Blog", "Alnylam Up on Positive Phase I Data - Analyst Blog", "Positive Data on Pacira's Exparel - Analyst Blog", "Pipeline Progress at Alexion - Analyst Blog", "Sarepta Therapeutics (SRPT) Worth Considering: Stock Surges 18.0% - Analyst Blog", "Positive CHMP Opinion for NVO Candidate - Analyst Blog", "Repros Continues to Climb - Analyst Blog", "Pipeline Progress at Omeros - Analyst Blog", "CHMP Positive on GSK/THRX candidate - Analyst Blog", "Strength Seen in Isis Pharmaceuticals (ISIS): Stock Soars 14.1% - Analyst Blog", "Actelion Acquires Ceptaris - Analyst Blog", "Relatively Small Gains For Healthcare Stocks Compared to Other Sectors Today", "Sector Update: Healthcare", "Encouraging News for Alexion - Analyst Blog", "Data on MDCO's Oritavancin - Analyst Blog", "Pipeline Progress at Gilead - Analyst Blog", "New Phase I data on Omeros' OMS824 - Analyst Blog", "Data from Alexion's Soliris Study - Analyst Blog", "Dendreon's Provenge Cleared in the EU - Analyst Blog", "Relatively Small Gains For Healthcare Stocks Compared to Other Sectors Today", "Sector Update: Healthcare", "Encouraging News for Alexion - Analyst Blog", "Data on MDCO's Oritavancin - Analyst Blog", "Pipeline Progress at Gilead - Analyst Blog", "New Phase I data on Omeros' OMS824 - Analyst Blog", "Data from Alexion's Soliris Study - Analyst Blog", "Dendreon's Provenge Cleared in the EU - Analyst Blog", "Positive Results on Ventrus' Candidate, Shares Up - Analyst Blog", "Data on Actelion's Opsumit - Analyst Blog", "Loss Widens at Pluristem - Analyst Blog", "Peregrine Reports In-Line Loss - Analyst Blog", "Sector Update: Healthcare Edging Higher in Pre-Market", "Sector Update: Healthcare", "Rigel Pharma Trims Workforce - Analyst Blog", "Encouraging Data on Xenoport's XP23829 - Analyst Blog", "Mid-Morning Market Update: Markets Open Higher; Koch Industries To Acquire Molex For $38.50/Share", "Sector Update: Healthcare Flat in Pre-Bell; Isis Pharmaceuticals Collaborates with Biogen", "Sector Update: Healthcare", "Pipeline Progress at AstraZeneca - Analyst Blog", "Bayer Looking to Expand in Russia - Analyst Blog", "Market Wrap for Monday, September 9: Nasdaq Bounces To 13 Year High", "CLOSING UPDATE: Stocks Pad Early Gains After Syria Signals Possible End to Stand-Off Over Chemical Weapons", "Glaxo to Divest Lucozade and Ribena - Analyst Blog", "Sector Update: Healthcare", "Mid-Afternoon Market Update: Markets Lead by the NASDAQ as Various Health Names Drop", "Healthcare Stocks Inching Higher As Other Sectors Race Ahead; Isis Pharma Up 10% on Biogen Co-op Pact", "Sector Update: Healthcare", "Mid-Day Market Update: Dow Rises Over 100 Points; Apple Shares Gain", "Setback for Glaxo's Cancer Pipeline - Analyst Blog", "FDA Licensure for Merck Facility - Analyst Blog", "Healthcare Stocks Lagging Rest of Market; Oncolytics Biotech Jumps On Positive Data for Cancer Drug", "Endocyte - Nihon Medi-Physics Collaborate - Analyst Blog", "Myriad's Decisive Test Now Available - Analyst Blog", "Amgen/Cytokinetics Drug Misses Primary Endpoint - Analyst Blog", "Progress on ARIAD's Iclusig - Analyst Blog", "Data on MDCO's Cangrelor - Analyst Blog", "Good News for Chelsea Therapeutics - Analyst Blog", "Priority Review for Takeda Candidate - Analyst Blog", "Bayer's Stivarga Filed in the EU - Analyst Blog", "Astellas and Merck Collaborate - Analyst Blog", "Spectrum Pharma Launches Marqibo - Analyst Blog", "Pipeline Progress at Elan - Analyst Blog", "Interim Phase II Data on Isis Candidate - Analyst Blog", "AstraZeneca Reports Onglyza Data - Analyst Blog", "New Data on Actelion's Opsumit - Analyst Blog", "Sanofi's Aubagio Gets EU Nod - Analyst Blog", "Myriad, AstraZeneca Boost Alliance - Analyst Blog", "Astellas and Merck Collaborate - Analyst Blog", "Spectrum Pharma Launches Marqibo - Analyst Blog", "Pipeline Progress at Elan - Analyst Blog", "Simcere to Go Private - Analyst Blog", "Orexigen Provides Contrave Update - Analyst Blog", "Bull of the Day: Biogen Idec (BIIB) - Bull of the Day", "Affymetrix Upped to Outperform - Analyst Blog", "Data on Actelion's Opsumit Published - Analyst Blog", "Bayer's Stivarga Cleared in the EU - Analyst Blog", "PRIMECAP Trims Top Biotechs and More", "Actelion Inches Close to Ceptaris - Analyst Blog", "Amgen to Acquire Onyx Pharma - Analyst Blog", "Loss Narrows at Immunomedics - Analyst Blog", "Amgen to Present Data at ESC - Analyst Blog", "Biogen Multiple Sclerosis Drug May Become Blockbuster", "Neutral on Onyx Pharma - Analyst Blog", "XOMA Prices Offering - Analyst Blog", "Pipeline Setback for GTx - Analyst Blog", "Wider-than-Expected Loss at Savient - Analyst Blog", "Repros Reports Androxal Interim Data - Analyst Blog", "Lannett, Jerome Stevens Extend Contract - Analyst Blog", "XOMA Raises Funds - Analyst Blog", "Sizing Up Jackson Hole - Analyst Blog", "Swiss Approval for Takeda/ Dainippon's Latuda - Analyst Blog", "Ligand, CURx Collaborate - Analyst Blog", "Beating the S&P 2-to-1", "Australia Approves Novartis' Bexsero - Analyst Blog", "Apricus' Loss Narrows Y/Y - Analyst Blog", "Amgen's Onyx Acquisition Could be Delayed - Analyst Blog", "Update on Chelsea's Northera - Analyst Blog", "Sizing Up Jackson Hole - Analyst Blog", "Swiss Approval for Takeda/ Dainippon's Latuda - Analyst Blog", "Will Perrigo Company (PRGO) Beat Earnings? - Analyst Blog", "ENDP to Offload Anatomical Pathology Unit - Analyst Blog", "AVEO Pharma Cuts Q2 Loss - Analyst Blog", "Simcere Misses Earnings Estimates in Q2 - Analyst Blog", "Myriad Outstrips Q4 and FY Earnings Estimates - Analyst Blog", "Eli Lilly Scores with Necitumumab - Analyst Blog", "Earnings Beat at Perrigo in Q4, Sales Dip - Analyst Blog", "Narrower Q2 Loss at Medivation - Analyst Blog", "Onyx Pharma Narrows Loss in Q2 - Analyst Blog", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 14, 2013", "Dendreon Cuts Loss, Shares Fall on Weak Guidance - Analyst Blog", "Narrower-than-Expected Loss at Nektar - Analyst Blog", "Osiris Up on Grafix Data - Analyst Blog", "Major Setback for Vical - Analyst Blog", "Loss Widens at Repros in Q2 - Analyst Blog", "Narrower Q2 Loss at Medivation - Analyst Blog", "XenoPort's Loss Widens Y/Y - Analyst Blog", "Glaxo Seeks Votrient Label Expansion in EU - Analyst Blog", "Wider-than-Expected Loss at Spectrum Pharma - Analyst Blog", "Affymetrix Rolls Out Advanced Assay - Analyst Blog", "Narrower Q2 Loss at Geron - Analyst Blog", "Rigel Pharma Narrows Q2 Loss - Analyst Blog", "Endo Health Beats on Earnings & Revs. in Q2 - Analyst Blog", "Positive Data on Bayer/Regeneron's Eye Drug - Analyst Blog", "Sanofi's Vaccine Progresses - Analyst Blog", "Earnings Down, Outlook Lowered at Sanofi - Analyst Blog", "Approval Delayed for Glaxo Drug - Analyst Blog", "Bayer Inks Oncology Deal - Analyst Blog", "Affymetrix Rise on Turnaround 2Q Earnings - Analyst Blog", "Anika Soars on Strong Q2 Results - Analyst Blog", "Affymetrix Sees Earnings After Two Years - Analyst Blog", "Earnings Beat at AstraZeneca in 2Q - Analyst Blog", "Earnings Beat for Teva - Analyst Blog", "Narrower-Than-Expected Loss at Optimer - Analyst Blog", "Narrower-Than-Expected Loss at AMAG - Analyst Blog", "Earnings Increase at Bayer in 2Q - Analyst Blog", "Acorda Misses on Earnings by a Penny - Analyst Blog", "Isis Earns $2M from Glaxo - Analyst Blog", "Benzinga Market Primer: Friday, July 26: Futures Flat On Mixed Global Stocks Overnight", "Breakeven Earnings at Elan - Analyst Blog", "Benzinga Market Primer: Thursday, July 25: Futures Lower After Technical Breakdown", "Huge Earnings Beat from Biogen; Outlook Up Again - Analyst Blog", "Pre-Market Earnings Report for July 25, 2013 : MMM, BMY, CELG, CL, BIIB, GM, DOW, PCP, POT, GG, SIRI, NBL", "Will Biogen (BIIB) Beat Earnings Estimates? - Analyst Blog", "Amgen Beats on Earnings & Revs in Q2 - Analyst Blog", "Isis Earns $2M from Glaxo - Analyst Blog", "Benzinga Market Primer: Friday, July 26: Futures Flat On Mixed Global Stocks Overnight", "Breakeven Earnings at Elan - Analyst Blog", "Benzinga Market Primer: Thursday, July 25: Futures Lower After Technical Breakdown", "Huge Earnings Beat from Biogen; Outlook Up Again - Analyst Blog", "Pre-Market Earnings Report for July 25, 2013 : MMM, BMY, CELG, CL, BIIB, GM, DOW, PCP, POT, GG, SIRI, NBL", "Will Biogen (BIIB) Beat Earnings Estimates? - Analyst Blog", "Amgen Beats on Earnings & Revs in Q2 - Analyst Blog", "Will McKesson Corporation (MCK) Beat Earnings Estimates This Quarter? - Analyst Blog", "Will Forest Labs (FRX) Beat Earnings Estimates This Quarter? - Analyst Blog", "Will Eli Lilly (LLY) Beat Earnings Estimates This Quarter? - Analyst Blog", "Will Alexion (ALXN) Beat Earnings Estimates This Quarter? - Analyst Blog", "Will AmerisourceBergen (ABC) Beat Earnings Estimates This Quarter? - Analyst Blog", "Pharmacyclics Seeks US Approval, Shares Soar - Analyst Blog", "Acorda Expands Pipeline - Analyst Blog", "Will Actavis (ACT) Beat Earnings Estimates? - Analyst Blog", "Will McKesson Corporation (MCK) Beat Earnings Estimates This Quarter? - Analyst Blog", "Will Forest Labs (FRX) Beat Earnings Estimates This Quarter? - Analyst Blog", "Will Eli Lilly (LLY) Beat Earnings Estimates This Quarter? - Analyst Blog", "Will Alexion (ALXN) Beat Earnings Estimates This Quarter? - Analyst Blog", "Will AmerisourceBergen (ABC) Beat Earnings Estimates This Quarter? - Analyst Blog", "Pharmacyclics Seeks US Approval, Shares Soar - Analyst Blog", "Acorda Expands Pipeline - Analyst Blog", "Will Actavis (ACT) Beat Earnings Estimates? - Analyst Blog", "Will McKesson Corporation (MCK) Beat Earnings Estimates This Quarter? - Analyst Blog", "Will Forest Labs (FRX) Beat Earnings Estimates This Quarter? - Analyst Blog", "Will Eli Lilly (LLY) Beat Earnings Estimates This Quarter? - Analyst Blog", "Will Alexion (ALXN) Beat Earnings Estimates This Quarter? - Analyst Blog", "Will AmerisourceBergen (ABC) Beat Earnings Estimates This Quarter? - Analyst Blog", "Pharmacyclics Seeks US Approval, Shares Soar - Analyst Blog", "Acorda Expands Pipeline - Analyst Blog", "Will Actavis (ACT) Beat Earnings Estimates? - Analyst Blog", "Australian Approval for Vertex' Kalydeco - Analyst Blog", "Bayer Initiates Phase III Study - Analyst Blog", "Cytokinetics' Update on Study - Analyst Blog", "Perrigo Attains 52- week High - Analyst Blog", "Update on Threshold Pharma's TH-302 - Analyst Blog", "BioMarin Stays Neutral - Analyst Blog", "New Data on Biogen's Eloctate - Analyst Blog", "Biogen Idec Inc. (BIIB): Today's Most Compelling Stock Buy", "Australian Approval for Vertex' Kalydeco - Analyst Blog", "Bayer Initiates Phase III Study - Analyst Blog", "Cytokinetics' Update on Study - Analyst Blog", "Perrigo Attains 52- week High - Analyst Blog", "Update on Threshold Pharma's TH-302 - Analyst Blog", "BioMarin Stays Neutral - Analyst Blog", "New Data on Biogen's Eloctate - Analyst Blog", "Biogen Idec Inc. (BIIB): Today's Most Compelling Stock Buy", "Australian Approval for Vertex' Kalydeco - Analyst Blog", "Bayer Initiates Phase III Study - Analyst Blog", "Cytokinetics' Update on Study - Analyst Blog", "Perrigo Attains 52- week High - Analyst Blog", "Update on Threshold Pharma's TH-302 - Analyst Blog", "BioMarin Stays Neutral - Analyst Blog", "New Data on Biogen's Eloctate - Analyst Blog", "Biogen Idec Inc. (BIIB): Today's Most Compelling Stock Buy", "pSivida Starts Phase III Study - Analyst Blog", "FDA Accepts The Medicines Co.'s NDA - Analyst Blog", "Zoetis Looking to Expand - Analyst Blog", "Isis Pharma Up on Phase II Data - Analyst Blog", "Positive Data on Infinity's Oncology Candidate - Analyst Blog", "AstraZeneca/BMY Present Forxiga Data - Analyst Blog", "Celgene Inks Oncology Deal - Analyst Blog", "Data on Acorda Pipeline Candidate - Analyst Blog", "Integra Grows European Portfolio - Analyst Blog", "Celgene presents Revlimid Data - Analyst Blog", "Affymetrix Upgraded to Neutral - Analyst Blog", "Isis Pharma Up on Phase II Data - Analyst Blog", "Positive Data on Infinity's Oncology Candidate - Analyst Blog", "AstraZeneca/BMY Present Forxiga Data - Analyst Blog", "Celgene Inks Oncology Deal - Analyst Blog", "Another Setback for Idenix - Analyst Blog", "Draft Guidance from NICE for pSivida's Iluvien - Analyst Blog", "Pluristem Updates on IC Study - Analyst Blog", "CELG Presents Positive Long-term Data - Analyst Blog", "Market Wrap for Wednesday, June 12: Stock and Bond Markets Fall Mid-Week; Liquidity Concerns Remain a Focus", "Market Close Report: NASDAQ Composite index closes at 3,445.26 down -20.11 points", "CHMP Positive on Teva's Lonquex - Analyst Blog", "3 Impressive Biotech ETFs Crushing the Market - ETF News And Commentary", "Market Close Report: NASDAQ Composite index closes at 3,307.02 up 27.76 points", "Benzinga Market Primer: Friday, April 26", "Biogen's Earnings Surpass Expectations - Analyst Blog", "Benzinga Market Primer: Thursday, April 25", "Acorda Initiates Study on rHIgM22 - Analyst Blog", "Elan Narrows Y/Y Loss - Analyst Blog", "Isis Pharma's ISIS-SMNRx Progresses - Analyst Blog", "Equal-Weight ETF Trounces Traditional S&P 500 Peers", "Market Close Report: NASDAQ Composite index closes at 3,307.02 up 27.76 points", "Benzinga Market Primer: Friday, April 26", "Biogen's Earnings Surpass Expectations - Analyst Blog", "Benzinga Market Primer: Thursday, April 25", "Acorda Initiates Study on rHIgM22 - Analyst Blog", "Elan Narrows Y/Y Loss - Analyst Blog", "Pre-Market Earnings Report for April 25, 2013 : XOM, MMM, MO, COP, BMY, OXY, UPS, CL, CELG, BIIB, DOW, D", "Data on Teva's Milprosa - Analyst Blog", "Elan Responds to Royalty Pharma Offer - Analyst Blog", "Biotech Alkermes Poised To Swell On Pipeline Wins", "ETF Showdown: A Pharma Fight", "SNY's Aubagio Gets Argentinean Nod - Analyst Blog", "Vertex-Bristol-Myers Collaborate for HCV - Analyst Blog", "Illumina Introduces TruSight Tumor - Analyst Blog", "The Best Advice on Managing Portfolio Risk", "Teva's Quartette Approved in the US - Analyst Blog", "Elan Gets Takeover Clarity - Analyst Blog", "Positive Data on Repros' Androxal - Analyst Blog", "Elan Sells Off Tysabri Stake - Analyst Blog", "Zacks Rank #1 Addition for Tuesday - Tale of the Tape", "FDA Approves Biogen's Tecfidera - Analyst Blog", "Market Close Report: NASDAQ Composite index closes at 3,267.52 up 11 points", "QLT Sells PPDS Technology - Analyst Blog", "Positive Data on Biogen's Plegridy - Analyst Blog", "CHMP Positive on Biogen's Tecfidera - Analyst Blog", "Moving Averages Indicate These Sector ETFs Could be Stretched", "CHMP in Favor of Sanofi's Aubagio - Analyst Blog", "More Protection for Biogen's Tecfidera - Analyst Blog", "New Data on Biogen/Elan's Tysabri - Analyst Blog", "Biogen Files Hemophilia B Application - Analyst Blog", "Biotech Breakout Boosting ETFs", "Teva Enrolls Patients in MS Study - Analyst Blog", "Elan to Share Tysabri Proceeds - Analyst Blog", "Standard Review for Biogen Drug - Analyst Blog", "Royalty Pharma Eyes Elan Corp. - Analyst Blog", "SPPI Beats in 4Q on Higher Sales - Analyst Blog", "Elan Updates Future Plans - Analyst Blog", "Merck Signs Biosimilars Deal - Analyst Blog", "Update on Elan's Plans - Analyst Blog", "Data on Biogen Hemophilia Candidates - Analyst Blog", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 11, 2013", "Elan Beats on Sales, Loses Tysabri - Analyst Blog", "Market Wrap for Wednesday, February 6: Major Averages Close Near Unchanged; Euro Falls", "Closing Update: Dow, S&P Edge Higher, Nasdaq Drifts Lower as Markets Creep Back Toward Highs", "Elan to Sell Remaining ALKS Stake - Analyst Blog", "Company News for January 29, 2013 - Corporate Summary", "Earnings Miss at Acorda - Analyst Blog", "Data on Biogen Hemophilia Candidates - Analyst Blog", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 11, 2013", "Elan Beats on Sales, Loses Tysabri - Analyst Blog", "Market Wrap for Wednesday, February 6: Major Averages Close Near Unchanged; Euro Falls", "Pre-Market Earnings Report for January 28, 2013 : CAT, BIIB, ROP, BBD, ONB, NDZ", "ELN/BIIB Seek Label Expansion - Analyst Blog", "Alkermes Maintains Fiscal 2013 View - Analyst Blog", "Market Close Report: NASDAQ Composite index closes at 3,153.66 down -.64 points", "Pipeline Update from Alnylam - Analyst Blog", "Pre-Market Most Active for Jan 3, 2013 : BAC, BIIB, F, TGT, BHP, QQQ, VOD, NOK, SIRI, CSCO, MLNX, KEP", "Zacks #5 Rank Additions for Thursday - Tale of the Tape", "Zacks #1 Rank Additions for Thursday - Tale of the Tape", "CHMP Negative on Isis' Kynamro - Analyst Blog", "Isis Pharma, AstraZeneca Ink Deal - Analyst Blog", "These ETFs Are Awash in 2013 Takeover Targets", "Biogen Submits Hemophilia B BLA - Analyst Blog", "Sanofi's Aubagio Gets Australian Nod - Analyst Blog", "Reshuffling The Lineup For The Health Care Model", "Alnylam-Tekmira Settle Up - Analyst Blog", "Alkermes Reverts to Neutral - Analyst Blog", "PDLI's EPS In Line, Revenue Misses - Analyst Blog", "Revenues Decline at Alnylam - Analyst Blog", "Acorda Beats on All Fronts - Analyst Blog", "PDLI Guides Q4 Royalty Rev to $86M - Analyst Blog", "Sanofi's Aubagio Gets Australian Nod - Analyst Blog", "Reshuffling The Lineup For The Health Care Model", "Alnylam-Tekmira Settle Up - Analyst Blog", "Alkermes Reverts to Neutral - Analyst Blog", "PDLI's EPS In Line, Revenue Misses - Analyst Blog", "Revenues Decline at Alnylam - Analyst Blog", "Edward Owens' Vanguard Health Care Fund Does More Shedding Than Adding in Third Quarter", "BIIB's BG-12 Review Period Extended - Analyst Blog", "Pipeline Setback at Abbott - Analyst Blog", "Acorda Initiated at Neutral - Analyst Blog", "EPS Beat for Abbott, Sales Miss - Analyst Blog", "Positive Data on Novartis' Gilenya - Analyst Blog", "New Data on Elan-Biogen's Tysabri - Analyst Blog", "Isis Pharma Owns 18% of Regulus - Analyst Blog", "Acorda's Ampyra Patent Extended - Analyst Blog", "BIIB's BG-12 Review Period Extended - Analyst Blog", "Pipeline Setback at Abbott - Analyst Blog", "52-Week High Guru Stocks: BIIB, GE, BDX, IR, PFE", "Biogen Idec - Momentum", "Back to Neutral on Alkermes - Analyst Blog", "Biogen Sells Benlysta Rights - Analyst Blog", "PDLI-AxoGen Complete Financing Deal - Analyst Blog", "Sanofi MS Drug Gets Approval - Analyst Blog", "PDLI Guides Q3 Royalty Rev to $85M - Analyst Blog", "Alnylam Presents Data on ALN-RSV01 - Analyst Blog", "Elan Starts Phase II ELND005 Study - Analyst Blog", "Disciplined Columbia Fund Rallies From Mediocre 2011", "Alnylam & Monsanto Collaborate - Analyst Blog", "Sanofi's Lemtrada US Filing Update - Analyst Blog", "Sanofi - Oncodesign Join Forces - Analyst Blog", "Teva's Quartette Filing Accepted - Analyst Blog", "Biogen Inks Deal with Regulus - Analyst Blog", "Elan to Split into Two Companies - Analyst Blog", "Acorda Reports Data on Ampyra study - Analyst Blog", "Take Advantage of Dips in the Market, Add Market Leaders to Your Portfolio", "Update on Teva's Laquinimod - Analyst Blog", "Isis Loss Down on Higher Revenues - Analyst Blog", "Alnylam/Isis's Regulus to Go Public - Analyst Blog", "PDL BioPharma Beats Zacks Estimates - Analyst Blog", "Alnylam Earns Milestone Payment - Analyst Blog", "Top-Performing Funds Latch On To Biotech And Discount Retail Stocks", "Acorda Misses on Earnings, Sales Up - Analyst Blog", "Loss at Elan Wider than Expected - Analyst Blog", "Biotechs In Motion As New Drug Pipeline Brims", "Angiomax Drives MDCO's Results - Analyst Blog", "Weekly Top Insider Sells: GOOG, FIS, ORCL, and BIIB", "PDL BioPharma Beats Zacks Estimates - Analyst Blog", "Alnylam Earns Milestone Payment - Analyst Blog", "Top-Performing Funds Latch On To Biotech And Discount Retail Stocks", "Abbott Beats on EPS, Affirms View - Analyst Blog", "Better Investors: Men or Women?", "Isis Pharma Stays Neutral - Analyst Blog", "Strategy targets more upside in Biogen", "Biogen Beats on All Fronts - Analyst Blog", "Isis-Biogen Collaborate Again - Analyst Blog", "Novartis Presents Data on Gilenya - Analyst Blog", "PDL BioPharma Guides Q2 Royalty Rev to $125M - Analyst Blog", "Acorda Commences Patient Enrollment - Analyst Blog", "Dr. Reddy's & Merck Serono Team Up - Analyst Blog", "New Lease Agreements for Alexandria - Analyst Blog", "Positive Data for Sanofi's Aubagio - Analyst Blog", "Biogen Initiates Hemophilia Studies - Analyst Blog", "The Zacks Analyst Blog Highlights: Biogen, Teva Pharmaceutical, Pfizer, Novartis and U.S. Bancorp - Press Releases", "Biogen Tysabri Canadian Label Update - Analyst Blog", "AVEO's AV-203 in Phase I - Analyst Blog", "The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Bristol-Myers Squibb, Teva Pharmaceutical, Biogen Idec and Elan - Press Releases", "Data on Elan & Biogen's Tysabri - Analyst Blog", "Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's, Biogen Idec, Abbott, Novartis - Press Releases", "The ONLY Way You Should be Investing in Stocks Right Now", "Standard Review for Isis' Kynamro - Analyst Blog", "The Zacks Analyst Blog Highlights: Biogen, Teva Pharmaceutical, Pfizer, Novartis and U.S. Bancorp - Press Releases", "Earnings Beat at PDL BioPharma - Analyst Blog", "Revenues Climb at Acorda - Analyst Blog", "Bearish John Hussman Sold Heavily in the First Quarter; New Portfolio Update", "Elan Misses 1Q EPS, Revenues Rise - Analyst Blog", "Earnings Miss for Biogen - Analyst Blog", "MDCO Beats, Ties with AstraZeneca - Analyst Blog", "Standard Review for Biogen's BG-12 - Analyst Blog", "Isis Loss Widens on Higher Expenses - Analyst Blog", "Earnings Beat at PDL BioPharma - Analyst Blog", "Biogen Inks Deal with MAKScientific - Analyst Blog", "Elan Sells 76% Stake in Alkermes - Analyst Blog", "Biogen Seeks Approval for BG-12 - Analyst Blog", "The Zacks Analyst Blog Highlights: Encana, Enbridge, BankAtlantic Bancorp, BB&T and Biogen Idec - Press Releases", "Disappointing Results at Novartis - Analyst Blog", "PDL BioPharma Q4 EPS In Line - Analyst Blog", "Fourth Quarter Beat for MDCO - Analyst Blog", "Earnings Beat for Acorda - Analyst Blog", "Biogen to Buy Stromedix - Analyst Blog", "Elan's 4Q Loss Wider Than Expected - Analyst Blog", "3 Biotechnology Stocks for Short-Term Traders", "How Many Stocks Should You Own? - Investment Ideas", "Biogen-Samsung Set Up JV - Analyst Blog", "PDL BioPharma Q4 EPS In Line - Analyst Blog", "Fourth Quarter Beat for MDCO - Analyst Blog", "Earnings Beat for Acorda - Analyst Blog", "Biogen to Buy Stromedix - Analyst Blog", "Elan's 4Q Loss Wider Than Expected - Analyst Blog", "3 Biotechnology Stocks for Short-Term Traders", "How Many Stocks Should You Own? - Investment Ideas", "Biogen-Samsung Set Up JV - Analyst Blog", "EPS Beat for Biogen; Outlook Weak - Analyst Blog", "Biogen & Elan Announce Tysabri Trial - Analyst Blog", "Earnings Preview: Biogen - Analyst Blog", "Label Expansion for Merck KGaA Drug - Analyst Blog", "The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs, Bristol-Myers Squibb and Biogen - Press Releases", "Abbott Beats on EPS, Guides In-Line - Analyst Blog", "Medicines Co. Settles with APP - Analyst Blog", "The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases", "EPS Beat for Biogen; Outlook Weak - Analyst Blog", "Biogen & Elan Announce Tysabri Trial - Analyst Blog", "Earnings Preview: Biogen - Analyst Blog", "Label Expansion for Merck KGaA Drug - Analyst Blog", "The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs, Bristol-Myers Squibb and Biogen - Press Releases", "Abbott Beats on EPS, Guides In-Line - Analyst Blog", "Medicines Co. Settles with APP - Analyst Blog", "The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases", "EPS Beat for Biogen; Outlook Weak - Analyst Blog", "Biogen & Elan Announce Tysabri Trial - Analyst Blog", "Earnings Preview: Biogen - Analyst Blog", "Label Expansion for Merck KGaA Drug - Analyst Blog", "The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs, Bristol-Myers Squibb and Biogen - Press Releases", "Abbott Beats on EPS, Guides In-Line - Analyst Blog", "Medicines Co. Settles with APP - Analyst Blog", "The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases", "EPS Beat for Biogen; Outlook Weak - Analyst Blog", "Biogen & Elan Announce Tysabri Trial - Analyst Blog", "Earnings Preview: Biogen - Analyst Blog", "Label Expansion for Merck KGaA Drug - Analyst Blog", "The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs, Bristol-Myers Squibb and Biogen - Press Releases", "Abbott Beats on EPS, Guides In-Line - Analyst Blog", "Medicines Co. Settles with APP - Analyst Blog", "The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases", "EPS Beat for Biogen; Outlook Weak - Analyst Blog", "Biogen & Elan Announce Tysabri Trial - Analyst Blog", "Earnings Preview: Biogen - Analyst Blog", "Label Expansion for Merck KGaA Drug - Analyst Blog", "The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs, Bristol-Myers Squibb and Biogen - Press Releases", "Abbott Beats on EPS, Guides In-Line - Analyst Blog", "Medicines Co. Settles with APP - Analyst Blog", "The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases"], "Elapsed Time": ["3 DAYS AGO", "3 DAYS AGO", "3 DAYS AGO", "5 DAYS AGO", "JUN 19, 2020", "JUN 19, 2020", "JUN 19, 2020", "JUN 18, 2020", "3 DAYS AGO", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 17, 2020", "JUN 18, 2020", "JUN 14, 2020", "JUN 12, 2020", "JUN 11, 2020", "JUN 10, 2020", "JUN 10, 2020", "JUN 9, 2020", "JUN 8, 2020", "JUN 15, 2020", "JUN 4, 2020", "JUN 1, 2020", "MAY 29, 2020", "MAY 23, 2020", "MAY 22, 2020", "MAY 22, 2020", "MAY 19, 2020", "JUN 4, 2020", "MAY 17, 2020", "MAY 17, 2020", "MAY 13, 2020", "MAY 12, 2020", "MAY 11, 2020", "MAY 6, 2020", "MAY 5, 2020", "MAY 17, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 1, 2020", "APR 30, 2020", "APR 29, 2020", "APR 27, 2020", "MAY 4, 2020", "APR 23, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 24, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 19, 2020", "APR 19, 2020", "APR 22, 2020", "APR 17, 2020", "APR 17, 2020", "APR 16, 2020", "APR 16, 2020", "APR 12, 2020", "APR 10, 2020", "APR 9, 2020", "APR 19, 2020", "APR 17, 2020", "APR 6, 2020", "APR 6, 2020", "APR 6, 2020", "APR 5, 2020", "APR 4, 2020", "APR 9, 2020", "APR 3, 2020", "APR 2, 2020", "APR 1, 2020", "MAR 31, 2020", "MAR 30, 2020", "MAR 27, 2020", "MAR 26, 2020", "APR 3, 2020", "APR 3, 2020", "MAR 24, 2020", "MAR 23, 2020", "MAR 23, 2020", "MAR 20, 2020", "MAR 17, 2020", "MAR 16, 2020", "MAR 25, 2020", "MAR 15, 2020", "MAR 15, 2020", "MAR 15, 2020", "MAR 15, 2020", "MAR 13, 2020", "MAR 13, 2020", "MAR 12, 2020", "MAR 15, 2020", "MAR 12, 2020", "MAR 10, 2020", "MAR 9, 2020", "MAR 5, 2020", "MAR 3, 2020", "FEB 29, 2020", "FEB 29, 2020", "MAR 12, 2020", "FEB 28, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 26, 2020", "FEB 26, 2020", "FEB 26, 2020", "FEB 25, 2020", "FEB 28, 2020", "FEB 24, 2020", "FEB 21, 2020", "FEB 19, 2020", "FEB 18, 2020", "FEB 18, 2020", "FEB 18, 2020", "FEB 16, 2020", "FEB 25, 2020", "FEB 16, 2020", "FEB 16, 2020", "FEB 16, 2020", "FEB 16, 2020", "FEB 15, 2020", "FEB 13, 2020", "FEB 11, 2020", "FEB 16, 2020", "FEB 10, 2020", "FEB 10, 2020", "FEB 7, 2020", "FEB 7, 2020", "FEB 7, 2020", "FEB 5, 2020", "FEB 5, 2020", "FEB 11, 2020", "FEB 5, 2020", "FEB 4, 2020", "JAN 31, 2020", "JAN 31, 2020", "JAN 31, 2020", "JAN 30, 2020", "JAN 30, 2020", "FEB 5, 2020", "JAN 30, 2020", "JAN 30, 2020", "JAN 30, 2020", "JAN 30, 2020", "JAN 29, 2020", "JAN 29, 2020", "JAN 27, 2020", "JAN 30, 2020", "JAN 24, 2020", "JAN 23, 2020", "JAN 21, 2020", "JAN 21, 2020", "JAN 19, 2020", "JAN 19, 2020", "JAN 19, 2020", "JAN 25, 2020", "JAN 17, 2020", "JAN 16, 2020", "JAN 16, 2020", "JAN 16, 2020", "JAN 15, 2020", "JAN 14, 2020", "JAN 13, 2020", "JAN 19, 2020", "JAN 13, 2020", "JAN 11, 2020", "JAN 10, 2020", "JAN 9, 2020", "JAN 8, 2020", "JAN 5, 2020", "JAN 3, 2020", "JAN 13, 2020", "DEC 24, 2019", "DEC 19, 2019", "DEC 19, 2019", "DEC 17, 2019", "DEC 15, 2019", "DEC 15, 2019", "DEC 15, 2019", "DEC 24, 2019", "DEC 13, 2019", "DEC 13, 2019", "DEC 12, 2019", "DEC 9, 2019", "DEC 9, 2019", "DEC 8, 2019", "DEC 7, 2019", "DEC 15, 2019", "DEC 5, 2019", "NOV 27, 2019", "NOV 27, 2019", "NOV 22, 2019", "NOV 15, 2019", "NOV 14, 2019", "NOV 12, 2019", "DEC 6, 2019", "DEC 5, 2019", "NOV 9, 2019", "NOV 8, 2019", "NOV 7, 2019", "NOV 1, 2019", "NOV 1, 2019", "NOV 12, 2019", "OCT 31, 2019", "OCT 31, 2019", "OCT 28, 2019", "OCT 26, 2019", "OCT 24, 2019", "OCT 24, 2019", "OCT 23, 2019", "NOV 1, 2019", "OCT 23, 2019", "OCT 23, 2019", "OCT 23, 2019", "OCT 22, 2019", "OCT 22, 2019", "OCT 22, 2019", "OCT 22, 2019", "OCT 23, 2019", "OCT 23, 2019", "OCT 22, 2019", "OCT 22, 2019", "OCT 22, 2019", "OCT 22, 2019", "OCT 22, 2019", "OCT 22, 2019", "OCT 22, 2019", "OCT 18, 2019", "OCT 14, 2019", "OCT 10, 2019", "OCT 9, 2019", "OCT 9, 2019", "OCT 7, 2019", "OCT 3, 2019", "OCT 22, 2019", "OCT 1, 2019", "OCT 1, 2019", "SEP 30, 2019", "SEP 27, 2019", "SEP 24, 2019", "SEP 16, 2019", "SEP 14, 2019", "OCT 2, 2019", "SEP 11, 2019", "SEP 9, 2019", "SEP 3, 2019", "SEP 1, 2019", "AUG 30, 2019", "AUG 25, 2019", "AUG 21, 2019", "SEP 13, 2019", "SEP 11, 2019", "SEP 9, 2019", "SEP 3, 2019", "SEP 1, 2019", "AUG 30, 2019", "AUG 25, 2019", "AUG 21, 2019", "SEP 13, 2019", "JUL 23, 2019", "JUL 23, 2019", "JUL 23, 2019", "JUL 23, 2019", "JUL 23, 2019", "JUL 22, 2019", "JUL 22, 2019", "JUL 24, 2019", "JUL 17, 2019", "JUL 16, 2019", "JUL 8, 2019", "JUL 8, 2019", "JUL 4, 2019", "JUN 30, 2019", "JUN 30, 2019", "JUL 20, 2019", "JUN 25, 2019", "JUN 25, 2019", "JUN 25, 2019", "JUN 19, 2019", "JUN 18, 2019", "JUN 17, 2019", "JUN 17, 2019", "JUN 25, 2019", "JUN 25, 2019", "JUN 6, 2019", "JUN 3, 2019", "JUN 3, 2019", "MAY 26, 2019", "MAY 24, 2019", "JUN 13, 2019", "MAY 15, 2019", "MAY 14, 2019", "MAY 9, 2019", "MAY 9, 2019", "MAY 7, 2019", "MAY 6, 2019", "MAY 2, 2019", "MAY 23, 2019", "MAY 15, 2019", "MAY 14, 2019", "MAY 9, 2019", "APR 25, 2019", "APR 24, 2019", "APR 24, 2019", "APR 24, 2019", "MAY 2, 2019", "APR 23, 2019", "APR 22, 2019", "APR 17, 2019", "APR 17, 2019", "APR 17, 2019", "APR 17, 2019", "APR 17, 2019", "APR 24, 2019", "APR 17, 2019", "APR 16, 2019", "APR 16, 2019", "APR 14, 2019", "APR 12, 2019", "APR 11, 2019", "APR 11, 2019", "APR 17, 2019", "APR 9, 2019", "APR 6, 2019", "APR 6, 2019", "APR 4, 2019", "APR 4, 2019", "APR 4, 2019", "APR 4, 2019", "APR 11, 2019", "APR 3, 2019", "APR 2, 2019", "APR 1, 2019", "MAR 31, 2019", "MAR 30, 2019", "MAR 28, 2019", "MAR 28, 2019", "APR 3, 2019", "MAR 28, 2019", "MAR 27, 2019", "MAR 26, 2019", "MAR 26, 2019", "MAR 26, 2019", "MAR 26, 2019", "MAR 26, 2019", "MAR 28, 2019", "MAR 28, 2019", "MAR 27, 2019", "MAR 26, 2019", "MAR 25, 2019", "MAR 24, 2019", "MAR 23, 2019", "MAR 22, 2019", "MAR 25, 2019", "MAR 22, 2019", "MAR 22, 2019", "MAR 22, 2019", "MAR 22, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 22, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 13, 2019", "MAR 12, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 15, 2019", "MAR 14, 2019", "MAR 13, 2019", "MAR 13, 2019", "MAR 12, 2019", "MAR 21, 2019", "MAR 4, 2019", "MAR 4, 2019", "MAR 4, 2019", "MAR 4, 2019", "MAR 4, 2019", "MAR 4, 2019", "MAR 4, 2019", "MAR 4, 2019", "MAR 4, 2019", "MAR 4, 2019", "FEB 27, 2019", "FEB 26, 2019", "FEB 26, 2019", "FEB 25, 2019", "FEB 25, 2019", "MAR 4, 2019", "FEB 22, 2019", "FEB 21, 2019", "FEB 21, 2019", "FEB 20, 2019", "FEB 19, 2019", "FEB 17, 2019", "FEB 17, 2019", "FEB 22, 2019", "FEB 14, 2019", "FEB 14, 2019", "FEB 14, 2019", "FEB 13, 2019", "FEB 11, 2019", "FEB 8, 2019", "FEB 7, 2019", "FEB 15, 2019", "FEB 14, 2019", "FEB 14, 2019", "FEB 1, 2019", "JAN 30, 2019", "JAN 29, 2019", "JAN 29, 2019", "FEB 7, 2019", "JAN 29, 2019", "JAN 29, 2019", "JAN 29, 2019", "JAN 29, 2019", "JAN 29, 2019", "JAN 29, 2019", "JAN 29, 2019", "JAN 29, 2019", "JAN 29, 2019", "JAN 28, 2019", "JAN 28, 2019", "JAN 26, 2019", "JAN 24, 2019", "JAN 21, 2019", "JAN 21, 2019", "JAN 29, 2019", "JAN 29, 2019", "JAN 28, 2019", "JAN 28, 2019", "JAN 11, 2019", "JAN 9, 2019", "JAN 9, 2019", "JAN 8, 2019", "JAN 19, 2019", "JAN 6, 2019", "JAN 4, 2019", "JAN 4, 2019", "DEC 27, 2018", "DEC 24, 2018", "DEC 21, 2018", "DEC 21, 2018", "JAN 7, 2019", "DEC 21, 2018", "DEC 21, 2018", "DEC 21, 2018", "DEC 20, 2018", "DEC 18, 2018", "DEC 18, 2018", "DEC 18, 2018", "DEC 21, 2018", "DEC 18, 2018", "DEC 18, 2018", "DEC 17, 2018", "DEC 16, 2018", "DEC 16, 2018", "DEC 16, 2018", "DEC 15, 2018", "DEC 18, 2018", "DEC 18, 2018", "DEC 18, 2018", "DEC 17, 2018", "DEC 12, 2018", "DEC 11, 2018", "DEC 10, 2018", "DEC 7, 2018", "DEC 13, 2018", "DEC 3, 2018", "NOV 29, 2018", "NOV 22, 2018", "NOV 21, 2018", "NOV 21, 2018", "NOV 18, 2018", "NOV 18, 2018", "DEC 4, 2018", "NOV 15, 2018", "NOV 14, 2018", "NOV 12, 2018", "NOV 12, 2018", "NOV 9, 2018", "NOV 8, 2018", "NOV 7, 2018", "NOV 18, 2018", "OCT 31, 2018", "OCT 30, 2018", "OCT 26, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 24, 2018", "NOV 5, 2018", "OCT 31, 2018", "OCT 30, 2018", "OCT 26, 2018", "OCT 24, 2018", "OCT 23, 2018", "OCT 23, 2018", "OCT 23, 2018", "OCT 23, 2018", "OCT 22, 2018", "OCT 22, 2018", "OCT 21, 2018", "OCT 19, 2018", "OCT 19, 2018", "OCT 19, 2018", "OCT 15, 2018", "OCT 22, 2018", "OCT 22, 2018", "OCT 22, 2018", "OCT 21, 2018", "OCT 19, 2018", "OCT 19, 2018", "OCT 10, 2018", "OCT 8, 2018", "OCT 15, 2018", "OCT 4, 2018", "OCT 4, 2018", "OCT 2, 2018", "SEP 28, 2018", "SEP 26, 2018", "SEP 21, 2018", "SEP 21, 2018", "OCT 8, 2018", "SEP 20, 2018", "SEP 17, 2018", "SEP 17, 2018", "SEP 16, 2018", "SEP 16, 2018", "SEP 14, 2018", "SEP 14, 2018", "SEP 21, 2018", "SEP 13, 2018", "SEP 12, 2018", "SEP 12, 2018", "SEP 11, 2018", "SEP 11, 2018", "SEP 10, 2018", "SEP 6, 2018", "SEP 13, 2018", "AUG 31, 2018", "AUG 31, 2018", "AUG 30, 2018", "AUG 29, 2018", "AUG 27, 2018", "AUG 27, 2018", "AUG 24, 2018", "SEP 5, 2018", "AUG 22, 2018", "AUG 17, 2018", "AUG 17, 2018", "AUG 17, 2018", "AUG 16, 2018", "AUG 16, 2018", "AUG 15, 2018", "AUG 23, 2018", "AUG 11, 2018", "AUG 9, 2018", "AUG 6, 2018", "AUG 6, 2018", "AUG 6, 2018", "AUG 3, 2018", "AUG 3, 2018", "AUG 13, 2018", "AUG 2, 2018", "AUG 1, 2018", "AUG 1, 2018", "AUG 1, 2018", "AUG 1, 2018", "JUL 31, 2018", "JUL 27, 2018", "AUG 3, 2018", "JUL 26, 2018", "JUL 26, 2018", "JUL 26, 2018", "JUL 26, 2018", "JUL 25, 2018", "JUL 25, 2018", "JUL 25, 2018", "JUL 27, 2018", "JUL 25, 2018", "JUL 25, 2018", "JUL 24, 2018", "JUL 24, 2018", "JUL 24, 2018", "JUL 24, 2018", "JUL 24, 2018", "JUL 25, 2018", "JUL 24, 2018", "JUL 24, 2018", "JUL 24, 2018", "JUL 24, 2018", "JUL 23, 2018", "JUL 23, 2018", "JUL 23, 2018", "JUL 24, 2018", "JUL 24, 2018", "JUL 24, 2018", "JUL 24, 2018", "JUL 18, 2018", "JUL 18, 2018", "JUL 16, 2018", "JUL 15, 2018", "JUL 23, 2018", "JUL 15, 2018", "JUL 15, 2018", "JUL 13, 2018", "JUL 13, 2018", "JUL 13, 2018", "JUL 13, 2018", "JUL 12, 2018", "JUL 15, 2018", "JUL 12, 2018", "JUL 11, 2018", "JUL 11, 2018", "JUL 11, 2018", "JUL 10, 2018", "JUL 10, 2018", "JUL 10, 2018", "JUL 12, 2018", "JUL 12, 2018", "JUL 9, 2018", "JUL 9, 2018", "JUL 9, 2018", "JUL 9, 2018", "JUL 8, 2018", "JUL 10, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 7, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 3, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUN 25, 2018", "JUN 20, 2018", "JUN 20, 2018", "JUN 19, 2018", "JUN 19, 2018", "JUL 2, 2018", "JUN 18, 2018", "JUN 18, 2018", "JUN 18, 2018", "JUN 18, 2018", "JUN 18, 2018", "JUN 18, 2018", "JUN 17, 2018", "JUN 18, 2018", "JUN 17, 2018", "JUN 15, 2018", "JUN 15, 2018", "JUN 15, 2018", "JUN 14, 2018", "JUN 13, 2018", "JUN 13, 2018", "JUN 17, 2018", "JUN 11, 2018", "JUN 8, 2018", "JUN 8, 2018", "JUN 7, 2018", "JUN 6, 2018", "JUN 6, 2018", "JUN 6, 2018", "JUN 13, 2018", "JUN 4, 2018", "JUN 3, 2018", "MAY 30, 2018", "MAY 24, 2018", "MAY 24, 2018", "MAY 24, 2018", "MAY 24, 2018", "JUN 4, 2018", "MAY 18, 2018", "MAY 17, 2018", "MAY 17, 2018", "MAY 15, 2018", "MAY 15, 2018", "MAY 14, 2018", "MAY 14, 2018", "MAY 21, 2018", "MAY 11, 2018", "MAY 10, 2018", "MAY 9, 2018", "MAY 9, 2018", "MAY 2, 2018", "MAY 1, 2018", "MAY 1, 2018", "MAY 11, 2018", "APR 30, 2018", "APR 28, 2018", "APR 27, 2018", "APR 27, 2018", "APR 26, 2018", "APR 26, 2018", "APR 25, 2018", "APR 30, 2018", "APR 25, 2018", "APR 25, 2018", "APR 24, 2018", "APR 24, 2018", "APR 24, 2018", "APR 24, 2018", "APR 24, 2018", "APR 25, 2018", "APR 24, 2018", "APR 24, 2018", "APR 23, 2018", "APR 23, 2018", "APR 23, 2018", "APR 23, 2018", "APR 20, 2018", "APR 24, 2018", "APR 20, 2018", "APR 20, 2018", "APR 20, 2018", "APR 18, 2018", "APR 16, 2018", "APR 15, 2018", "APR 15, 2018", "APR 20, 2018", "APR 20, 2018", "APR 12, 2018", "APR 12, 2018", "APR 12, 2018", "APR 11, 2018", "APR 11, 2018", "APR 10, 2018", "APR 12, 2018", "APR 10, 2018", "APR 10, 2018", "APR 9, 2018", "APR 9, 2018", "APR 7, 2018", "APR 6, 2018", "APR 6, 2018", "APR 10, 2018", "APR 4, 2018", "MAR 30, 2018", "MAR 25, 2018", "MAR 24, 2018", "MAR 22, 2018", "MAR 21, 2018", "MAR 20, 2018", "APR 5, 2018", "MAR 19, 2018", "MAR 18, 2018", "MAR 18, 2018", "MAR 16, 2018", "MAR 14, 2018", "MAR 14, 2018", "MAR 14, 2018", "MAR 19, 2018", "MAR 13, 2018", "MAR 13, 2018", "MAR 13, 2018", "MAR 13, 2018", "MAR 12, 2018", "MAR 12, 2018", "MAR 9, 2018", "MAR 14, 2018", "MAR 1, 2018", "FEB 26, 2018", "FEB 26, 2018", "FEB 23, 2018", "FEB 22, 2018", "FEB 21, 2018", "FEB 20, 2018", "MAR 6, 2018", "FEB 19, 2018", "FEB 18, 2018", "FEB 17, 2018", "FEB 16, 2018", "FEB 16, 2018", "FEB 16, 2018", "FEB 16, 2018", "FEB 20, 2018", "FEB 19, 2018", "FEB 18, 2018", "FEB 14, 2018", "FEB 14, 2018", "FEB 14, 2018", "FEB 14, 2018", "FEB 14, 2018", "FEB 15, 2018", "FEB 10, 2018", "FEB 10, 2018", "FEB 9, 2018", "FEB 9, 2018", "FEB 8, 2018", "FEB 8, 2018", "FEB 3, 2018", "FEB 13, 2018", "JAN 29, 2018", "JAN 29, 2018", "JAN 29, 2018", "JAN 26, 2018", "JAN 26, 2018", "JAN 26, 2018", "JAN 26, 2018", "JAN 29, 2018", "JAN 25, 2018", "JAN 25, 2018", "JAN 25, 2018", "JAN 25, 2018", "JAN 25, 2018", "JAN 25, 2018", "JAN 25, 2018", "JAN 26, 2018", "JAN 25, 2018", "JAN 25, 2018", "JAN 24, 2018", "JAN 24, 2018", "JAN 24, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 25, 2018", "JAN 25, 2018", "JAN 24, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 22, 2018", "JAN 19, 2018", "JAN 19, 2018", "JAN 19, 2018", "JAN 18, 2018", "JAN 17, 2018", "JAN 22, 2018", "JAN 15, 2018", "JAN 14, 2018", "JAN 13, 2018", "JAN 11, 2018", "JAN 9, 2018", "JAN 8, 2018", "JAN 8, 2018", "JAN 15, 2018", "JAN 5, 2018", "JAN 5, 2018", "JAN 4, 2018", "JAN 3, 2018", "JAN 3, 2018", "JAN 2, 2018", "DEC 29, 2017", "JAN 8, 2018", "DEC 27, 2017", "DEC 27, 2017", "DEC 22, 2017", "DEC 22, 2017", "DEC 21, 2017", "DEC 21, 2017", "DEC 21, 2017", "DEC 27, 2017", "DEC 21, 2017", "DEC 21, 2017", "DEC 21, 2017", "DEC 20, 2017", "DEC 20, 2017", "DEC 20, 2017", "DEC 20, 2017", "DEC 21, 2017", "DEC 20, 2017", "DEC 14, 2017", "DEC 14, 2017", "DEC 13, 2017", "DEC 13, 2017", "DEC 12, 2017", "DEC 11, 2017", "DEC 20, 2017", "DEC 5, 2017", "DEC 4, 2017", "NOV 30, 2017", "NOV 30, 2017", "NOV 30, 2017", "NOV 30, 2017", "DEC 6, 2017", "NOV 29, 2017", "NOV 29, 2017", "NOV 29, 2017", "NOV 28, 2017", "NOV 27, 2017", "NOV 27, 2017", "NOV 27, 2017", "NOV 30, 2017", "NOV 27, 2017", "NOV 22, 2017", "NOV 22, 2017", "NOV 21, 2017", "NOV 20, 2017", "NOV 18, 2017", "NOV 17, 2017", "NOV 27, 2017", "NOV 27, 2017", "NOV 22, 2017", "NOV 22, 2017", "NOV 21, 2017", "NOV 20, 2017", "NOV 18, 2017", "NOV 17, 2017", "NOV 27, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 14, 2017", "NOV 13, 2017", "NOV 11, 2017", "NOV 10, 2017", "NOV 9, 2017", "NOV 16, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 14, 2017", "NOV 13, 2017", "NOV 11, 2017", "NOV 10, 2017", "NOV 9, 2017", "NOV 16, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 14, 2017", "NOV 13, 2017", "NOV 11, 2017", "NOV 10, 2017", "NOV 9, 2017", "NOV 16, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 14, 2017", "NOV 13, 2017", "NOV 11, 2017", "NOV 10, 2017", "NOV 9, 2017", "NOV 16, 2017", "NOV 6, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 2, 2017", "NOV 2, 2017", "NOV 1, 2017", "OCT 25, 2017", "OCT 23, 2017", "OCT 23, 2017", "OCT 23, 2017", "OCT 20, 2017", "OCT 17, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 17, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 13, 2017", "OCT 12, 2017", "OCT 10, 2017", "OCT 9, 2017", "OCT 16, 2017", "OCT 6, 2017", "OCT 6, 2017", "OCT 5, 2017", "OCT 5, 2017", "OCT 5, 2017", "OCT 5, 2017", "OCT 5, 2017", "OCT 6, 2017", "OCT 6, 2017", "OCT 6, 2017", "OCT 4, 2017", "OCT 4, 2017", "OCT 4, 2017", "OCT 4, 2017", "OCT 5, 2017", "OCT 4, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 4, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 2, 2017", "OCT 2, 2017", "OCT 2, 2017", "OCT 2, 2017", "OCT 2, 2017", "OCT 3, 2017", "SEP 28, 2017", "SEP 28, 2017", "SEP 26, 2017", "SEP 25, 2017", "SEP 19, 2017", "SEP 19, 2017", "SEP 19, 2017", "SEP 29, 2017", "SEP 18, 2017", "SEP 15, 2017", "SEP 13, 2017", "SEP 13, 2017", "SEP 11, 2017", "SEP 11, 2017", "SEP 11, 2017", "SEP 19, 2017", "SEP 6, 2017", "AUG 31, 2017", "AUG 30, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 28, 2017", "SEP 7, 2017", "SEP 6, 2017", "AUG 31, 2017", "AUG 30, 2017", "AUG 29, 2017", "AUG 23, 2017", "AUG 22, 2017", "AUG 21, 2017", "AUG 28, 2017", "AUG 17, 2017", "AUG 17, 2017", "AUG 16, 2017", "AUG 15, 2017", "AUG 14, 2017", "AUG 11, 2017", "AUG 9, 2017", "AUG 18, 2017", "AUG 8, 2017", "AUG 7, 2017", "AUG 7, 2017", "AUG 4, 2017", "AUG 1, 2017", "JUL 31, 2017", "JUL 28, 2017", "AUG 8, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 25, 2017", "JUL 25, 2017", "JUL 25, 2017", "JUL 28, 2017", "JUL 25, 2017", "JUL 25, 2017", "JUL 25, 2017", "JUL 25, 2017", "JUL 24, 2017", "JUL 24, 2017", "JUL 23, 2017", "JUL 25, 2017", "JUL 19, 2017", "JUL 19, 2017", "JUL 18, 2017", "JUL 18, 2017", "JUL 18, 2017", "JUL 17, 2017", "JUL 17, 2017", "JUL 20, 2017", "JUL 19, 2017", "JUL 12, 2017", "JUL 10, 2017", "JUL 10, 2017", "JUL 6, 2017", "JUL 5, 2017", "JUL 16, 2017", "JUL 13, 2017", "JUL 13, 2017", "JUL 1, 2017", "JUN 29, 2017", "JUN 26, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUL 5, 2017", "JUN 21, 2017", "JUN 19, 2017", "JUN 16, 2017", "JUN 16, 2017", "JUN 15, 2017", "JUN 15, 2017", "JUN 14, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 19, 2017", "JUN 13, 2017", "JUN 12, 2017", "JUN 9, 2017", "JUN 6, 2017", "JUN 14, 2017", "JUN 14, 2017", "JUN 2, 2017", "JUN 2, 2017", "JUN 2, 2017", "MAY 31, 2017", "MAY 31, 2017", "MAY 31, 2017", "JUN 6, 2017", "JUN 5, 2017", "JUN 2, 2017", "JUN 2, 2017", "JUN 2, 2017", "MAY 26, 2017", "MAY 26, 2017", "MAY 25, 2017", "MAY 31, 2017", "MAY 24, 2017", "MAY 21, 2017", "MAY 18, 2017", "MAY 17, 2017", "MAY 16, 2017", "MAY 16, 2017", "MAY 15, 2017", "MAY 24, 2017", "MAY 11, 2017", "MAY 11, 2017", "MAY 10, 2017", "MAY 9, 2017", "MAY 7, 2017", "MAY 5, 2017", "MAY 5, 2017", "MAY 12, 2017", "MAY 4, 2017", "MAY 4, 2017", "MAY 4, 2017", "MAY 3, 2017", "MAY 2, 2017", "MAY 2, 2017", "APR 28, 2017", "MAY 5, 2017", "APR 26, 2017", "APR 26, 2017", "APR 26, 2017", "APR 25, 2017", "APR 25, 2017", "APR 25, 2017", "APR 25, 2017", "APR 27, 2017", "APR 25, 2017", "APR 25, 2017", "APR 25, 2017", "APR 25, 2017", "APR 24, 2017", "APR 24, 2017", "APR 24, 2017", "APR 25, 2017", "APR 24, 2017", "APR 24, 2017", "APR 23, 2017", "APR 20, 2017", "APR 20, 2017", "APR 19, 2017", "APR 18, 2017", "APR 24, 2017", "APR 18, 2017", "APR 17, 2017", "APR 10, 2017", "APR 10, 2017", "APR 7, 2017", "APR 6, 2017", "APR 5, 2017", "APR 18, 2017", "APR 3, 2017", "APR 3, 2017", "MAR 31, 2017", "MAR 31, 2017", "MAR 31, 2017", "MAR 29, 2017", "MAR 29, 2017", "APR 5, 2017", "MAR 22, 2017", "MAR 21, 2017", "MAR 21, 2017", "MAR 21, 2017", "MAR 17, 2017", "MAR 17, 2017", "MAR 17, 2017", "MAR 28, 2017", "MAR 16, 2017", "MAR 16, 2017", "MAR 16, 2017", "MAR 16, 2017", "MAR 16, 2017", "MAR 16, 2017", "MAR 16, 2017", "MAR 16, 2017", "MAR 16, 2017", "MAR 13, 2017", "MAR 13, 2017", "MAR 10, 2017", "MAR 10, 2017", "MAR 9, 2017", "MAR 8, 2017", "MAR 16, 2017", "MAR 7, 2017", "MAR 7, 2017", "MAR 7, 2017", "MAR 6, 2017", "MAR 6, 2017", "MAR 6, 2017", "MAR 3, 2017", "MAR 7, 2017", "MAR 1, 2017", "MAR 1, 2017", "FEB 28, 2017", "FEB 28, 2017", "FEB 27, 2017", "FEB 27, 2017", "FEB 23, 2017", "MAR 2, 2017", "MAR 1, 2017", "FEB 21, 2017", "FEB 20, 2017", "FEB 19, 2017", "FEB 16, 2017", "FEB 15, 2017", "FEB 13, 2017", "FEB 22, 2017", "FEB 11, 2017", "FEB 10, 2017", "FEB 10, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 7, 2017", "FEB 13, 2017", "FEB 11, 2017", "FEB 3, 2017", "FEB 3, 2017", "FEB 2, 2017", "FEB 2, 2017", "FEB 2, 2017", "FEB 2, 2017", "FEB 6, 2017", "FEB 2, 2017", "JAN 30, 2017", "JAN 27, 2017", "JAN 26, 2017", "JAN 26, 2017", "JAN 26, 2017", "JAN 26, 2017", "FEB 2, 2017", "JAN 26, 2017", "JAN 26, 2017", "JAN 25, 2017", "JAN 25, 2017", "JAN 25, 2017", "JAN 24, 2017", "JAN 24, 2017", "JAN 26, 2017", "JAN 20, 2017", "JAN 19, 2017", "JAN 19, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 21, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 16, 2017", "JAN 16, 2017", "JAN 13, 2017", "JAN 13, 2017", "JAN 13, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 16, 2017", "JAN 11, 2017", "JAN 10, 2017", "JAN 10, 2017", "JAN 12, 2017", "JAN 9, 2017", "JAN 6, 2017", "JAN 6, 2017", "JAN 6, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 9, 2017", "JAN 4, 2017", "JAN 4, 2017", "JAN 3, 2017", "DEC 30, 2016", "DEC 28, 2016", "DEC 28, 2016", "DEC 28, 2016", "JAN 4, 2017", "JAN 4, 2017", "DEC 27, 2016", "DEC 27, 2016", "DEC 27, 2016", "DEC 27, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 28, 2016", "DEC 27, 2016", "DEC 20, 2016", "DEC 20, 2016", "DEC 20, 2016", "DEC 18, 2016", "DEC 16, 2016", "DEC 14, 2016", "DEC 21, 2016", "DEC 13, 2016", "DEC 13, 2016", "DEC 13, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 11, 2016", "DEC 14, 2016", "DEC 9, 2016", "DEC 9, 2016", "DEC 9, 2016", "DEC 9, 2016", "DEC 9, 2016", "DEC 9, 2016", "DEC 9, 2016", "DEC 10, 2016", "DEC 8, 2016", "DEC 8, 2016", "DEC 7, 2016", "DEC 6, 2016", "DEC 6, 2016", "DEC 2, 2016", "DEC 2, 2016", "DEC 8, 2016", "DEC 1, 2016", "NOV 30, 2016", "NOV 30, 2016", "NOV 29, 2016", "NOV 25, 2016", "NOV 24, 2016", "NOV 23, 2016", "DEC 1, 2016", "NOV 23, 2016", "NOV 23, 2016", "NOV 23, 2016", "NOV 23, 2016", "NOV 23, 2016", "NOV 23, 2016", "NOV 23, 2016", "NOV 23, 2016", "NOV 22, 2016", "NOV 22, 2016", "NOV 22, 2016", "NOV 21, 2016", "NOV 21, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 22, 2016", "NOV 22, 2016", "NOV 22, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 15, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 9, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "OCT 28, 2016", "OCT 28, 2016", "OCT 28, 2016", "NOV 3, 2016", "OCT 28, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 26, 2016", "OCT 26, 2016", "OCT 28, 2016", "OCT 26, 2016", "OCT 26, 2016", "OCT 26, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 21, 2016", "OCT 20, 2016", "OCT 26, 2016", "OCT 19, 2016", "OCT 19, 2016", "OCT 18, 2016", "OCT 18, 2016", "OCT 17, 2016", "OCT 14, 2016", "OCT 14, 2016", "OCT 19, 2016", "OCT 12, 2016", "OCT 12, 2016", "OCT 11, 2016", "OCT 11, 2016", "OCT 10, 2016", "OCT 7, 2016", "OCT 7, 2016", "OCT 13, 2016", "OCT 5, 2016", "OCT 5, 2016", "SEP 28, 2016", "SEP 28, 2016", "SEP 28, 2016", "SEP 28, 2016", "SEP 28, 2016", "OCT 7, 2016", "OCT 5, 2016", "OCT 5, 2016", "SEP 26, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 19, 2016", "SEP 28, 2016", "SEP 18, 2016", "SEP 17, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 14, 2016", "SEP 13, 2016", "SEP 19, 2016", "SEP 13, 2016", "SEP 12, 2016", "SEP 9, 2016", "SEP 8, 2016", "SEP 8, 2016", "SEP 7, 2016", "SEP 7, 2016", "SEP 13, 2016", "SEP 13, 2016", "SEP 12, 2016", "SEP 2, 2016", "SEP 2, 2016", "AUG 31, 2016", "AUG 31, 2016", "SEP 6, 2016", "AUG 24, 2016", "AUG 22, 2016", "AUG 17, 2016", "AUG 16, 2016", "AUG 16, 2016", "AUG 16, 2016", "AUG 15, 2016", "AUG 25, 2016", "AUG 12, 2016", "AUG 12, 2016", "AUG 10, 2016", "AUG 10, 2016", "AUG 10, 2016", "AUG 9, 2016", "AUG 9, 2016", "AUG 15, 2016", "AUG 12, 2016", "AUG 12, 2016", "AUG 5, 2016", "AUG 4, 2016", "AUG 4, 2016", "AUG 4, 2016", "AUG 4, 2016", "AUG 8, 2016", "AUG 8, 2016", "AUG 6, 2016", "AUG 5, 2016", "AUG 4, 2016", "AUG 4, 2016", "AUG 2, 2016", "AUG 2, 2016", "AUG 4, 2016", "AUG 2, 2016", "AUG 2, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 2, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "JUL 29, 2016", "JUL 29, 2016", "JUL 28, 2016", "JUL 28, 2016", "JUL 28, 2016", "JUL 28, 2016", "JUL 27, 2016", "AUG 1, 2016", "JUL 25, 2016", "JUL 25, 2016", "JUL 22, 2016", "JUL 22, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 25, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 20, 2016", "JUL 21, 2016", "JUL 20, 2016", "JUL 19, 2016", "JUL 16, 2016", "JUL 15, 2016", "JUL 15, 2016", "JUL 15, 2016", "JUL 15, 2016", "JUL 20, 2016", "JUL 20, 2016", "JUL 19, 2016", "JUL 8, 2016", "JUL 8, 2016", "JUL 7, 2016", "JUN 30, 2016", "JUL 14, 2016", "JUN 28, 2016", "JUN 27, 2016", "JUN 24, 2016", "JUN 24, 2016", "JUN 24, 2016", "JUN 23, 2016", "JUN 21, 2016", "JUN 29, 2016", "JUN 21, 2016", "JUN 16, 2016", "JUN 13, 2016", "JUN 13, 2016", "JUN 12, 2016", "JUN 10, 2016", "JUN 10, 2016", "JUN 21, 2016", "JUN 9, 2016", "JUN 9, 2016", "JUN 8, 2016", "JUN 8, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 9, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 4, 2016", "JUN 3, 2016", "JUN 3, 2016", "JUN 7, 2016", "JUN 2, 2016", "JUN 2, 2016", "JUN 1, 2016", "JUN 1, 2016", "JUN 1, 2016", "MAY 31, 2016", "MAY 31, 2016", "JUN 3, 2016", "MAY 30, 2016", "MAY 28, 2016", "MAY 26, 2016", "MAY 24, 2016", "MAY 24, 2016", "MAY 19, 2016", "MAY 19, 2016", "MAY 31, 2016", "MAY 13, 2016", "MAY 12, 2016", "MAY 12, 2016", "MAY 10, 2016", "MAY 10, 2016", "MAY 5, 2016", "MAY 5, 2016", "MAY 16, 2016", "MAY 13, 2016", "MAY 12, 2016", "MAY 2, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "MAY 4, 2016", "APR 28, 2016", "APR 28, 2016", "APR 27, 2016", "APR 27, 2016", "APR 22, 2016", "APR 22, 2016", "APR 22, 2016", "APR 29, 2016", "APR 28, 2016", "APR 28, 2016", "APR 21, 2016", "APR 21, 2016", "APR 21, 2016", "APR 21, 2016", "APR 22, 2016", "APR 22, 2016", "APR 21, 2016", "APR 21, 2016", "APR 21, 2016", "APR 18, 2016", "APR 18, 2016", "APR 18, 2016", "APR 21, 2016", "APR 21, 2016", "APR 21, 2016", "APR 20, 2016", "APR 8, 2016", "APR 8, 2016", "APR 7, 2016", "APR 6, 2016", "APR 18, 2016", "APR 15, 2016", "APR 12, 2016", "APR 11, 2016", "APR 8, 2016", "APR 8, 2016", "APR 7, 2016", "APR 6, 2016", "APR 18, 2016", "APR 4, 2016", "MAR 28, 2016", "MAR 28, 2016", "MAR 15, 2016", "MAR 13, 2016", "MAR 11, 2016", "MAR 17, 2016", "MAR 16, 2016", "MAR 16, 2016", "MAR 16, 2016", "MAR 16, 2016", "MAR 15, 2016", "MAR 4, 2016", "FEB 26, 2016", "MAR 11, 2016", "MAR 10, 2016", "MAR 8, 2016", "MAR 7, 2016", "FEB 18, 2016", "FEB 15, 2016", "FEB 12, 2016", "FEB 26, 2016", "FEB 11, 2016", "FEB 11, 2016", "FEB 10, 2016", "FEB 9, 2016", "FEB 9, 2016", "FEB 7, 2016", "FEB 5, 2016", "FEB 12, 2016", "FEB 4, 2016", "FEB 3, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "JAN 29, 2016", "FEB 4, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 28, 2016", "JAN 26, 2016", "JAN 26, 2016", "JAN 25, 2016", "JAN 25, 2016", "JAN 20, 2016", "JAN 20, 2016", "JAN 18, 2016", "JAN 27, 2016", "JAN 16, 2016", "JAN 15, 2016", "JAN 15, 2016", "JAN 14, 2016", "JAN 14, 2016", "JAN 8, 2016", "JAN 8, 2016", "JAN 18, 2016", "DEC 27, 2015", "DEC 26, 2015", "DEC 24, 2015", "DEC 21, 2015", "DEC 17, 2015", "DEC 16, 2015", "DEC 16, 2015", "JAN 7, 2016", "DEC 27, 2015", "DEC 26, 2015", "DEC 24, 2015", "DEC 10, 2015", "DEC 9, 2015", "DEC 7, 2015", "DEC 14, 2015", "DEC 4, 2015", "DEC 3, 2015", "DEC 3, 2015", "DEC 2, 2015", "DEC 2, 2015", "DEC 1, 2015", "NOV 30, 2015", "DEC 7, 2015", "NOV 30, 2015", "NOV 27, 2015", "NOV 25, 2015", "NOV 25, 2015", "NOV 25, 2015", "NOV 24, 2015", "NOV 24, 2015", "NOV 30, 2015", "NOV 23, 2015", "NOV 19, 2015", "NOV 18, 2015", "NOV 17, 2015", "NOV 16, 2015", "NOV 16, 2015", "NOV 15, 2015", "NOV 24, 2015", "NOV 11, 2015", "NOV 11, 2015", "NOV 11, 2015", "NOV 9, 2015", "NOV 7, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 11, 2015", "NOV 4, 2015", "NOV 4, 2015", "NOV 2, 2015", "OCT 30, 2015", "OCT 30, 2015", "OCT 28, 2015", "OCT 28, 2015", "NOV 5, 2015", "OCT 24, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 22, 2015", "OCT 22, 2015", "OCT 21, 2015", "OCT 27, 2015", "OCT 24, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 22, 2015", "OCT 22, 2015", "OCT 21, 2015", "OCT 27, 2015", "OCT 21, 2015", "OCT 21, 2015", "OCT 21, 2015", "OCT 21, 2015", "OCT 21, 2015", "OCT 20, 2015", "OCT 20, 2015", "OCT 21, 2015", "OCT 20, 2015", "OCT 19, 2015", "OCT 17, 2015", "OCT 15, 2015", "OCT 12, 2015", "OCT 9, 2015", "OCT 8, 2015", "OCT 20, 2015", "OCT 7, 2015", "OCT 7, 2015", "OCT 7, 2015", "OCT 6, 2015", "OCT 5, 2015", "OCT 2, 2015", "OCT 1, 2015", "OCT 8, 2015", "SEP 26, 2015", "SEP 25, 2015", "SEP 25, 2015", "SEP 23, 2015", "SEP 22, 2015", "SEP 17, 2015", "SEP 17, 2015", "OCT 1, 2015", "SEP 14, 2015", "SEP 14, 2015", "SEP 13, 2015", "SEP 4, 2015", "SEP 4, 2015", "SEP 3, 2015", "SEP 2, 2015", "SEP 10, 2015", "AUG 30, 2015", "AUG 27, 2015", "AUG 26, 2015", "AUG 25, 2015", "AUG 25, 2015", "AUG 23, 2015", "AUG 20, 2015", "AUG 31, 2015", "AUG 30, 2015", "AUG 27, 2015", "AUG 26, 2015", "AUG 25, 2015", "AUG 7, 2015", "AUG 7, 2015", "AUG 19, 2015", "AUG 6, 2015", "AUG 5, 2015", "AUG 5, 2015", "AUG 5, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 3, 2015", "AUG 6, 2015", "JUL 31, 2015", "JUL 30, 2015", "JUL 30, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 27, 2015", "AUG 1, 2015", "JUL 27, 2015", "JUL 27, 2015", "JUL 27, 2015", "JUL 27, 2015", "JUL 27, 2015", "JUL 27, 2015", "JUL 24, 2015", "JUL 27, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 23, 2015", "JUL 23, 2015", "JUL 23, 2015", "JUL 23, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 23, 2015", "JUL 21, 2015", "JUL 21, 2015", "JUL 17, 2015", "JUL 22, 2015", "JUL 15, 2015", "JUL 15, 2015", "JUL 14, 2015", "JUL 14, 2015", "JUL 14, 2015", "JUL 13, 2015", "JUL 12, 2015", "JUL 16, 2015", "JUL 15, 2015", "JUL 10, 2015", "JUL 9, 2015", "JUL 8, 2015", "JUL 8, 2015", "JUL 7, 2015", "JUL 10, 2015", "JUL 6, 2015", "JUL 3, 2015", "JUL 2, 2015", "JUL 2, 2015", "JUL 2, 2015", "JUL 2, 2015", "JUL 2, 2015", "JUL 7, 2015", "JUL 6, 2015", "JUL 3, 2015", "JUL 2, 2015", "JUL 1, 2015", "JUL 1, 2015", "JUL 1, 2015", "JUN 29, 2015", "JUL 2, 2015", "JUN 29, 2015", "JUN 25, 2015", "JUN 23, 2015", "JUN 23, 2015", "JUN 19, 2015", "JUN 14, 2015", "JUN 12, 2015", "JUN 29, 2015", "JUN 29, 2015", "JUN 25, 2015", "JUN 23, 2015", "JUN 4, 2015", "JUN 2, 2015", "MAY 30, 2015", "MAY 28, 2015", "JUN 11, 2015", "MAY 23, 2015", "MAY 21, 2015", "MAY 17, 2015", "MAY 14, 2015", "MAY 13, 2015", "MAY 11, 2015", "MAY 7, 2015", "MAY 26, 2015", "MAY 23, 2015", "MAY 21, 2015", "MAY 17, 2015", "MAY 14, 2015", "MAY 13, 2015", "MAY 11, 2015", "MAY 7, 2015", "MAY 26, 2015", "MAY 23, 2015", "MAY 21, 2015", "MAY 5, 2015", "MAY 5, 2015", "MAY 5, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 6, 2015", "MAY 6, 2015", "MAY 6, 2015", "MAY 5, 2015", "MAY 5, 2015", "MAY 5, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 6, 2015", "MAY 6, 2015", "MAY 6, 2015", "MAY 5, 2015", "MAY 5, 2015", "MAY 5, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 6, 2015", "MAY 6, 2015", "MAY 6, 2015", "MAY 5, 2015", "MAY 5, 2015", "MAY 5, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 6, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 4, 2015", "APR 30, 2015", "APR 30, 2015", "APR 30, 2015", "APR 28, 2015", "APR 28, 2015", "APR 28, 2015", "APR 25, 2015", "APR 28, 2015", "APR 23, 2015", "APR 23, 2015", "APR 23, 2015", "APR 23, 2015", "APR 23, 2015", "APR 23, 2015", "APR 23, 2015", "APR 23, 2015", "APR 23, 2015", "APR 23, 2015", "APR 22, 2015", "APR 22, 2015", "APR 22, 2015", "APR 22, 2015", "APR 23, 2015", "APR 22, 2015", "APR 22, 2015", "APR 22, 2015", "APR 22, 2015", "APR 22, 2015", "APR 22, 2015", "APR 21, 2015", "APR 22, 2015", "APR 21, 2015", "APR 21, 2015", "APR 21, 2015", "APR 21, 2015", "APR 21, 2015", "APR 21, 2015", "APR 21, 2015", "APR 21, 2015", "APR 21, 2015", "APR 21, 2015", "APR 21, 2015", "APR 21, 2015", "APR 20, 2015", "APR 20, 2015", "APR 20, 2015", "APR 21, 2015", "APR 20, 2015", "APR 20, 2015", "APR 19, 2015", "APR 17, 2015", "APR 17, 2015", "APR 17, 2015", "APR 16, 2015", "APR 20, 2015", "APR 16, 2015", "APR 15, 2015", "APR 15, 2015", "APR 15, 2015", "APR 14, 2015", "APR 14, 2015", "APR 14, 2015", "APR 16, 2015", "APR 16, 2015", "APR 15, 2015", "APR 15, 2015", "APR 15, 2015", "APR 14, 2015", "APR 5, 2015", "APR 13, 2015", "APR 4, 2015", "APR 4, 2015", "APR 2, 2015", "APR 2, 2015", "APR 1, 2015", "APR 1, 2015", "APR 1, 2015", "APR 4, 2015", "MAR 30, 2015", "MAR 30, 2015", "MAR 29, 2015", "MAR 28, 2015", "MAR 26, 2015", "MAR 25, 2015", "MAR 25, 2015", "MAR 31, 2015", "MAR 30, 2015", "MAR 24, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 21, 2015", "MAR 25, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 19, 2015", "MAR 17, 2015", "MAR 16, 2015", "MAR 15, 2015", "MAR 13, 2015", "MAR 13, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 19, 2015", "MAR 17, 2015", "MAR 16, 2015", "MAR 15, 2015", "MAR 13, 2015", "MAR 13, 2015", "MAR 20, 2015", "MAR 10, 2015", "MAR 9, 2015", "MAR 8, 2015", "MAR 7, 2015", "MAR 6, 2015", "MAR 3, 2015", "MAR 2, 2015", "MAR 10, 2015", "MAR 10, 2015", "MAR 9, 2015", "MAR 8, 2015", "MAR 7, 2015", "MAR 6, 2015", "MAR 3, 2015", "MAR 2, 2015", "MAR 10, 2015", "MAR 1, 2015", "MAR 1, 2015", "FEB 27, 2015", "FEB 25, 2015", "FEB 22, 2015", "FEB 12, 2015", "FEB 11, 2015", "FEB 14, 2015", "FEB 11, 2015", "FEB 10, 2015", "FEB 10, 2015", "FEB 10, 2015", "FEB 10, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 11, 2015", "FEB 7, 2015", "FEB 7, 2015", "FEB 7, 2015", "FEB 6, 2015", "FEB 6, 2015", "FEB 5, 2015", "FEB 5, 2015", "FEB 8, 2015", "JAN 30, 2015", "JAN 30, 2015", "JAN 30, 2015", "JAN 30, 2015", "JAN 30, 2015", "JAN 29, 2015", "FEB 1, 2015", "JAN 27, 2015", "JAN 27, 2015", "JAN 26, 2015", "JAN 26, 2015", "JAN 21, 2015", "JAN 21, 2015", "JAN 29, 2015", "JAN 15, 2015", "JAN 14, 2015", "JAN 13, 2015", "JAN 13, 2015", "JAN 12, 2015", "JAN 11, 2015", "JAN 9, 2015", "JAN 15, 2015", "JAN 9, 2015", "JAN 9, 2015", "JAN 8, 2015", "JAN 7, 2015", "JAN 7, 2015", "JAN 6, 2015", "JAN 6, 2015", "JAN 9, 2015", "DEC 31, 2014", "DEC 30, 2014", "DEC 30, 2014", "DEC 26, 2014", "DEC 26, 2014", "DEC 26, 2014", "DEC 24, 2014", "JAN 6, 2015", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 21, 2014", "DEC 19, 2014", "DEC 19, 2014", "DEC 19, 2014", "DEC 19, 2014", "DEC 18, 2014", "DEC 22, 2014", "DEC 16, 2014", "DEC 16, 2014", "DEC 16, 2014", "DEC 16, 2014", "DEC 16, 2014", "DEC 16, 2014", "DEC 16, 2014", "DEC 16, 2014", "DEC 15, 2014", "DEC 15, 2014", "DEC 15, 2014", "DEC 15, 2014", "DEC 12, 2014", "DEC 12, 2014", "DEC 12, 2014", "DEC 16, 2014", "DEC 15, 2014", "DEC 15, 2014", "DEC 15, 2014", "DEC 15, 2014", "DEC 12, 2014", "DEC 12, 2014", "DEC 12, 2014", "DEC 12, 2014", "DEC 10, 2014", "DEC 10, 2014", "DEC 10, 2014", "DEC 9, 2014", "DEC 9, 2014", "DEC 9, 2014", "DEC 9, 2014", "DEC 10, 2014", "DEC 10, 2014", "DEC 10, 2014", "DEC 10, 2014", "DEC 9, 2014", "DEC 8, 2014", "DEC 8, 2014", "DEC 8, 2014", "DEC 9, 2014", "DEC 9, 2014", "DEC 9, 2014", "DEC 9, 2014", "DEC 8, 2014", "DEC 6, 2014", "DEC 5, 2014", "DEC 5, 2014", "DEC 8, 2014", "DEC 8, 2014", "DEC 8, 2014", "DEC 8, 2014", "DEC 4, 2014", "DEC 4, 2014", "DEC 4, 2014", "DEC 4, 2014", "DEC 5, 2014", "DEC 5, 2014", "DEC 5, 2014", "DEC 4, 2014", "DEC 4, 2014", "DEC 3, 2014", "DEC 3, 2014", "DEC 3, 2014", "DEC 4, 2014", "DEC 2, 2014", "DEC 2, 2014", "DEC 2, 2014", "DEC 2, 2014", "DEC 2, 2014", "DEC 2, 2014", "DEC 2, 2014", "DEC 3, 2014", "DEC 2, 2014", "DEC 2, 2014", "DEC 2, 2014", "DEC 2, 2014", "DEC 1, 2014", "DEC 1, 2014", "DEC 2, 2014", "NOV 28, 2014", "NOV 27, 2014", "NOV 26, 2014", "NOV 26, 2014", "NOV 26, 2014", "NOV 26, 2014", "NOV 25, 2014", "NOV 28, 2014", "NOV 25, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 21, 2014", "NOV 25, 2014", "NOV 25, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 20, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 17, 2014", "NOV 17, 2014", "NOV 19, 2014", "NOV 17, 2014", "NOV 14, 2014", "NOV 14, 2014", "NOV 14, 2014", "NOV 14, 2014", "NOV 13, 2014", "NOV 11, 2014", "NOV 17, 2014", "NOV 17, 2014", "NOV 14, 2014", "NOV 14, 2014", "NOV 14, 2014", "NOV 10, 2014", "NOV 10, 2014", "NOV 9, 2014", "NOV 11, 2014", "NOV 7, 2014", "NOV 7, 2014", "NOV 7, 2014", "NOV 7, 2014", "NOV 7, 2014", "NOV 6, 2014", "NOV 6, 2014", "NOV 7, 2014", "NOV 7, 2014", "NOV 7, 2014", "NOV 5, 2014", "NOV 4, 2014", "NOV 3, 2014", "OCT 31, 2014", "OCT 31, 2014", "NOV 6, 2014", "OCT 31, 2014", "OCT 31, 2014", "OCT 31, 2014", "OCT 31, 2014", "OCT 30, 2014", "OCT 30, 2014", "OCT 29, 2014", "OCT 31, 2014", "OCT 31, 2014", "OCT 29, 2014", "OCT 28, 2014", "OCT 28, 2014", "OCT 28, 2014", "OCT 28, 2014", "OCT 28, 2014", "OCT 29, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 24, 2014", "OCT 23, 2014", "OCT 22, 2014", "OCT 27, 2014", "OCT 22, 2014", "OCT 22, 2014", "OCT 22, 2014", "OCT 22, 2014", "OCT 21, 2014", "OCT 21, 2014", "OCT 20, 2014", "OCT 22, 2014", "OCT 19, 2014", "OCT 17, 2014", "OCT 16, 2014", "OCT 15, 2014", "OCT 13, 2014", "OCT 12, 2014", "OCT 8, 2014", "OCT 20, 2014", "OCT 19, 2014", "OCT 4, 2014", "OCT 3, 2014", "SEP 27, 2014", "SEP 25, 2014", "SEP 22, 2014", "SEP 22, 2014", "OCT 7, 2014", "OCT 5, 2014", "OCT 4, 2014", "OCT 3, 2014", "SEP 18, 2014", "SEP 18, 2014", "SEP 18, 2014", "SEP 18, 2014", "SEP 19, 2014", "SEP 19, 2014", "SEP 19, 2014", "SEP 16, 2014", "SEP 15, 2014", "SEP 15, 2014", "SEP 12, 2014", "SEP 12, 2014", "SEP 17, 2014", "SEP 11, 2014", "SEP 10, 2014", "SEP 10, 2014", "SEP 3, 2014", "SEP 2, 2014", "AUG 22, 2014", "AUG 20, 2014", "SEP 12, 2014", "SEP 11, 2014", "SEP 10, 2014", "SEP 10, 2014", "SEP 3, 2014", "SEP 2, 2014", "AUG 22, 2014", "AUG 20, 2014", "SEP 12, 2014", "SEP 11, 2014", "SEP 10, 2014", "SEP 10, 2014", "SEP 3, 2014", "SEP 2, 2014", "AUG 22, 2014", "AUG 20, 2014", "SEP 12, 2014", "SEP 11, 2014", "SEP 10, 2014", "SEP 10, 2014", "SEP 3, 2014", "SEP 2, 2014", "AUG 22, 2014", "JUL 25, 2014", "AUG 19, 2014", "AUG 19, 2014", "AUG 14, 2014", "AUG 11, 2014", "AUG 11, 2014", "JUL 31, 2014", "JUL 28, 2014", "JUL 25, 2014", "AUG 19, 2014", "JUL 25, 2014", "JUL 25, 2014", "JUL 25, 2014", "JUL 24, 2014", "JUL 24, 2014", "JUL 24, 2014", "JUL 24, 2014", "JUL 25, 2014", "JUL 25, 2014", "JUL 25, 2014", "JUL 25, 2014", "JUL 24, 2014", "JUL 24, 2014", "JUL 24, 2014", "JUL 24, 2014", "JUL 25, 2014", "JUL 24, 2014", "JUL 24, 2014", "JUL 24, 2014", "JUL 24, 2014", "JUL 24, 2014", "JUL 24, 2014", "JUL 23, 2014", "JUL 24, 2014", "JUL 23, 2014", "JUL 23, 2014", "JUL 23, 2014", "JUL 23, 2014", "JUL 23, 2014", "JUL 21, 2014", "JUL 21, 2014", "JUL 23, 2014", "JUL 11, 2014", "JUL 11, 2014", "JUL 10, 2014", "JUL 10, 2014", "JUL 8, 2014", "JUL 7, 2014", "JUL 7, 2014", "JUL 8, 2014", "JUL 8, 2014", "JUL 8, 2014", "JUL 3, 2014", "JUL 2, 2014", "JUL 2, 2014", "JUL 2, 2014", "JUL 2, 2014", "JUL 7, 2014", "JUL 1, 2014", "JUL 1, 2014", "JUL 1, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUL 1, 2014", "JUN 27, 2014", "JUN 26, 2014", "JUN 26, 2014", "JUN 26, 2014", "JUN 25, 2014", "JUN 25, 2014", "JUN 24, 2014", "JUN 27, 2014", "JUN 18, 2014", "JUN 18, 2014", "JUN 18, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 11, 2014", "JUN 10, 2014", "JUN 24, 2014", "JUN 6, 2014", "JUN 5, 2014", "MAY 29, 2014", "MAY 29, 2014", "MAY 29, 2014", "MAY 28, 2014", "MAY 27, 2014", "JUN 9, 2014", "MAY 23, 2014", "MAY 14, 2014", "MAY 8, 2014", "MAY 8, 2014", "MAY 7, 2014", "MAY 7, 2014", "MAY 6, 2014", "MAY 27, 2014", "MAY 5, 2014", "MAY 1, 2014", "APR 25, 2014", "APR 24, 2014", "APR 24, 2014", "APR 24, 2014", "APR 23, 2014", "MAY 5, 2014", "APR 23, 2014", "APR 23, 2014", "APR 23, 2014", "APR 23, 2014", "APR 23, 2014", "APR 22, 2014", "APR 22, 2014", "APR 23, 2014", "APR 22, 2014", "APR 22, 2014", "APR 22, 2014", "APR 22, 2014", "APR 22, 2014", "APR 21, 2014", "APR 21, 2014", "APR 22, 2014", "APR 16, 2014", "APR 15, 2014", "APR 14, 2014", "APR 14, 2014", "APR 11, 2014", "APR 10, 2014", "APR 10, 2014", "APR 17, 2014", "APR 3, 2014", "MAR 31, 2014", "MAR 31, 2014", "MAR 26, 2014", "MAR 26, 2014", "MAR 24, 2014", "MAR 24, 2014", "APR 7, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 20, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 24, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 20, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 17, 2014", "MAR 17, 2014", "MAR 17, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 18, 2014", "MAR 13, 2014", "MAR 12, 2014", "MAR 12, 2014", "MAR 11, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 13, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 7, 2014", "MAR 7, 2014", "MAR 7, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 6, 2014", "MAR 6, 2014", "MAR 6, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 4, 2014", "MAR 4, 2014", "MAR 4, 2014", "MAR 3, 2014", "MAR 5, 2014", "MAR 3, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 25, 2014", "FEB 25, 2014", "FEB 25, 2014", "FEB 27, 2014", "FEB 26, 2014", "FEB 26, 2014", "FEB 26, 2014", "FEB 25, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 21, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 19, 2014", "FEB 19, 2014", "FEB 21, 2014", "FEB 18, 2014", "FEB 18, 2014", "FEB 18, 2014", "FEB 14, 2014", "FEB 14, 2014", "FEB 14, 2014", "FEB 13, 2014", "FEB 19, 2014", "FEB 11, 2014", "FEB 11, 2014", "FEB 11, 2014", "FEB 11, 2014", "FEB 10, 2014", "FEB 10, 2014", "FEB 10, 2014", "FEB 13, 2014", "FEB 10, 2014", "FEB 7, 2014", "FEB 7, 2014", "FEB 6, 2014", "FEB 6, 2014", "FEB 6, 2014", "FEB 6, 2014", "FEB 10, 2014", "FEB 10, 2014", "FEB 7, 2014", "FEB 4, 2014", "FEB 4, 2014", "FEB 3, 2014", "FEB 3, 2014", "FEB 3, 2014", "FEB 6, 2014", "FEB 3, 2014", "JAN 31, 2014", "JAN 29, 2014", "JAN 29, 2014", "JAN 29, 2014", "JAN 29, 2014", "JAN 29, 2014", "FEB 3, 2014", "JAN 28, 2014", "JAN 28, 2014", "JAN 28, 2014", "JAN 28, 2014", "JAN 27, 2014", "JAN 27, 2014", "JAN 27, 2014", "JAN 28, 2014", "JAN 28, 2014", "JAN 17, 2014", "JAN 14, 2014", "JAN 14, 2014", "JAN 13, 2014", "JAN 10, 2014", "JAN 10, 2014", "JAN 23, 2014", "JAN 7, 2014", "JAN 3, 2014", "DEC 31, 2013", "DEC 10, 2013", "DEC 5, 2013", "DEC 4, 2013", "DEC 3, 2013", "JAN 9, 2014", "JAN 7, 2014", "JAN 3, 2014", "DEC 31, 2013", "NOV 25, 2013", "NOV 22, 2013", "NOV 22, 2013", "DEC 2, 2013", "NOV 19, 2013", "NOV 6, 2013", "NOV 4, 2013", "NOV 1, 2013", "OCT 31, 2013", "OCT 31, 2013", "OCT 31, 2013", "NOV 20, 2013", "OCT 28, 2013", "OCT 28, 2013", "OCT 28, 2013", "OCT 25, 2013", "OCT 25, 2013", "OCT 25, 2013", "OCT 25, 2013", "OCT 29, 2013", "OCT 23, 2013", "OCT 18, 2013", "OCT 17, 2013", "OCT 16, 2013", "OCT 15, 2013", "OCT 14, 2013", "OCT 9, 2013", "OCT 25, 2013", "OCT 23, 2013", "OCT 18, 2013", "OCT 17, 2013", "OCT 16, 2013", "OCT 15, 2013", "OCT 14, 2013", "OCT 9, 2013", "OCT 8, 2013", "OCT 8, 2013", "OCT 8, 2013", "OCT 4, 2013", "SEP 24, 2013", "SEP 24, 2013", "SEP 20, 2013", "SEP 20, 2013", "SEP 23, 2013", "SEP 23, 2013", "SEP 23, 2013", "SEP 23, 2013", "SEP 20, 2013", "SEP 20, 2013", "SEP 20, 2013", "SEP 20, 2013", "SEP 18, 2013", "SEP 18, 2013", "SEP 16, 2013", "SEP 16, 2013", "SEP 16, 2013", "SEP 13, 2013", "SEP 13, 2013", "SEP 18, 2013", "SEP 18, 2013", "SEP 18, 2013", "SEP 16, 2013", "SEP 16, 2013", "SEP 16, 2013", "SEP 13, 2013", "SEP 13, 2013", "SEP 18, 2013", "SEP 12, 2013", "SEP 12, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 11, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 10, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 6, 2013", "SEP 6, 2013", "SEP 9, 2013", "SEP 6, 2013", "SEP 6, 2013", "SEP 5, 2013", "SEP 5, 2013", "SEP 5, 2013", "SEP 5, 2013", "SEP 5, 2013", "SEP 6, 2013", "SEP 4, 2013", "SEP 4, 2013", "SEP 4, 2013", "SEP 3, 2013", "SEP 3, 2013", "SEP 3, 2013", "SEP 3, 2013", "SEP 5, 2013", "SEP 4, 2013", "SEP 4, 2013", "SEP 4, 2013", "AUG 29, 2013", "AUG 28, 2013", "AUG 28, 2013", "AUG 30, 2013", "AUG 30, 2013", "AUG 30, 2013", "AUG 30, 2013", "AUG 26, 2013", "AUG 26, 2013", "AUG 26, 2013", "AUG 28, 2013", "AUG 23, 2013", "AUG 22, 2013", "AUG 21, 2013", "AUG 21, 2013", "AUG 21, 2013", "AUG 21, 2013", "AUG 20, 2013", "AUG 26, 2013", "AUG 19, 2013", "AUG 19, 2013", "AUG 19, 2013", "AUG 16, 2013", "AUG 16, 2013", "AUG 16, 2013", "AUG 16, 2013", "AUG 19, 2013", "AUG 19, 2013", "AUG 19, 2013", "AUG 14, 2013", "AUG 14, 2013", "AUG 14, 2013", "AUG 14, 2013", "AUG 14, 2013", "AUG 15, 2013", "AUG 15, 2013", "AUG 13, 2013", "AUG 13, 2013", "AUG 13, 2013", "AUG 12, 2013", "AUG 12, 2013", "AUG 14, 2013", "AUG 13, 2013", "AUG 13, 2013", "AUG 13, 2013", "AUG 8, 2013", "AUG 8, 2013", "AUG 8, 2013", "AUG 8, 2013", "AUG 12, 2013", "AUG 7, 2013", "AUG 7, 2013", "AUG 7, 2013", "AUG 7, 2013", "AUG 6, 2013", "AUG 6, 2013", "AUG 6, 2013", "AUG 7, 2013", "AUG 5, 2013", "AUG 5, 2013", "AUG 2, 2013", "AUG 2, 2013", "AUG 2, 2013", "AUG 2, 2013", "AUG 1, 2013", "AUG 5, 2013", "JUL 31, 2013", "JUL 26, 2013", "JUL 25, 2013", "JUL 25, 2013", "JUL 25, 2013", "JUL 24, 2013", "JUL 24, 2013", "JUL 31, 2013", "JUL 31, 2013", "JUL 26, 2013", "JUL 25, 2013", "JUL 25, 2013", "JUL 25, 2013", "JUL 24, 2013", "JUL 24, 2013", "JUL 31, 2013", "JUL 23, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 11, 2013", "JUL 11, 2013", "JUL 24, 2013", "JUL 23, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 11, 2013", "JUL 11, 2013", "JUL 24, 2013", "JUL 23, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 11, 2013", "JUL 11, 2013", "JUL 24, 2013", "JUL 10, 2013", "JUL 9, 2013", "JUL 9, 2013", "JUL 8, 2013", "JUL 8, 2013", "JUL 8, 2013", "JUL 8, 2013", "JUL 11, 2013", "JUL 10, 2013", "JUL 9, 2013", "JUL 9, 2013", "JUL 8, 2013", "JUL 8, 2013", "JUL 8, 2013", "JUL 8, 2013", "JUL 11, 2013", "JUL 10, 2013", "JUL 9, 2013", "JUL 9, 2013", "JUL 8, 2013", "JUL 8, 2013", "JUL 8, 2013", "JUL 8, 2013", "JUL 11, 2013", "JUL 5, 2013", "JUL 5, 2013", "JUL 3, 2013", "JUN 25, 2013", "JUN 25, 2013", "JUN 24, 2013", "JUN 27, 2013", "JUN 27, 2013", "JUN 27, 2013", "JUN 26, 2013", "JUN 26, 2013", "JUN 25, 2013", "JUN 25, 2013", "JUN 24, 2013", "JUN 27, 2013", "JUN 21, 2013", "JUN 21, 2013", "JUN 20, 2013", "JUN 13, 2013", "JUN 12, 2013", "JUN 4, 2013", "JUN 3, 2013", "JUN 11, 2013", "APR 29, 2013", "APR 26, 2013", "APR 25, 2013", "APR 25, 2013", "APR 25, 2013", "APR 25, 2013", "APR 24, 2013", "APR 30, 2013", "APR 29, 2013", "APR 26, 2013", "APR 25, 2013", "APR 25, 2013", "APR 25, 2013", "APR 25, 2013", "APR 24, 2013", "APR 18, 2013", "APR 16, 2013", "APR 16, 2013", "APR 11, 2013", "APR 10, 2013", "APR 8, 2013", "APR 8, 2013", "APR 19, 2013", "APR 4, 2013", "APR 4, 2013", "APR 4, 2013", "APR 3, 2013", "APR 2, 2013", "MAR 28, 2013", "MAR 28, 2013", "APR 5, 2013", "MAR 27, 2013", "MAR 25, 2013", "MAR 25, 2013", "MAR 25, 2013", "MAR 22, 2013", "MAR 19, 2013", "MAR 13, 2013", "MAR 28, 2013", "MAR 8, 2013", "MAR 7, 2013", "MAR 5, 2013", "FEB 26, 2013", "FEB 25, 2013", "FEB 25, 2013", "FEB 21, 2013", "MAR 11, 2013", "FEB 11, 2013", "FEB 7, 2013", "FEB 7, 2013", "FEB 6, 2013", "FEB 6, 2013", "FEB 4, 2013", "JAN 29, 2013", "FEB 14, 2013", "FEB 11, 2013", "FEB 7, 2013", "FEB 7, 2013", "JAN 28, 2013", "JAN 25, 2013", "JAN 17, 2013", "JAN 9, 2013", "JAN 29, 2013", "JAN 8, 2013", "JAN 3, 2013", "JAN 3, 2013", "DEC 27, 2012", "DEC 17, 2012", "DEC 14, 2012", "DEC 12, 2012", "JAN 8, 2013", "NOV 23, 2012", "NOV 19, 2012", "NOV 19, 2012", "NOV 16, 2012", "NOV 7, 2012", "NOV 7, 2012", "NOV 2, 2012", "DEC 7, 2012", "NOV 23, 2012", "NOV 19, 2012", "NOV 19, 2012", "NOV 16, 2012", "NOV 7, 2012", "NOV 7, 2012", "NOV 1, 2012", "OCT 19, 2012", "OCT 19, 2012", "OCT 18, 2012", "OCT 17, 2012", "OCT 12, 2012", "OCT 12, 2012", "OCT 12, 2012", "OCT 23, 2012", "OCT 19, 2012", "OCT 19, 2012", "SEP 24, 2012", "SEP 24, 2012", "SEP 18, 2012", "SEP 14, 2012", "OCT 10, 2012", "SEP 13, 2012", "SEP 7, 2012", "SEP 6, 2012", "SEP 6, 2012", "SEP 5, 2012", "AUG 29, 2012", "AUG 28, 2012", "SEP 14, 2012", "AUG 20, 2012", "AUG 16, 2012", "AUG 14, 2012", "AUG 14, 2012", "AUG 13, 2012", "AUG 9, 2012", "AUG 9, 2012", "AUG 22, 2012", "AUG 6, 2012", "AUG 6, 2012", "AUG 2, 2012", "AUG 1, 2012", "JUL 30, 2012", "JUL 27, 2012", "JUL 26, 2012", "AUG 6, 2012", "AUG 6, 2012", "AUG 6, 2012", "AUG 2, 2012", "JUL 18, 2012", "JUL 13, 2012", "JUL 11, 2012", "JUL 10, 2012", "JUL 24, 2012", "JUL 2, 2012", "JUN 15, 2012", "JUN 14, 2012", "JUN 14, 2012", "JUN 8, 2012", "JUN 8, 2012", "JUN 4, 2012", "JUL 6, 2012", "MAY 29, 2012", "MAY 25, 2012", "MAY 24, 2012", "MAY 21, 2012", "MAY 18, 2012", "MAY 14, 2012", "MAY 11, 2012", "MAY 30, 2012", "MAY 29, 2012", "MAY 8, 2012", "MAY 4, 2012", "MAY 2, 2012", "MAY 1, 2012", "MAY 1, 2012", "APR 26, 2012", "MAY 11, 2012", "MAY 9, 2012", "MAY 8, 2012", "MAR 19, 2012", "MAR 16, 2012", "MAR 5, 2012", "FEB 29, 2012", "APR 25, 2012", "FEB 24, 2012", "FEB 23, 2012", "FEB 21, 2012", "FEB 17, 2012", "FEB 14, 2012", "FEB 9, 2012", "FEB 3, 2012", "FEB 28, 2012", "FEB 24, 2012", "FEB 23, 2012", "FEB 21, 2012", "FEB 17, 2012", "FEB 14, 2012", "FEB 9, 2012", "FEB 3, 2012", "FEB 28, 2012", "JAN 31, 2012", "JAN 30, 2012", "JAN 30, 2012", "JAN 27, 2012", "JAN 26, 2012", "JAN 25, 2012", "JAN 24, 2012", "FEB 1, 2012", "JAN 31, 2012", "JAN 30, 2012", "JAN 30, 2012", "JAN 27, 2012", "JAN 26, 2012", "JAN 25, 2012", "JAN 24, 2012", "FEB 1, 2012", "JAN 31, 2012", "JAN 30, 2012", "JAN 30, 2012", "JAN 27, 2012", "JAN 26, 2012", "JAN 25, 2012", "JAN 24, 2012", "FEB 1, 2012", "JAN 31, 2012", "JAN 30, 2012", "JAN 30, 2012", "JAN 27, 2012", "JAN 26, 2012", "JAN 25, 2012", "JAN 24, 2012", "FEB 1, 2012", "JAN 31, 2012", "JAN 30, 2012", "JAN 30, 2012", "JAN 27, 2012", "JAN 26, 2012", "JAN 25, 2012", "JAN 24, 2012", "FEB 1, 2012"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/tuesday-sector-leaders%3A-healthcare-services-2020-06-23", "https://www.nasdaq.com/articles/why-the-coming-year-will-make-or-break-biogens-stock-2020-06-23", "https://www.nasdaq.com/articles/meet-the-pharma-company-that-just-had-a-bigger-ipo-than-modernas-2020-06-23", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-bristol-myers-squibb-2020-06-21", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-biib-lbtya-2020-06-19", "https://www.nasdaq.com/articles/sp-500-movers%3A-biib-viac-2020-06-19", "https://www.nasdaq.com/articles/fda-nod-for-epzm-rare-court-rules-in-myls-favor-ocuphire-to-hop-onto-nasdaq-alpn-soars", "https://www.nasdaq.com/articles/oversold-conditions-for-biogen-biib-2020-06-18", "https://www.nasdaq.com/articles/tuesday-sector-leaders%3A-healthcare-services-2020-06-23", "https://www.nasdaq.com/articles/sp-500-closes-nominally-higher-amid-covid-19-spikes-muted-data-2020-06-18", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-18-2020%3A-bbirexnhcmbiibmyl-2020-06-18", "https://www.nasdaq.com/articles/sp-500-closes-nominally-higher-amid-covid-19-spikes-muted-data-2020-06-18-0", "https://www.nasdaq.com/articles/wall-street-oscillates-amid-covid-19-spikes-muted-data-2020-06-18", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-18-2020%3A-biibrexnhcm-2020-06-18", "https://www.nasdaq.com/articles/sp-500-muted-as-virus-cases-rise-jobless-claims-weigh-2020-06-18", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-spotify-first-solar-janone-designer-brands-2020-06-18", "https://www.nasdaq.com/articles/biogen-loses-patent-case-over-its-best-selling-drug-2020-06-18", "https://www.nasdaq.com/articles/stock-alert%3A-biogen-tanks-6-2020-06-18", "https://www.nasdaq.com/articles/u.s.-court-rules-in-favor-of-mylan-over-biogens-key-ms-drug-patent-2020-06-18", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-quicklogic-fox-factory-francescas-holdings-2020-06-18", "https://www.nasdaq.com/articles/u.s.-district-court-rules-for-mylan-in-ms-drug-patent-battle-with-biogen-2020-06-18", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-biogen-2020-06-18", "https://www.nasdaq.com/articles/stock-market-today%3A-stocks-mixed-on-disappointing-jobless-claims-2020-06-18", "https://www.nasdaq.com/articles/as-biogen-stock-struggles-look-elsewhere-for-biotech-exposure-2020-06-17", "https://www.nasdaq.com/articles/sp-500-dow-muted-as-virus-cases-rise-jobless-claims-weigh-2020-06-18", "https://www.nasdaq.com/articles/better-buy%3A-crispr-therapeutics-vs.-sangamo-therapeutics-2020-06-14", "https://www.nasdaq.com/articles/ibb-vrtx-biib-ilmn%3A-large-outflows-detected-at-etf-2020-06-12", "https://www.nasdaq.com/articles/biib-makes-notable-cross-below-critical-moving-average-2020-06-11", "https://www.nasdaq.com/articles/should-you-sell-biogen-stock-2020-06-10", "https://www.nasdaq.com/articles/biogen%3A-new-results-from-nurture-study-reveals-sustained-benefit-of-spinraza-2020-06-10", "https://www.nasdaq.com/articles/japans-fujifilm-to-spend-%24928-mln-to-double-capacity-of-danish-drug-facility-2020-06-09", "https://www.nasdaq.com/articles/7-of-the-best-blue-chip-stocks-to-buy-2020-06-08", "https://www.nasdaq.com/articles/implied-moat-analyst-target-price%3A-%2458-2020-06-15", "https://www.nasdaq.com/articles/despite-recent-speed-bumps-biogens-stock-will-soon-grow-again-2020-06-04", "https://www.nasdaq.com/articles/vir-biotechnology-is-bucking-the-biotech-covid-19-trends-and-stands-to-win-2020-06-01", "https://www.nasdaq.com/articles/got-%243000-here-are-3-great-biotech-stocks-to-buy-right-now-2020-05-29", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-axsome-therapeutics-2020-05-23", "https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-ive-ibm-fis-biib-2020-05-22", "https://www.nasdaq.com/articles/7-top-rated-biotech-stocks-to-buy-on-the-hunt-for-a-vaccine-2020-05-22", "https://www.nasdaq.com/articles/nothing-will-stop-biogen-stock-from-moving-higher-2020-05-19", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-inflow-2020-06-04", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-5-17-2020-2020-05-17", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-warren-buffett-5-17-2020-2020-05-17", "https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-mtum-amd-biib-hum-2020-05-13", "https://www.nasdaq.com/articles/5-stocks-buffett-probably-bought-in-the-first-quarter-2020-05-12", "https://www.nasdaq.com/articles/the-all-important-question-buffett-will-answer-this-week-2020-05-11", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-gm-axcella-beyond-meat-smiledirect-2020-05-06", "https://www.nasdaq.com/articles/apple-sells-%248.5-billion-in-bonds-to-fuel-share-buybacks-2020-05-05", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-joel-greenblatt-5-17-2020-2020-05-17", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-04-2020%3A-egrxvirraretevabiib-2020-05-04", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-04-2020%3A-virraretevabiib-2020-05-04", "https://www.nasdaq.com/articles/why-biogen-shares-fell-6.18-in-april-2020-05-04", "https://www.nasdaq.com/articles/has-biogen-found-the-answer-to-treating-alzheimers-2020-05-01", "https://www.nasdaq.com/articles/ibb-gild-vrtx-biib%3A-etf-inflow-alert-2020-04-30", "https://www.nasdaq.com/articles/better-buy%3A-cara-therapeutics-vs.-sangamo-therapeutics-2020-04-29", "https://www.nasdaq.com/articles/at-least-14-borrowers-rush-into-us-high-grade-primary-2020-04-27", "https://www.nasdaq.com/articles/apple-borrows-on-the-cheap-to-fund-buybacks-dividends-2020-05-04", "https://www.nasdaq.com/articles/japanese-shares-snap-3-day-losing-streak-as-battered-stocks-bought-back-2020-04-23", "https://www.nasdaq.com/articles/biogen-reports-first-quarter-results-shares-plunge-9.4-2020-04-22", "https://www.nasdaq.com/articles/biogen-inc-biib-q1-2020-earnings-call-transcript-2020-04-22", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-22-2020%3A-biibimmuprtavbiv-2020-04-22", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-cnne-biib-sfnc-2020-04-22", "https://www.nasdaq.com/articles/johnson-johnson-and-abbvie-earn-a-new-fda-approval-for-imbruvica-2020-04-22", "https://www.nasdaq.com/articles/analysts-forecast-13-upside-for-the-holdings-of-tok-2020-04-24", "https://www.nasdaq.com/articles/why-biogen-stock-is-sinking-today-2020-04-22", "https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-ibb-vrtx-biib-regn-2020-04-22", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-biib-lrcx-2020-04-22", "https://www.nasdaq.com/articles/sp-500-movers%3A-biib-expe-2020-04-22", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-22-2020%3A-bntx-pfe-tmo-biib-xlv-ibb-vht-iyh-2020-04-22", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-saexploration-holdings-unit-corp-expedia-group-2020-04-22", "https://www.nasdaq.com/articles/biogen-delays-alzheimers-drug-filing-plans-shares-fall-2020-04-22", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-snap-peck-company-vbi-vaccines-2020-04-22", "https://www.nasdaq.com/articles/biogen-posts-marginal-rise-in-first-quarter-sales-2020-04-22", "https://www.nasdaq.com/articles/biogen-q1-20-earnings-conference-call-at-8%3A00-am-et-2020-04-22", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-co-diagnostics-xeris-pharma-cyclacel-pharma-2020-04-20", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-dupont-occidental-petroleum-safe-t-group-2020-04-20", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-safe-t-group-ford-motor-facebook-2020-04-20", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-martin-zweig-4-19-2020-2020-04-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-4-19-2020-2020-04-19", "https://www.nasdaq.com/articles/biogen-q1-results-top-estimates-quick-facts-2020-04-22", "https://www.nasdaq.com/articles/biogen-reaches-analyst-target-price-2020-04-17", "https://www.nasdaq.com/articles/biogen-is-building-a-covid-19-biobank-with-the-broad-institute-2020-04-17", "https://www.nasdaq.com/articles/biogen-joins-consortium-for-building-covid-19-biobank-2020-04-16-0", "https://www.nasdaq.com/articles/biogen-joins-consortium-for-building-covid-19-biobank-2020-04-16", "https://www.nasdaq.com/articles/better-buy%3A-alnylam-pharmaceuticals-vs.-vir-biotechnology-2020-04-12", "https://www.nasdaq.com/articles/should-investors-take-a-chance-on-biogen-2020-04-10", "https://www.nasdaq.com/articles/biib-may-29th-options-begin-trading-2020-04-09", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-warren-buffett-4-19-2020-2020-04-19", "https://www.nasdaq.com/articles/biogen-reaches-analyst-target-price-2020-04-17", "https://www.nasdaq.com/articles/gsk-to-partner-with-vir-for-potential-covid-19-treatments-invest-%24250-mln-2020-04-06-1", "https://www.nasdaq.com/articles/gsk-to-partner-with-vir-for-potential-covid-19-treatments-invest-%24250-mln-2020-04-06-0", "https://www.nasdaq.com/articles/gsk-to-partner-with-vir-for-potential-covid-19-treatments-invest-%24250-mln-2020-04-06", "https://www.nasdaq.com/articles/3-warren-buffett-stocks-i-absolutely-positively-wouldnt-buy-right-now-2020-04-05", "https://www.nasdaq.com/articles/why-gilead-sciences-is-the-hottest-stock-to-buy-today-2020-04-04", "https://www.nasdaq.com/articles/3-big-stock-charts-for-thursday%3A-goldman-sachs-fedex-and-biogen-2020-04-09", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-biogen-2020-04-03", "https://www.nasdaq.com/articles/why-biogen-shares-rose-2.59-in-march-2020-04-02", "https://www.nasdaq.com/articles/so-your-biotech-announced-positive-phase-3-results-celebrating-could-be-premature-2020-04", "https://www.nasdaq.com/articles/ibb-vrtx-biib-ilmn%3A-etf-outflow-alert-2020-03-31", "https://www.nasdaq.com/articles/4-reasons-drug-stocks-are-a-buy-right-now-2020-03-30", "https://www.nasdaq.com/articles/first-week-of-biib-may-15th-options-trading-2020-03-27", "https://www.nasdaq.com/articles/bristol-myers-squibbs-multiple-sclerosis-drug-a-potential-blockbuster-wins-fda-approval", "https://www.nasdaq.com/articles/investors-are-wondering%3A-wheres-warren-buffett-2020-04-03", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-biogen-2020-04-03", "https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-biogen-2020-03-24", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-inflow-2020-03-23", "https://www.nasdaq.com/articles/are-these-warren-buffett-stocks-a-buy-at-beaten-down-prices-2020-03-23", "https://www.nasdaq.com/articles/berkshires-recent-purchases-show-why-value-investing-still-works-2020-03-20", "https://www.nasdaq.com/articles/why-biogen-gw-pharmaceuticals-and-vertex-pharmaceuticals-stocks-jumped-today-2020-03-17", "https://www.nasdaq.com/articles/7-biotech-stocks-to-buy-and-hold-in-2020-2020-03-16", "https://www.nasdaq.com/articles/4-reasons-biotech-stocks-are-a-buy-right-now-2020-03-25", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-warren-buffett-3-15-2020-2020-03-15", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-joel-greenblatt-3-15-2020-2020-03-15", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-martin-zweig-3-15-2020-2020-03-15", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-amgen-2020-03-15", "https://www.nasdaq.com/articles/why-these-drug-stocks-soared-today-2020-03-13", "https://www.nasdaq.com/articles/3-ways-coronavirus-lockdowns-put-biotech-and-big-pharma-on-hold-2020-03-13", "https://www.nasdaq.com/articles/biogen-and-vir-biotechnology-to-collaborate-to-find-a-treatment-for-the-coronavirus-2020", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-3-15-2020-2020-03-15", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-12-2020%3A-virbiibcemiazn-2020-03-12", "https://www.nasdaq.com/articles/ibb-gild-vrtx-biib%3A-large-outflows-detected-at-etf-2020-03-10", "https://www.nasdaq.com/articles/coronavirus-concerns-have-big-pharma-working-from-home-2020-03-09", "https://www.nasdaq.com/articles/is-ishares-nasdaq-biotechnology-index-fund-a-buy-2020-03-05", "https://www.nasdaq.com/articles/why-biogen-stock-rose-14.7-in-february-2020-03-03", "https://www.nasdaq.com/articles/former-biogen-ceo-to-become-biotechs-new-coronavirus-czar-2020-02-29", "https://www.nasdaq.com/articles/investors-endure-wild-ride-in-this-biotech-taking-on-covid-19-2020-02-29", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-12-2020%3A-poaivirbiibcemiazn-2020-03-12", "https://www.nasdaq.com/articles/biogen-could-score-a-major-win-if-alzheimers-drug-gets-the-green-light-2020-02-28", "https://www.nasdaq.com/articles/sangamo-therapeutics-and-biogen-announce-gene-therapy-deal-stock-up-39-2020-02-28", "https://www.nasdaq.com/articles/biogen-sangamo-sign-deal-to-develop-gene-therapies-for-neurological-diseases-2020-02-27", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-revenues-rose-85-in-2019-2020-02-26", "https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-ibb-gild-vrtx-biib-2020-02-26", "https://www.nasdaq.com/articles/warren-buffett-is-buying-this-stock-faster-than-any-other-2020-02-26", "https://www.nasdaq.com/articles/3-top-stocks-you-should-watch-to-invest-like-berkshire-hathaway-2020-02-25", "https://www.nasdaq.com/articles/heres-why-sangamo-therapeutics-jumped-higher-today-2020-02-28", "https://www.nasdaq.com/articles/warren-buffetts-2-pure-play-pharma-picks-are-real-head-scratchers-2020-02-24", "https://www.nasdaq.com/articles/top-stocks-warren-buffett-just-bought-2020-02-21", "https://www.nasdaq.com/articles/warren-buffetts-big-biotech-bet-is-1-of-his-riskiest-wagers-ever-2020-02-19", "https://www.nasdaq.com/articles/ibb-gild-vrtx-biib%3A-etf-outflow-alert-2020-02-18", "https://www.nasdaq.com/articles/16-stocks-warren-buffett-is-buying-and-selling-2020-02-18", "https://www.nasdaq.com/articles/stock-alert%3A-warren-buffetts-berkshire-hathaway-reveals-stake-in-kroger-biogen-2020-02-18", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/why-did-warren-buffett-buy-these-6-stocks-in-q4-2020-02-25", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-warren-buffett-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-david-dreman-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-joel-greenblatt-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-bristol-myers-squibb-2020-02-16", "https://www.nasdaq.com/articles/warren-buffetts-berkshire-hathaway-dives-into-biotechnology-2020-02-15", "https://www.nasdaq.com/articles/3-biotech-stocks-that-made-early-shareholders-millionaires-2020-02-13", "https://www.nasdaq.com/articles/tuesday-sector-laggards%3A-consumer-products-healthcare-2020-02-11", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-martin-zweig-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/a-double-failure-of-alzheimers-drugs-2020-02-10", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2020-02-10", "https://www.nasdaq.com/articles/3-biotech-companies-analyzed-2020-02-07", "https://www.nasdaq.com/articles/roche-presents-spinal-muscular-atrophy-drug-data-2020-02-07", "https://www.nasdaq.com/articles/is-this-under-the-radar-stock-set-to-succeed-in-alzheimers-disease-2020-02-07", "https://www.nasdaq.com/articles/why-amgen-stock-dropped-10.4-in-january-2020-02-05", "https://www.nasdaq.com/articles/biogen-surges-after-winning-crucial-multiple-sclerosis-drug-patent-2020-02-05", "https://www.nasdaq.com/articles/will-biogens-big-patent-victory-ease-investor-worries-about-its-alzheimers-drug-2020-02-11", "https://www.nasdaq.com/articles/why-biogen-shares-soared-today-2020-02-05", "https://www.nasdaq.com/articles/look-under-the-hood%3A-iwx-has-11-upside-2020-02-04", "https://www.nasdaq.com/articles/pfizers-biosimilar-ruxience-gets-eu-regulatory-backing-2020-01-31", "https://www.nasdaq.com/articles/pfizers-biosimilar-ruxience-gets-eu-regulatory-backing-2020-01-31-0", "https://www.nasdaq.com/articles/biogen-is-now-oversold-biib-2020-01-31", "https://www.nasdaq.com/articles/amgen-revenue-slipped-1-in-the-fourth-quarter-2020-01-31", "https://www.nasdaq.com/articles/biogen-inc-biib-q4-2019-earnings-call-transcript-2020-01-30", "https://www.nasdaq.com/articles/heres-why-alkermes-jumped-almost-11-today-2020-02-05", "https://www.nasdaq.com/articles/is-biogen-stock-a-buy-2020-01-30", "https://www.nasdaq.com/articles/is-eli-lilly-stock-overvalued-2020-01-30", "https://www.nasdaq.com/articles/biogen-guides-fy20-in-line-with-estimates-quick-facts-2020-01-30", "https://www.nasdaq.com/articles/biogen-inc.-q4-adjusted-earnings-beat-estimates-2020-01-30", "https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-ibb-gild-vrtx-biib-2020-01-29", "https://www.nasdaq.com/articles/2-of-the-best-healthcare-stocks-to-buy-today-2020-01-29", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-aal-biib-2020-01-27", "https://www.nasdaq.com/articles/biogens-earnings-per-share-jumped-19-in-fourth-quarter-2020-01-30", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-biib-casa-xrx-2020-01-24", "https://www.nasdaq.com/articles/roches-spinal-muscular-atrophy-drug-meets-primary-endpoint-in-infants-2020-01-23", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2020-01-21", "https://www.nasdaq.com/articles/2-reasons-to-be-optimistic-about-biogens-alzheimers-drug-2020-01-21", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-joel-greenblatt-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-david-dreman-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/is-biogen-stock-a-buy-2020-01-25", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-cme-biib-pm-2020-01-17", "https://www.nasdaq.com/articles/thursday-sector-laggards%3A-healthcare-energy-2020-01-16", "https://www.nasdaq.com/articles/why-biogen-stock-slumped-last-year-2020-01-16", "https://www.nasdaq.com/articles/5-reasons-2020-will-be-a-big-year-for-ionis-pharmaceuticals-2020-01-16", "https://www.nasdaq.com/articles/3-big-stock-charts-for-wednesday%3A-biogen-cooper-companies-and-maxim-2020-01-15", "https://www.nasdaq.com/articles/new-research-shows-probiotics-can-help-prevent-parkinsons-2020-01-14", "https://www.nasdaq.com/articles/biogen-buys-azheimers-and-parkinsons-drug-from-pfizer-2020-01-13", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/biogen-to-acquire-clinical-stage-pf-05251749-from-pfizer-quick-facts-2020-01-13", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-gilead-sciences-2020-01-11", "https://www.nasdaq.com/articles/biogen-reaches-analyst-target-price-2020-01-10", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-blk-whr-biib-2020-01-09", "https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-biogen-2020-01-08", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-biogen-2020-01-05", "https://www.nasdaq.com/articles/ibb-gild-vrtx-biib%3A-etf-outflow-alert-2020-01-03", "https://www.nasdaq.com/articles/ibb-gild-vrtx-biib%3A-large-inflows-detected-at-etf-2020-01-13", "https://www.nasdaq.com/articles/2-biotech-stocks-poised-to-soar-in-2020-2019-12-24", "https://www.nasdaq.com/articles/make-the-shift-toward-value-stocks-with-these-5-picks-2019-12-19", "https://www.nasdaq.com/articles/why-longer-term-investors-should-buy-amarin-stock-on-weakness-2019-12-19", "https://www.nasdaq.com/articles/7-biotech-stocks-to-buy-and-hold-in-2020-2019-12-17", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-joel-greenblatt-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2019-12-24", "https://www.nasdaq.com/articles/is-biogen-too-cheap-to-ignore-2019-12-13", "https://www.nasdaq.com/articles/biogen-stops-development-of-gosuranemab-for-progressive-supranuclear-palsy-2019-12-13", "https://www.nasdaq.com/articles/should-investors-be-worried-about-biogens-alzheimers-drug-2019-12-12", "https://www.nasdaq.com/articles/commit-to-buy-biogen-at-%24230-earn-9.7-using-options-2019-12-09", "https://www.nasdaq.com/articles/why-shares-of-pdl-biopharma-are-soaring-today-2019-12-09", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-amgen-2019-12-08", "https://www.nasdaq.com/articles/why-biogens-alzheimers-drug-presentation-left-investors-uninspired-2019-12-07", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-david-dreman-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/5-top-stock-trades-for-friday%3A-rh-dg-kr-biib-2019-12-05", "https://www.nasdaq.com/articles/why-abbvie-is-a-dividend-growth-stock-thats-too-cheap-to-ignore-2019-11-27", "https://www.nasdaq.com/articles/why-biogens-recent-rebound-may-not-last-at-least-for-now-2019-11-27", "https://www.nasdaq.com/articles/biogens-data-shows-improved-gastrointestinal-tolerability-with-vumerity-2019-11-22", "https://www.nasdaq.com/articles/moat-stt-biib-bmy%3A-large-inflows-detected-at-etf-2019-11-15", "https://www.nasdaq.com/articles/thursday-sector-laggards%3A-consumer-products-healthcare-2019-11-14", "https://www.nasdaq.com/articles/7-biotech-stocks-to-buy-with-plenty-of-power-in-the-pipeline-2019-11-12", "https://www.nasdaq.com/articles/pjp-mdco-lly-biib%3A-etf-inflow-alert-2019-12-06", "https://www.nasdaq.com/articles/5-top-stock-trades-for-friday%3A-rh-dg-kr-biib-2019-12-05", "https://www.nasdaq.com/articles/2-biotech-stocks-fighting-alzheimers-disease-to-own-now-2019-11-09", "https://www.nasdaq.com/articles/biogens-alzheimers-drug-goes-from-bust-to-boon-plus-why-walgreens-is-shuttering-200", "https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-moat-stt-biib-bmy-2019-11-07", "https://www.nasdaq.com/articles/is-there-still-room-to-profit-from-biogen-2019-11-01", "https://www.nasdaq.com/articles/earningspalooza-2019%3A-round-4-2019-11-01", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-rok-cpb-biib-2019-11-12", "https://www.nasdaq.com/articles/what-should-investors-think-of-biogens-alzheimers-drug-candidate-2019-10-31", "https://www.nasdaq.com/articles/how-the-aducanumab-surprise-helped-biogen-stock-2019-10-31", "https://www.nasdaq.com/articles/2-biotech-stocks-that-soared-last-week-2019-10-28", "https://www.nasdaq.com/articles/5-top-healthcare-etfs-2019-10-26", "https://www.nasdaq.com/articles/first-trust-nyse-arca-biotechnology-index-fund-experiences-big-outflow-2019-10-24", "https://www.nasdaq.com/articles/validea-warren-buffett-strategy-daily-upgrade-report-10-24-2019-2019-10-24", "https://www.nasdaq.com/articles/biogen-ceo-confident-its-alzheimers-drug-will-get-fda-approval-2019-10-23", "https://www.nasdaq.com/articles/massive-news-in-alzheimers-drugs-2019-11-01", "https://www.nasdaq.com/articles/biogens-stock-could-more-than-quadruple-in-value-in-5-years-2019-10-23", "https://www.nasdaq.com/articles/heres-why-biogens-big-gain-wont-last-long-2019-10-23", "https://www.nasdaq.com/articles/is-biogen-a-buy-after-the-biggest-biotech-bombshell-in-years-2019-10-23", "https://www.nasdaq.com/articles/2-stocks-that-flew-high-on-tuesday-2019-10-23", "https://www.nasdaq.com/articles/what-happened-in-the-stock-market-today-2019-10-22", "https://www.nasdaq.com/articles/health-care-sector-update-for-10-22-2019%3A-oblnnlnkbiibarwr-2019-10-22", "https://www.nasdaq.com/articles/tuesday-sector-leaders%3A-energy-healthcare-2019-10-22", "https://www.nasdaq.com/articles/biogen-reaches-analyst-target-price-2019-10-23", "https://www.nasdaq.com/articles/biogens-stock-could-more-than-quadruple-in-value-in-5-years-2019-10-23", "https://www.nasdaq.com/articles/biogen-inc-biib-q3-2019-earnings-call-transcript-2019-10-22", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-has-biib-2019-10-22", "https://www.nasdaq.com/articles/sp-500-movers%3A-has-biib-2019-10-22", "https://www.nasdaq.com/articles/health-care-sector-update-for-10-22-2019%3A-biib-cnc-nvs-jnj-pfe-abt-mrk-amgn-2019-10-22", "https://www.nasdaq.com/articles/why-biogen-stock-is-on-fire-today-2019-10-22", "https://www.nasdaq.com/articles/biogen-q3-profit-tops-estimates-revenue-up-5-quick-facts-2019-10-22", "https://www.nasdaq.com/articles/health-care-sector-update-for-10-22-2019%3A-nlnkbiibarwr-2019-10-22", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-wgo-biib-axta-2019-10-18", "https://www.nasdaq.com/articles/why-did-the-market-whack-this-ipo-2019-10-14", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-gilead-sciences-2019-10-10", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-lnn-biib-uaa-2019-10-09", "https://www.nasdaq.com/articles/insiders-buy-the-holdings-of-vht-etf-2019-10-09", "https://www.nasdaq.com/articles/implied-moat-analyst-target-price%3A-%2456-2019-10-07", "https://www.nasdaq.com/articles/biogen-canada-reports-positive-results-on-spinal-muscular-atrophy-study-2019-10-03", "https://www.nasdaq.com/articles/biogen-plans-to-submit-bla-for-aducanumab-in-alzheimers-disease-shares-jump-2019-10-22", "https://www.nasdaq.com/articles/a-biotech-set-to-dominate-the-next-20-years-2019-10-01", "https://www.nasdaq.com/articles/biogen-appoints-alfred-sandrock-as-evp-research-and-development-2019-10-01", "https://www.nasdaq.com/articles/2-biotechs-tackling-the-challenge-of-lou-gehrigs-disease-2019-09-30", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-amgen-2019-09-27", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-isrg-biib-cof-2019-09-24", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-biib-mro-wday-2019-09-16", "https://www.nasdaq.com/articles/3-biotech-stocks-that-show-the-good-the-bad-and-the-ugly-side-of-this-sector-2019-09-14", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-biib-clx-mac-2019-10-02", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2019-09-11", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-biib-cat-mktx-2019-09-09", "https://www.nasdaq.com/articles/insiders-buy-the-holdings-of-moat-etf-2019-09-03", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-biogen-2019-09-01", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-ci-itw-biib-2019-08-30", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-celgene-2019-08-25", "https://www.nasdaq.com/articles/health-care-sector-update-for-08-21-2019%3A-nvtabiibaltpfealc-2019-08-21", "https://www.nasdaq.com/articles/eisai-biogen-to-discontinue-elenbecestat-phase-iii-studies-quick-facts-2019-09-13", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2019-09-11", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-biib-cat-mktx-2019-09-09", "https://www.nasdaq.com/articles/insiders-buy-the-holdings-of-moat-etf-2019-09-03", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-biogen-2019-09-01", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-ci-itw-biib-2019-08-30", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-celgene-2019-08-25", "https://www.nasdaq.com/articles/health-care-sector-update-for-08-21-2019%3A-nvtabiibaltpfealc-2019-08-21", "https://www.nasdaq.com/articles/eisai-biogen-to-discontinue-elenbecestat-phase-iii-studies-quick-facts-2019-09-13", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-biib-cwen-gs-2019-07-23", "https://www.nasdaq.com/articles/biogen-inc-biib-q2-2019-earnings-call-transcript-2019-07-23", "https://www.nasdaq.com/articles/biogen-earnings%3A-biib-stock-surges-on-big-q2-earnings-beat-2019-07-23", "https://www.nasdaq.com/articles/insiders-buy-the-holdings-of-moat-etf-2019-07-23", "https://www.nasdaq.com/articles/biogen-q2-profit-rises-lifts-2019-outlook-2019-07-23", "https://www.nasdaq.com/articles/ms-franchise-spinraza-likely-to-be-key-catalysts-for-biogen-stock-2019-07-22", "https://www.nasdaq.com/articles/notable-earnings-to-watch-on-july-23-an-jblu-biib-cmg-ko-hog-has-txn-2019-07-22", "https://www.nasdaq.com/articles/biogen-raises-guidance-as-it-looks-to-the-pipeline-for-growth-2019-07-24", "https://www.nasdaq.com/articles/the-multibillion-dollar-race-for-gene-therapy-manufacturing-is-on-2019-07-17", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-cost-biib-ulta-2019-07-16", "https://www.nasdaq.com/articles/notable-monday-option-activity%3A-med-epam-biib-2019-07-08", "https://www.nasdaq.com/articles/why-biogen-stock-has-plummeted-in-2019-2019-07-08", "https://www.nasdaq.com/articles/why-amicus-therapeutics-stock-perked-up-in-june-2019-07-04", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-add-to-your-watchlist-2019-06-30", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-right-now-2019-06-30", "https://www.nasdaq.com/articles/8-more-big-pharma-events-in-2019-you-dont-want-to-miss-2019-07-20", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2019-06-25", "https://www.nasdaq.com/articles/the-10-biggest-biotech-stocks-2019-06-25", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-ntes-biib-2019-06-25", "https://www.nasdaq.com/articles/3-large-cap-biotech-stocks-to-buy-for-massive-gains-2019-06-19", "https://www.nasdaq.com/articles/3-big-drugmakers-most-likely-to-make-acquisitions-after-pfizers-surprise-deal-2019-06-18", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-gild-biib-vrtx-2019-06-17", "https://www.nasdaq.com/articles/insiders-buy-the-holdings-of-jkd-etf-2019-06-17", "https://www.nasdaq.com/articles/nasdaq-today%3A-hard-to-keep-track-of-the-losers-2019-06-25", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2019-06-25", "https://www.nasdaq.com/articles/pain-pain-go-away-suicide-disease-drug-pipeline-2019-06-07", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-amgen-2019-06-03", "https://www.nasdaq.com/articles/analysts-anticipate-17-upside-holdings-jkd-2019-06-03", "https://www.nasdaq.com/articles/can-novartis-convince-insurers-%242.1-million-gene-therapy-great-deal-2019-05-26", "https://www.nasdaq.com/articles/approval-game-changing-gene-therapy-sma-delivers-win-novartis-and-regenxbio-2019-05-24", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-regn-biib-grmn-2019-06-13", "https://www.nasdaq.com/articles/ibb-gild-celg-biib%3A-etf-outflow-alert-2019-05-15", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-40-way-there-2019-05-14", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-biib-fro-fdx-2019-05-09", "https://www.nasdaq.com/articles/stock-buybacks-surge-2019-05-09", "https://www.nasdaq.com/articles/ibb-biib-vrtx-ilmn%3A-large-outflows-detected-etf-2019-05-07", "https://www.nasdaq.com/articles/monday-5/6-insider-buying-report%3A-biib-unh-2019-05-06", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-abmd-biib-oxy-2019-05-02", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-fxh-brkr-md-biib-2019-05-23", "https://www.nasdaq.com/articles/ibb-gild-celg-biib%3A-etf-outflow-alert-2019-05-15", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-40-way-there-2019-05-14", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-biib-fro-fdx-2019-05-09", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-ibb-celg-gild-biib-2019-04-25", "https://www.nasdaq.com/articles/biogen-inc-biib-q1-2019-earnings-call-transcript-2019-04-24", "https://www.nasdaq.com/articles/biogen-earnings-biib-stock-slips-despite-q1-beat-2019-04-24", "https://www.nasdaq.com/articles/earnings-reaction-history%3A-biogen-idec-36.4-follow-through-indicator-2.8-sensitive-2019-04", "https://www.nasdaq.com/articles/sum-pieces%3A-qqxt-could-be-worth-59-2019-05-02", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-hiiq-biib-ea-2019-04-23", "https://www.nasdaq.com/articles/better-buy-biogen-vs-abbvie-2019-04-22", "https://www.nasdaq.com/articles/heres-why-ionis-pharmaceuticals-slumped-today-2019-04-17", "https://www.nasdaq.com/articles/2-beaten-down-bluechips-are-they-buys-2019-04-17", "https://www.nasdaq.com/articles/2-beaten-down-blue-chips-are-they-buys-2019-04-17", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2019-04-17", "https://www.nasdaq.com/articles/heres-why-ionis-pharmaceuticals-slumped-today-2019-04-17-0", "https://www.nasdaq.com/articles/biogen-inc.-q1-adjusted-earnings-beat-estimates-2019-04-24", "https://www.nasdaq.com/articles/2-beaten-down-bluechips-are-they-buys-2019-04-17-0", "https://www.nasdaq.com/articles/relative-strength-alert-biogen-2019-04-16", "https://www.nasdaq.com/articles/relative-strength-alert-biogen-2019-04-16-0", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-vs-biogen-2019-04-14", "https://www.nasdaq.com/articles/health-care-sector-update-04122019-bhvnvivexfortcon-2019-04-12-0", "https://www.nasdaq.com/articles/notable-thursday-option-activity-srpt-unm-biib-2019-04-11", "https://www.nasdaq.com/articles/risk-tolerant-investors-turn-your-eyes-exelixis-stock-2019-04-11", "https://www.nasdaq.com/articles/2-beaten-down-blue-chips-are-they-buys-2019-04-17-0", "https://www.nasdaq.com/articles/biogen-biib-dips-more-than-broader-markets%3A-what-you-should-know-2019-04-09-0", "https://www.nasdaq.com/articles/should-biogen-investors-be-extra-nervous-right-now-2019-04-06", "https://www.nasdaq.com/articles/should-biogen-investors-be-extra-nervous-right-now-2019-04-06-0", "https://www.nasdaq.com/articles/1-biotech-biogen-should-buy-probably-wont-2019-04-04", "https://www.nasdaq.com/articles/mgk-biib-cl-schw-large-outflows-detected-etf-2019-04-04", "https://www.nasdaq.com/articles/why-biogen-stock-tanked-march-2019-04-04", "https://www.nasdaq.com/articles/1-biotech-biogen-should-buy-probably-wont-2019-04-04-0", "https://www.nasdaq.com/articles/notable-thursday-option-activity-srpt-unm-biib-2019-04-11-0", "https://www.nasdaq.com/articles/biogen-sma-drug-price-novartis-estimates-its-treatment-far-too-high-us-group-2019-04-03", "https://www.nasdaq.com/articles/3-healthcare-stocks-to-trade-now-2019-04-02", "https://www.nasdaq.com/articles/celgene-gets-positive-chmp-nod-for-revlimid-label-expansion-2019-04-01-0", "https://www.nasdaq.com/articles/2-blockbuster-gene-therapy-programs-watch-2019-2019-03-31", "https://www.nasdaq.com/articles/3-leading-alzheimers-disease-drugs-development-after-biogens-aducanumab-flop-2019-03-30", "https://www.nasdaq.com/articles/biogen-beat-bargain-and-bristol-myers-mega-merger-rocks-2019-03-28", "https://www.nasdaq.com/articles/why-biogens-alzheimers-drug-failure-may-have-silver-lining-2019-03-28", "https://www.nasdaq.com/articles/why-nightstar-therapeutics-stock-skyrocketed-71-march-2019-04-03", "https://www.nasdaq.com/articles/biogen-beat-bargain-and-bristol-myers-mega-merger-rocks-2019-03-28-0", "https://www.nasdaq.com/articles/novartis-nvs-receives-fda-approval-for-ms-drug-mayzent-2019-03-27-0", "https://www.nasdaq.com/articles/abbvies-psoriasis-drug-skyrizi-gets-first-approval-in-japan-2019-03-26", "https://www.nasdaq.com/articles/biogens-bad-news-everyone-2019-03-26", "https://www.nasdaq.com/articles/celgene-celg-submits-nda-for-ms-drug-to-fda-for-review-2019-03-26", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-769152-5398-points-2019-03-26", "https://www.nasdaq.com/articles/why-viacom-ferroglobe-and-biogen-jumped-today-2019-03-26", "https://www.nasdaq.com/articles/analysts-predict-12-upside-divb-2019-03-28", "https://www.nasdaq.com/articles/biogen-beat-bargain-and-bristol-myers-mega-merger-rocks-2019-03-28-0", "https://www.nasdaq.com/articles/novartis-nvs-receives-fda-approval-for-ms-drug-mayzent-2019-03-27-0", "https://www.nasdaq.com/articles/abbvies-psoriasis-drug-skyrizi-gets-first-approval-in-japan-2019-03-26", "https://www.nasdaq.com/articles/notable-monday-option-activity-nwsa-biib-jpm-2019-03-25", "https://www.nasdaq.com/articles/it-safe-buy-biogen-stock-right-now-2019-03-24", "https://www.nasdaq.com/articles/2-biotech-takeout-targets-perfect-biogen-2019-03-23", "https://www.nasdaq.com/articles/sustainable-business-practices-transparency-land-nasdaq-companies-top-2017s-100-best-ranking-2019-03-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsla-orly-2019-03-25", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-inflow-2019-03-22", "https://www.nasdaq.com/articles/biogen-stock-fell-too-far-unfortunate-news-2019-03-22", "https://www.nasdaq.com/articles/company-news-for-mar-22-2019-2019-03-22", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-3222019-2019-03-22", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-surges-250-points-micron-shares-gain-upbeat-earnings-2019", "https://www.nasdaq.com/articles/mid-day-market-update-superconductor-technologies-rises-after-q4-results-staffing-360", "https://www.nasdaq.com/articles/mid-day-market-update-superconductor-technologies-rises-after-q4-results-staffing-360-0", "https://www.nasdaq.com/articles/biogen-stock-crashes-on-termination-of-alzheimers-studies-2019-03-22", "https://www.nasdaq.com/articles/biogen-news-biib-stock-plummets-alzheimers-drug-failure-2019-03-21", "https://www.nasdaq.com/articles/biogen-becomes-oversold-biib-2019-03-21", "https://www.nasdaq.com/articles/biogens-big-bet-alzheimers-disease-bust-2019-03-21", "https://www.nasdaq.com/articles/jobless-claims-dip-philly-fed-swings-biogen-biib-plummets-2019-03-21-0", "https://www.nasdaq.com/articles/stock-market-news-biogen-bombs-micron-moves-higher-2019-03-21", "https://www.nasdaq.com/articles/why-biogen-stock-crashing-today-2019-03-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-mu-2019-03-21", "https://www.nasdaq.com/articles/whats-next-biogen-after-its-alzheimers-disease-drug-flop-2019-03-21", "https://www.nasdaq.com/articles/sp-500-movers-biib-cag-2019-03-21", "https://www.nasdaq.com/articles/initial-jobless-claims-decline-2019-03-21", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-conagra-earnings-top-expectations-2019-03-0", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-conagra-earnings-top-expectations-2019-03-21", "https://www.nasdaq.com/articles/jobless-claims-dip-philly-fed-swings-biogen-biib-plummets-2019-03-21", "https://www.nasdaq.com/articles/alkermes-focuses-on-pipeline-depends-on-partners-for-funds-2019-03-21", "https://www.nasdaq.com/articles/health-care-sector-update-03212019-biib-ogen-nvcn-jnj-pfe-abt-mrk-amgn-2019-03-21", "https://www.nasdaq.com/articles/assessing-impact-biogen-biib-news-2019-03-21", "https://www.nasdaq.com/articles/pre-market-most-active-mar-21-2019-biib-mu-sqqq-qqq-nok-eqh-opk-eric-chl-lyg-cag-acb-2019", "https://www.nasdaq.com/articles/us-futures-drop-dovish-fed-white-house-us-china-trade-talk-2019-03-21", "https://www.nasdaq.com/articles/stock-market-today-biogen-crushed-after-failure-alzheimers-drug-2019-03-21", "https://www.nasdaq.com/articles/biogen-bad-news-buy-now-2019-03-21", "https://www.nasdaq.com/articles/nasdaq-composite-index-closes-502-points-week-rising-5th-straight-day-2019-03-21", "https://www.nasdaq.com/articles/close-update-technology-sector-rally-sends-us-stocks-higher-nasdaq-leads-major-indexes", "https://www.nasdaq.com/articles/health-care-sector-update-03212019-lifeogennvcnnvcntobiib-2019-03-21", "https://www.nasdaq.com/articles/wall-street-tips-lower-ahead-opening-bell-dovish-fed-white-house-us-china-trade-talk-2019", "https://www.nasdaq.com/articles/pre-market-most-active-mar-21-2019-biib-mu-sqqq-qqq-nok-eqh-opk-eric-chl-lyg-cag-acb-2019", "https://www.nasdaq.com/articles/us-futures-drop-dovish-fed-white-house-us-china-trade-talk-2019-03-21", "https://www.nasdaq.com/articles/stock-market-today-biogen-crushed-after-failure-alzheimers-drug-2019-03-21", "https://www.nasdaq.com/articles/biogen-bad-news-buy-now-2019-03-21", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-march-14-2019-2019-03-13", "https://www.nasdaq.com/articles/celgene-celg-submits-application-for-ms-drug-in-europe-2019-03-12", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-surges-250-points-micron-shares-gain-upbeat-earnings-0", "https://www.nasdaq.com/articles/health-care-sector-update-03212019-ogennvcnbiib-2019-03-21", "https://www.nasdaq.com/articles/us-stocks-push-higher-after-dovish-federal-reserve-signals-goldilocks-markets-pound-slips", "https://www.nasdaq.com/articles/pdl-biopharma-pdli-q4-earnings-top-mark-revenues-fall-y-y-2019-03-15", "https://www.nasdaq.com/articles/ibb-celg-biib-gild-large-inflows-detected-etf-2019-03-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-visa-honeywell-biogen-humana-and-eog-resources-2019-03", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-march-14-2019-2019-03-13", "https://www.nasdaq.com/articles/celgene-celg-submits-application-for-ms-drug-in-europe-2019-03-12", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-surges-250-points-micron-shares-gain-upbeat-earnings-0", "https://www.nasdaq.com/articles/why-nightstar-therapeutics-stock-soaring-today-2019-03-04", "https://www.nasdaq.com/articles/health-care-sector-update-03042019-nite-biib-asnd-avxl-jnj-pfe-mrk-abt-amgn-2019-03-04", "https://www.nasdaq.com/articles/stock-market-today-biogen-buys-gene-therapy-company-nightstar-therapeutics-2019-03-04", "https://www.nasdaq.com/articles/us-stock-indexes-kick-week-slump-dow-leads-key-gauges-lower-2019-03-04", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-funds-its-pipeline-more-40-drugs-2019-03-04", "https://www.nasdaq.com/articles/health-care-sector-update-03042019-asndcsiintritvtyniteino-2019-03-04", "https://www.nasdaq.com/articles/mid-afternoon-market-update-nightstar-therapeutics-surges-acquisition-news-evoke-pharma", "https://www.nasdaq.com/articles/abbvie-gets-chmp-nod-for-psoriasis-candidate-risankizumab-2019-03-04", "https://www.nasdaq.com/articles/biogen-buy-nightstar-therapeutics-about-800-mln-2019-03-04", "https://www.nasdaq.com/articles/health-care-sector-update-03042019-csiintritvtyniteino-2019-03-04", "https://www.nasdaq.com/articles/heres-why-ionis-pharmaceuticals-jumped-higher-today-2019-02-27", "https://www.nasdaq.com/articles/alkermes-alks-and-biogens-nda-for-biib098-accepted-by-fda-2019-02-26", "https://www.nasdaq.com/articles/2-more-gene-therapy-stocks-big-pharmas-buyout-radar-2019-02-26", "https://www.nasdaq.com/articles/novartis-in-licenses-rights-to-heart-candidate-from-ionis-2019-02-25", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-oew-2019-02-25", "https://www.nasdaq.com/articles/biogen-buy-nightstar-therapeutics-800-mln-cash-deal-2019-03-04", "https://www.nasdaq.com/articles/novartis-gene-therapy-cost-effective-900000-us-group-2019-02-22", "https://www.nasdaq.com/articles/biogen-takes-over-114-spot-vulcan-materials-2019-02-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-ntes-hsic-2019-02-21", "https://www.nasdaq.com/articles/abbvies-ra-candidate-upadacitinib-gets-fda-priority-review-2019-02-20", "https://www.nasdaq.com/articles/alkermes-breaks-1-billion-2019-02-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-warren-buffett-2172019-2019-02-17", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-peter-lynch-2172019-2019-02-17", "https://www.nasdaq.com/articles/novartis-gene-therapy-would-be-cost-effective-900000-us-group-2019-02-22", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-biib-ilmn-regn-2019-02-14", "https://www.nasdaq.com/articles/should-you-buy-viking-therapeutics-after-gilead-drug-failure-2019-02-14", "https://www.nasdaq.com/articles/despite-ma-spree-biotech-etfs-slide-mixed-earnings-2019-02-14", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-14-2019-2019-02-13", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-visa-charter-biogen-bp-and-bbt-2019-02-11", "https://www.nasdaq.com/articles/top-research-reports-visa-charter-communications-biogen-2019-02-08", "https://www.nasdaq.com/articles/biib-crosses-below-key-moving-average-level-2019-02-07", "https://www.nasdaq.com/articles/alkermes-alks-q4-earnings-revenues-surpass-estimates-2019-02-15", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-biib-ilmn-regn-2019-02-14", "https://www.nasdaq.com/articles/should-you-buy-viking-therapeutics-after-gilead-drug-failure-2019-02-14", "https://www.nasdaq.com/articles/6-biotech-stocks-watch-now-2019-02-01", "https://www.nasdaq.com/articles/biogen-looks-2020-2019-01-30", "https://www.nasdaq.com/articles/biogen-biib-q4-earnings-beat-estimates-revenues-up-y-y-2019-01-29", "https://www.nasdaq.com/articles/biogen-beats-estimates-multiple-sclerosis-drugs-sales-2019-01-29", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-728835-down-8693-points-2019-02-07", "https://www.nasdaq.com/articles/biogen-biib-beats-revenues-and-earnings-estimates-in-q4-2019-01-29", "https://www.nasdaq.com/articles/biogen-beats-estimates-spinraza-tecfidera-strength-2019-01-29", "https://www.nasdaq.com/articles/biogen-q4-results-top-estimates-sees-2019-results-line-view-2019-01-29", "https://www.nasdaq.com/articles/should-franklin-libertyq-u.s.-equity-etf-flql-be-on-your-investing-radar-2019-01-29", "https://www.nasdaq.com/articles/drugmaker-biogens-fourth-quarter-revenue-rises-66-pct-2019-01-29", "https://www.nasdaq.com/articles/earnings-reaction-history-biogen-idec-455-follow-through-indicator-31-sensitive-2019-01-29", "https://www.nasdaq.com/articles/health-care-sector-update-01292019-jnjcgcweedtobiibagn-2019-01-29", "https://www.nasdaq.com/articles/march-2020-options-now-available-biogen-biib-2019-01-29", "https://www.nasdaq.com/articles/biogen-inc-biib-q4-2018-earnings-conference-call-transcript-2019-01-29", "https://www.nasdaq.com/articles/pre-market-earnings-report-january-29-2019-pfe-vz-mmm-lmt-dhr-biib-agn-hca-glw-pcar-rok", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-dish-algn-biib-2019-01-28", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-1262019-2019-01-26", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2019-01-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pfizer-biogen-schwab-sysco-and-philips-2019-01-21", "https://www.nasdaq.com/articles/biogen-biib-q4-earnings-coming-up%3A-whats-in-the-cards-2019-01-21", "https://www.nasdaq.com/articles/health-care-sector-update-01292019-cgcweedtobiibagn-2019-01-29", "https://www.nasdaq.com/articles/biogen-inc-biib-q4-2018-earnings-conference-call-transcript-2019-01-29", "https://www.nasdaq.com/articles/pre-market-earnings-report-january-29-2019-pfe-vz-mmm-lmt-dhr-biib-agn-hca-glw-pcar-rok", "https://www.nasdaq.com/articles/mizuho%3A-7-long-term-value-stocks-to-buy-now-2019-01-14", "https://www.nasdaq.com/articles/7-pharmaceutical-stocks-that-just-raised-prices-this-year-2019-01-11", "https://www.nasdaq.com/articles/value-added-7-top-stocks-2019-2019-01-09", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-loxo-celg-gain-j.p.-morgan-healthcare-conference-in-focus-2019-01", "https://www.nasdaq.com/articles/best-health-care-stocks-buy-2019-2019-01-08", "https://www.nasdaq.com/articles/better-buy-biogen-vs-gilead-sciences-2019-01-19", "https://www.nasdaq.com/articles/all-pre-jpm-news-healthcare-investors-need-know-2019-01-06", "https://www.nasdaq.com/articles/biogen-skyhawk-announce-collaboration-quick-facts-2019-01-04", "https://www.nasdaq.com/articles/biogen-begins-improved-dosing-regimen-on-tysabri-in-phase-iii-2019-01-04", "https://www.nasdaq.com/articles/perrigo-stock-up-as-appeal-date-for-irish-tax-bill-nears-2018-12-27", "https://www.nasdaq.com/articles/perrigo-plunges-on-%241.9b-tax-bill-from-irish-government-2018-12-24", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2018-12-21", "https://www.nasdaq.com/articles/why-shares-perrigo-are-plunging-today-2018-12-21", "https://www.nasdaq.com/articles/biogen-inks-two-deals-to-make-drugs-for-neurological-diseases-2019-01-07", "https://www.nasdaq.com/articles/health-care-sector-update-12212018-apvojazzrcktprgo-2018-12-21", "https://www.nasdaq.com/articles/abbvie-abbv-seeks-approval-for-ra-candidate-upadacitinib-2018-12-21", "https://www.nasdaq.com/articles/health-care-sector-update-12212018-jazzrcktprgo-2018-12-21", "https://www.nasdaq.com/articles/us-body-says-gene-therapy-may-be-more-cost-effective-spinal-muscular-atrophy-2018-12-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-nxpi-2018-12-18", "https://www.nasdaq.com/articles/sp-500-movers-biib-ba-2018-12-18", "https://www.nasdaq.com/articles/alkermes-biogen-submit-nda-to-fda-for-multiple-sclerosis-drug-2018-12-18", "https://www.nasdaq.com/articles/health-care-sector-update-12212018-prgo-pti-rckt-jnj-pfe-abt-mrk-amgn-2018-12-21", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-678391-3018-points-2018-12-18", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-ba-biib-bhf-2018-12-18", "https://www.nasdaq.com/articles/roches-sma-candidate-risdiplam-gets-prime-designation-in-eu-2018-12-17", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-12162018-2018-12-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-warren-buffett-12162018-2018-12-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-peter-lynch-12162018-2018-12-16", "https://www.nasdaq.com/articles/better-buy-biogen-vs-amgen-2018-12-15", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-qus-2018-12-18", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-678391-3018-points-2018-12-18", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-ba-biib-bhf-2018-12-18", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-december-13-2018-2018-12-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-alexion-pharmaceuticals-regeneron", "https://www.nasdaq.com/articles/4-biotech-stocks-investors-can-add-their-portfolio-2019-2018-12-11", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-inflow-2018-12-10", "https://www.nasdaq.com/articles/biogen-biib-in-licenses-als-candidate-biib067-from-ionis-2018-12-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-conatus-pharmaceuticals-biogen-ionis", "https://www.nasdaq.com/articles/abbvie-presents-long-term-data-on-cancer-drugs-at-ash-2018-2018-12-03", "https://www.nasdaq.com/articles/tevas-rituxan-biosimilar-gets-fda-nod-in-non-hodgkin-lymphoma-2018-11-29", "https://www.nasdaq.com/articles/why-is-biogen-biib-up-4.5-since-last-earnings-report-2018-11-22", "https://www.nasdaq.com/articles/biib-january-2019-options-begin-trading-2018-11-21", "https://www.nasdaq.com/articles/should-you-invest-invesco-dynamic-biotechnology-genome-etf-pbe-2018-11-21", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-peter-lynch-11182018-2018-11-18", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-11182018-2018-11-18", "https://www.nasdaq.com/articles/fda-accepts-bla-gives-priority-review-to-novartis-avxs-101-2018-12-04", "https://www.nasdaq.com/articles/implied-moat-analyst-target-price-51-2018-11-15", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-15-2018-2018-11-14", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-collects-royalties-and-spends-it-all-2018-11-12", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-iyh-biib-dhr-esrx-2018-11-12", "https://www.nasdaq.com/articles/6-pharmaceutical-stocks-to-buy-after-the-midterms-2018-11-09", "https://www.nasdaq.com/articles/pdl-biopharma-pdli-q3-earnings-top-revenues-rise-stock-up-2018-11-08", "https://www.nasdaq.com/articles/5-top-stocks-make-most-divided-congress-2018-11-07", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-warren-buffett-11182018-2018-11-18", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2018-10-31", "https://www.nasdaq.com/articles/whats-in-the-cards-for-abbvie-abbv-this-earnings-season-2018-10-30", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-biib-z-aks-2018-10-26", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-biib-tops-mack-plunges-regns-asthma-drug-gets-fda-nod-2018-10-24", "https://www.nasdaq.com/articles/biogen-becomes-oversold-biib-2018-10-24", "https://www.nasdaq.com/articles/biogen-rides-spinraza-wave-double-digit-growth-2018-10-24", "https://www.nasdaq.com/articles/alkermes-makes-financial-progress-its-pipeline-moves-forward-2018-10-24", "https://www.nasdaq.com/articles/biogen-stock-rebounds-after-impressive-q3-earnings-2018-11-05", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2018-10-31", "https://www.nasdaq.com/articles/whats-in-the-cards-for-abbvie-abbv-this-earnings-season-2018-10-30", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-biib-z-aks-2018-10-26", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-biib-tops-mack-plunges-regns-asthma-drug-gets-fda-nod-2018-10-24", "https://www.nasdaq.com/articles/health-care-sector-update-10232018-biibptittph-2018-10-23", "https://www.nasdaq.com/articles/biogen-inc-biib-q3-2018-earnings-conference-call-transcript-2018-10-23", "https://www.nasdaq.com/articles/biogen-breaks-below-200-day-moving-average-notable-biib-2018-10-23", "https://www.nasdaq.com/articles/biogen-earnings-10-highlights-biibs-q3-2018-10-23", "https://www.nasdaq.com/articles/biib-alks-q3-earnings-due-on-oct-23%3A-whats-in-store-2018-10-22", "https://www.nasdaq.com/articles/pre-market-earnings-report-october-23-2018-vz-mcd-mmm-utx-lmt-nee-cat-biib-cnc-glw-pcar-rf", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-amgen-inc-2018-10-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-ebay-pypl-2018-10-19", "https://www.nasdaq.com/articles/alkermes-boasts-strong-portfolio-and-impressive-pipeline-2018-10-19", "https://www.nasdaq.com/articles/biogen-biib-q3-earnings-coming-up%3A-whats-in-the-cards-2018-10-19", "https://www.nasdaq.com/articles/coriums-cori-shares-surge-on-merger-agreement-with-gurnet-2018-10-15", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2018-10-22", "https://www.nasdaq.com/articles/biib-alks-q3-earnings-due-on-oct-23%3A-whats-in-store-2018-10-22", "https://www.nasdaq.com/articles/pre-market-earnings-report-october-23-2018-vz-mcd-mmm-utx-lmt-nee-cat-biib-cnc-glw-pcar-rf", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-amgen-inc-2018-10-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-ebay-pypl-2018-10-19", "https://www.nasdaq.com/articles/roche-rhhby-presents-encouraging-data-on-ms-drug-ocrevus-2018-10-10", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gild-biib-present-data-vtgn-gains-on-fast-track-status-2018-10-10", "https://www.nasdaq.com/articles/commit-buy-biogen-250-earn-63-using-options-2018-10-08", "https://www.nasdaq.com/articles/implied-analyst-12-month-target-ryh-2018-10-15", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-gild-biib-celg-2018-10-04", "https://www.nasdaq.com/articles/roche-rhhby-presents-encouraging-data-on-sma-drug-risdiplam-2018-10-04", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-biib-epay-tree-2018-10-02", "https://www.nasdaq.com/articles/3-biotech-stocks-with-rising-estimates-in-the-past-month-2018-09-28", "https://www.nasdaq.com/articles/ibb-biib-gild-celg-etf-inflow-alert-2018-09-26", "https://www.nasdaq.com/articles/3-drug-biotech-stocks-in-focus-on-world-alzheimers-day-2018-09-21", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-wells-fargo-schlumberger-biogen-american-express-and", "https://www.nasdaq.com/articles/novartis-applications-for-ms-drug-accepted-by-fda-ema-2018-10-08", "https://www.nasdaq.com/articles/top-research-reports-wells-fargo-schlumberger-biogen-2018-09-20", "https://www.nasdaq.com/articles/better-buy-celgene-corp-vs-biogen-2018-09-17", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-biib-egov-anab-2018-09-17", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-warren-buffett-9162018-2018-09-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-peter-lynch-9162018-2018-09-16", "https://www.nasdaq.com/articles/ibb-biib-gild-celg-large-outflows-detected-etf-2018-09-14", "https://www.nasdaq.com/articles/acorda-acor-stock-dips-fda-delays-decision-on-inbrija-2018-09-14", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-buy-2018-09-21", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-biogen-2018-09-13", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-september-13-2018-2018-09-12", "https://www.nasdaq.com/articles/look-under-hood-eqwl-has-10-upside-2018-09-12", "https://www.nasdaq.com/articles/alkermes-expands-study-to-evaluate-alks-4230-keytruda-combo-2018-09-11", "https://www.nasdaq.com/articles/acorda-gets-unfavorable-court-ruling-for-ampyra-stock-down-2018-09-11", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-akam-jbht-biib-2018-09-10", "https://www.nasdaq.com/articles/pbe-ilmn-biib-vrtx-etf-inflow-alert-2018-09-06", "https://www.nasdaq.com/articles/3-biotech-stocks-analysts-say-are-market-winners-2018-09-13", "https://www.nasdaq.com/articles/biotech-fund-flows-including-etf-activity-remain-driver-watch-2018-08-31", "https://www.nasdaq.com/articles/notable-friday-option-activity-grub-cool-biib-2018-08-31", "https://www.nasdaq.com/articles/nasdaq-100-movers-dltr-biib-2018-08-30", "https://www.nasdaq.com/articles/can-akcea-therapeutics-inc-and-ionis-pharmaceuticals-inc-recover-2018-08-29", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-biib-gild-celg-2018-08-27", "https://www.nasdaq.com/articles/gene-editing-major-technology-watch-2018-08-27", "https://www.nasdaq.com/articles/notable-friday-option-activity-pvh-pypl-biib-2018-08-24", "https://www.nasdaq.com/articles/biogen-begins-phase-iii-study-on-ischemic-stroke-candidate-2018-09-05", "https://www.nasdaq.com/articles/3-terrible-stocks-retirees-2018-08-22", "https://www.nasdaq.com/articles/lilly-lly-hits-52-week-high-can-the-run-continue-2018-08-17", "https://www.nasdaq.com/articles/is-biogen-biib-outperforming-other-medical-stocks-this-year-2018-08-17", "https://www.nasdaq.com/articles/has-biogen-biib-outpaced-other-medical-stocks-this-year-2018-08-17", "https://www.nasdaq.com/articles/pain-therapeutics-shares-rally-on-alzheimers-study-grant-2018-08-16", "https://www.nasdaq.com/articles/vertexs-cystic-fibrosis-drug-gets-fda-nod-for-children-2018-08-16", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-august-16-2018-2018-08-15", "https://www.nasdaq.com/articles/biogen-biib-down-10.1-since-last-earnings-report%3A-can-it-rebound-2018-08-23", "https://www.nasdaq.com/articles/why-biogens-stock-ripped-higher-july-2018-08-11", "https://www.nasdaq.com/articles/pdl-biopharma-pdli-q2-earnings-top-revenues-slump-y-y-2018-08-09", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2018-08-06", "https://www.nasdaq.com/articles/sp-500-posts-5th-straight-weekly-gain-5-great-picks-2018-08-06", "https://www.nasdaq.com/articles/5-stocks-should-start-paying-dividends-2018-08-06", "https://www.nasdaq.com/articles/interesting-biib-put-and-call-options-june-2020-2018-08-03", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include%3A-biogen-thermo-fisher-hca-gilead-and-qualcomm-2018", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-royalties-rise-so-do-expenses-2018-08-13", "https://www.nasdaq.com/articles/5-cheap-peg-stocks-suitable-for-garp-investors-2018-08-02", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-ionis-ions-this-earnings-season-2018-08-01", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-celgene-amgen-vertex-impress-in-q2-gileads-ceo-to-exit-2018-08-01", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-comcast-united-technologies-biogen-mondelez-and-valero", "https://www.nasdaq.com/articles/wednesday-sector-leaders-healthcare-financial-2018-08-01", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2018-07-31", "https://www.nasdaq.com/articles/collaborations-help-alkermes-flip-profitability-2018-07-27", "https://www.nasdaq.com/articles/avoid-treating-biogen-speculative-drug-stock-2018-08-03", "https://www.nasdaq.com/articles/nasdaq-100-movers-fb-xlnx-2018-07-26", "https://www.nasdaq.com/articles/why-biogens-stock-slumping-today-2018-07-26", "https://www.nasdaq.com/articles/thursdays-etf-unusual-volume-fbt-2018-07-26", "https://www.nasdaq.com/articles/thursday-sector-laggards-healthcare-materials-2018-07-26", "https://www.nasdaq.com/articles/why-every-investor-should-hold-shares-biogen-stock-2018-07-25", "https://www.nasdaq.com/articles/company-news-for-jul-25-2018-2018-07-25", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-biogen-gains-on-q2-results-agios-gets-fda-nod-for-leukemia-drug", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-inflow-2018-07-27", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-7252018-2018-07-25", "https://www.nasdaq.com/articles/biogen-posts-solid-earnings-biotech-waits-clinical-trial-data-2018-07-25", "https://www.nasdaq.com/articles/wall-street-rises-after-strong-earnings-tech-health-care-sectors-2018-07-24", "https://www.nasdaq.com/articles/us-stocks-trend-higher-after-strong-earnings-tech-health-care-sectors-2018-07-24", "https://www.nasdaq.com/articles/biogen-biib-q2-earnings-sales-beat-estimates-shares-up-2018-07-24", "https://www.nasdaq.com/articles/nasdaq-100-movers-has-biib-2018-07-24", "https://www.nasdaq.com/articles/morning-movers-biogen-alphabet-verizon-soar-earnings-lift-dow-2018-07-24", "https://www.nasdaq.com/articles/bet-these-5-biotech-stocks-trump-raises-trade-tensions-2018-07-25", "https://www.nasdaq.com/articles/earnings-reaction-history-biogen-idec-455-follow-through-indicator-31-sensitive-2018-07-24", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-784077-down-110-points-2018-07-24", "https://www.nasdaq.com/articles/health-care-sector-update-07242018-bmybiibimrnlly-2018-07-24", "https://www.nasdaq.com/articles/health-care-sector-update-07242018-biibimrnlly-2018-07-24", "https://www.nasdaq.com/articles/biib-lly-q2-earnings-on-jul-24%3A-here-are-the-key-predictions-2018-07-23", "https://www.nasdaq.com/articles/5-top-stock-trades-for-tuesday-buy-sell-or-hold-tesla-2018-07-23", "https://www.nasdaq.com/articles/5-surprising-things-you-probably-didnt-know-about-alzheimers-drug-pipelines-2018-07-23", "https://www.nasdaq.com/articles/biogen-biib-q2-earnings-beat-shares-up-2018-07-24", "https://www.nasdaq.com/articles/earnings-reaction-history-biogen-idec-455-follow-through-indicator-31-sensitive-2018-07-24", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-784077-down-110-points-2018-07-24", "https://www.nasdaq.com/articles/biogen-biib-to-report-q2-earnings%3A-whats-in-the-cards-2018-07-19", "https://www.nasdaq.com/articles/abbvie-settles-with-mylan-to-delay-humira-biosimilar-in-u.s.-2018-07-18", "https://www.nasdaq.com/articles/new-drugs-and-expected-growth-could-trigger-a-recovery-for-celgene-stock-2018-07-18", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pepsico-eli-lilly-broadcom-biogen-and-marathon-2018-07", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-warren-buffett-7152018-2018-07-15", "https://www.nasdaq.com/articles/pre-market-earnings-report-july-24-2018-vz-mmm-utx-lly-lmt-biib-shw-kmb-cnc-iqv-pcar-agr", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-7152018-2018-07-15", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-amgen-2018-07-15", "https://www.nasdaq.com/articles/top-analyst-reports-pepsico-eli-lilly-broadcom-2018-07-13", "https://www.nasdaq.com/articles/better-know-biotech-regenxbio-inc-2018-07-13", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-wynn-fdx-biib-2018-07-13", "https://www.nasdaq.com/articles/are-we-cusp-big-alzheimers-disease-breakthrough-2018-07-13", "https://www.nasdaq.com/articles/dopamine-and-weather-part-2-2018-07-12", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-peter-lynch-7152018-2018-07-15", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-buy-2018-07-12", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ibb-gild-amgn-biib-2018-07-11", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-biibs-gain-on-alzheimers-data-regulatory-updates-more-2018-07-11", "https://www.nasdaq.com/articles/sad-truth-biotech-investing-strategy-almost-always-works-2018-07-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-cern-idxx-2018-07-10", "https://www.nasdaq.com/articles/cti-biopharma-falls-after-failure-of-pivotal-lymphoma-study-2018-07-10", "https://www.nasdaq.com/articles/morning-movers-pepsi-jumps-celgene-climbs-chipotle-slides-2018-07-10", "https://www.nasdaq.com/articles/abbvies-imbruvica-fails-in-phase-iii-blood-cancer-study-2018-07-12", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-buy-2018-07-12", "https://www.nasdaq.com/articles/why-cti-biopharma-corp-sinking-today-2018-07-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-ttwo-bidu-2018-07-09", "https://www.nasdaq.com/articles/stock-market-news-for-jul-9-2018-2018-07-09", "https://www.nasdaq.com/articles/biogen-reaches-analyst-target-price-2018-07-09", "https://www.nasdaq.com/articles/5-top-stock-trades-for-monday-2018-07-08", "https://www.nasdaq.com/articles/biogen-right-alzheimers-stock-wrong-time-2018-07-10", "https://www.nasdaq.com/articles/why-biogen-inc-stock-soared-152-today-2018-07-06", "https://www.nasdaq.com/articles/biib-makes-bullish-cross-above-critical-moving-average-2018-07-06", "https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-over-1-black-box-shares-spike-higher-2018-07-06-0", "https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-over-1-black-box-shares-spike-higher-2018-07-06", "https://www.nasdaq.com/articles/biogen-inc-stock-shoots-higher-alzheimers-drug-trial-2018-07-06", "https://www.nasdaq.com/articles/sp-500-movers-qrvo-biib-2018-07-06", "https://www.nasdaq.com/articles/nasdaq-100-movers-lrcx-biib-2018-07-06", "https://www.nasdaq.com/articles/3-biotech-stocks-soared-week-are-they-buys-2018-07-07", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-higher-us-adds-213000-jobs-june-2018-07-06-0", "https://www.nasdaq.com/articles/biogens-alzheimer-disease-candidate-succeeds-in-phase-ii-2018-07-06", "https://www.nasdaq.com/articles/morning-movers-dow-erases-losses-payrolls-shine-biogen-soars-costco-dips-2018-07-06", "https://www.nasdaq.com/articles/health-care-sector-update-07062018-biibcelgrgls-2018-07-06", "https://www.nasdaq.com/articles/pre-market-most-active-jul-6-2018-anw-db-shv-iq-biib-sny-qqq-sqqq-tvix-nok-baba-bp-2018-07", "https://www.nasdaq.com/articles/what-happened-stock-market-today-2018-07-06", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-768839-10196-points-2018-07-06", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-higher-us-adds-213000-jobs-june-2018-07-06", "https://www.nasdaq.com/articles/health-care-sector-update-07062018-celgtgtxbiibrgls-2018-07-06", "https://www.nasdaq.com/articles/why-biotech-stocks-rallied-biogens-alzheimers-test-2018-07-06", "https://www.nasdaq.com/articles/fridays-etf-movers-ibb-gdx-2018-07-06", "https://www.nasdaq.com/articles/mid-day-update-us-shares-rise-second-day-boosted-positive-data-2018-07-06", "https://www.nasdaq.com/articles/health-care-sector-update-07062018-tgtxbiibcelgrgls-2018-07-06", "https://www.nasdaq.com/articles/notable-friday-option-activity-amzn-biib-googl-2018-07-06", "https://www.nasdaq.com/articles/ibb-gild-amgn-biib-large-outflows-detected-etf-2018-07-03", "https://www.nasdaq.com/articles/close-update-wall-street-ends-high-note-after-jobs-data-beats-expectations-2018-07-06", "https://www.nasdaq.com/articles/health-care-sector-update-07062018-celgtgtxbiibrgls-2018-07-06", "https://www.nasdaq.com/articles/top-analyst-reports-johnson-johnson-biogen-general-motors-2018-06-28", "https://www.nasdaq.com/articles/ibb-gild-biib-celg-etf-inflow-alert-2018-06-25", "https://www.nasdaq.com/articles/first-week-august-17th-options-trading-biogen-biib-2018-06-20", "https://www.nasdaq.com/articles/dont-get-too-excited-about-ptc-therapeutics-yet-2018-06-20", "https://www.nasdaq.com/articles/commit-purchase-biogen-195-earn-34-using-options-2018-06-19", "https://www.nasdaq.com/articles/ptc-therapeutics-spinal-muscular-atrophy-study-successful-2018-06-19", "https://www.nasdaq.com/articles/sanofis-blood-clotting-drug-gets-positive-chmp-opinion-2018-07-02", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-774703-65-points-2018-06-18", "https://www.nasdaq.com/articles/why-biogen-baytex-energy-and-catalyst-biosciences-slumped-today-2018-06-18", "https://www.nasdaq.com/articles/monday-sector-laggards-consumer-products-healthcare-2018-06-18", "https://www.nasdaq.com/articles/mondays-etf-unusual-volume-ixj-2018-06-18", "https://www.nasdaq.com/articles/notable-monday-option-activity-fb-biib-gww-2018-06-18", "https://www.nasdaq.com/articles/heres-why-ptc-therapeutics-soaring-while-biogen-and-ionis-struggle-2018-06-18", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-warren-buffett-6172018-2018-06-17", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-jd-2018-06-18", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-peter-lynch-6172018-2018-06-17", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-ibb-biib-gild-celg-2018-06-15", "https://www.nasdaq.com/articles/zacks-value-investor-highlights%3A-gilead-sciences-biogen-celgene-lannett-and-valeant-2018", "https://www.nasdaq.com/articles/roche-announces-positive-data-on-gazyva-and-ms-drug-ocrevus-2018-06-15", "https://www.nasdaq.com/articles/analysts-anticipate-oew-will-reach-37-2018-06-14", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-axon-soars-amgen-drugs-get-fda-ec-nod-2018-06-13", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-june-14-2018-2018-06-13", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-6172018-2018-06-17", "https://www.nasdaq.com/articles/gilead-sciences-top-socially-responsible-dividend-stock-32-yield-gild-2018-06-11", "https://www.nasdaq.com/articles/biogen-inks-deal-with-tms-to-acquire-phase-ii-stroke-asset-2018-06-08", "https://www.nasdaq.com/articles/roche-rituxan-label-expanded-by-fda-for-pemphigus-vulgaris-2018-06-08", "https://www.nasdaq.com/articles/pfizer-boosts-venture-capital-efforts-neuroscience-in-focus-2018-06-07", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-inflow-2018-06-06", "https://www.nasdaq.com/articles/health-care-sector-update-06062018-entaitciclrbalksbiib-2018-06-06", "https://www.nasdaq.com/articles/health-care-sector-update-06062018-itciclrbalksbiib-2018-06-06", "https://www.nasdaq.com/articles/drug-stocks-next-hot-industry-or-value-traps-2018-06-13", "https://www.nasdaq.com/articles/biogen-inc-stock-got-an-upgrade-but-should-you-listen-2018-06-04", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-celgene-2018-06-03", "https://www.nasdaq.com/articles/validea-john-neff-strategy-daily-upgrade-report-5302018-2018-05-30", "https://www.nasdaq.com/articles/3-top-biosimilars-will-lift-pfizer-inc-stock-even-more-2018-05-24", "https://www.nasdaq.com/articles/3-big-pharma-stocks-huge-future-growth-potential-2018-05-24", "https://www.nasdaq.com/articles/why-is-biogen-biib-up-6.7-since-its-last-earnings-report-2018-05-24", "https://www.nasdaq.com/articles/10-top-health-care-stocks-never-break-sweat-2018-05-24", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-june-2018-06-04", "https://www.nasdaq.com/articles/better-buy-acadia-pharmaceuticals-vs-biogen-2018-05-18", "https://www.nasdaq.com/articles/sp-500-analyst-moves-biib-2018-05-17", "https://www.nasdaq.com/articles/sangamo-therapeutics-stock-history-2018-05-17", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-may-16-2018-2018-05-15", "https://www.nasdaq.com/articles/better-buy-amgen-inc-vs-biogen-inc-2018-05-15", "https://www.nasdaq.com/articles/novartis-multiple-sclerosis-drug-gets-fda-nod-for-adolescents-2018-05-14", "https://www.nasdaq.com/articles/moats-holdings-could-mean-14-gain-potential-2018-05-14", "https://www.nasdaq.com/articles/ibb-biib-celg-vrtx-etf-outflow-alert-2018-05-21", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-adbe-celg-biib-2018-05-11", "https://www.nasdaq.com/articles/ibb-celg-biib-vrtx-etf-inflow-alert-2018-05-10", "https://www.nasdaq.com/articles/3-stocks-turned-10000-1-million-2018-05-09", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-prepares-launch-2018-05-09", "https://www.nasdaq.com/articles/ibb-celg-biib-vrtx-etf-outflow-alert-2018-05-02", "https://www.nasdaq.com/articles/whats-in-the-cards-for-ionis-ions-this-earnings-season-2018-05-01", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2018-05-01", "https://www.nasdaq.com/articles/nasdaq-100-movers-symc-regn-2018-05-11", "https://www.nasdaq.com/articles/the-good-and-the-bad-news-with-biogen-inc-earnings-results-2018-04-30", "https://www.nasdaq.com/articles/biogen-inc-buy-2018-04-28", "https://www.nasdaq.com/articles/alkermes-alks-reports-wider-than-expected-loss-in-q1-2018-04-27", "https://www.nasdaq.com/articles/heres-why-275-biogen-inc-stock-looks-realistic-2018-04-27", "https://www.nasdaq.com/articles/promising-step-medical-marijuana-2018-04-26", "https://www.nasdaq.com/articles/after-bumpy-ride-alkermes-confirms-its-back-track-2018-04-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-chkp-biib-2018-04-25", "https://www.nasdaq.com/articles/biogens-1-billion-bet-ionis-2018-04-30", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-4252018-2018-04-25", "https://www.nasdaq.com/articles/biogen-posts-double-digit-profits-has-cash-burn-2018-04-25", "https://www.nasdaq.com/articles/biogen-biib-q1-earnings-beat-sales-miss-shares-down-2018-04-24", "https://www.nasdaq.com/articles/health-care-sector-update-04242018-lly-incy-biib-cnc-2018-04-24", "https://www.nasdaq.com/articles/biogen-biib-q1-earnings-beat-sales-miss-2018-04-24", "https://www.nasdaq.com/articles/earnings-reaction-history-biogen-idec-545-follow-through-indicator-50-sensitive-2018-04-24", "https://www.nasdaq.com/articles/why-ionis-pharmaceuticals-crashed-today-2018-04-24", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-prta-down-amgn-revises-view-biib-misses-on-sales-2018-04-25", "https://www.nasdaq.com/articles/eli-lilly-and-co-produced-monstrous-q1-beat-it-enough-2018-04-24", "https://www.nasdaq.com/articles/health-care-sector-update-04242018-incy-biibcnc-2018-04-24", "https://www.nasdaq.com/articles/drug-biotech-stock-q1-earnings-due-on-apr-24%3A-lly-biib-amgn-2018-04-23", "https://www.nasdaq.com/articles/roche-rhhby-presents-encouraging-data-on-ms-drug-ocrevus-2018-04-23", "https://www.nasdaq.com/articles/why-biogen-inc-giving-ionis-another-1-billion-2018-04-23", "https://www.nasdaq.com/articles/pre-market-earnings-report-april-24-2018-vz-ko-mmm-lmt-utx-cat-lly-nee-biib-trv-shw-fcx", "https://www.nasdaq.com/articles/novartis-nvs-reports-encouraging-data-on-ms-candidate-2018-04-20", "https://www.nasdaq.com/articles/health-care-sector-update-04242018-enzholxbiibcncincy-2018-04-24", "https://www.nasdaq.com/articles/health-care-sector-update-04202018-ions-biib-rigl-cmta-vxrt-2018-04-20", "https://www.nasdaq.com/articles/health-care-sector-update-04202018-vxrtcmiaionsbiibriglnabi-2018-04-20", "https://www.nasdaq.com/articles/health-care-sector-update-04202018-cmiaionsbiibrigl-2018-04-20", "https://www.nasdaq.com/articles/big-biotech-etf-can-bounce-back-2018-04-18", "https://www.nasdaq.com/articles/it-time-give-alkermes-2018-04-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-4152018-2018-04-15", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-warren-buffett-4152018-2018-04-15", "https://www.nasdaq.com/articles/whats-in-store-for-biogen-biib-this-earnings-season-2018-04-20", "https://www.nasdaq.com/articles/health-care-sector-update-04202018-ions-biib-rigl-cmta-vxrt-2018-04-20", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-nextera-danaher-biogen-facebook-and-apple-2018-04-12", "https://www.nasdaq.com/articles/why-one-drug-flop-tanked-incytes-stock-2018-04-12", "https://www.nasdaq.com/articles/mylan-fujifilm-kyowa-team-up-to-market-humira-biosimilar-2018-04-12", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-spectrum-up-incyte-down-avexis-to-merge-with-novartis-2018-04-11", "https://www.nasdaq.com/articles/top-research-reports-nextera-danaher-biogen-2018-04-11", "https://www.nasdaq.com/articles/novartis-acquisition-avexis-bad-news-biogen-2018-04-10", "https://www.nasdaq.com/articles/ibb-gild-biib-vrtx-etf-outflow-alert-2018-04-12", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-idcc-dal-biib-2018-04-10", "https://www.nasdaq.com/articles/novartis-acquisition-avexis-takes-aim-biogen-2018-04-10", "https://www.nasdaq.com/articles/why-avexis-inc-stock-soaring-today-2018-04-09", "https://www.nasdaq.com/articles/novartis-inks-%248.7-billion-gene-therapy-deal-to-buy-avexis-2018-04-09", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-472018-2018-04-07", "https://www.nasdaq.com/articles/biogen-cracks-the-case-with-abbvie-for-humira-biosimilar-2018-04-06", "https://www.nasdaq.com/articles/expect-chaos-continue-todays-jobs-report-2018-04-06", "https://www.nasdaq.com/articles/abbvies-ra-candidate-meets-primary-endpoints-in-phase-iii-2018-04-10", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-biib-vrtx-ilmn-2018-04-04", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-amgen-inc-2018-03-30", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-biogen-inc-2018-03-25", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-buy-2018-03-24", "https://www.nasdaq.com/articles/better-buy-celgene-corporation-vs-biogen-inc-2018-03-22", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-oef-chtr-dhr-biib-2018-03-21", "https://www.nasdaq.com/articles/buy-bottom-biogen-inc-stock-100-return-2018-03-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-mu-fb-2018-04-05", "https://www.nasdaq.com/articles/despite-struggles-celgene-corporation-stock-still-buy-2018-03-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-3182018-2018-03-18", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-warren-buffett-3182018-2018-03-18", "https://www.nasdaq.com/articles/why-multiple-sclerosis-is-a-promising-but-risky-space-2018-03-16", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regn-cuts-praluent-price-orex-to-file-for-bankruptcy-2018-03-14", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-march-15-2018-2018-03-14", "https://www.nasdaq.com/articles/bull-day-regeneron-regn-2018-03-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-abbvie-novartis-teva-and-celgene-2018-03-19", "https://www.nasdaq.com/articles/why-biogen-stock-slumped-february-2018-03-13", "https://www.nasdaq.com/articles/biogen-to-buy-mid-stage-neuropsychiatry-asset-from-pfizer-2018-03-13", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-bbh-celg-biib-vrtx-2018-03-13", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-751101-down-7731-points-2018-03-13", "https://www.nasdaq.com/articles/biogen-now-oversold-biib-2018-03-12", "https://www.nasdaq.com/articles/health-care-sector-update-03122018-srptbiibpfesvraalnysny-2018-03-12", "https://www.nasdaq.com/articles/pdl-biopharma-pdli-q4-earnings-beat-revenues-rise-y-y-2018-03-09", "https://www.nasdaq.com/articles/biogen-inc-buy-2018-03-14", "https://www.nasdaq.com/articles/more-commercial-revenue-its-way-ionis-pharmaceuticals-2018-03-01", "https://www.nasdaq.com/articles/biogen-biib-down-17.2-since-earnings-report%3A-can-it-rebound-2018-02-26", "https://www.nasdaq.com/articles/notable-monday-option-activity-lgih-biib-khc-2018-02-26", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-celgene-corporation-2018-02-23", "https://www.nasdaq.com/articles/whats-in-the-cards-for-ionis-ions-this-earnings-season-2018-02-22", "https://www.nasdaq.com/articles/ionis-out-licenses-second-candidate-to-astrazeneca-earns-%2430m-2018-02-21", "https://www.nasdaq.com/articles/agree-purchase-biogen-270-earn-91-annualized-using-options-2018-02-20", "https://www.nasdaq.com/articles/are-alzheimers-focused-stocks-set-for-a-financial-windfall-2018-03-06", "https://www.nasdaq.com/articles/buy-biogen-stock-dip-2018-02-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-warren-buffett-2182018-2018-02-18", "https://www.nasdaq.com/articles/3-biotech-stocks-soared-week-are-they-buys-2018-02-17", "https://www.nasdaq.com/articles/acorda-acor-q4-earnings-miss-estimates-revenues-beat-2018-02-16", "https://www.nasdaq.com/articles/fda-sets-the-stage-for-earlier-stage-alzheimers-treatments-2018-02-16", "https://www.nasdaq.com/articles/biogen-now-oversold-2018-02-16", "https://www.nasdaq.com/articles/notable-friday-option-activity-cohu-biib-fdx-2018-02-16", "https://www.nasdaq.com/articles/ibb-biib-celg-regn-etf-inflow-alert-2018-02-20", "https://www.nasdaq.com/articles/buy-biogen-stock-dip-2018-02-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-warren-buffett-2182018-2018-02-18", "https://www.nasdaq.com/articles/merck-mrk-halts-another-late-stage-study-on-alzheimers-2018-02-14", "https://www.nasdaq.com/articles/nasdaq-composite-index-closes-3155-points-week-rising-4th-straight-day-2018-02-14", "https://www.nasdaq.com/articles/why-biogen-groupon-and-omeros-slumped-today-2018-02-14", "https://www.nasdaq.com/articles/biib-makes-notable-cross-below-critical-moving-average-2018-02-14", "https://www.nasdaq.com/articles/heres-why-alkermes-spiked-today-2018-02-14", "https://www.nasdaq.com/articles/validea-warren-buffett-strategy-daily-upgrade-report-2152018-2018-02-15", "https://www.nasdaq.com/articles/3-biotech-stocks-soared-week-are-they-buys-2018-02-10", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-2102018-2018-02-10", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-novartis-bp-and-biogen-2018-02-09", "https://www.nasdaq.com/articles/notable-friday-option-activity-pwr-biib-itw-2018-02-09", "https://www.nasdaq.com/articles/biogen-halts-tysabri-development-in-stroke-as-study-fails-2018-02-08", "https://www.nasdaq.com/articles/analysts-expect-mgk-hit-128-2018-02-08", "https://www.nasdaq.com/articles/3-top-obesity-drug-stocks-consider-buying-now-2018-02-03", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-14-2018-2018-02-13", "https://www.nasdaq.com/articles/indexes-edge-lower-dr-pepper-surges-goldman-leads-dow-2018-01-29", "https://www.nasdaq.com/articles/sanofi-will-buy-ablynx-48-billion-heels-116-billion-bioverativ-deal-2018-01-29", "https://www.nasdaq.com/articles/biogen-inc-caps-solid-2017-waits-aducanumab-2018-01-29", "https://www.nasdaq.com/articles/biogen-inc-beckoning-bulls-2018-01-26", "https://www.nasdaq.com/articles/why-insurers-havent-and-wont-push-back-rare-disease-drugs-2018-01-26", "https://www.nasdaq.com/articles/5-biotech-and-pharmaceutical-stocks-going-bonkers-2018-01-26", "https://www.nasdaq.com/articles/biogen-earns-relative-strength-rating-upgrade-hits-key-threshold-2018-01-26", "https://www.nasdaq.com/articles/could-sanofis-ablynx-deal-spur-biopharma-buying-spree-2018-01-29", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-tmo-biib-antm-2018-01-25", "https://www.nasdaq.com/articles/biogen-biib-q4-earnings-miss-sales-top-2018-view-upbeat-2018-01-25", "https://www.nasdaq.com/articles/health-care-sector-update-01252018-jnj-pfe-abt-mrk-amgn-var-xlnx-kpti-ocul-smmt-sn-2018-01", "https://www.nasdaq.com/articles/biogen-biib-q4-earnings-miss-sales-top-stock-up-2018-01-25", "https://www.nasdaq.com/articles/nasdaq-rebounds-intel-boeing-lift-dow-varian-nails-breakout-2018-01-25", "https://www.nasdaq.com/articles/biogen-revenue-tops-spinraza-ms-drugs-deliver-upside-2018-01-25", "https://www.nasdaq.com/articles/earnings-reaction-history-biogen-idec-500-follow-through-indicator-51-sensitive-2018-01-25", "https://www.nasdaq.com/articles/biogen-sees-its-composite-rating-rise-98-2018-01-26", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-tmo-biib-antm-2018-01-25", "https://www.nasdaq.com/articles/biogen-biib-q4-earnings-miss-sales-top-2018-view-upbeat-2018-01-25", "https://www.nasdaq.com/articles/pre-market-earnings-report-january-25-2018-mmm-unp-cat-celg-biib-rtn-noc-px-shw-luv-fcau", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-lvs-hlf-biib-2018-01-24", "https://www.nasdaq.com/articles/intel-starbucks-biotechs-lead-earnings-rush-investing-action-plan-2018-01-24", "https://www.nasdaq.com/articles/3-pharma-and-biotech-stocks-to-watch-out-for-in-2018-2018-01-23", "https://www.nasdaq.com/articles/first-trust-mega-cap-alphadex-fund-insider-buying-index-registering-109-2018-01-23", "https://www.nasdaq.com/articles/health-care-sector-update-01252018-oculkptibiibsnnxlnx-2018-01-25", "https://www.nasdaq.com/articles/health-care-sector-update-01252018-kptibiibsnnxlnx-2018-01-25", "https://www.nasdaq.com/articles/will-sanofis-big-hemophilia-deal-pay-2018-01-24", "https://www.nasdaq.com/articles/why-2017-was-year-remember-ionis-pharmaceuticals-inc-2018-01-22", "https://www.nasdaq.com/articles/celgene-will-buy-juno-therapeutics-9-billion-sanofi-acquires-bioverativ-2018-01-22", "https://www.nasdaq.com/articles/whats-in-the-cards-for-biogen-biib-this-earnings-season-2018-01-22", "https://www.nasdaq.com/articles/sanofi-to-acquire-haemophilia-focused-bioverativ-stock-dips-2018-01-22", "https://www.nasdaq.com/articles/why-bioverativ-inc-stock-soaring-today-2018-01-22", "https://www.nasdaq.com/articles/biotech-ma-strong-start-2018-more-deals-follow-2018-01-23", "https://www.nasdaq.com/articles/insiders-were-right-biib-makes-new-52-week-high-2018-01-23", "https://www.nasdaq.com/articles/mid-day-update-wall-street-cautiously-optimistic-washington-scrambling-avert-shutdown-2018", "https://www.nasdaq.com/articles/heres-why-acorda-therapeutics-inc-stock-surging-today-2018-01-19", "https://www.nasdaq.com/articles/correction-futures-reverse-early-gains-focus-shifts-washington-2018-01-19", "https://www.nasdaq.com/articles/futures-reverse-early-gains-focus-shifts-washington-2018-01-19", "https://www.nasdaq.com/articles/stocks-rising-relative-strength-biogen-2018-01-18", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-psx-biib-jci-2018-01-17", "https://www.nasdaq.com/articles/bioverativ-inc-stock-gets-64-premium-acquisition-sanofi-2018-01-22", "https://www.nasdaq.com/articles/roche-ms-drug-ocrevus-gets-marketing-authorization-in-europe-2018-01-15", "https://www.nasdaq.com/articles/will-2018-be-biogen-incs-best-year-yet-2018-01-14", "https://www.nasdaq.com/articles/will-2018-be-ionis-pharmaceuticals-incs-best-year-yet-2018-01-13", "https://www.nasdaq.com/articles/biogen-trying-close-key-technical-measure-2018-01-11", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-mck-abbv-biib-2018-01-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-shpg-stx-2018-01-08", "https://www.nasdaq.com/articles/pfizer-to-stall-rd-for-alzheimers-parkinsons-cut-jobs-2018-01-08", "https://www.nasdaq.com/articles/3-pharma-and-biotech-stocks-watch-out-2018-2018-01-15", "https://www.nasdaq.com/articles/biogen-unlikely-see-spinraza-rival-2018-avexis-delayed-2018-01-05", "https://www.nasdaq.com/articles/iwf-nvda-low-biib-etf-outflow-alert-2018-01-05", "https://www.nasdaq.com/articles/biotech-stock-roundup-gwph-submits-epidiolex-eu-sangamo-inks-deal-pfizer-2018-01-04", "https://www.nasdaq.com/articles/stocks-generating-improved-relative-strength-biogen-2018-01-03", "https://www.nasdaq.com/articles/generalists-biotech-sidelines-tax-reform-sweeps-us-2018-01-03", "https://www.nasdaq.com/articles/tuesday-sector-leaders-healthcare-services-2018-01-02", "https://www.nasdaq.com/articles/best-stocks-2017-biotechs-shined-despite-lack-profits-2017-12-29", "https://www.nasdaq.com/articles/monday-sector-laggards-healthcare-services-2018-01-08", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-gild-lly-biib-2017-12-27", "https://www.nasdaq.com/articles/biotech-stock-roundup-biib-celg-hit-pipeline-news-acquisition-deals-ignyta-sucampo-2017-12", "https://www.nasdaq.com/articles/biogens-alzheimers-drug-misses-goal-in-interim-analysis-2017-12-22", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pfizer-fedex-abbott-biogen-and-marathon-petroleum-2017", "https://www.nasdaq.com/articles/biogen-shares-drop-after-alzheimers-drug-misses-testing-2017-12-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-payx-ntes-2017-12-21", "https://www.nasdaq.com/articles/top-8-market-moving-healthcare-stories-2017-2017-12-21", "https://www.nasdaq.com/articles/another-reason-2018-might-not-be-banner-year-biotech-mergers-2017-12-27", "https://www.nasdaq.com/articles/stocks-inch-higher-shutdown-threat-looms-2017-12-21", "https://www.nasdaq.com/articles/top-research-reports-for-pfizer-fedex-abbott-2017-12-21", "https://www.nasdaq.com/articles/notable-thursday-option-activity-kmx-biib-algn-2017-12-21", "https://www.nasdaq.com/articles/3-pharma-biotech-pipeline-areas-keep-eye-2018-2017-12-20", "https://www.nasdaq.com/articles/biogen-ionis-ink-deal-for-spinal-muscular-atrophy-therapies-2017-12-20", "https://www.nasdaq.com/articles/orbimed-advisors-llc-buys-clementia-pharmaceuticals-inc-aetna-inc-universal-health", "https://www.nasdaq.com/articles/biotech-stock-roundup-label-expansion-exelixiss-cabometyx-fda-nod-sparks-gene-therapy-2017", "https://www.nasdaq.com/articles/celgene-whacked-after-blood-drug-regimen-fails-phase-3-trial-2017-12-21", "https://www.nasdaq.com/articles/stock-leads-oil-plays-apple-fine-how-far-will-bitcoin-etf-fall-2017-12-20", "https://www.nasdaq.com/articles/stocks-close-lower-oracle-falls-after-earnings-2017-12-14", "https://www.nasdaq.com/articles/biogen-ionis-sink-competitor-plans-rival-drug-spinraza-2017-12-14", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-december-14-2017-2017-12-13", "https://www.nasdaq.com/articles/5-biotech-buyout-candidates-2018-2017-12-13", "https://www.nasdaq.com/articles/biogen-sees-rs-rating-rise-72-2017-12-12", "https://www.nasdaq.com/articles/these-5-top-stocks-are-near-buys-bullish-pattern-action-plan-2017-12-11", "https://www.nasdaq.com/articles/indexes-dip-tax-reform-gets-done-bullish-sentiment-rises-2017-12-20", "https://www.nasdaq.com/articles/looking-top-stocks-strongest-performing-sectors-2017-12-05", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-iyh-tmo-biib-aet-2017-12-04", "https://www.nasdaq.com/articles/sp-500-analyst-moves-biib-2017-11-30", "https://www.nasdaq.com/articles/heres-whats-unusual-about-regeneron-pharmaceuticals-latest-deal-2017-11-30", "https://www.nasdaq.com/articles/thursday-1130-insider-buying-report-biib-mdco-2017-11-30", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amazon-abbvie-biogen-mccormick-and-hyatt-2017-11-30", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-nod-amgen-pcsk9-inhibitor-revance-rt002-data-2017-12-06", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-down-eylea-data-biogen-alkermes-ms-deal-2017-11-29", "https://www.nasdaq.com/articles/biogen-acquires-worldwide-license-for-alkermes-ms-candidate-revised-2017-11-29", "https://www.nasdaq.com/articles/top-research-reports-amazon-abbvie-biogen-2017-11-29", "https://www.nasdaq.com/articles/biogen-acquires-worldwide-license-for-alkermes-ms-candidate-2017-11-28", "https://www.nasdaq.com/articles/sphera-funds-management-ltd-buys-cellcom-israel-allergan-plc-teva-pharmaceutical-0", "https://www.nasdaq.com/articles/biogens-multiple-sclerosis-franchise-getting-new-lease-life-2017-11-27", "https://www.nasdaq.com/articles/zacks-value-trader-highlights%3A-general-electric-macys-biogen-chipotle-and-exxon-mobil-2017", "https://www.nasdaq.com/articles/no-1-ranked-medical-stock-tests-support-new-base-2017-11-30", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-biib-tsn-ilmn-2017-11-27", "https://www.nasdaq.com/articles/should-you-buy-beaten-down-blue-chip-stocks-2017-11-22", "https://www.nasdaq.com/articles/biotech-stock-roundup-rare-drug-gets-fda-nod-acorda-cytokinetics-hit-pipeline-setbacks", "https://www.nasdaq.com/articles/bet-biogen-inc-easy-profits-new-year-2017-11-21", "https://www.nasdaq.com/articles/ibd-rating-upgrades-biogen-shows-improved-price-strength-2017-11-20", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-2017-11-18", "https://www.nasdaq.com/articles/why-its-time-put-pfizer-inc-stock-your-watchlist-2017-11-17", "https://www.nasdaq.com/articles/biogen-inc-buys-its-way-out-competition-2017-11-27", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-biib-tsn-ilmn-2017-11-27", "https://www.nasdaq.com/articles/should-you-buy-beaten-down-blue-chip-stocks-2017-11-22", "https://www.nasdaq.com/articles/biotech-stock-roundup-rare-drug-gets-fda-nod-acorda-cytokinetics-hit-pipeline-setbacks", "https://www.nasdaq.com/articles/bet-biogen-inc-easy-profits-new-year-2017-11-21", "https://www.nasdaq.com/articles/ibd-rating-upgrades-biogen-shows-improved-price-strength-2017-11-20", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-2017-11-18", "https://www.nasdaq.com/articles/why-its-time-put-pfizer-inc-stock-your-watchlist-2017-11-17", "https://www.nasdaq.com/articles/biogen-inc-buys-its-way-out-competition-2017-11-27", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-16-2017-2017-11-15", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-11152017-2017-11-15", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-sets-itself-growth-2017-11-14", "https://www.nasdaq.com/articles/can-marijuana-cure-alzheimers-disease-2017-11-13", "https://www.nasdaq.com/articles/better-buy-acadia-pharmaceuticals-vs-biogen-2017-11-11", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-earnings-results-fuel-volatility-2017-11-10", "https://www.nasdaq.com/articles/sphera-funds-management-ltd-buys-cellcom-israel-allergan-plc-teva-pharmaceutical", "https://www.nasdaq.com/articles/americafirst-capital-management-llc-buys-sysco-corp-exelon-corp-thermo-fisher-scientific", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-16-2017-2017-11-15", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-11152017-2017-11-15", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-sets-itself-growth-2017-11-14", "https://www.nasdaq.com/articles/can-marijuana-cure-alzheimers-disease-2017-11-13", "https://www.nasdaq.com/articles/better-buy-acadia-pharmaceuticals-vs-biogen-2017-11-11", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-earnings-results-fuel-volatility-2017-11-10", "https://www.nasdaq.com/articles/sphera-funds-management-ltd-buys-cellcom-israel-allergan-plc-teva-pharmaceutical", "https://www.nasdaq.com/articles/americafirst-capital-management-llc-buys-sysco-corp-exelon-corp-thermo-fisher-scientific", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-16-2017-2017-11-15", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-11152017-2017-11-15", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-sets-itself-growth-2017-11-14", "https://www.nasdaq.com/articles/can-marijuana-cure-alzheimers-disease-2017-11-13", "https://www.nasdaq.com/articles/better-buy-acadia-pharmaceuticals-vs-biogen-2017-11-11", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-earnings-results-fuel-volatility-2017-11-10", "https://www.nasdaq.com/articles/sphera-funds-management-ltd-buys-cellcom-israel-allergan-plc-teva-pharmaceutical", "https://www.nasdaq.com/articles/americafirst-capital-management-llc-buys-sysco-corp-exelon-corp-thermo-fisher-scientific", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-16-2017-2017-11-15", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-11152017-2017-11-15", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-sets-itself-growth-2017-11-14", "https://www.nasdaq.com/articles/can-marijuana-cure-alzheimers-disease-2017-11-13", "https://www.nasdaq.com/articles/better-buy-acadia-pharmaceuticals-vs-biogen-2017-11-11", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-earnings-results-fuel-volatility-2017-11-10", "https://www.nasdaq.com/articles/sphera-funds-management-ltd-buys-cellcom-israel-allergan-plc-teva-pharmaceutical", "https://www.nasdaq.com/articles/americafirst-capital-management-llc-buys-sysco-corp-exelon-corp-thermo-fisher-scientific", "https://www.nasdaq.com/articles/biogen-shows-rising-relative-strength-still-shy-key-threshold-2017-11-06", "https://www.nasdaq.com/articles/pdl-biopharma-pdli-q3-earnings-beat-revenues-rise-y-y-2017-11-03", "https://www.nasdaq.com/articles/lipe-dalton-buys-citigroup-inc-synchrony-financial-mckesson-corp-sells-american-2017-11-03", "https://www.nasdaq.com/articles/westend-advisors-llc-buys-bank-america-corporation-spdr-portfolio-short-term-corporate", "https://www.nasdaq.com/articles/biogen-sees-ibd-rs-rating-climb-73-2017-11-02", "https://www.nasdaq.com/articles/stoneridge-investment-partners-llc-buys-altria-group-inc-mondelez-international-inc-merck", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-ionis-ions-this-earnings-season-2017-11-01", "https://www.nasdaq.com/articles/whats-biogens-big-risk-2017-10-25", "https://www.nasdaq.com/articles/ibds-no-1-group-under-pressure-these-6-key-earnings-loom-sp-500-futures-2017-10-23", "https://www.nasdaq.com/articles/pre-market-earnings-report-october-24-2017-mcd-mmm-utx-lly-lmt-cat-biib-gm-shw-nvs-glw", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-biib-intc-fcx-2017-10-23", "https://www.nasdaq.com/articles/ishares-us-healthcare-etf-experiences-big-inflow-2017-10-20", "https://www.nasdaq.com/articles/tuesday-sector-leaders-healthcare-utilities-2017-10-17", "https://www.nasdaq.com/articles/biib-crosses-above-average-analyst-target-2017-10-16", "https://www.nasdaq.com/articles/ibd-biotech-innovator-awards-2017-10-16", "https://www.nasdaq.com/articles/stock-indexes-slightly-trump-threatens-drug-firms-2017-10-17", "https://www.nasdaq.com/articles/biogen-biomarkers-mark-way-alzheimers-parkinsons-treatments-2017-10-16", "https://www.nasdaq.com/articles/trump-likely-sign-executive-order-drug-pricing-any-day-2017-10-16", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-fcx-bmy-biib-2017-10-16", "https://www.nasdaq.com/articles/why-these-biotech-players-look-poised-crush-earnings-views-2017-10-13", "https://www.nasdaq.com/articles/no-1-ranked-medical-stock-breaking-out-q3-earnings-due-2017-10-12", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-celgene-2017-10-10", "https://www.nasdaq.com/articles/emergent-biosolutions-acquires-sanofis-smallpox-vaccine-unit-2017-10-09", "https://www.nasdaq.com/articles/6-top-biotech-companies-innovation-earn-recognition-new-awards-2017-10-16", "https://www.nasdaq.com/articles/no-side-effects-to-this-bullish-trade-on-celgene-corporation-celg-stock-2017-10-06", "https://www.nasdaq.com/articles/notable-friday-option-activity-gdot-biib-crm-2017-10-06", "https://www.nasdaq.com/articles/acadias-antipsychotic-drug-gets-breakthrough-therapy-status-2017-10-05", "https://www.nasdaq.com/articles/catabasis-dmd-candidate-slows-disease-progression-stock-up-2017-10-05", "https://www.nasdaq.com/articles/ligand-lgnd-signs-deal-to-acquire-crystal-bioscience-2017-10-05", "https://www.nasdaq.com/articles/nasdaq-100-movers-celg-nclh-2017-10-05", "https://www.nasdaq.com/articles/117-ovlc-holdings-seeing-recent-insider-buys-2017-10-05", "https://www.nasdaq.com/articles/intercept-dives-along-ocaliva-prescriptions-fda-warning-2017-10-06", "https://www.nasdaq.com/articles/no-side-effects-to-this-bullish-trade-on-celgene-corporation-celg-stock-2017-10-06", "https://www.nasdaq.com/articles/notable-friday-option-activity-gdot-biib-crm-2017-10-06", "https://www.nasdaq.com/articles/emergent-completes-acquisition-of-anthrax-drug-raxibacumab-2017-10-04", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-vht-agn-tmo-biib-2017-10-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-jd-myl-2017-10-04", "https://www.nasdaq.com/articles/allergans-botox-gets-fda-nod-for-forehead-line-treatment-2017-10-04", "https://www.nasdaq.com/articles/morning-movers-constellation-brands-jumps-biogen-bounces-celgene-slips-2017-10-05", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include-article-texas-instruments-applied-materials-pepsico", "https://www.nasdaq.com/articles/mallinckrodt-neuroprotexeon-team-up-for-inhalation-therapy-2017-10-03", "https://www.nasdaq.com/articles/after-intepirdine-flunked-alzheimers-disease-axovant-sciences-buy-2017-10-03", "https://www.nasdaq.com/articles/allergans-snda-for-anti-infective-avycaz-accepted-by-fda-2017-10-03", "https://www.nasdaq.com/articles/3-top-ranked-big-biotech-stocks-to-buy-now-2017-10-03", "https://www.nasdaq.com/articles/5-top-roe-stocks-buy-markets-snub-geopolitical-threats-2017-10-03", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-procter-gamble-petrochina-biogen-accenture-and-norfolk", "https://www.nasdaq.com/articles/amgen-enters-into-an-immuno-oncology-partnership-with-cytomx-2017-10-04", "https://www.nasdaq.com/articles/endocyte-inks-deal-for-prostate-cancer-candidate-shares-up-2017-10-03", "https://www.nasdaq.com/articles/avexis-flies-ptc-sinks-spinal-muscular-atrophy-data-2017-10-03", "https://www.nasdaq.com/articles/novo-nordisks-fiasp-gets-fda-nod-for-diabetes-in-adults-2017-10-02", "https://www.nasdaq.com/articles/lilly-lly-makes-leadership-changes-to-executive-positions-2017-10-02", "https://www.nasdaq.com/articles/top-stock-reports-procter-gamble-petrochina-biogen-2017-10-02", "https://www.nasdaq.com/articles/top-stock-reports-for-procter-gamble-petrochina-biogen-2017-10-02", "https://www.nasdaq.com/articles/4-biotech-stocks-and-1-etf-to-buy-as-they-bolt-higher-2017-10-02", "https://www.nasdaq.com/articles/why-ptc-therapeutics-inc-dropped-today-2017-10-03", "https://www.nasdaq.com/articles/biotechs-beating-market-are-they-buy-range-2017-09-28", "https://www.nasdaq.com/articles/why-amgens-drug-win-sent-abbvie-stock-stratosphere-2017-09-28", "https://www.nasdaq.com/articles/moat-oilu-big-etf-outflows-2017-09-26", "https://www.nasdaq.com/articles/is-biogen-inc.-biib-a-great-stock-for-value-investors-2017-09-25", "https://www.nasdaq.com/articles/sorry-qualcomm-inc.-qcom-stock-bears-it-has-bottomed-2017-09-19", "https://www.nasdaq.com/articles/play-the-support-test-in-vaneck-vectors-gold-miners-etf-gdx-2017-09-19", "https://www.nasdaq.com/articles/think-before-you-chase-nvidia-corporation-nvda-stocks-momentum-2017-09-19", "https://www.nasdaq.com/articles/notable-friday-option-activity-biib-rjf-tsn-2017-09-29", "https://www.nasdaq.com/articles/billionaire-george-soros-fund-bought-these-3-pharma-stocks-should-you-2017-09-18", "https://www.nasdaq.com/articles/ibb-biib-regn-alxn-etf-inflow-alert-2017-09-15", "https://www.nasdaq.com/articles/4-biotech-stocks-for-the-long-term-2017-09-13", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-september-14-2017-2017-09-13", "https://www.nasdaq.com/articles/biib-january-2020-options-begin-trading-2017-09-11", "https://www.nasdaq.com/articles/why-biogen-stock-raced-higher-august-2017-09-11", "https://www.nasdaq.com/articles/biogen-reaches-analyst-target-price-2017-09-11", "https://www.nasdaq.com/articles/profit-from-the-biogen-inc-biib-stock-dip-2017-09-19", "https://www.nasdaq.com/articles/novartis-nvs-ms-drug-gilenya-positive-in-long-term-study-2017-09-06", "https://www.nasdaq.com/articles/thursday-sector-leaders-healthcare-energy-2017-08-31", "https://www.nasdaq.com/articles/5-biotech-stocks-that-are-breaking-higher-2017-08-30", "https://www.nasdaq.com/articles/biogen-alzheimers-drug-shows-promise-in-long-term-study-2017-08-29", "https://www.nasdaq.com/articles/company-news-for-august-29-2017-2017-08-29", "https://www.nasdaq.com/articles/trade-of-the-day%3A-biogen-inc-biib-stock-is-coiling-2017-08-29", "https://www.nasdaq.com/articles/vanguard-russell-1000-etf-insider-buying-index-registering-119-2017-08-28", "https://www.nasdaq.com/articles/abbvie-submits-nda-for-endometriosis-candidate-to-the-fda-2017-09-07", "https://www.nasdaq.com/articles/novartis-nvs-ms-drug-gilenya-positive-in-long-term-study-2017-09-06", "https://www.nasdaq.com/articles/thursday-sector-leaders-healthcare-energy-2017-08-31", "https://www.nasdaq.com/articles/5-biotech-stocks-that-are-breaking-higher-2017-08-30", "https://www.nasdaq.com/articles/biogen-alzheimers-drug-shows-promise-in-long-term-study-2017-08-29", "https://www.nasdaq.com/articles/heres-simple-reason-why-multiple-sclerosis-drugs-cost-so-much-2017-08-23", "https://www.nasdaq.com/articles/orbimed-advisors-llc-buys-cigna-corp-clovis-oncology-inc-gilead-sciences-inc-sells-centene", "https://www.nasdaq.com/articles/biogen-6-other-multiple-sclerosis-drug-stocks-focus-heres-why-2017-08-21", "https://www.nasdaq.com/articles/monday-sector-leaders-healthcare-technology-communications-2017-08-28", "https://www.nasdaq.com/articles/orbimed-advisors-llc-buys-cigna-corp-clovis-oncology-inc-gilead-sciences-inc-sells-0", "https://www.nasdaq.com/articles/notable-thursday-option-activity-de-nvda-biib-2017-08-17", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-tqqq-goog-amgn-biib-2017-08-16", "https://www.nasdaq.com/articles/what-you-see-and-what-you-get-neurology-perception-2017-08-15", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-august-15-2017-2017-08-14", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-growing-royalties-advancing-pipeline-and-getting-back-rights", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-activision-cigna-kraft-heinz-and-equinix-2017-08", "https://www.nasdaq.com/articles/we-did-math-oef-can-go-119-2017-08-18", "https://www.nasdaq.com/articles/top-analyst-reports-biogen-activision-cigna-2017-08-08", "https://www.nasdaq.com/articles/these-3-biotechs-just-crushed-analyst-expectations-2017-08-07", "https://www.nasdaq.com/articles/pdl-biopharma-pdli-q2-earnings-beat-revenues-rise-y-y-2017-08-07", "https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-biogen-2017-08-04", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-ionis-ions-this-earnings-season-2017-08-01", "https://www.nasdaq.com/articles/7-explosive-healthcare-stocks-to-buy-now-2017-07-31", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-vht-lly-tmo-biib-2017-07-28", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-vht-tmo-biib-aet-2017-08-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-biogen-top-q2-estimates-update-incyte-ra-drug-2017-07-26", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-642275-2017-07", "https://www.nasdaq.com/articles/biogen-inc-wants-be-fastest-growing-large-cap-biotech-company-2017-07-26", "https://www.nasdaq.com/articles/validea-warren-buffett-strategy-daily-upgrade-report-2017-07-26", "https://www.nasdaq.com/articles/lgt-capital-partners-ltd-buys-dr-pepper-snapple-group-inc-unitedhealth-group-inc-starbucks", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-ctrn-pcrx-biib-2017-07-25", "https://www.nasdaq.com/articles/lilly-lly-q2-earnings-top-baricitinib-re-filing-delayed-2017-07-25", "https://www.nasdaq.com/articles/acorda-acor-q2-earnings-miss-estimates-revenues-in-line-2017-07-28", "https://www.nasdaq.com/articles/wal-mart-stores-inc-wmt-stock-is-perking-up-2017-07-25", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-tuesday%3A-alphabet-inc-googl-biogen-inc-biib-and-michael-kors-holdings", "https://www.nasdaq.com/articles/earnings-reaction-history-biogen-idec-583-follow-through-indicator-53-sensitive-2017-07-25", "https://www.nasdaq.com/articles/biogen-biib-tops-q2-earnings-sales-spinraza-sales-up-2017-07-25", "https://www.nasdaq.com/articles/big-pharma-q2-earnings-releases-on-jul-25%3A-lly-biib-amgn-2017-07-24", "https://www.nasdaq.com/articles/pre-market-earnings-report-july-25-2017-mmm-mcd-utx-lly-dd-cat-biib-gm-kmb-hca-pcar-trow", "https://www.nasdaq.com/articles/these-5-drugs-could-be-worth-45-billion-and-theyre-not-even-market-yet-2017-07-23", "https://www.nasdaq.com/articles/biogen-biib-tops-q2-earnings-and-revenue-2017-07-25", "https://www.nasdaq.com/articles/can-biogen-biib-keep-the-earnings-streak-alive-in-q2-2017-07-19", "https://www.nasdaq.com/articles/biotech-stock-roundup-vertex-boosted-cf-data-fda-nod-gilead-puma-drugs-2017-07-19", "https://www.nasdaq.com/articles/agree-purchase-biogen-200-earn-4-using-options-2017-07-18", "https://www.nasdaq.com/articles/insiders-buy-holdings-bbh-etf-2017-07-18", "https://www.nasdaq.com/articles/avexis-inc-buy-high-2017-07-18", "https://www.nasdaq.com/articles/biogen-breaks-above-200-day-moving-average-bullish-biib-2017-07-17", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-vhc-agn-biib-2017-07-17", "https://www.nasdaq.com/articles/itot-tmo-cost-biib-etf-inflow-alert-2017-07-20", "https://www.nasdaq.com/articles/can-biogen-biib-keep-the-earnings-streak-alive-in-q2-2017-07-19", "https://www.nasdaq.com/articles/math-shows-bbh-can-go-140-2017-07-12", "https://www.nasdaq.com/articles/amgen-inc.-amgn-stock-is-the-cure-for-ailing-portfolios-2017-07-10", "https://www.nasdaq.com/articles/bib-biib-regn-vrtx-etf-outflow-alert-2017-07-10", "https://www.nasdaq.com/articles/3-hot-biotech-stocks-ready-sectors-next-breakout-2017-07-06", "https://www.nasdaq.com/articles/biotech-stock-roundup-cara-plunges-study-data-regulatory-updates-more-2017-07-05", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-celgene-corporation-2017-07-16", "https://www.nasdaq.com/articles/top-stock-reports-boeing-abbvie-us-bancorp-2017-07-13", "https://www.nasdaq.com/articles/3-charts-show-why-buy-gilead-sciences-stock-now-2017-07-02", "https://www.nasdaq.com/articles/4-reasons-avexis-inc-rally-could-continue-2017-07-01", "https://www.nasdaq.com/articles/biotech-stock-roundup-eu-nod-regeneron-ra-drug-portola-soars-fda-nod-2017-06-29", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-jkd-mo-biib-antm-2017-06-26", "https://www.nasdaq.com/articles/update-wall-street-weighed-down-oil-declines-health-stocks-lift-nasdaq-2017-06-21", "https://www.nasdaq.com/articles/5-biotech-stocks-that-are-roaring-back-to-life-2017-06-21", "https://www.nasdaq.com/articles/3-reasons-sizzling-hot-bioverativ-stock-can-go-even-higher-2017-07-05", "https://www.nasdaq.com/articles/7-healthcare-stocks-to-buy-now-2017-06-21", "https://www.nasdaq.com/articles/monday-sector-leaders-healthcare-technology-communications-2017-06-19", "https://www.nasdaq.com/articles/bear-day-bioverativ-bivv-2017-06-16", "https://www.nasdaq.com/articles/nektar-nktr-stock-rallied-almost-50-this-year%3A-heres-why-2017-06-16", "https://www.nasdaq.com/articles/will-these-cutting-edge-cancer-killers-reignite-biotech-rally-2017-06-15", "https://www.nasdaq.com/articles/dont-be-scared-of-biogen-inc-biib-stock-2017-06-15", "https://www.nasdaq.com/articles/biogen-loses-top-executive-again-cfo-clancy-to-join-alexion-2017-06-14", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-cmg-biib-aapl-2017-06-21", "https://www.nasdaq.com/articles/7-healthcare-stocks-to-buy-now-2017-06-21", "https://www.nasdaq.com/articles/monday-sector-leaders-healthcare-technology-communications-2017-06-19", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-june-14-2017-2017-06-13", "https://www.nasdaq.com/articles/insiders-buy-holdings-vone-etf-2017-06-12", "https://www.nasdaq.com/articles/2-reasons-why-biogens-shares-slumped-may-2017-06-09", "https://www.nasdaq.com/articles/3-stocks-could-be-life-changers-2017-06-06", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-alxn-2017-06-14", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-wednesday%3A-ford-motor-company-f-alexion-pharmaceuticals-inc.-alxn-and", "https://www.nasdaq.com/articles/biotech-etf-experiences-big-outflow-2017-06-02", "https://www.nasdaq.com/articles/biogen-ionis-spinraza-granted-marketing-authorization-in-eu-2017-06-02", "https://www.nasdaq.com/articles/notable-friday-option-activity-len-biib-rrc-2017-06-02", "https://www.nasdaq.com/articles/5-drug-stocks-focus-world-ms-day-2017-05-31", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-unitedhealth-group-union-pacific-biogen-united", "https://www.nasdaq.com/articles/celgenes-stock-may-be-incredibly-overvalued-right-now-heres-why-2017-05-31", "https://www.nasdaq.com/articles/why-ionis-pharmaceuticals-inc-swooned-6-may-2017-06-06", "https://www.nasdaq.com/articles/biogen-inc-biib-stock-can-help-you-earn-income-from-thin-air-2017-06-05", "https://www.nasdaq.com/articles/biotech-etf-experiences-big-outflow-2017-06-02", "https://www.nasdaq.com/articles/biogen-ionis-spinraza-granted-marketing-authorization-in-eu-2017-06-02", "https://www.nasdaq.com/articles/notable-friday-option-activity-len-biib-rrc-2017-06-02", "https://www.nasdaq.com/articles/stock-exchange-time-reconsider-health-care-2017-05-26", "https://www.nasdaq.com/articles/biogen-biib-down-9.5-since-earnings-report%3A-can-it-rebound-2017-05-26", "https://www.nasdaq.com/articles/biogens-fampyra-conditional-approval-converted-to-standard-2017-05-25", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2017-05-31", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-jnj-c-biib-2017-05-24", "https://www.nasdaq.com/articles/why-long-term-investors-should-prefer-celgene-over-biogen-2017-05-21", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-vv-biib-pypl-dhr-2017-05-18", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-inks-deal-boost-pipeline-sangamo-soars-pfizer-deal-2017-05-17", "https://www.nasdaq.com/articles/want-get-biotech-check-out-these-3-stocks-2017-05-16", "https://www.nasdaq.com/articles/biogen-biib-buys-stroke-candidate-cirara-for-%24120m-2017-05-16", "https://www.nasdaq.com/articles/notable-monday-option-activity-rtn-biib-mon-2017-05-15", "https://www.nasdaq.com/articles/jeff-ubben-buys-1-sells-1-1st-quarter-2017-05-24", "https://www.nasdaq.com/articles/biogen-enters-oversold-territory-biib-2017-05-11", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-incs-first-royalties-roll-2017-05-11", "https://www.nasdaq.com/articles/ishares-russell-1000-growth-etf-experiences-big-outflow-2017-05-10", "https://www.nasdaq.com/articles/iyhs-underlying-holdings-could-mean-10-gain-potential-2017-05-09", "https://www.nasdaq.com/articles/why-biogen-inc-shareholders-have-something-worry-about-2017-05-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-exxon-mobil-jpmorgan-union-pacific-biogen-and-becton", "https://www.nasdaq.com/articles/friday-sector-laggards-healthcare-financial-2017-05-05", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-may-15-2017-2017-05-12", "https://www.nasdaq.com/articles/whats-in-the-cards-for-ionis-ions-this-earnings-season-2017-05-04", "https://www.nasdaq.com/articles/whats-behind-ionis-pharmaceuticals-20-rally-april-2017-05-04", "https://www.nasdaq.com/articles/top-research-reports-may-4-2017-2017-05-04", "https://www.nasdaq.com/articles/morningstar-wide-moat-etf-insider-buying-index-registering-120-2017-05-03", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-bib-biib-regn-ilmn-2017-05-02", "https://www.nasdaq.com/articles/tuesday-52-insider-buying-report-biib-wwd-2017-05-02", "https://www.nasdaq.com/articles/acorda-acor-q1-loss-wider-than-expected-revenues-miss-2017-04-28", "https://www.nasdaq.com/articles/notable-friday-option-activity-biib-nwl-nke-2017-05-05", "https://www.nasdaq.com/articles/pharma-stocks-q1-earnings-roster-for-apr-27%3A-celg-abbv-bmy-2017-04-26", "https://www.nasdaq.com/articles/better-buy-amgen-inc-vs-biogen-2017-04-26", "https://www.nasdaq.com/articles/biogen-inc-earnings-new-drug-sparks-life-2017-04-26", "https://www.nasdaq.com/articles/biogen-inc-biib-stock-pops-strong-q1-earnings-2017-04-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-esrx-biib-2017-04-25", "https://www.nasdaq.com/articles/lilly-lly-tops-q1-earnings-misses-sales-shares-down-2017-04-25", "https://www.nasdaq.com/articles/biogen-biib-q1-earnings-sales-top-spinraza-sales-strong-2017-04-25", "https://www.nasdaq.com/articles/better-buy-ionis-pharmaceuticals-inc-vs-bluebird-bio-2017-04-27", "https://www.nasdaq.com/articles/health-care-sector-update-04252017-biib-esrx-jnj-pfe-abt-mrk-amgn-2017-04-25", "https://www.nasdaq.com/articles/earnings-reaction-history-biogen-idec-583-follow-through-indicator-50-sensitive-2017-04-25", "https://www.nasdaq.com/articles/spinrazas-fast-start-puts-ionis-path-profit-2017-04-25", "https://www.nasdaq.com/articles/biogen-and-alzheimers-theres-fundamental-problem-here-2017-04-25", "https://www.nasdaq.com/articles/mondays-vital-data%3A-apple-inc.-aapl-visa-inc-v-and-micron-technology-inc-mu-2017-04-24", "https://www.nasdaq.com/articles/3-key-factors-look-out-biogens-q1-results-2017-04-24", "https://www.nasdaq.com/articles/make-biogen-inc-biib-stock-pay-you-even-with-no-dividend-2017-04-24", "https://www.nasdaq.com/articles/biogen-biib-beats-on-q1-earnings-and-revenue-2017-04-25", "https://www.nasdaq.com/articles/pre-market-earnings-report-april-25-2017-ko-mmm-mcd-lly-lmt-dd-biib-cat-spgi-vlo-glw-bhi", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-aapl-isrg-biib-2017-04-24", "https://www.nasdaq.com/articles/3-stocks-growth-investors-should-love-2017-04-23", "https://www.nasdaq.com/articles/marijuana-stocks-420-special-2017-04-20", "https://www.nasdaq.com/articles/whats-in-store-for-biogen-biib-this-earnings-season-2017-04-20", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-crl-hits-incyte-pipeline-setbacks-weigh-oncomed-2017-04-19", "https://www.nasdaq.com/articles/bristol-myers-and-nordic-ink-biomarker-collaboration-deal-2017-04-18", "https://www.nasdaq.com/articles/drug-stocks-q1-earnings-releases-on-apr-25%3A-lly-biib-nvs-2017-04-24", "https://www.nasdaq.com/articles/commit-buy-biogen-140-earn-26-using-options-2017-04-18", "https://www.nasdaq.com/articles/biogen-to-license-alzheimer-candidate-from-bristol-myers-2017-04-17", "https://www.nasdaq.com/articles/abbvies-elagolix-meets-primary-endpoint-in-phase-ii-study-2017-04-10", "https://www.nasdaq.com/articles/roche-just-scored-one-biggest-pharma-wins-2017-2017-04-10", "https://www.nasdaq.com/articles/3-big-stock-charts-for-friday%3A-biogen-inc-biib-american-airlines-group-inc-aal-and-cisco", "https://www.nasdaq.com/articles/acorda-acor-to-reduce-workforce-focus-on-product-pipeline-2017-04-06", "https://www.nasdaq.com/articles/peek-under-hood-bbh-has-14-upside-2017-04-05", "https://www.nasdaq.com/articles/7-most-expensive-prescription-drugs-world-2017-04-18", "https://www.nasdaq.com/articles/3-biotech-trades-for-the-faux-doomsday-scenario-2017-04-03", "https://www.nasdaq.com/articles/acordas-acor-ms-drug-patents-invalidated-shares-plunge-2017-04-03", "https://www.nasdaq.com/articles/why-acorda-therapeutics-inc-and-forward-pharma-got-crushed-today-2017-03-31", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-drops-50-points-trc-companies-shares-spike-higher-2017-03", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-px-biib-expe-2017-03-31", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-vrtx-2017-03-29", "https://www.nasdaq.com/articles/roches-ocrevus-wins-fda-approval-for-2-forms-of-sclerosis-2017-03-29", "https://www.nasdaq.com/articles/wednesday-sector-laggards-utilities-healthcare-2017-04-05", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-down-repatha-data-nektar-surges-pain-results-2017-03-22", "https://www.nasdaq.com/articles/3-biotech-stocks-are-broker-favorites-2017-03-21", "https://www.nasdaq.com/articles/health-care-sector-update-03212017-biibptieaxsm-2017-03-21", "https://www.nasdaq.com/articles/billionaires-best-healthcare-stock-picks-2017-so-far-2017-03-21", "https://www.nasdaq.com/articles/avexis-inc-stock-spiking-again-today-heres-why-2017-03-17", "https://www.nasdaq.com/articles/stock-market-news-for-march-17-2017-2017-03-17", "https://www.nasdaq.com/articles/alkermes-starts-phase-iii-study-to-treat-multiple-sclerosis-2017-03-17", "https://www.nasdaq.com/articles/biotech-etfs-defy-trump-tweets-rally-what-can-send-them-higher-2017-03-28", "https://www.nasdaq.com/articles/biib-crosses-below-key-moving-average-level-2017-03-16", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-ibb-biib-regn-incy-2017-03-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-qvca-2017-03-16", "https://www.nasdaq.com/articles/sp-500-movers-biib-orcl-2017-03-16", "https://www.nasdaq.com/articles/biogen-inc-biib%3A-profit-from-the-biib-stock-bears-2017-03-16", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-590076-71-points-2017-03-16", "https://www.nasdaq.com/articles/thursday-sector-laggards-healthcare-utilities-2017-03-16", "https://www.nasdaq.com/articles/mid-day-market-update-us-stocks-turn-negative-gopro-shares-spike-higher-2017-03-16", "https://www.nasdaq.com/articles/thursdays-etf-movers-itb-bbh-2017-03-16", "https://www.nasdaq.com/articles/acordas-four-ampyra-patents-upheld-by-ptab-shares-rise-2017-03-13", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-march-14-2017-2017-03-13", "https://www.nasdaq.com/articles/biogen-spinoff-takes-flight-focus-hemophilia-drugs-2017-03-10", "https://www.nasdaq.com/articles/abbvie-stock-upgraded-what-you-need-know-2017-03-10", "https://www.nasdaq.com/articles/why-ionis-pharmaceuticals-rallied-12-february-2017-03-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-trump-tweet-hits-biotech-stocks-concert-gains-vertex-deal-2017-03-08", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-mpc-biib-hum-2017-03-16", "https://www.nasdaq.com/articles/repros-rprx-q4-earnings%3A-whats-in-store-for-the-stock-2017-03-07", "https://www.nasdaq.com/articles/right-time-invest-biotech-stocks-2017-03-07", "https://www.nasdaq.com/articles/5-things-biogens-ceo-just-said-you-dont-want-miss-2017-03-07", "https://www.nasdaq.com/articles/inovio-ino%3A-whats-in-the-cards-this-earnings-season-2017-03-06", "https://www.nasdaq.com/articles/biodelivery-bdsi%3A-whats-in-store-this-earnings-season-2017-03-06", "https://www.nasdaq.com/articles/4-things-alkermes-wants-investors-know-2017-03-06", "https://www.nasdaq.com/articles/new-features-individual-portfolio-tracker-and-value-screens-tracker-2017-03-03", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-iyh-gild-agn-biib-2017-03-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-att-visa-biogen-tesla-and-pge-2017-03-01", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-turns-profit-other-drugmakers-money-2017-03-01", "https://www.nasdaq.com/articles/get-biogen-inc-biib-stock-it-breaks-out-2017-02-28", "https://www.nasdaq.com/articles/perrigo-to-sell-tysabri-royalties-issues-tepid-2017-view-2017-02-28", "https://www.nasdaq.com/articles/qual-kmb-peg-biib-etf-inflow-alert-2017-02-27", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2017-02-27", "https://www.nasdaq.com/articles/heres-why-celgenes-latest-drug-so-exciting-2017-02-23", "https://www.nasdaq.com/articles/why-celgenes-shares-rallied-higher-february-2017-03-02", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-att-visa-biogen-tesla-and-pge-2017-03-01", "https://www.nasdaq.com/articles/ionis-ions-q4-earnings%3A-whats-in-the-cards-for-the-stock-2017-02-21", "https://www.nasdaq.com/articles/3-top-drug-stocks-can-be-purchased-cheap-winter-2017-02-20", "https://www.nasdaq.com/articles/could-celgene-have-another-billion-dollar-blockbuster-its-hands-2017-02-19", "https://www.nasdaq.com/articles/why-ionis-pharmaceuticals-ions-looks-worth-risk-2017-02-16", "https://www.nasdaq.com/articles/another-potential-alzheimers-disease-treatment-bites-dust-whats-next-2017-02-15", "https://www.nasdaq.com/articles/bib-biib-regn-ilmn-large-outflows-detected-etf-2017-02-13", "https://www.nasdaq.com/articles/andreas-halvorsen-buys-maker-first-class-cancer-treatments-calithera-biosciences-2017-02", "https://www.nasdaq.com/articles/potential-20-billion-indication-2-must-have-biotechs-taking-alzheimers-disease-2017-02-11", "https://www.nasdaq.com/articles/biogen-risky-stock-2017-02-10", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-13-2017-2017-02-10", "https://www.nasdaq.com/articles/how-biogen-inc-biib-stock-could-gain-another-25-2017-02-08", "https://www.nasdaq.com/articles/whats-behind-bioverativs-spin-out-and-should-you-buy-2017-02-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-gilead-report-4q-results-ariad-seeks-eu-nod-brigatinib-2017-02", "https://www.nasdaq.com/articles/ironic-twist-generics-take-aim-teva-pharmaceutical-2017-02-07", "https://www.nasdaq.com/articles/primecap-management-buys-astrazeneca-plc-alkermes-plc-whirlpool-sells-union-pacific-2017", "https://www.nasdaq.com/articles/potential-20-billion-indication-2-must-have-biotechs-taking-alzheimers-disease-2017-02-11", "https://www.nasdaq.com/articles/why-forward-pharma-stock-surged-107-january-2017-02-03", "https://www.nasdaq.com/articles/its-scratch-not-ding-biogen-inc-biib-stock-2017-02-03", "https://www.nasdaq.com/articles/qual-kmb-peg-biib-etf-outflow-alert-2017-02-02", "https://www.nasdaq.com/articles/5-drugmakers-battle-over-10-billion-hemophilia-market-2017-02-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-tsco-2017-02-02", "https://www.nasdaq.com/articles/implied-ryh-analyst-target-price-172-2017-02-02", "https://www.nasdaq.com/articles/3-healthcare-tickers-that-will-return-profits-in-3-months-2017-02-06", "https://www.nasdaq.com/articles/biotech-stock-roundup-celgene-biogen-abbv-post-q4-results-catabasis-falls-dmd-data-2017-02", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-att-biogen-qualcomm-facebook-and-royal-caribbean-2017", "https://www.nasdaq.com/articles/biogen-inc-makes-lackluster-revenue-growth-2017-01-27", "https://www.nasdaq.com/articles/how-to-trade-biogen-inc-biib-stock-after-its-q4-beat-2017-01-26", "https://www.nasdaq.com/articles/biogen-biib-q4-earnings-top-estimates-17-sales-view-soft-2017-01-26", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-johnson-johnson-biogen-celgene-and-bristol-myers-squibb", "https://www.nasdaq.com/articles/biogen-biib-beats-on-q4-earnings-misses-sales-2017-01-26", "https://www.nasdaq.com/articles/what-could-make-biogen-crash-2017-02-02", "https://www.nasdaq.com/articles/earnings-reaction-history-biogen-idec-500-follow-through-indicator-45-sensitive-2017-01-26", "https://www.nasdaq.com/articles/notable-thursday-option-activity-pypl-biib-mjn-2017-01-26", "https://www.nasdaq.com/articles/perrigos-prgo-generic-version-of-topicort-okayed-by-fda-2017-01-25", "https://www.nasdaq.com/articles/drug-stock-earnings-to-watch-on-jan-26%3A-biib-celg-bmy-2017-01-25", "https://www.nasdaq.com/articles/pre-market-earnings-report-january-26-2017-cmcsa-celg-bmy-dow-biib-cat-f-rtn-noc-px-aep", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2017-01-24", "https://www.nasdaq.com/articles/biogen-inc-biib-stock-enters-uncharted-waters-2017-01-24", "https://www.nasdaq.com/articles/3-top-biotech-stocks-you-can-still-buy-dow-20000-2017-01-26", "https://www.nasdaq.com/articles/nektar-therapeutics-undervalued-biopharmaceuticals-company-plenty-pipeline-2017-01-20", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-nano-biib-swks-2017-01-19", "https://www.nasdaq.com/articles/biogen-biib-q4-earnings%3A-whats-in-store-for-the-stock-2017-01-19", "https://www.nasdaq.com/articles/alcobra-stock-down-on-poor-late-stage-data-on-adhd-drug-2017-01-18", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-microsoft-biogen-home-depot-bristol-myers-and-berkshire", "https://www.nasdaq.com/articles/why-forward-pharma-stock-gained-482-tuesday-2017-01-18", "https://www.nasdaq.com/articles/biogen-to-pay-%241.25b-to-forward-pharma-in-tecfidera-lawsuit-2017-01-18", "https://www.nasdaq.com/articles/5-drugs-are-way-cheaper-canada-2017-01-21", "https://www.nasdaq.com/articles/mid-day-market-update-clayton-williams-energy-surges-acquisition-news-christopher-banks", "https://www.nasdaq.com/articles/agree-buy-biogen-180-earn-53-using-options-2017-01-17", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-morgan-stanley-tops-q4-estimates-2017-01-17", "https://www.nasdaq.com/articles/why-netflix-inc.-nflx-stock-could-pop-after-q4-earnings-2017-01-17", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-tuesday%3A-chipotle-mexican-grill-inc.-cmg-noble-energy-inc.-nbl-and", "https://www.nasdaq.com/articles/biogen-inc-biib-will-win-a-battle-but-could-lose-the-war-2017-01-17", "https://www.nasdaq.com/articles/why-clayton-williams-energy-forward-pharma-and-luxottica-jumped-today-2017-01-17", "https://www.nasdaq.com/articles/midday-update-stocks-pressured-trumps-dollar-warning-earnings-and-inauguration-sell-0ff", "https://www.nasdaq.com/articles/biogens-multiple-sclerosis-franchise-to-drive-growth-in-2017-2017-01-17", "https://www.nasdaq.com/articles/close-update-wall-street-braces-sell-fact-reaction-after-inauguration-2017-01-17", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alibaba-costco-walgreens-boots-biogen-and-paypal-2017", "https://www.nasdaq.com/articles/biogen-biib-presents-positive-phase-iii-data-on-spinraza-2017-01-16", "https://www.nasdaq.com/articles/biogens-stock-ready-heat-after-forgettable-2016-2017-01-13", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-557412-2017-01", "https://www.nasdaq.com/articles/top-research-reports-alibaba-costco-walgreens-2017-01-13", "https://www.nasdaq.com/articles/merrimack-mack-goes-uphill%3A-is-a-turnaround-likely-2017-01-17", "https://www.nasdaq.com/articles/biogens-multiple-sclerosis-franchise-to-drive-growth-in-2017-2017-01-17", "https://www.nasdaq.com/articles/close-update-wall-street-braces-sell-fact-reaction-after-inauguration-2017-01-17", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alibaba-costco-walgreens-boots-biogen-and-paypal-2017", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-biib-mrk-amgn-2017-01-11", "https://www.nasdaq.com/articles/stock-market-news-for-january-10-2017-2017-01-10", "https://www.nasdaq.com/articles/3-big-reasons-and-8-smaller-ones-buy-ionis-pharmaceuticals-stock-2017-01-10", "https://www.nasdaq.com/articles/energous-corp-shines-brightly-as-the-next-fortune-building-company-watt-2017-01-12", "https://www.nasdaq.com/articles/could-very-well-be-greatest-drug-advancement-decade-2017-01-09", "https://www.nasdaq.com/articles/biogen-licenses-amunixs-xten-technology-for-factor-ix-drug-2017-01-06", "https://www.nasdaq.com/articles/biotech-investing-3-bold-predictions-2017-2017-01-06", "https://www.nasdaq.com/articles/biogens-new-ceo-lots-questions-few-answers-2017-01-06", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-iyh-celg-biib-aet-2017-01-05", "https://www.nasdaq.com/articles/ionis-ions-stock-up-on-positive-type-ii-diabetes-drug-data-2017-01-05", "https://www.nasdaq.com/articles/5-slides-every-ionis-pharmaceuticals-inc-investor-needs-see-2017-01-05", "https://www.nasdaq.com/articles/top-stocks-buy-now-21st-century-cures-act-has-passed-2017-01-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-inotek-plunges-pipeline-setback-kite-files-ind-study-initiation-2017", "https://www.nasdaq.com/articles/biogen-playing-fire-2017-01-04", "https://www.nasdaq.com/articles/my-worst-predictions-biotech-2016-2017-01-03", "https://www.nasdaq.com/articles/abbvies-humira-and-imbruvica-drive-performance-in-2016-2016-12-30", "https://www.nasdaq.com/articles/ishares-edge-msci-usa-quality-factor-etf-experiences-big-outflow-2016-12-28", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-nod-biogenionis-drug-seattle-genetics-hit-clinical-hold-2016-12", "https://www.nasdaq.com/articles/why-twilio-northern-dynasty-minerals-and-ionis-pharmaceuticals-slumped-today-2016-12-28", "https://www.nasdaq.com/articles/did-biogen-just-throw-towel-celgene-2017-01-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-inotek-plunges-pipeline-setback-kite-files-ind-study-initiation-2017", "https://www.nasdaq.com/articles/ionis-biogen-spinraza-approved-for-spinal-muscular-atrophy-2016-12-27", "https://www.nasdaq.com/articles/3-biggest-risks-pfizer-2017-2016-12-27", "https://www.nasdaq.com/articles/health-care-sector-update-12272016-ionsbiibcapnengx-2016-12-27", "https://www.nasdaq.com/articles/3-biggest-risks-abbvie-2017-2016-12-27", "https://www.nasdaq.com/articles/biotech-stock-roundup-conatus-soars-novartis-deal-early-fda-nod-clovis-drug-2016-12-21", "https://www.nasdaq.com/articles/2016s-worst-clinical-failures-2016-12-21", "https://www.nasdaq.com/articles/will-spinraza-supercharge-biogens-top-line-next-year-2016-12-28", "https://www.nasdaq.com/articles/health-care-sector-update-12272016-sgen-ions-jnj-pfe-abt-mrk-amgn-2016-12-27", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-tuesday%3A-biogen-inc-biib-conatus-pharmaceuticals-inc-cnat-and-general", "https://www.nasdaq.com/articles/biogen-names-commercial-officer-as-new-ceo-shares-fall-2016-12-20", "https://www.nasdaq.com/articles/3-reasons-biogen-inc-stock-set-soar-2017-2016-12-20", "https://www.nasdaq.com/articles/3-low-volatility-biotech-stocks-buy-2016-12-18", "https://www.nasdaq.com/articles/oef-wba-twx-biib-etf-outflow-alert-2016-12-16", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-barclays-netflix-nike-biogen-and-china-petroleum", "https://www.nasdaq.com/articles/biogen-biib-board-okays-hemophilia-business-spin-off-2016-12-21", "https://www.nasdaq.com/articles/top-research-reports-barclays-netflix-and-nike-2016-12-13", "https://www.nasdaq.com/articles/trade-valeant-pharmaceuticals-intl-inc-vrx-stock-for-free-profits-2016-12-13", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-sale-2016-12-13", "https://www.nasdaq.com/articles/biogen-presents-positive-early-data-from-alzheimers-study-2016-12-12", "https://www.nasdaq.com/articles/lilly-astrazeneca-expand-alzheimer-disease-collaboration-2016-12-12", "https://www.nasdaq.com/articles/3-most-profit-friendly-biotech-stocks-2016-12-12", "https://www.nasdaq.com/articles/better-buy-amgen-inc-vs-biogen-2016-12-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-ophthotech-slumps-fovista-results-achaogen-skyrockets-data-2016-12", "https://www.nasdaq.com/articles/does-new-alzheimers-data-make-biogen-stock-buy-now-2016-12-09", "https://www.nasdaq.com/articles/stock-market-news-for-december-09-2016-2016-12-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-lrcx-biib-2016-12-09", "https://www.nasdaq.com/articles/should-you-buy-drug-stocks-their-post-election-drop-2016-12-09", "https://www.nasdaq.com/articles/sp-500-movers-grmn-biib-2016-12-09", "https://www.nasdaq.com/articles/health-care-sector-update-12092016-biib-2016-12-09", "https://www.nasdaq.com/articles/pre-market-most-active-dec-9-2016-swc-mgm-bac-tlk-lvs-mpel-wynn-vod-vale-sqqq-biib-tvix", "https://www.nasdaq.com/articles/biogens-aducanumab-game-changing-alzheimers-drug-2016-12-10", "https://www.nasdaq.com/articles/stock-market-news-for-december-08-2016-2016-12-08", "https://www.nasdaq.com/articles/3-best-biotech-stocks-2017-2016-12-08", "https://www.nasdaq.com/articles/biogen-breaks-below-200-day-moving-average-notable-biib-2016-12-07", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-2016-12-06", "https://www.nasdaq.com/articles/can-biogen-beat-broader-markets-2017-2016-12-06", "https://www.nasdaq.com/articles/how-can-value-screener-record-trends-explain-market-valuations-2016-12-02", "https://www.nasdaq.com/articles/stock-exchange-model-picks-teach-us-manage-risk-2016-12-02", "https://www.nasdaq.com/articles/biogen-inc-biib-stock-trade-showcases-the-art-of-the-steal-2016-12-08", "https://www.nasdaq.com/articles/3-things-you-need-know-about-ionis-pharmaceuticals-pipeline-2016-12-01", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-amgen-2016-11-30", "https://www.nasdaq.com/articles/biotech-stock-roundup-actelion-soars-acquisition-talks-another-clinical-hold-juno-2016-11", "https://www.nasdaq.com/articles/charles-payne-on-biotech%3A-biogen-inc-biib-intercept-pharmaceuticals-inc-icpt-2016-11-29", "https://www.nasdaq.com/articles/will-lillys-solanezumab-setback-weigh-other-alzheimers-stocks-2016-11-25", "https://www.nasdaq.com/articles/lillys-alzheimer-drug-fails-phase-iii-study-stock-down-2016-11-24", "https://www.nasdaq.com/articles/eli-lilly-and-co-lly-drug-failure-doesnt-answer-the-bigger-question-2016-11-23", "https://www.nasdaq.com/articles/gw-pharmaceuticals-gwph%3A-what-awaits-in-q4-earnings-2016-12-01", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-ea-2016-11-23", "https://www.nasdaq.com/articles/pre-market-most-active-nov-23-2016-lly-nvo-tgt-mt-bac-de-juno-biib-eric-qqq-xiv-tvix-2016", "https://www.nasdaq.com/articles/pre-market-most-active-nov-23-2016-lly-de-rdy-nvo-biib-eric-mt-sny-juno-qqq-xiv-tvix-2016", "https://www.nasdaq.com/articles/eli-lillys-alzheimers-drug-bust-2016-11-23", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-538068-down-567-points-2016-11-23", "https://www.nasdaq.com/articles/3-potentially-huge-catalysts-ionis-pharmaceuticals-inc-2017-2016-11-23", "https://www.nasdaq.com/articles/why-biogen-shareholders-lost-3-billion-today-2016-11-23", "https://www.nasdaq.com/articles/instant-analysis-eli-lilly-drops-pre-holiday-alzheimers-bomb-2016-11-23", "https://www.nasdaq.com/articles/acorda-stops-post-stroke-development-program-on-ampyra-2016-11-22", "https://www.nasdaq.com/articles/5-biotech-stocks-george-soros-buying-2016-11-22", "https://www.nasdaq.com/articles/3-biotechs-dont-pay-dividends-could-2016-11-22", "https://www.nasdaq.com/articles/13-billion-opportunity-5-companies-could-dominate-alzheimers-disease-market-2016-11-21", "https://www.nasdaq.com/articles/3-irrefutable-reasons-sell-johnson-johnson-stock-2016-11-21", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-honda-intel-csx-and-general-growth-properties", "https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-to-buy-for-huge-gains-2016-11-17", "https://www.nasdaq.com/articles/are-biogen-and-gilead-sciences-denial-2016-11-22", "https://www.nasdaq.com/articles/acorda-stops-post-stroke-development-program-on-ampyra-2016-11-22", "https://www.nasdaq.com/articles/5-biotech-stocks-george-soros-buying-2016-11-22", "https://www.nasdaq.com/articles/xlv-jnj-gild-biib-etf-inflow-alert-2016-11-10", "https://www.nasdaq.com/articles/3-biotech-stocks-you-must-buy-for-donald-trumps-presidency-2016-11-10", "https://www.nasdaq.com/articles/perrigo-prgo-beats-on-q3-earnings-revenues-view-intact-2016-11-10", "https://www.nasdaq.com/articles/peek-into-drug-stocks-q3-earnings-on-nov-11%3A-xbit-reph-2016-11-10", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-celgene-corporation-2016-11-15", "https://www.nasdaq.com/articles/why-biogen-inc-stock-lost-105-its-value-october-2016-11-09", "https://www.nasdaq.com/articles/why-ionis-pharma-rocketing-25-higher-today-2016-11-09", "https://www.nasdaq.com/articles/biogens-growth-far-weaker-you-may-think-2016-11-08", "https://www.nasdaq.com/articles/company-news-for-november-08-2016-2016-11-08", "https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-biogen-2016-11-08", "https://www.nasdaq.com/articles/spinal-muscular-atrophy-focus-biogen-ions-shoot-data-2016-11-08", "https://www.nasdaq.com/articles/drug-stock-earnings-to-watch-on-nov-9%3A-myl-ions-more-2016-11-08", "https://www.nasdaq.com/articles/how-donald-trump-presidency-could-affect-biotech-stocks-2016-11-09", "https://www.nasdaq.com/articles/midday-update-wall-streets-appetite-risk-returns-after-clinton-cleared-fbi-2016-11-07", "https://www.nasdaq.com/articles/mid-day-market-update-dow-gains-over-300-points-concordia-international-shares-drop", "https://www.nasdaq.com/articles/nasdaq-100-movers-lvnta-biib-2016-11-07", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-lendingclub-posts-narrower-expected-loss", "https://www.nasdaq.com/articles/3-mid-cap-stocks-buy-november-2016-11-07", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-bristol-myers-biogen-merck-celgene-and-ariad", "https://www.nasdaq.com/articles/close-update-stocks-soar-fbi-clears-potential-path-clinton-election-day-2016-11-07", "https://www.nasdaq.com/articles/why-ionis-pharmaceuticals-inc-skyrocketed-higher-today-2016-11-07", "https://www.nasdaq.com/articles/midday-update-wall-streets-appetite-risk-returns-after-clinton-cleared-fbi-2016-11-07", "https://www.nasdaq.com/articles/mid-day-market-update-dow-gains-over-300-points-concordia-international-shares-drop", "https://www.nasdaq.com/articles/nasdaq-100-movers-lvnta-biib-2016-11-07", "https://www.nasdaq.com/articles/make-valeant-pharmaceuticals-intl-inc-vrx-stock-pay-you-2016-10-28", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-qual-peg-cost-biib-2016-10-28", "https://www.nasdaq.com/articles/5-reasons-ionis-pharmaceuticals-top-stock-buy-now-2016-10-28", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-merck-eli-lilly-abbvie-and-immunogen-2016-10-28", "https://www.nasdaq.com/articles/biib-crosses-below-key-moving-average-level-2016-11-03", "https://www.nasdaq.com/articles/heres-why-biogen-should-buy-ionis-pharmaceuticals-2016-10-28", "https://www.nasdaq.com/articles/bioverativ-could-be-why-investors-should-buy-biogen-2016-10-27", "https://www.nasdaq.com/articles/key-takeaways-biogens-q3-call-tecfidera-pipeline-biosimilars-2016-10-27", "https://www.nasdaq.com/articles/peek-into-drug-stocks-earnings-on-oct-28%3A-abbv-imgn-2016-10-27", "https://www.nasdaq.com/articles/biogen-inc-working-what-its-got-it-looks-diversify-2016-10-27", "https://www.nasdaq.com/articles/midday-update-stocks-trim-losses-supply-related-bounce-oil-2016-10-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-aapl-akam-2016-10-26", "https://www.nasdaq.com/articles/acorda-acor-reports-wider-q3-loss-revenues-down-y-y-2016-10-28", "https://www.nasdaq.com/articles/biogen-biib-beats-on-q3-earnings-tecfidera-propels-sales-2016-10-26", "https://www.nasdaq.com/articles/biogen-biib-beats-on-q3-earnings-and-sales-2016-10-26", "https://www.nasdaq.com/articles/biogen-inc-biib-stock-rises-better-expected-quarter-2016-10-26", "https://www.nasdaq.com/articles/drug-stock-earnings-to-watch-on-oct-26%3A-biib-mdco-more-2016-10-25", "https://www.nasdaq.com/articles/pre-market-earnings-report-october-26-2016-ko-cmcsa-ba-mdlz-biib-spg-gd-noc-bsx-stt-wm-nsc", "https://www.nasdaq.com/articles/best-and-worst-biotech-etfs-2016-tell-tale-about-industry-2016-10-21", "https://www.nasdaq.com/articles/can-biogen-biib-keep-the-earnings-streak-alive-in-q3-2016-10-20", "https://www.nasdaq.com/articles/biotech-stock-roundup-clinical-holds-hit-inovio-aduro-vertex-q3-results-miss-estimates", "https://www.nasdaq.com/articles/biotech-stock-roundup-ariad-down-drug-pricing-tweet-regeneron-study-clinical-hold-2016-10", "https://www.nasdaq.com/articles/3-stocks-that-will-be-bought-out-before-twitter-2016-10-19", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2016-10-18", "https://www.nasdaq.com/articles/commit-buy-biogen-180-earn-5-using-options-2016-10-18", "https://www.nasdaq.com/articles/alzheimers-remains-top-priority-big-pharma-2016-10-17", "https://www.nasdaq.com/articles/biomarin-issues-encouraging-update-on-hemophilia-a-drug-2016-10-14", "https://www.nasdaq.com/articles/avexis-major-threat-ionis-pharmaceuticals-2016-10-14", "https://www.nasdaq.com/articles/ishares-edge-msci-usa-quality-factor-etf-experiences-big-outflow-2016-10-19", "https://www.nasdaq.com/articles/stock-market-news-for-october-12-2016-2016-10-12", "https://www.nasdaq.com/articles/biotech-stock-roundup-alnylam-slumps-revusiran-update-tesaro-impresses-esmo-2016-10-12", "https://www.nasdaq.com/articles/3-biotechs-most-likely-be-acquired-2016-10-11", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-right-now-2016-10-11", "https://www.nasdaq.com/articles/better-buy-biogen-vs-celgene-2016-10-10", "https://www.nasdaq.com/articles/6-healthcare-stocks-investors-cant-miss-in-q3-earnings-2016-10-07", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-nlnk-srpt-biib-2016-10-07", "https://www.nasdaq.com/articles/why-top-columbia-fund-loads-facebook-other-stock-leaders-2016-10-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-summit-soars-sarepta-deal-regeneron-presents-data-2016-10-05", "https://www.nasdaq.com/articles/better-buy-anavex-life-sciences-corp-vs-ionis-pharmaceuticals-inc-2016-10-05", "https://www.nasdaq.com/articles/instant-analysis-biogens-agreement-anavex-life-sciences-2016-09-28", "https://www.nasdaq.com/articles/will-celgene-depose-biogen-become-top-dog-multiple-sclerosis-2016-09-28", "https://www.nasdaq.com/articles/health-care-sector-update-09282016-athx-avxl-biib-galt-2016-09-28", "https://www.nasdaq.com/articles/anavex-life-sciences-corp.-avxl-scores-big-on-biogen-test-2016-09-28", "https://www.nasdaq.com/articles/why-anavex-life-sciences-corp-rocketed-higher-today-2016-09-28", "https://www.nasdaq.com/articles/key-reason-ionis-pharmaceuticals-inc-gained-another-24-september-2016-10-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-summit-soars-sarepta-deal-regeneron-presents-data-2016-10-05", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-moat-biib-tif-stt-2016-09-26", "https://www.nasdaq.com/articles/implied-analyst-12-month-target-iwl-2016-09-26", "https://www.nasdaq.com/articles/stock-market-news-for-september-21-2016-2016-09-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-tobira-soars-acquisition-deal-fda-says-yes-sarepta-dmd-drug-2016-09", "https://www.nasdaq.com/articles/trade-of-the-day%3A-ishares-nasdaq-biotechnology-index-etf-ibb-is-turning-things-around-2016", "https://www.nasdaq.com/articles/3-ways-ionis-pharmaceuticals-inc-beating-competition-2016-09-19", "https://www.nasdaq.com/articles/health-care-sector-update-09282016-vsaravxlbiibgalt-2016-09-28", "https://www.nasdaq.com/articles/marijuana-could-be-answer-curing-alzheimers-disease-study-shows-2016-09-18", "https://www.nasdaq.com/articles/new-market-biggest-investment-idea-decade-2016-09-17", "https://www.nasdaq.com/articles/3-stocks-to-trade-now-for-new-years-profits-2016-09-15", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-xbi%3A-the-bears-got-nothin-on-biotech-stocks-2016-09-15", "https://www.nasdaq.com/articles/stock-market-news-for-september-15-2016-2016-09-15", "https://www.nasdaq.com/articles/biotech-stock-roundup-horizon-raptor-acquisition-deal-geron-down-pipeline-news-2016-09-14", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-september-14-2016-2016-09-13", "https://www.nasdaq.com/articles/could-alzheimers-disease-drug-really-be-worth-20-billion-2016-09-19", "https://www.nasdaq.com/articles/why-applied-genetic-technologies-corp-tanking-today-2016-09-13", "https://www.nasdaq.com/articles/how-tides-are-turning-alzheimers-research-2016-09-12", "https://www.nasdaq.com/articles/nasdaq-100-movers-swks-stx-2016-09-09", "https://www.nasdaq.com/articles/ixj-mdt-lly-biib-large-outflows-detected-etf-2016-09-08", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-2016-09-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-colucid-soars-migraine-data-dynavax-drug-fda-panel-meeting-cancelled", "https://www.nasdaq.com/articles/gw-pharmaceuticals-plc-adr-gwph-boards-the-buyout-rumor-mill-2016-09-07", "https://www.nasdaq.com/articles/perrigo-up-as-starboard-reveals-stake-changes-proposed-2016-09-13", "https://www.nasdaq.com/articles/why-applied-genetic-technologies-corp-tanking-today-2016-09-13", "https://www.nasdaq.com/articles/how-tides-are-turning-alzheimers-research-2016-09-12", "https://www.nasdaq.com/articles/biogen-biib-aducanumab-gets-fast-track-status-in-the-u.s.-2016-09-02", "https://www.nasdaq.com/articles/health-care-sector-update-09022016-biibatecgmedeltp-2016-09-02", "https://www.nasdaq.com/articles/tesla-motors-inc-tsla-needs-more-cash-for-gigafactory-model-3-2016-08-31", "https://www.nasdaq.com/articles/health-care-sector-update-08312016-biibveevatos-2016-08-31", "https://www.nasdaq.com/articles/spdr-gold-trust-etf-gld-is-ready-to-rally-2016-09-06", "https://www.nasdaq.com/articles/biotech-stock-roundup-medivation-pfizer-clovis-priority-review-2016-08-24", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-qld-txn-chtr-biib-2016-08-22", "https://www.nasdaq.com/articles/biotech-stock-roundup-vertex-slips-study-halt-aurinia-plunges-lupus-data-2016-08-17", "https://www.nasdaq.com/articles/sarah-ketterer-takes-3-positions-2nd-quarter-2016-08-16", "https://www.nasdaq.com/articles/another-endorsement-biotech-etfs-2016-08-16", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-begins-shift-focus-2016-08-16", "https://www.nasdaq.com/articles/allergan-buy-forsight-vision5-boost-glaucoma-pipeline-2016-08-15", "https://www.nasdaq.com/articles/analysts-anticipate-12-gains-ahead-ryh-2016-08-25", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-biomarin-abbvie-amgen-and-biogen-2016-08-12", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-august-15-2016-2016-08-12", "https://www.nasdaq.com/articles/biogen-inc-biib-stock-biotech-standout-2016-08-10", "https://www.nasdaq.com/articles/perrigo-prgo-misses-q2-earnings-estimates-cuts-16-view-2016-08-10", "https://www.nasdaq.com/articles/ionis-ions-q2-loss-narrower-than-expected-issues-outlook-2016-08-10", "https://www.nasdaq.com/articles/qual-peg-biib-nke-large-outflows-detected-etf-2016-08-09", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-intel-align-technology-qorvo-and-biogen-2016-08-09", "https://www.nasdaq.com/articles/top-3-research-reports-august-15-2016-2016-08-15", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-biomarin-abbvie-amgen-and-biogen-2016-08-12", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-august-15-2016-2016-08-12", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-anglogold-ashanti-biogen-qualcomm-tallgrass-energy-gp-and", "https://www.nasdaq.com/articles/allergan-plc-will-downtrend-continue-agn-stock-2016-08-04", "https://www.nasdaq.com/articles/stop-dreaming-biogen-isnt-sale-2016-08-04", "https://www.nasdaq.com/articles/5-best-peg-stocks-for-a-lucrative-value-investing-2016-08-04", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-ions-q2-earnings%3A-stock-to-beat-2016-08-04", "https://www.nasdaq.com/articles/intercept-icpt-reports-narrower-than-expected-q2-loss-2016-08-08", "https://www.nasdaq.com/articles/how-shows-greys-anatomy-influence-patient-perceptions-healthcare-2016-08-08", "https://www.nasdaq.com/articles/does-biogens-latest-win-make-its-shares-buy-2016-08-06", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-anglogold-ashanti-biogen-qualcomm-tallgrass-energy-gp-and", "https://www.nasdaq.com/articles/allergan-plc-will-downtrend-continue-agn-stock-2016-08-04", "https://www.nasdaq.com/articles/why-biogen-inc-soared-18-july-2016-08-02", "https://www.nasdaq.com/articles/why-avon-products-inc.-avp-biogen-inc-biib-and-sodastream-international-ltd-soda-are-3-of", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-513773-down-4647-points-2016-08-02", "https://www.nasdaq.com/articles/why-sangamo-biosciences-inc-fell-29-today-2016-08-04", "https://www.nasdaq.com/articles/biogen-biib-stock-surges-8-takeover-rumors-2016-08-02", "https://www.nasdaq.com/articles/2-biotech-funds-leading-nascent-bull-market-which-right-you-2016-08-02", "https://www.nasdaq.com/articles/midday-update-stocks-return-session-lows-oil-tumbles-towards-40barrel-2016-08-01", "https://www.nasdaq.com/articles/why-biogen-inc-biib-stock-is-soaring-today-2016-08-01", "https://www.nasdaq.com/articles/why-ionis-pharmaceuticals-inc-skyrocked-higher-today-2016-08-01", "https://www.nasdaq.com/articles/qqq-etf-posts-52-week-high-energy-stocks-sag-oil-drops-40-2016-08-01", "https://www.nasdaq.com/articles/nasdaq-100-movers-ctxs-biib-2016-08-01", "https://www.nasdaq.com/articles/biogen-inc-biib-tacks-7b-market-value-buyout-talk-2016-08-02", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-higher-tesla-acquire-solarcity-2016-08-01", "https://www.nasdaq.com/articles/us-equity-futures-slightly-higher-mergers-provide-boost-2016-08-01", "https://www.nasdaq.com/articles/why-ionis-pharmaceuticals-inc-ions-newell-brands-inc-nwl-and-trina-solar-limited-adr-tsl", "https://www.nasdaq.com/articles/these-legendary-ceos-could-catch-lightning-bottle-again-2016-08-01", "https://www.nasdaq.com/articles/health-care-sector-update-08012016-eyegionskerxbiib-2016-08-01", "https://www.nasdaq.com/articles/mid-afternoon-market-update-trina-solar-gains-following-go-private-deal-insperity-shares", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-ions-stock-surges-36-clinical-trial-success-2016-08-01", "https://www.nasdaq.com/articles/sp-500-movers-rig-biib-2016-08-01", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-bib-amgn-celg-biib-2016-07-29", "https://www.nasdaq.com/articles/ucb-ucbjf-posts-1h16-results-reaffirms-2016-guidance-2016-07-29", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-gilead-abbvie-amgen-and-celgene-2016-07-28", "https://www.nasdaq.com/articles/amgen-amgn-tops-q2-earnings-revenues-raises-view-2016-07-28", "https://www.nasdaq.com/articles/vertex-vrtx-posts-narrower-q2-loss-revenues-fall-short-2016-07-28", "https://www.nasdaq.com/articles/2-large-cap-drug-stocks-watch-earnings-abbv-mrk-2016-07-28", "https://www.nasdaq.com/articles/5-undervalued-growth-stocks-buy-today-2016-07-27", "https://www.nasdaq.com/articles/health-care-sector-update-08012016-itekionskerxbiib-2016-08-01", "https://www.nasdaq.com/articles/whats-store-these-5-drug-stocks-q2-earnings-2016-07-25", "https://www.nasdaq.com/articles/week-could-decide-whether-biotech-etfs-rally-sizzles-or-fizzles-2016-07-25", "https://www.nasdaq.com/articles/biogen-inc-how-double-digit-growth-got-trumped-2016-07-22", "https://www.nasdaq.com/articles/spy-etf-posts-fourth-weekly-gain-chip-and-biotech-giants-surge-2016-07-22", "https://www.nasdaq.com/articles/biib-makes-bullish-cross-above-critical-moving-average-2016-07-21", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-bib-biib-regn-myl-2016-07-21", "https://www.nasdaq.com/articles/etrade-financial-corp%3A-etfc-stock-stepping-into-the-spotlight-2016-07-21", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-bristol-myers-pfizer-sanofi-amgen-and-biogen-2016-07-25", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-zafgen-celgene-amgen-abbvie-and-biogen-2016-07-21", "https://www.nasdaq.com/articles/futures-trade-lower-amid-data-earnings-deluge-2016-07-21", "https://www.nasdaq.com/articles/thursdays-vital-data%3A-microsoft-corporation-msft-intel-corporation-intc-and-facebook-inc", "https://www.nasdaq.com/articles/biogen-biib-beats-on-q2-earnings-by-a-huge-margin-2016-07-21", "https://www.nasdaq.com/articles/biogen-inc-biib-stock%3A-q2-earnings-end-a-year-of-misery-2016-07-21", "https://www.nasdaq.com/articles/earnings-reaction-history-biogen-idec-333-follow-through-indicator-38-sensitive-2016-07-21", "https://www.nasdaq.com/articles/biib-stock-what-know-about-biogen-inc-thursday-morning-2016-07-20", "https://www.nasdaq.com/articles/biogen-biib-stock-q2-earnings-beat-raised-outlook-2016-07-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-celgene-immuno-oncology-deal-zafgen-drops-lead-drug-2016-07-20", "https://www.nasdaq.com/articles/medical-stocks-to-post-earnings-this-week%3A-abt-biib-aliof-2016-07-19", "https://www.nasdaq.com/articles/4-rock-solid-cheap-biotech-stocks-2016-07-16", "https://www.nasdaq.com/articles/agree-buy-biogen-135-earn-35-using-options-2016-07-15", "https://www.nasdaq.com/articles/nasdaq-100-movers-nclh-incy-2016-07-15", "https://www.nasdaq.com/articles/biogen-biib-q2-earnings-will-stock-disappoint-2016-07-15", "https://www.nasdaq.com/articles/does-biogens-lower-pe-ratio-make-it-better-buy-celgene-2016-07-15", "https://www.nasdaq.com/articles/pre-market-earnings-report-july-21-2016-slb-unp-biib-gm-bk-trv-ppg-bbt-shw-jci-luv-nue", "https://www.nasdaq.com/articles/biotech-stock-roundup-celgene-immuno-oncology-deal-zafgen-drops-lead-drug-2016-07-20", "https://www.nasdaq.com/articles/medical-stocks-to-post-earnings-this-week%3A-abt-biib-aliof-2016-07-19", "https://www.nasdaq.com/articles/juno-juno-suffers-setback-pivotal-study-clinical-hold-2016-07-08", "https://www.nasdaq.com/articles/why-biogen-inc-stock-dropped-157-june-2016-07-08", "https://www.nasdaq.com/articles/stock-market-news-for-july-07-2016-2016-07-07", "https://www.nasdaq.com/articles/3-reasons-buy-biogen-2016-06-30", "https://www.nasdaq.com/articles/how-much-do-stock-prices-matter-biotech-2016-07-14", "https://www.nasdaq.com/articles/better-buy-nantkwest-inc-vs-ionis-pharmaceuticals-2016-06-28", "https://www.nasdaq.com/articles/3-reasons-anavex-stock-could-rise-2016-06-27", "https://www.nasdaq.com/articles/the-ishares-nasdaq-biotechnology-index-ibb%3A-biotech-stocks-are-pushing-for-recovery-2016", "https://www.nasdaq.com/articles/3-stocks-that-can-and-should-start-paying-dividends-2016-06-24", "https://www.nasdaq.com/articles/2-biotech-stocks-wont-pay-dividend-anytime-soon-and-1-should-2016-06-24", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-celgene-corporation-2016-06-23", "https://www.nasdaq.com/articles/3-biotech-stocks-to-buy-now%3A-celg-regn-and-biib-2016-06-21", "https://www.nasdaq.com/articles/these-3-biotechs-are-down-more-36-year-and-theyre-bargains-2016-06-29", "https://www.nasdaq.com/articles/why-biogen-inc-down-225-2016-2016-06-21", "https://www.nasdaq.com/articles/stock-market-news-for-june-16-2016-2016-06-16", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-ishares-nasdaq-biotechnology-biogen-alexion-pharma", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-june-14-2016-2016-06-13", "https://www.nasdaq.com/articles/biogen-buy-after-its-clinical-failure-2016-06-12", "https://www.nasdaq.com/articles/biotech-buzz-asco-winners-and-losers-and-biogens-discouraging-failure-2016-06-10", "https://www.nasdaq.com/articles/4-stocks-crushed-biotechnology-etf-ibb-week-2016-06-10", "https://www.nasdaq.com/articles/these-5-biotech-stocks-are-ridiculously-cheap-2016-06-21", "https://www.nasdaq.com/articles/bbhs-holdings-imply-25-gain-potential-2016-06-09", "https://www.nasdaq.com/articles/better-buy-anavex-life-sciences-corp-vs-biogen-2016-06-09", "https://www.nasdaq.com/articles/forget-biogen-biib-buy-these-5-biotech-stocks-instead-2016-06-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-slips-ms-results-asco-data-focus-2016-06-08", "https://www.nasdaq.com/articles/mid-day-market-update-ldr-rises-acquisition-news-dryships-shares-drop-2016-06-07", "https://www.nasdaq.com/articles/instant-analysis-biogens-anti-lingo-1-flunks-game-changing-study-ms-2016-06-07", "https://www.nasdaq.com/articles/ibb-ishares-nasdaq-biotechnology-index-etf-still-buy-2016-06-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-merrimack-pharmaceuticals-retrophin-idera", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-wdc-2016-06-07", "https://www.nasdaq.com/articles/sp-500-movers-biib-wdc-2016-06-07", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-higher-valeant-earnings-miss-views-2016-06-07", "https://www.nasdaq.com/articles/why-biogen-lendingclub-and-valeant-pharmaceuticals-slumped-today-2016-06-07", "https://www.nasdaq.com/articles/these-drug-stocks-just-disappointed-investors-are-they-buys-2016-06-07", "https://www.nasdaq.com/articles/why-biogen-inc-biib-lendingclub-corp-lc-and-valeant-pharmaceuticals-intl-inc-vrx-are-three", "https://www.nasdaq.com/articles/why-biogen-biib-stock-plunging-today-2016-06-07", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-cytr-biib-z-2016-06-07", "https://www.nasdaq.com/articles/mid-afternoon-market-update-navistar-climbs-following-earnings-beat-biogen-shares-tumble", "https://www.nasdaq.com/articles/biogen-inc-biib-loses-8b-drug-failure-upside-remains-2016-06-07", "https://www.nasdaq.com/articles/tuesdays-etf-movers-xop-ibb-2016-06-07", "https://www.nasdaq.com/articles/why-biogen-incs-shares-couldnt-find-synergy-today-2016-06-07", "https://www.nasdaq.com/articles/new-17-billion-market-youve-probably-never-heard-and-3-stocks-poised-profit-2016-06-04", "https://www.nasdaq.com/articles/joel-greenblatt-bets-ebay-intel-biogen-2016-06-03", "https://www.nasdaq.com/articles/3-reasons-abbvies-and-biogens-latest-ms-drug-might-flop-2016-06-03", "https://www.nasdaq.com/articles/tuesday-sector-laggards-healthcare-utilities-2016-06-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-sarepta-biogen-abbvie-intercept-and-ionis-2016-06-02", "https://www.nasdaq.com/articles/kite-kite-and-biogens-drugs-included-in-prime-initiative-2016-06-02", "https://www.nasdaq.com/articles/las-vegas-sands-corp.%3A-ride-the-bull-without-the-risk-lvs-2016-06-01", "https://www.nasdaq.com/articles/biogen-inc-run-bulls-triple-digit-profits-biib-2016-06-01", "https://www.nasdaq.com/articles/biotech-stock-roundup-sarepta-shoots-fda-delay-ionis-falls-pipeline-news-2016-06-01", "https://www.nasdaq.com/articles/nasdaq-100-movers-chtr-biib-2016-05-31", "https://www.nasdaq.com/articles/roches-subcutaneous-formulation-of-mabthera-gets-eu-nod-2016-05-31", "https://www.nasdaq.com/articles/10-great-stocks-that-will-make-a-splash-this-summer-2016-06-03", "https://www.nasdaq.com/articles/biogen-abbvies-multiple-sclerosis-drug-gets-fda-nod-2016-05-30", "https://www.nasdaq.com/articles/last-weeks-best-healthcare-etf-2016-05-28", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-biib-2016-05-26", "https://www.nasdaq.com/articles/best-buys-biopharma-today-2016-05-24", "https://www.nasdaq.com/articles/better-buy-alnylam-pharmaceuticals-inc-vs-ionis-pharmaceuticals-inc-2016-05-24", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-ivw-mo-pcln-biib-2016-05-19", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-ahp-wday-biib-2016-05-19", "https://www.nasdaq.com/articles/10-biotech-stocks-with-symptoms-of-strong-growth-2016-05-31", "https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-biogen-2016-05-13", "https://www.nasdaq.com/articles/perrigo-prgo-tops-q1-earnings-2016-earnings-view-intact-2016-05-12", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-may-13-2016-2016-05-12", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-iwb-lly-twx-biib-2016-05-10", "https://www.nasdaq.com/articles/stock-market-news-for-may-10-2016-2016-05-10", "https://www.nasdaq.com/articles/ionis-incurs-wider-than-expected-loss-in-q1-stock-down-2016-05-05", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-gilead-celgene-medivation-and-biogen-2016-05-05", "https://www.nasdaq.com/articles/biogen-inc-biib-spinout%3A-a-graceful-exit-for-the-hemophilia-biz-2016-05-16", "https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-biogen-2016-05-13", "https://www.nasdaq.com/articles/perrigo-prgo-tops-q1-earnings-2016-earnings-view-intact-2016-05-12", "https://www.nasdaq.com/articles/biotech-etfs-sink-on-mixed-q1-results-2016-05-02", "https://www.nasdaq.com/articles/ibb-biib-celg-regn-etf-inflow-alert-2016-04-29", "https://www.nasdaq.com/articles/acorda-acor-q1-earnings-decline-yy-ampyra-focus-2016-04-29", "https://www.nasdaq.com/articles/3-drug-stocks-reporting-early-next-week%3A-pfe-myl-mnk-2016-04-29", "https://www.nasdaq.com/articles/alkermes-alks-reports-narrower-than-expected-q1-loss-2016-04-29", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-vs-biogen-2016-05-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-sarepta-catalyst-pharmaceuticals-abbvie-and", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-johnson-johnson-biogen-novartis-baxalta-incorporated", "https://www.nasdaq.com/articles/drug-stocks-earnings-previews%3A-kerx-bxlt-bmrn-agen-imgn-2016-04-27", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-tops-q1-earnings-sarepta-catalyst-plunge-regulatory-news-2016", "https://www.nasdaq.com/articles/biogen-inc%3A-market-takes-the-bull-by-the-horns-despite-sales-miss-biib-2016-04-22", "https://www.nasdaq.com/articles/biogen-inc-earnings-explode-higher-revenue-not-so-much-2016-04-22", "https://www.nasdaq.com/articles/dow-jones-holds-18000-despite-weak-tech-earnings-2016-04-22", "https://www.nasdaq.com/articles/drug-stocks-q1-earnings-preview%3A-aegr-aeri-mack-prta-2016-04-29", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-sarepta-catalyst-pharmaceuticals-abbvie-and", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-johnson-johnson-biogen-novartis-baxalta-incorporated", "https://www.nasdaq.com/articles/alibaba-group-holding-ltd%3A-baba-goes-boom-and-bulls-take-note-2016-04-21", "https://www.nasdaq.com/articles/biogen-biib-tops-q1-earnings-slight-revenue-miss-2016-04-21", "https://www.nasdaq.com/articles/biogen-inc-biib%3A-embrace-the-drug-trade-2016-04-21", "https://www.nasdaq.com/articles/health-care-sector-update-04212016-nvs-biib-2016-04-21", "https://www.nasdaq.com/articles/6-mega-cap-tech-stocks-at-the-brink-of-imploding-2016-04-22", "https://www.nasdaq.com/articles/7-a-rated-stocks-with-rock-solid-foundations-2016-04-22", "https://www.nasdaq.com/articles/key-morning-earnings-april-21-biib-gm-ua-vz-2016-04-21", "https://www.nasdaq.com/articles/energy-select-sector-spdr-etf%3A-get-paid-to-gas-up-on-xle-2016-04-21", "https://www.nasdaq.com/articles/alibaba-group-holding-ltd%3A-baba-goes-boom-and-bulls-take-note-2016-04-21", "https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-outflow-2016-04-18", "https://www.nasdaq.com/articles/biogen-inc-bet-biib-healthy-profits-2016-04-18", "https://www.nasdaq.com/articles/health-care-sector-update-04182016-mdvn-biib-amgn-mrk-abt-pfe-jnj-2016-04-18", "https://www.nasdaq.com/articles/biogen-biib-beats-on-1q-earnings-by-a-wide-margin-2016-04-21", "https://www.nasdaq.com/articles/thursday-sector-leaders-healthcare-services-2016-04-21", "https://www.nasdaq.com/articles/health-care-sector-update-04212016-biibcbaytrxc-2016-04-21", "https://www.nasdaq.com/articles/astrazeneca-eli-lilly-alzheimers-disease-drug-in-phase-iii-2016-04-11", "https://www.nasdaq.com/articles/commit-buy-biogen-150-earn-52-using-options-2016-04-08", "https://www.nasdaq.com/articles/ionis-tanks-fda-clinical-hold-on-ionis-ttrrx-phase-iii-study-2016-04-08", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-spxt-2016-04-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-gileads-hiv-drug-approved-regeneron-positive-data-2016-04-06", "https://www.nasdaq.com/articles/will-ms-franchise-sales-boost-biogens-biib-1q-earnings-2016-04-18", "https://www.nasdaq.com/articles/will-perrigo-prgo-surprise-earnings-estimates-in-q1-2016-04-15", "https://www.nasdaq.com/articles/clubcorp-holdings-inc-countering-bulls-2016-04-12", "https://www.nasdaq.com/articles/astrazeneca-eli-lilly-alzheimers-disease-drug-in-phase-iii-2016-04-11", "https://www.nasdaq.com/articles/commit-buy-biogen-150-earn-52-using-options-2016-04-08", "https://www.nasdaq.com/articles/ionis-tanks-fda-clinical-hold-on-ionis-ttrrx-phase-iii-study-2016-04-08", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-spxt-2016-04-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-gileads-hiv-drug-approved-regeneron-positive-data-2016-04-06", "https://www.nasdaq.com/articles/will-ms-franchise-sales-boost-biogens-biib-1q-earnings-2016-04-18", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-biogen-inc-2016-04-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-amgen-regeneron-ionis-and-biogen-2016-03-28", "https://www.nasdaq.com/articles/9-things-you-need-know-about-biosimilar-drugs-2016-03-28", "https://www.nasdaq.com/articles/better-short-biotech-etf-or-invest-inverse-counterpart-2016-03-15", "https://www.nasdaq.com/articles/how-ride-next-wave-potential-alzheimers-drugs-2016-03-13", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-march-14-2016-2016-03-11", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-valeant-pfizer-amgen-and-biogen-2016-03-17", "https://www.nasdaq.com/articles/ishares-sp-500-growth-etf-experiences-big-outflow-2016-03-16", "https://www.nasdaq.com/articles/stock-market-news-for-march-16-2016-2016-03-16", "https://www.nasdaq.com/articles/eli-lilly-down-alters-primary-endpoint-of-solanezumab-2016-03-16", "https://www.nasdaq.com/articles/john-buckingham-trades-etfs-4th-quarter-2016-03-16", "https://www.nasdaq.com/articles/3-stocks-are-ridiculously-cheap-right-now-2016-03-05", "https://www.nasdaq.com/articles/what-does-trumps-healthcare-plan-mean-investors-2016-03-04", "https://www.nasdaq.com/articles/ionis-incurs-wider-than-expected-loss-in-q4-shares-down-2016-02-26", "https://www.nasdaq.com/articles/biogen-inc-regenerate-profits-bear-trapped-biib-2016-03-11", "https://www.nasdaq.com/articles/better-buy-amgen-inc-vs-biogen-2016-03-10", "https://www.nasdaq.com/articles/better-big-biotech-stock-biogen-vs-celgene-2016-03-08", "https://www.nasdaq.com/articles/vug-abbv-ups-biib-large-outflows-detected-etf-2016-03-07", "https://www.nasdaq.com/articles/perrigo-lags-on-q4-earnings-and-revenues-updates-view-2016-02-18", "https://www.nasdaq.com/articles/3-biotechs-could-snap-back-and-soar-even-higher-2016-02-15", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-iyh-jnj-biib-tmo-2016-02-12", "https://www.nasdaq.com/articles/alkermes-q4-loss-narrower-than-expected-updates-pipeline-2016-02-26", "https://www.nasdaq.com/articles/why-biogen-incs-stock-sank-january-2016-02-11", "https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-biogen-2016-02-11", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-11-2016-2016-02-10", "https://www.nasdaq.com/articles/agony-high-returns-2016-02-09", "https://www.nasdaq.com/articles/biotech-etfs-slide-as-stocks-report-mixed-q4-results-2016-02-09", "https://www.nasdaq.com/articles/biogen-inc-takes-aim-johnson-johnson-2016-02-07", "https://www.nasdaq.com/articles/notable-friday-option-activity-biib-eigi-ally-2016-02-05", "https://www.nasdaq.com/articles/acorda-q4-earnings-decline-yy-ampyra-pipeline-focus-2016-02-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-gilead-abbvie-intrexon-and-newlink-2016-02-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-amgen-top-estimates-zika-virus-grabs-attention-2016-02-03", "https://www.nasdaq.com/articles/start-new-year-right-3-best-biotech-stocks-2016-02-02", "https://www.nasdaq.com/articles/4-top-ranked-biotech-stocks-sale-2016-02-02", "https://www.nasdaq.com/articles/biogen-inc-slows-lets-keep-perspective-2016-02-02", "https://www.nasdaq.com/articles/financial-sector-update-02022016-pdlibiibacccacc-2016-02-02", "https://www.nasdaq.com/articles/biotech-etf-ibb-hits-new-52-week-low-2016-01-29", "https://www.nasdaq.com/articles/fbt-tech-qgen-biib-large-outflows-detected-etf-2016-02-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-aapl-biib-2016-01-27", "https://www.nasdaq.com/articles/sp-500-movers-tss-cof-2016-01-27", "https://www.nasdaq.com/articles/biogen-biib-beats-4q-earnings-revenues-2016-01-27", "https://www.nasdaq.com/articles/us-stocks-eye-lower-open-ahead-fed-announcement-oil-weighs-commodities-stocks-2016-01-27", "https://www.nasdaq.com/articles/us-equities-futures-slip-amid-weaker-oil-prices-apple-disappointment-fed-decision-tap-2016", "https://www.nasdaq.com/articles/why-biogen-freeport-mcmoran-and-hawaiian-holdings-jumped-today-2016-01-27", "https://www.nasdaq.com/articles/biogen-biib-looks-good%3A-stock-adds-5.2-in-session-2016-01-28", "https://www.nasdaq.com/articles/celgene-celg-to-report-q4-earnings%3A-what-to-expect-2016-01-26", "https://www.nasdaq.com/articles/pre-market-earnings-report-january-27-2016-ba-utx-biib-emc-gd-antm-itw-eric-stt-nsc-pgr", "https://www.nasdaq.com/articles/will-biogen-biib-beat-4q-earnings-ms-franchise-sales-2016-01-25", "https://www.nasdaq.com/articles/will-bristol-myers-bmy-beat-q4-earnings-expectations-2016-01-25", "https://www.nasdaq.com/articles/weekly-play-sell-calls-sector-ibb-2016-01-20", "https://www.nasdaq.com/articles/biotech-stock-roundup-sarepta-plunges-briefing-documents-acorda-buy-biotie-2016-01-20", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-biogen-cytokinetics-and-bristol-myers", "https://www.nasdaq.com/articles/3-healthcare-stocks-you-dont-have-babysit-2016-01-27", "https://www.nasdaq.com/articles/abbvies-management-just-made-some-pretty-bold-predictions-2016-01-16", "https://www.nasdaq.com/articles/4-biotech-stocks-looking-good-this-earnings-season-2016-01-15", "https://www.nasdaq.com/articles/biogens-ceo-sums-everything-you-need-know-about-company-1-comment-2016-01-15", "https://www.nasdaq.com/articles/7-battered-biotech-stocks-bargains-or-busts-2016-01-14", "https://www.nasdaq.com/articles/was-celgene-corporations-bad-news-really-bad-2016-01-14", "https://www.nasdaq.com/articles/agree-buy-biogen-160-earn-61-using-options-2016-01-08", "https://www.nasdaq.com/articles/potential-7-billion-waste-celgene-corporation-2016-01-08", "https://www.nasdaq.com/articles/biogens-biib-biosimilar-of-amgens-enbrel-gets-eu-nod-2016-01-18", "https://www.nasdaq.com/articles/biggest-healthcare-ma-news-2015-2015-12-27", "https://www.nasdaq.com/articles/great-news-government-agency-just-received-big-raise-2015-12-26", "https://www.nasdaq.com/articles/biotech-industry-could-offer-early-profit-2016-2015-12-24", "https://www.nasdaq.com/articles/top-biotech-stocks-buy-2016-2015-12-21", "https://www.nasdaq.com/articles/alkermes-hits-52-week-high-on-pipeline-update-aristada-2015-12-17", "https://www.nasdaq.com/articles/health-care-sector-update-12162015-mrns-biib-alks-2015-12-16", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-hikes-first-quarter-dividend-ariad-lowers-iclusig-outlook-2015", "https://www.nasdaq.com/articles/jean-hynes-finds-her-pot-gold-2016-01-07", "https://www.nasdaq.com/articles/biggest-healthcare-ma-news-2015-2015-12-27", "https://www.nasdaq.com/articles/great-news-government-agency-just-received-big-raise-2015-12-26", "https://www.nasdaq.com/articles/biotech-industry-could-offer-early-profit-2016-2015-12-24", "https://www.nasdaq.com/articles/positive-clinical-data-sends-isis-pharmaceuticals-inc-soaring-november-2015-12-10", "https://www.nasdaq.com/articles/novartis-biosimilar-for-pfizers-enbrel-accepted-in-the-eu-2015-12-09", "https://www.nasdaq.com/articles/do-eli-lilly-and-biogen-have-alzheimers-all-wrong-anavex-life-sciences-thinks-so-2015-12", "https://www.nasdaq.com/articles/isis-biogen-initiate-amyotrophic-lateral-sclerosis-study-2015-12-14", "https://www.nasdaq.com/articles/insight-eli-lillys-alzheimers-drugs-coming-soon-2015-12-04", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-ibb-regn-biib-alxn-2015-12-03", "https://www.nasdaq.com/articles/pdl-biopharma-receives-%24133.7-million-in-cash-payments-2015-12-03", "https://www.nasdaq.com/articles/anavex-life-sciences-corp-stock-worth-buying-2015-12-02", "https://www.nasdaq.com/articles/biotech-stock-roundup-repros-tanks-crl-abbvie-multiple-myeloma-drug-approved-2015-12-02", "https://www.nasdaq.com/articles/worlds-largest-investing-firm-bought-these-2-biotech-stocks-should-you-2015-12-01", "https://www.nasdaq.com/articles/theres-00000000000028-chance-drug-doesnt-work-2015-11-30", "https://www.nasdaq.com/articles/3-most-important-drugs-isis-pharmaceuticals-pipeline-2015-12-07", "https://www.nasdaq.com/articles/bristol-myers-cancer-drug-opdivo-gets-crl-from-the-fda-2015-11-30", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biomarin-amgen-vertex-gilead-biogen-and-repros-2015-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-kalobios-soars-shkreli-steps-fda-panel-not-convinced-about-biomarin", "https://www.nasdaq.com/articles/bristol-myers-opdivo-gets-fda-nod-for-another-indication-2015-11-25", "https://www.nasdaq.com/articles/biomarins-bmrn-kyndrisa-fails-to-impress-fda-panel-2015-11-25", "https://www.nasdaq.com/articles/gileads-gild-cocktail-hiv-drug-genvoya-approved-in-eu-2015-11-24", "https://www.nasdaq.com/articles/health-care-sector-update-11242015-syn-nvs-biib-2015-11-24", "https://www.nasdaq.com/articles/26-billion-hedge-fund-just-bought-9-million-shares-stock-should-you-follow-2015-11-30", "https://www.nasdaq.com/articles/biogens-biib-biosimilar-of-pfizers-enbrel-gets-chmp-nod-2015-11-23", "https://www.nasdaq.com/articles/amgens-repatha-too-bloody-pricey-uk-2015-11-19", "https://www.nasdaq.com/articles/biotech-stock-roundup-clovis-plunges-label-expansion-gileads-harvoni-2015-11-18", "https://www.nasdaq.com/articles/why-sangamo-biosciences-shares-rose-26-october-2015-11-17", "https://www.nasdaq.com/articles/primecap-sells-stake-technology-company-2015-11-16", "https://www.nasdaq.com/articles/these-biotech-stocks-may-start-paying-dividends-2016-2015-11-16", "https://www.nasdaq.com/articles/pro-forma-profit-isis-pharmaceuticals-inc-2015-11-15", "https://www.nasdaq.com/articles/bristol-myers-opdivo-label-now-includes-renal-cell-cancer-2015-11-24", "https://www.nasdaq.com/articles/nasdaq-100-movers-gmcr-biib-2015-11-11", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-12-2015-2015-11-11", "https://www.nasdaq.com/articles/biogen-among-murray-stahls-holdings-growing-earnings-2015-11-11", "https://www.nasdaq.com/articles/what-does-2016-hold-closely-watched-biotech-etf-2015-11-09", "https://www.nasdaq.com/articles/59-billion-buyout-1-number-underpins-shires-huge-dyax-bet-2015-11-07", "https://www.nasdaq.com/articles/biotech-sees-better-than-expected-earnings%3A-etfs-in-focus-2015-11-06", "https://www.nasdaq.com/articles/gilead-and-2-biotech-picks-value-investors-will-love-2015-11-06", "https://www.nasdaq.com/articles/vug-ma-ups-biib-large-inflows-detected-etf-2015-11-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvies-humira-remains-strong-shire-buy-dyax-2015-11-04", "https://www.nasdaq.com/articles/drug-going-be-big-threat-biogen-and-novartis-next-year-2015-11-04", "https://www.nasdaq.com/articles/big-changes-ahead-biogen-2015-11-02", "https://www.nasdaq.com/articles/12-companies-who-have-cut-jobs-2015-2015-10-30", "https://www.nasdaq.com/articles/after-hours-most-active-oct-30-2015-bac-hpq-mktx-cyn-nycb-foxa-qqq-hcbk-ge-pfe-msft-biib", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-tops-estimates-fda-approves-alexions-strensiq-2015-10-28", "https://www.nasdaq.com/articles/biogen-director-buys-310000-shares-2015-10-28", "https://www.nasdaq.com/articles/will-isis-pharmaceuticals-isis-surprise-in-q3-earnings-2015-11-05", "https://www.nasdaq.com/articles/specialty-drug-classes-are-costing-consumers-arm-and-leg-2015-10-24", "https://www.nasdaq.com/articles/acorda-up-on-q3-earnings-revenue-beat-ampyra-in-focus-2015-10-23", "https://www.nasdaq.com/articles/battle-royale-amgen-inc-vs-biogen-inc-2015-10-23", "https://www.nasdaq.com/articles/3-earnings-reports-surprised-us-2015-10-23", "https://www.nasdaq.com/articles/perrigo-beats-on-q3-earnings-misses-revenues-cuts-jobs-2015-10-22", "https://www.nasdaq.com/articles/biogens-beat-raise-and-yawn-2015-10-22", "https://www.nasdaq.com/articles/biogen-cut-11-its-workforce-part-restructuring-plan-2015-10-21", "https://www.nasdaq.com/articles/tuesday-1027-insider-buying-report-biib-dkl-2015-10-27", "https://www.nasdaq.com/articles/specialty-drug-classes-are-costing-consumers-arm-and-leg-2015-10-24", "https://www.nasdaq.com/articles/acorda-up-on-q3-earnings-revenue-beat-ampyra-in-focus-2015-10-23", "https://www.nasdaq.com/articles/battle-royale-amgen-inc-vs-biogen-inc-2015-10-23", "https://www.nasdaq.com/articles/3-earnings-reports-surprised-us-2015-10-23", "https://www.nasdaq.com/articles/perrigo-beats-on-q3-earnings-misses-revenues-cuts-jobs-2015-10-22", "https://www.nasdaq.com/articles/biogens-beat-raise-and-yawn-2015-10-22", "https://www.nasdaq.com/articles/biogen-cut-11-its-workforce-part-restructuring-plan-2015-10-21", "https://www.nasdaq.com/articles/tuesday-1027-insider-buying-report-biib-dkl-2015-10-27", "https://www.nasdaq.com/articles/commit-buy-biogen-180-earn-53-using-options-2015-10-21", "https://www.nasdaq.com/articles/biogen-tops-q3-earnings-announces-job-cuts-ups-view-2015-10-21", "https://www.nasdaq.com/articles/stock-market-news-for-october-21-2015-2015-10-21", "https://www.nasdaq.com/articles/biogen-biib-beats-on-3q-earnings-revenues-2015-10-21", "https://www.nasdaq.com/articles/earnings-reaction-history-biogen-idec-455-follow-through-indicator-38-sensitive-2015-10-21", "https://www.nasdaq.com/articles/stock-market-news-for-october-20-2015-2015-10-20", "https://www.nasdaq.com/articles/did-roche-unleash-biogens-worst-nightmare-2015-10-20", "https://www.nasdaq.com/articles/bbh-celg-biib-bxlt-large-outflows-detected-etf-2015-10-21", "https://www.nasdaq.com/articles/pre-market-earnings-report-october-21-2015-ko-ba-biib-abt-emc-gm-tmo-kmb-itw-bhi-stj-nlsn", "https://www.nasdaq.com/articles/will-tecfidera-slowdown-hit-biogen-biib-earnings-q3-2015-10-19", "https://www.nasdaq.com/articles/3-blue-chip-biotech-stocks-worth-buying-long-haul-2015-10-17", "https://www.nasdaq.com/articles/can-these-repurposed-antibodies-reshape-multiple-sclerosis-market-2015-10-15", "https://www.nasdaq.com/articles/frank-sands-undervalued-holdings-growing-eps-2015-10-12", "https://www.nasdaq.com/articles/biogen-roche-novartis-present-data-on-ms-drugs-in-spain-2015-10-09", "https://www.nasdaq.com/articles/stock-market-news-for-october-08-2015-2015-10-08", "https://www.nasdaq.com/articles/sanofi-unveils-new-positive-data-on-lemtrada-and-aubagio-2015-10-08", "https://www.nasdaq.com/articles/stock-market-news-for-october-07-2015-2015-10-07", "https://www.nasdaq.com/articles/3-large-cap-biotech-stocks-whose-valuations-should-make-you-skeptical-2015-10-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-pbm-lists-both-amgen-regeneron-pcsk9-inhibitors-fold-plunges-nda", "https://www.nasdaq.com/articles/acorda-soars-settles-ampyra-patent-dispute-with-allergan-2015-10-06", "https://www.nasdaq.com/articles/3-biotech-bargains-buy-2015-10-05", "https://www.nasdaq.com/articles/vug-ma-unp-biib-large-inflows-detected-etf-2015-10-02", "https://www.nasdaq.com/articles/coming-clash-big-biotechs-biogen-vs-celgene-2015-10-01", "https://www.nasdaq.com/articles/sanofi-unveils-new-positive-data-on-lemtrada-and-aubagio-2015-10-08", "https://www.nasdaq.com/articles/best-selling-drugs-world-2020-2015-09-26", "https://www.nasdaq.com/articles/stock-market-news-for-september-25-2015-2015-09-25", "https://www.nasdaq.com/articles/health-care-sector-update-09252015-navb-biib-amgn-2015-09-25", "https://www.nasdaq.com/articles/biotech-stock-roundup-clintons-tweet-shakes-biotech-stocks-amgen-pipeline-boosting-deals", "https://www.nasdaq.com/articles/5-biotech-stocks-hit-hard-hillary-clintons-tweet-2015-09-22", "https://www.nasdaq.com/articles/undervalued-stocks-among-richard-snows-recent-buys-2015-09-17", "https://www.nasdaq.com/articles/beaten-down-biogen-stock-bargain-2015-09-17", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-vertex-gilead-biogen-and-celgene-2015-10-01", "https://www.nasdaq.com/articles/merck-kgaa-intends-to-file-for-approval-of-ms-drug-in-eu-2015-09-14", "https://www.nasdaq.com/articles/better-buy-biogen-vs-gilead-sciences-2015-09-14", "https://www.nasdaq.com/articles/biotech-stock-roundup-biosimilar-competition-amgen-tetraphase-hit-disappointing-data-2015", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-iyh-abbv-mdt-biib-2015-09-04", "https://www.nasdaq.com/articles/roches-hemophilia-a-drug-gets-breakthrough-status-in-u.s.-2015-09-04", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-middle-turbulent-market-2015-09-03", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-news-ariad-takeover-target-2015-09-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-wynn-lila-2015-09-10", "https://www.nasdaq.com/articles/we-believe-healthcares-next-biotech-buyout-target-2015-08-30", "https://www.nasdaq.com/articles/ivw-nke-biib-kmi-large-outflows-detected-etf-2015-08-27", "https://www.nasdaq.com/articles/biotech-stock-roundup-acorda-gains-patent-issues-vital-crushed-liver-data-2015-08-26", "https://www.nasdaq.com/articles/biogen-biib-crumbles%3A-stock-falls-by-5.9-2015-08-25", "https://www.nasdaq.com/articles/acorda-acor-gets-favorable-outcome-in-ampyra-ipr-issue-2015-08-25", "https://www.nasdaq.com/articles/bull-or-bear-biotechs-post-earnings-buys-and-sells-2015-08-23", "https://www.nasdaq.com/articles/using-etfs-run-your-own-hedge-fund-2015-08-20", "https://www.nasdaq.com/articles/applied-genetic-meets-enrolment-milestone-in-xlrs-study-2015-08-31", "https://www.nasdaq.com/articles/we-believe-healthcares-next-biotech-buyout-target-2015-08-30", "https://www.nasdaq.com/articles/ivw-nke-biib-kmi-large-outflows-detected-etf-2015-08-27", "https://www.nasdaq.com/articles/biotech-stock-roundup-acorda-gains-patent-issues-vital-crushed-liver-data-2015-08-26", "https://www.nasdaq.com/articles/biogen-biib-crumbles%3A-stock-falls-by-5.9-2015-08-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsla-nvda-2015-08-07", "https://www.nasdaq.com/articles/emergent-biosolutions-tops-on-q2-earnings-plans-spin-off-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-kite-addresses-patient-death-concerns-omeros-soars-data-2015-08-19", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-tso-jpm-biib-2015-08-06", "https://www.nasdaq.com/articles/perrigo-beats-on-q2-earnings-revenues-in-line-keeps-view-analyst-blog-2015-08-05", "https://www.nasdaq.com/articles/heres-why-biogen-lost-20-billion-market-value-july-2015-08-05", "https://www.nasdaq.com/articles/what-company-will-be-fastest-growing-big-cap-biotech-2015-08-05", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-vug-orcl-v-biib-2015-08-04", "https://www.nasdaq.com/articles/mixed-biotech-earnings-put-these-etfs-in-focus-etf-news-and-commentary-2015-08-04", "https://www.nasdaq.com/articles/will-isis-pharmaceuticals-isis-beat-q2-earnings-estimates-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/3-crashing-healthcare-stocks-you-can-buy-2015-08-06", "https://www.nasdaq.com/articles/acorda-2q-earnings-revenues-top-ampyra-focus-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/attention-new-biotech-investors-biogen-incs-recent-weakness-your-opportunity-2015-07-30", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-abbvie-regeneron-amgen-and-xoma-press-releases", "https://www.nasdaq.com/articles/tuesday-728-insider-buying-report-biib-mjn-2015-07-28", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-ligand-pharmaceuticals-bluebird-bio-regeneron", "https://www.nasdaq.com/articles/3-big-biotech-buybacks-investors-should-love-2015-07-28", "https://www.nasdaq.com/articles/forget-biogen-buy-these-promising-biotech-stocks-instead-analyst-blog-2015-07-27", "https://www.nasdaq.com/articles/blockbuster-potential-biogen-incs-pipeline-2015-08-01", "https://www.nasdaq.com/articles/sp-500-movers-myl-biib-2015-07-27", "https://www.nasdaq.com/articles/nasdaq-100-movers-myl-biib-2015-07-27", "https://www.nasdaq.com/articles/stock-market-news-for-july-27-2015-market-news-2015-07-27", "https://www.nasdaq.com/articles/look-ahead-biotech-and-energy-etfs-watch-week-2015-07-27", "https://www.nasdaq.com/articles/5-things-biogens-management-wants-you-know-2015-07-27", "https://www.nasdaq.com/articles/big-day-biotech-and-its-not-going-so-well-2015-07-27", "https://www.nasdaq.com/articles/biogen-enters-oversold-territory-biib-2015-07-24", "https://www.nasdaq.com/articles/3-signs-healthcare-stock-bubble-might-have-just-popped-2015-07-27", "https://www.nasdaq.com/articles/biogen-tops-q2-earnings-cuts-view-tecfidera-issues-analyst-blog-2015-07-24", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-amzn-2015-07-24", "https://www.nasdaq.com/articles/sp-500-movers-biib-amzn-2015-07-24", "https://www.nasdaq.com/articles/3-alzheimers-drugs-investors-should-be-watching-2015-07-24", "https://www.nasdaq.com/articles/health-care-sector-update-07242015-cgix-reph-biib-2015-07-24", "https://www.nasdaq.com/articles/pre-market-most-active-jul-24-2015-exel-t-amzn-biib-itek-fb-stm-qqq-nok-un-alu-ci-2015-07", "https://www.nasdaq.com/articles/biogen-biib-beats-on-2q-earnings-misses-on-revenues-tale-of-the-tape-2015-07-24", "https://www.nasdaq.com/articles/biib-crosses-below-key-moving-average-level-2015-07-24", "https://www.nasdaq.com/articles/biogens-terrible-horrible-no-good-very-bad-week-2015-07-24", "https://www.nasdaq.com/articles/biogen-biib-stock-plummets-weak-guidance-stocks-news-2015-07-24", "https://www.nasdaq.com/articles/notable-friday-option-activity-biib-gt-xom-2015-07-24", "https://www.nasdaq.com/articles/september-4th-options-now-available-biogen-biib-2015-07-23", "https://www.nasdaq.com/articles/will-biogen-biib-surprise-in-2q-despite-tecfidera-issues-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/pre-market-earnings-report-july-24-2015-abbv-biib-spg-stt-vfc-jci-aal-mco-vtr-dte-xrx-col", "https://www.nasdaq.com/articles/eli-lilly-biogen-present-data-at-alzheimers-association-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/earnings-reaction-history-biogen-idec-400-follow-through-indicator-21-sensitive-2015-07-24", "https://www.nasdaq.com/articles/biogens-terrible-horrible-no-good-very-bad-week-2015-07-24", "https://www.nasdaq.com/articles/biogen-biib-stock-plummets-weak-guidance-stocks-news-2015-07-24", "https://www.nasdaq.com/articles/notable-friday-option-activity-biib-gt-xom-2015-07-24", "https://www.nasdaq.com/articles/september-4th-options-now-available-biogen-biib-2015-07-23", "https://www.nasdaq.com/articles/big-week-biogen-2015-07-21", "https://www.nasdaq.com/articles/celgene-buys-receptos-arena-pharmaceuticals-next-2015-07-21", "https://www.nasdaq.com/articles/notable-friday-option-activity-mat-sndk-biib-2015-07-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-pcsk9-inhibitor-first-gain-approval-exelixis-positive-data", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-eli-lilly-valeant-pharmaceuticals-international-biogen", "https://www.nasdaq.com/articles/isis-pharmaceuticals-up-on-milestone-payment-from-biogen-analyst-blog-2015-07-15", "https://www.nasdaq.com/articles/stock-market-news-for-july-14-2015-market-news-2015-07-14", "https://www.nasdaq.com/articles/health-care-sector-update-07142015-biib-cah-cpxx-2015-07-14", "https://www.nasdaq.com/articles/4-health-care-stocks-to-watch-out-for-this-earnings-season-earnings-esp-2015-07-14", "https://www.nasdaq.com/articles/biogen-biib-slips-2.8-lead-rd-executive-set-to-leave-analyst-blog-2015-07-13", "https://www.nasdaq.com/articles/15-trillion-reasons-invest-these-companies-2015-07-12", "https://www.nasdaq.com/articles/sp-500-analyst-moves-biib-2015-07-16", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-eli-lilly-valeant-pharmaceuticals-international-biogen", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-googl-biib-ko-2015-07-10", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-vertex-biogen-applied-genetic-gilead-and-alexion-press", "https://www.nasdaq.com/articles/vanguard-growth-etf-experiences-big-outflow-2015-07-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-vertex-cf-drug-approved-biogen-strikes-deal-gene-therapy-analyst", "https://www.nasdaq.com/articles/are-biotechs-bubble-2015-07-07", "https://www.nasdaq.com/articles/sp-500-movers-biib-gci-2015-07-10", "https://www.nasdaq.com/articles/forget-biogen-biib-buy-these-3-biotechnology-stocks-instead-stocks-news-2015-07-06", "https://www.nasdaq.com/articles/applied-genetic-up-on-biogen-deal-for-eye-disease-drugs-analyst-blog-2015-07-03", "https://www.nasdaq.com/articles/why-applied-genetic-technologies-corporation-stock-jumped-today-2015-07-02", "https://www.nasdaq.com/articles/mid-day-market-update-us-stocks-down-xoom-shares-jump-acquisition-news-2015-07-02", "https://www.nasdaq.com/articles/midday-update-stocks-surrender-opening-gains-after-technical-resistances-holds-2015-07-02", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-higher-centene-acquire-health-net-63b-2015-07-02", "https://www.nasdaq.com/articles/futures-build-early-gains-june-payroll-report-2015-07-02", "https://www.nasdaq.com/articles/biogen-sees-promise-gene-therapy-2015-07-07", "https://www.nasdaq.com/articles/forget-biogen-biib-buy-these-3-biotechnology-stocks-instead-stocks-news-2015-07-06", "https://www.nasdaq.com/articles/applied-genetic-up-on-biogen-deal-for-eye-disease-drugs-analyst-blog-2015-07-03", "https://www.nasdaq.com/articles/why-applied-genetic-technologies-corporation-stock-jumped-today-2015-07-02", "https://www.nasdaq.com/articles/biotech-stock-roundup-juno-celgene-immunotherapy-deal-biomarinsarepta-dmd-drugs-progress", "https://www.nasdaq.com/articles/stock-market-news-for-july-01-2015-market-news-2015-07-01", "https://www.nasdaq.com/articles/bayer-files-hemophilia-a-drug-marketing-application-in-japan-analyst-blog-2015-07-01", "https://www.nasdaq.com/articles/vug-orcl-v-biib-large-outflows-detected-etf-2015-06-29", "https://www.nasdaq.com/articles/close-update-stocks-give-back-early-gains-greece-uncertainty-escalating-2015-07-02", "https://www.nasdaq.com/articles/biogen-sobis-hemophilia-b-drug-alprolix-under-eu-review-analyst-blog-2015-06-29", "https://www.nasdaq.com/articles/transition-therapeutics-tanks-on-alzheimers-disease-data-analyst-blog-2015-06-25", "https://www.nasdaq.com/articles/stock-market-news-for-june-23-2015-market-news-2015-06-23", "https://www.nasdaq.com/articles/isis-pharmaceuticals-up-on-spinal-muscular-atrophy-data-analyst-blog-2015-06-23", "https://www.nasdaq.com/articles/stock-market-news-for-june-19-2015-market-news-2015-06-19", "https://www.nasdaq.com/articles/3-big-healthcare-trends-wall-street-overlooking-2015-06-14", "https://www.nasdaq.com/articles/isis-pharmaceuticals-up-on-positive-data-on-isis-smnrx-analyst-blog-2015-06-12", "https://www.nasdaq.com/articles/3-stocks-buy-if-biotech-crashes-2015-06-29", "https://www.nasdaq.com/articles/biogen-sobis-hemophilia-b-drug-alprolix-under-eu-review-analyst-blog-2015-06-29", "https://www.nasdaq.com/articles/transition-therapeutics-tanks-on-alzheimers-disease-data-analyst-blog-2015-06-25", "https://www.nasdaq.com/articles/gilead-sciences-incs-moat-filling-sand-2015-06-06", "https://www.nasdaq.com/articles/why-isis-pharmaceuticals-inc-exploded-higher-19-may-2015-06-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-vrtx-wynn-2015-06-02", "https://www.nasdaq.com/articles/investing-beginners-how-start-biotech-2015-05-30", "https://www.nasdaq.com/articles/oef-abbv-ba-biib-etf-outflow-alert-2015-05-28", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-june-12-2015-2015-06-11", "https://www.nasdaq.com/articles/healthcare-investment-opportunities-long-term-2015-05-23", "https://www.nasdaq.com/articles/stock-market-news-for-may-21-2015-market-news-2015-05-21", "https://www.nasdaq.com/articles/gilead-sciences-its-own-worst-enemy-2015-05-17", "https://www.nasdaq.com/articles/why-shares-sangamo-biosciences-fell-today-2015-05-14", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-buy-synageva-fda-panel-backs-vertexs-orkambi-analyst-blog", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-may-12-2015-2015-05-11", "https://www.nasdaq.com/articles/heres-why-biotech-blue-chip-stock-biogen-inc-lost-11-april-2015-05-07", "https://www.nasdaq.com/articles/pop-3-buy-if-biotech-stocks-burst-2015-05-26", "https://www.nasdaq.com/articles/healthcare-investment-opportunities-long-term-2015-05-23", "https://www.nasdaq.com/articles/stock-market-news-for-may-21-2015-market-news-2015-05-21", "https://www.nasdaq.com/articles/gilead-sciences-its-own-worst-enemy-2015-05-17", "https://www.nasdaq.com/articles/why-shares-sangamo-biosciences-fell-today-2015-05-14", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-buy-synageva-fda-panel-backs-vertexs-orkambi-analyst-blog", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-may-12-2015-2015-05-11", "https://www.nasdaq.com/articles/heres-why-biotech-blue-chip-stock-biogen-inc-lost-11-april-2015-05-07", "https://www.nasdaq.com/articles/pop-3-buy-if-biotech-stocks-burst-2015-05-26", "https://www.nasdaq.com/articles/healthcare-investment-opportunities-long-term-2015-05-23", "https://www.nasdaq.com/articles/stock-market-news-for-may-21-2015-market-news-2015-05-21", "https://www.nasdaq.com/articles/why-street-keeps-doubting-gilead-sciences-inc-2015-05-05", "https://www.nasdaq.com/articles/frothy-china-or-no-world-mutual-funds-topped-april-2015-05-05", "https://www.nasdaq.com/articles/zoetis-beats-on-q1-earnings-revenue-guidance-lowered-analyst-blog-2015-05-05", "https://www.nasdaq.com/articles/incyte-posts-wider-than-expected-q1-loss-jakafi-grows-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/integra-lifesciences-tops-q1-earnings-revenues-view-up-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/isis-pharmaceuticals-q1-loss-narrower-than-expected-analyst-blog-2015-05-06", "https://www.nasdaq.com/articles/mylan-q1-earnings-meet-expectations-2015-guidance-upheld-analyst-blog-2015-05-06", "https://www.nasdaq.com/articles/10-most-profitable-businesses-boston-2015-05-06", "https://www.nasdaq.com/articles/why-street-keeps-doubting-gilead-sciences-inc-2015-05-05", "https://www.nasdaq.com/articles/frothy-china-or-no-world-mutual-funds-topped-april-2015-05-05", "https://www.nasdaq.com/articles/zoetis-beats-on-q1-earnings-revenue-guidance-lowered-analyst-blog-2015-05-05", "https://www.nasdaq.com/articles/incyte-posts-wider-than-expected-q1-loss-jakafi-grows-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/integra-lifesciences-tops-q1-earnings-revenues-view-up-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/isis-pharmaceuticals-q1-loss-narrower-than-expected-analyst-blog-2015-05-06", "https://www.nasdaq.com/articles/mylan-q1-earnings-meet-expectations-2015-guidance-upheld-analyst-blog-2015-05-06", "https://www.nasdaq.com/articles/10-most-profitable-businesses-boston-2015-05-06", "https://www.nasdaq.com/articles/why-street-keeps-doubting-gilead-sciences-inc-2015-05-05", "https://www.nasdaq.com/articles/frothy-china-or-no-world-mutual-funds-topped-april-2015-05-05", "https://www.nasdaq.com/articles/zoetis-beats-on-q1-earnings-revenue-guidance-lowered-analyst-blog-2015-05-05", "https://www.nasdaq.com/articles/incyte-posts-wider-than-expected-q1-loss-jakafi-grows-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/integra-lifesciences-tops-q1-earnings-revenues-view-up-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/isis-pharmaceuticals-q1-loss-narrower-than-expected-analyst-blog-2015-05-06", "https://www.nasdaq.com/articles/mylan-q1-earnings-meet-expectations-2015-guidance-upheld-analyst-blog-2015-05-06", "https://www.nasdaq.com/articles/10-most-profitable-businesses-boston-2015-05-06", "https://www.nasdaq.com/articles/why-street-keeps-doubting-gilead-sciences-inc-2015-05-05", "https://www.nasdaq.com/articles/frothy-china-or-no-world-mutual-funds-topped-april-2015-05-05", "https://www.nasdaq.com/articles/zoetis-beats-on-q1-earnings-revenue-guidance-lowered-analyst-blog-2015-05-05", "https://www.nasdaq.com/articles/incyte-posts-wider-than-expected-q1-loss-jakafi-grows-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/integra-lifesciences-tops-q1-earnings-revenues-view-up-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/isis-pharmaceuticals-q1-loss-narrower-than-expected-analyst-blog-2015-05-06", "https://www.nasdaq.com/articles/qlt-qlti-reports-wider-than-expected-loss-in-q1-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/acorda-posts-1q-loss-ampyra-generic-challenges-focus-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-bristol-myers-squibb-biogen-actelion-and-horizon-pharma", "https://www.nasdaq.com/articles/biotechs-blue-chip-stocks-2015-05-04", "https://www.nasdaq.com/articles/kytheras-kyth-double-chin-drug-kybella-gets-fda-nod-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/will-isis-pharmaceuticals-isis-disappoint-in-q1-earnings-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/alkermes-q1-loss-narrower-than-expected-maintains-view-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/pharmacyclics-beats-on-q1-earnings-misses-revenues-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/synageva-q1-loss-narrower-than-expected-pipeline-in-focus-analyst-blog-2015-04-30", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-celladon-biogen-celgene-and-gilead-press-releases", "https://www.nasdaq.com/articles/vertex-posts-wider-1q-loss-affirms-kalydeco-outlook-analyst-blog-2015-04-30", "https://www.nasdaq.com/articles/bristol-myers-q1-earnings-beat-driven-by-strong-sales-analyst-blog-2015-04-28", "https://www.nasdaq.com/articles/stock-market-news-for-april-28-2015-market-news-2015-04-28", "https://www.nasdaq.com/articles/pfizer-beats-q1-earnings-cuts-view-currency-woes-analyst-blog-2015-04-28", "https://www.nasdaq.com/articles/fidelity-contrafund-beating-market-old-fashioned-way-2015-04-25", "https://www.nasdaq.com/articles/will-tevas-teva-earnings-streak-continue-in-q1-analyst-blog-2015-04-28", "https://www.nasdaq.com/articles/isis-pharmaceuticals-isis-ttr-effective-in-extension-study-analyst-blog-2015-04-23", "https://www.nasdaq.com/articles/acorda-reports-encouraging-data-on-ms-drug-analyst-blog-2015-04-23", "https://www.nasdaq.com/articles/emergent-biosolutions-resumes-biothrax-manufacturing-analyst-blog-2015-04-23", "https://www.nasdaq.com/articles/gilead-gild-announces-encouraging-data-on-its-hcv-drugs-analyst-blog-2015-04-23", "https://www.nasdaq.com/articles/capricors-cap-1002-gets-orphan-drug-status-in-the-u.s.-analyst-blog-2015-04-23", "https://www.nasdaq.com/articles/baxter-international-inc-where-decline-win-2015-04-23", "https://www.nasdaq.com/articles/eli-lilly-beats-1q-earnings-wide-margin-affirms-view-analyst-blog-2015-04-23", "https://www.nasdaq.com/articles/ultragenyx-announces-positive-data-from-triheptanoin-study-analyst-blog-2015-04-23", "https://www.nasdaq.com/articles/pre-market-earnings-report-april-24-2015-biib-spg-lyb-aal-stt-vtr-tyc-dte-xrx-cog-ims-lea", "https://www.nasdaq.com/articles/etf-preview-broad-market-etfs-mixed-earnings-spotlight-2015-04-23", "https://www.nasdaq.com/articles/illumina-ilmn-tops-q1-earnings-revenues-eps-view-up-analyst-blog-2015-04-22", "https://www.nasdaq.com/articles/actelion-aliof-beats-q1-earnings-revenue-expectations-analyst-blog-2015-04-22", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-biogen-geron-johnson-johnson-and", "https://www.nasdaq.com/articles/amgen-beats-q1-earnings-revenues-ups-earnings-view-analyst-blog-2015-04-22", "https://www.nasdaq.com/articles/will-biogens-biib-earnings-streak-continue-1q-analyst-blog-2015-04-23", "https://www.nasdaq.com/articles/pfizers-cancer-drug-meets-first-primary-endpoint-in-phase-iii-analyst-blog-2015-04-22", "https://www.nasdaq.com/articles/immunomedics-immu-provides-update-on-lead-adc-candidate-analyst-blog-2015-04-22", "https://www.nasdaq.com/articles/will-agenus-agen-disappoint-in-q1-earning-season-analyst-blog-2015-04-22", "https://www.nasdaq.com/articles/alnylam-reports-positive-patisiran-results-shares-up-analyst-blog-2015-04-22", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-starts-earnings-season-strong-note-setbacks-ampio-athersys", "https://www.nasdaq.com/articles/will-edwards-lifesciences-ew-top-q1-earnings-estimates-analyst-blog-2015-04-22", "https://www.nasdaq.com/articles/can-healthways-hway-pull-a-surprise-this-earnings-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/perrigo-beats-on-q3-earnings-gives-view-rejects-mylan-bid-analyst-blog-2015-04-22", "https://www.nasdaq.com/articles/forget-gilead-gild-buy-these-impressive-biotech-stocks-instead-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/bristol-myers-announces-positive-data-from-opdivo-study-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/pharmacyclics-announces-positive-results-on-imbruvica-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/c.-r.-bard-bcr-q1-earnings%3A-lutonix-dcb-holds-the-key-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/will-alexions-alxn-soliris-drive-q1-earnings-beat-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/actavis-botox-upper-limb-spasticity-label-expanded-by-fda-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/is-abbvie-abbv-set-to-top-1q-earnings-on-humira-hcv-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/fate-therapeutics-fate-jumps%3A-stock-moves-12.4-higher-tale-of-the-tape-2015-04-21", "https://www.nasdaq.com/articles/will-novartis-nvs-earnings-disappoint-this-quarter-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/will-baxters-bax-earnings-disappoint-estimates-in-q1-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/will-mead-johnsons-mjn-q1-earnings-surprise-estimates-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/resmed-rmd-poised-to-outshine-q3-earnings-estimates-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/clovis-oncology-clvs-falls%3A-stock-goes-down-5.3-tale-of-the-tape-2015-04-20", "https://www.nasdaq.com/articles/athersys-slumps-as-multistem-fails-in-mid-stage-study-analyst-blog-2015-04-20", "https://www.nasdaq.com/articles/bristol-myers-study-on-opdivo-halted-on-early-success-analyst-blog-2015-04-20", "https://www.nasdaq.com/articles/will-eli-lilly-lly-beat-earnings-in-1q-despite-generics-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/will-conmed-cnmd-disappoint-earnings-estimates-in-q1-analyst-blog-2015-04-20", "https://www.nasdaq.com/articles/will-abbott-labs-abt-disappoint-on-earnings-this-quarter-analyst-blog-2015-04-20", "https://www.nasdaq.com/articles/3-biotech-stocks-could-be-developing-billion-dollar-drugs-2015-04-19", "https://www.nasdaq.com/articles/biotech-investors-shouldnt-miss-these-stocks-this-earnings-earnings-esp-2015-04-17", "https://www.nasdaq.com/articles/will-intuitive-surgical-isrg-surprise-earnings-in-q1-analyst-blog-2015-04-17", "https://www.nasdaq.com/articles/can-illumina-ilmn-keep-the-earnings-streak-alive-in-q1-analyst-blog-2015-04-17", "https://www.nasdaq.com/articles/amgen-gets-fda-nod-for-chronic-heart-failure-drug-corlanor-analyst-blog-2015-04-16", "https://www.nasdaq.com/articles/will-amgen-amgn-keep-earnings-streak-alive-1q-analyst-blog-2015-04-20", "https://www.nasdaq.com/articles/abbvies-hcv-treatment-granted-priority-review-in-japan-analyst-blog-2015-04-16", "https://www.nasdaq.com/articles/biogen-reports-new-data-from-acute-optic-neuritis-study-analyst-blog-2015-04-15", "https://www.nasdaq.com/articles/bayer-to-expand-copanlisib-program-by-three-new-studies-analyst-blog-2015-04-15", "https://www.nasdaq.com/articles/biotech-stock-roundup-favorable-briefing-documents-mdcos-kengreal-alexion-soliris-label", "https://www.nasdaq.com/articles/jj-beats-q1-earnings-cuts-view-currency-woes-analyst-blog-2015-04-14", "https://www.nasdaq.com/articles/alnylam-reports-publication-of-new-data-on-hemophilia-drug-analyst-blog-2015-04-14", "https://www.nasdaq.com/articles/aeterna-zentaris-to-advance-hormone-drug-to-phase-iii-study-analyst-blog-2015-04-14", "https://www.nasdaq.com/articles/vivus-responds-to-tevas-filing-for-qsymia-generics-analyst-blog-2015-04-16", "https://www.nasdaq.com/articles/abbvies-hcv-treatment-granted-priority-review-in-japan-analyst-blog-2015-04-16", "https://www.nasdaq.com/articles/biogen-reports-new-data-from-acute-optic-neuritis-study-analyst-blog-2015-04-15", "https://www.nasdaq.com/articles/bayer-to-expand-copanlisib-program-by-three-new-studies-analyst-blog-2015-04-15", "https://www.nasdaq.com/articles/biotech-stock-roundup-favorable-briefing-documents-mdcos-kengreal-alexion-soliris-label", "https://www.nasdaq.com/articles/jj-beats-q1-earnings-cuts-view-currency-woes-analyst-blog-2015-04-14", "https://www.nasdaq.com/articles/why-smart-money-loves-biotech-stock-2015-04-05", "https://www.nasdaq.com/articles/will-pharmaceutical-sales-drive-jj-jnj-earnings-again-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/has-biotech-bubble-already-popped-2015-04-04", "https://www.nasdaq.com/articles/safest-biotech-bet-market-2015-04-04", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-iwf-act-biib-celg-2015-04-02", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-horizon-pharma-hyperion-therapeutics-conatus-amgen-and", "https://www.nasdaq.com/articles/stock-market-news-for-april-01-2015-market-news-2015-04-01", "https://www.nasdaq.com/articles/why-receptos-inc-shares-soared-higher-today-2015-04-01", "https://www.nasdaq.com/articles/biotech-stock-roundup-horizon-buy-hyperion-conatus-liver-disease-data-analyst-blog-2015-04", "https://www.nasdaq.com/articles/truly-staggering-cost-alzheimers-disease-2015-04-04", "https://www.nasdaq.com/articles/stock-market-news-for-march-30-2015-market-news-2015-03-30", "https://www.nasdaq.com/articles/biogen-abbvies-ms-drug-zinbryta-under-review-in-the-eu-analyst-blog-2015-03-30", "https://www.nasdaq.com/articles/based-study-alzheimers-disease-cure-could-be-around-corner-2015-03-29", "https://www.nasdaq.com/articles/could-these-experimental-drugs-eclipse-harvonis-historic-launch-2015-03-28", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-prothena-vertex-gilead-and-amgen-press-releases", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-soars-alzheimers-data-gilead-hcv-drugs-label-update-analyst", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-hsbc-holdings-goldman-sachs-acorda-therapeutics-biogen", "https://www.nasdaq.com/articles/biogens-biosimilar-version-of-remicade-under-eu-review-analyst-blog-2015-03-31", "https://www.nasdaq.com/articles/stock-market-news-for-march-30-2015-market-news-2015-03-30", "https://www.nasdaq.com/articles/2-stocks-to-beat-the-dollars-volatile-run-analyst-blog-2015-03-24", "https://www.nasdaq.com/articles/biogen-idec-biib-worth-watching%3A-stock-rises-9.8-tale-of-the-tape-2015-03-23", "https://www.nasdaq.com/articles/biogen-gains-on-positive-alzheimers-drug-interim-results-analyst-blog-2015-03-23", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-if-sector-crashes-2015-03-23", "https://www.nasdaq.com/articles/financial-sector-update-03232015-gnwbiibocnbrxbx-2015-03-23", "https://www.nasdaq.com/articles/1-biotech-stock-you-can-buy-and-hold-next-20-years-2015-03-21", "https://www.nasdaq.com/articles/tiny-biotech-offers-new-hope-parkinsons-disease-patients-2015-03-25", "https://www.nasdaq.com/articles/biogen-idec-incs-stock-bursts-higher-alzheimers-news-heres-why-2015-03-20", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-amgn-biib-celg-2015-03-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-dish-biib-2015-03-20", "https://www.nasdaq.com/articles/sp-500-movers-mac-biib-2015-03-20", "https://www.nasdaq.com/articles/us-stock-futures-follow-european-markets-higher-hopes-greece-deal-2015-03-20", "https://www.nasdaq.com/articles/pre-market-most-active-mar-20-2015-mac-biib-ctrp-nok-qqq-bac-fb-aapl-prta-nke-kbh-hseb", "https://www.nasdaq.com/articles/us-stock-futures-point-higher-after-weak-thursday-session-germany-sees-hope-greece-deal", "https://www.nasdaq.com/articles/midday-update-first-day-spring-brings-green-wall-street-nasdaq-hits-15-yr-high-2015-03-20", "https://www.nasdaq.com/articles/health-care-sector-update-03202015-biibprtathrx-2015-03-20", "https://www.nasdaq.com/articles/can-biotech-stock-go-good-great-2015-03-19", "https://www.nasdaq.com/articles/new-biotech-etfs-highlight-evolving-growth-opportunities-2015-03-17", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-biogen-amgen-spdr-sp-biotech-etf-bioshares", "https://www.nasdaq.com/articles/should-gilead-sciences-incs-slowing-growth-concern-investors-2015-03-15", "https://www.nasdaq.com/articles/3-biotech-etfs-crushing-market-2015-etf-news-and-commentary-2015-03-13", "https://www.nasdaq.com/articles/sp-500-analyst-moves-biib-2015-03-13", "https://www.nasdaq.com/articles/closing-update-session-long-surge-lifts-market-gauges-big-weekly-advance-nasdaq-composite", "https://www.nasdaq.com/articles/health-care-sector-update-03202015-biibprtathrx-2015-03-20", "https://www.nasdaq.com/articles/can-biotech-stock-go-good-great-2015-03-19", "https://www.nasdaq.com/articles/new-biotech-etfs-highlight-evolving-growth-opportunities-2015-03-17", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-biogen-amgen-spdr-sp-biotech-etf-bioshares", "https://www.nasdaq.com/articles/should-gilead-sciences-incs-slowing-growth-concern-investors-2015-03-15", "https://www.nasdaq.com/articles/3-biotech-etfs-crushing-market-2015-etf-news-and-commentary-2015-03-13", "https://www.nasdaq.com/articles/sp-500-analyst-moves-biib-2015-03-13", "https://www.nasdaq.com/articles/closing-update-session-long-surge-lifts-market-gauges-big-weekly-advance-nasdaq-composite", "https://www.nasdaq.com/articles/merck-kgaa-to-pay-%243m-to-opexa-for-tcelna-study-analyst-blog-2015-03-10", "https://www.nasdaq.com/articles/isis-pharmaceuticals-earns-milestone-payment-from-biogen-analyst-blog-2015-03-09", "https://www.nasdaq.com/articles/could-study-help-lead-cure-select-multiple-sclerosis-patients-2015-03-08", "https://www.nasdaq.com/articles/2-tiny-biotechs-could-have-blockbuster-opportunity-2015-03-07", "https://www.nasdaq.com/articles/health-care-sector-update-03062015-cala-isis-hznp-2015-03-06", "https://www.nasdaq.com/articles/top-funds-buying-rackspace-allergan-biogen-idec-apple-2015-03-03", "https://www.nasdaq.com/articles/isis-pharmaceuticals-up-on-q4-earnings-and-revenues-beat-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-xlv-mdt-biib-celg-2015-03-10", "https://www.nasdaq.com/articles/merck-kgaa-to-pay-%243m-to-opexa-for-tcelna-study-analyst-blog-2015-03-10", "https://www.nasdaq.com/articles/isis-pharmaceuticals-earns-milestone-payment-from-biogen-analyst-blog-2015-03-09", "https://www.nasdaq.com/articles/could-study-help-lead-cure-select-multiple-sclerosis-patients-2015-03-08", "https://www.nasdaq.com/articles/2-tiny-biotechs-could-have-blockbuster-opportunity-2015-03-07", "https://www.nasdaq.com/articles/health-care-sector-update-03062015-cala-isis-hznp-2015-03-06", "https://www.nasdaq.com/articles/top-funds-buying-rackspace-allergan-biogen-idec-apple-2015-03-03", "https://www.nasdaq.com/articles/isis-pharmaceuticals-up-on-q4-earnings-and-revenues-beat-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-xlv-mdt-biib-celg-2015-03-10", "https://www.nasdaq.com/articles/3-big-cap-biotechs-could-trounce-gilead-sciences-year-2015-03-01", "https://www.nasdaq.com/articles/why-dont-these-winning-stocks-pay-dividends-2015-03-01", "https://www.nasdaq.com/articles/ishares-sp-500-growth-etf-experiences-big-outflow-2015-02-27", "https://www.nasdaq.com/articles/5-things-biogen-idec-incs-management-wants-you-know-2015-02-25", "https://www.nasdaq.com/articles/forget-gilead-sciences-here-are-3-better-biotech-stocks-2015-02-12", "https://www.nasdaq.com/articles/sucampo-par-pharmaceuticals-enter-license-agreement-analyst-blog-2015-02-12", "https://www.nasdaq.com/articles/why-sangamo-biosciences-inc-shares-rocketed-higher-today-2015-02-11", "https://www.nasdaq.com/articles/3-stocks-were-huge-winners-last-week-2015-02-14", "https://www.nasdaq.com/articles/isis-pharma-to-get-%245m-from-biogen-analyst-blog-2015-02-11", "https://www.nasdaq.com/articles/how-profit-elon-musks-space-internet-2015-02-10", "https://www.nasdaq.com/articles/orexigen-gives-positive-updates-on-its-weight-loss-drug-analyst-blog-2015-02-10", "https://www.nasdaq.com/articles/alkermes-reports-positive-data-on-multiple-sclerosis-drug-analyst-blog-2015-02-10", "https://www.nasdaq.com/articles/oncolytics-seeks-orphan-drug-status-for-reolysin-in-the-u.s.-analyst-blog-2015-02-10", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-10-2015-2015-02-09", "https://www.nasdaq.com/articles/will-sangamo-sgmo-disappoint-this-earnings-season-analyst-blog-2015-02-09", "https://www.nasdaq.com/articles/charles-river-crl-beats-on-q4-earnings-and-revenues-analyst-blog-2015-02-11", "https://www.nasdaq.com/articles/3-biotech-stocks-weve-fallen-2015-02-07", "https://www.nasdaq.com/articles/these-common-medications-may-put-you-greater-risk-developing-dementia-2015-02-07", "https://www.nasdaq.com/articles/3-blockbuster-drugs-may-be-obsolete-5-years-2015-02-07", "https://www.nasdaq.com/articles/sanofi-misses-on-q4-earnings-maintains-diabetes-guidance-analyst-blog-2015-02-06", "https://www.nasdaq.com/articles/gilead-amgen-q4-earnings-weak-outlook-affect-biotech-etfs-etf-news-and-commentary-2015-02", "https://www.nasdaq.com/articles/perrigo-beats-on-earnings-fy15-guidance-in-line-analyst-blog-2015-02-05", "https://www.nasdaq.com/articles/allergan-beats-earnings-yet-again-on-strong-revenues-analyst-blog-2015-02-05", "https://www.nasdaq.com/articles/3-medical-advancements-you-may-be-missing-out-2015-02-08", "https://www.nasdaq.com/articles/iusg-vz-biib-hon-etf-outflow-alert-2015-01-30", "https://www.nasdaq.com/articles/biogen-tops-q4-earnings-provides-strong-outlook-for-2015-analyst-blog-2015-01-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-pcar-amzn-2015-01-30", "https://www.nasdaq.com/articles/sp-500-movers-pcar-biib-2015-01-30", "https://www.nasdaq.com/articles/why-biogen-idecs-shares-skyrocketed-higher-2015-01-30", "https://www.nasdaq.com/articles/vertex-posts-wider-4q-loss-affirms-kalydeco-outlook-analyst-blog-2015-01-29", "https://www.nasdaq.com/articles/could-be-game-changing-news-battle-against-multiple-sclerosis-2015-02-01", "https://www.nasdaq.com/articles/will-biogen-biib-surpass-q4-earnings-expectations-analyst-blog-2015-01-27", "https://www.nasdaq.com/articles/pre-market-earnings-report-january-28-2015-ba-biib-emc-gd-px-aep-tel-ip-trow-hes-abc-stj", "https://www.nasdaq.com/articles/commit-purchase-biogen-idec-240-earn-67-using-options-2015-01-26", "https://www.nasdaq.com/articles/how-will-ma-etfs-perform-2015-many-deals-lined-2015-01-26", "https://www.nasdaq.com/articles/biotech-stock-roundup-eu-approvals-abbvie-celgene-drugs-cytrx-partial-clinical-hold-lifted", "https://www.nasdaq.com/articles/state-union-address-investing-idea-precision-medicine-2015-01-21", "https://www.nasdaq.com/articles/biogen-idec-inc-earnings-worth-wait-2015-01-29", "https://www.nasdaq.com/articles/isis-pharmaceuticals-earns-milestone-payment-from-biogen-analyst-blog-2015-01-15", "https://www.nasdaq.com/articles/health-care-sector-update-01142015-azn-isis-vicl-2015-01-14", "https://www.nasdaq.com/articles/biogen-to-acquire-convergence-expand-pain-pipeline-analyst-blog-2015-01-13", "https://www.nasdaq.com/articles/seattle-genetics-bristol-myers-to-study-adcetris-opdivo-analyst-blog-2015-01-13", "https://www.nasdaq.com/articles/which-big-biotech-will-soar-2015-2015-01-12", "https://www.nasdaq.com/articles/better-healthcare-buy-big-or-little-biotechs-2015-01-11", "https://www.nasdaq.com/articles/iyh-biib-mdt-act-etf-inflow-alert-2015-01-09", "https://www.nasdaq.com/articles/abbvie-incs-insights-jp-morgan-healthcare-conference-2015-01-15", "https://www.nasdaq.com/articles/diving-deeper-biogens-lingo-results-2015-01-09", "https://www.nasdaq.com/articles/biogen-reveals-positive-data-from-acute-optic-neuritis-study-analyst-blog-2015-01-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-tsco-2015-01-08", "https://www.nasdaq.com/articles/3-biotech-stocks-could-trounce-gilead-sciences-inc-2015-2015-01-07", "https://www.nasdaq.com/articles/why-isis-pharmaceuticals-inc-stock-surged-19-december-2015-01-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-nxpi-biib-2015-01-06", "https://www.nasdaq.com/articles/why-biogen-idec-inc-stock-catapulted-10-higher-december-2015-01-06", "https://www.nasdaq.com/articles/isis-pharmaceuticals-improves-2014-outlook-shares-up-analyst-blog-2015-01-09", "https://www.nasdaq.com/articles/vug-celg-biib-act-large-inflows-detected-etf-2014-12-31", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-kalydeco-label-expanded-in-the-u.s.-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/ignytas-lead-oncology-candidate-gets-orphan-drug-status-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/devon-energy-achieves-107-analyst-rank-surpassing-biogen-idec-2014-12-26", "https://www.nasdaq.com/articles/stock-market-news-for-december-26-2014-market-news-2014-12-26", "https://www.nasdaq.com/articles/after-gilead-sciences-is-it-time-to-sell-biotech-stocks-analyst-blog-2014-12-26", "https://www.nasdaq.com/articles/vanda-gains-fanapt-rights-from-novartis-for-the-u.s.-region-analyst-blog-2014-12-24", "https://www.nasdaq.com/articles/isis-pharmaceuticals-up-on-collaboration-with-jj-analyst-blog-2015-01-06", "https://www.nasdaq.com/articles/3-drugmakers-facing-pivotal-2015-2014-12-22", "https://www.nasdaq.com/articles/puma-biotechnology-pbyi-jumps%3A-stock-moves-6.1-up-tale-of-the-tape-2014-12-22", "https://www.nasdaq.com/articles/prothena-corp.-prta-looks-good%3A-stock-moves-up-5.7-tale-of-the-tape-2014-12-22", "https://www.nasdaq.com/articles/orexigens-obesity-drug-mysimba-gets-chmp-nod-analyst-blog-2014-12-22", "https://www.nasdaq.com/articles/genomic-health-ghdx-shines-on-prospective-cancer-tests-analyst-blog-2014-12-22", "https://www.nasdaq.com/articles/roche-to-acquire-austrian-biotechnology-company-dutalys-analyst-blog-2014-12-22", "https://www.nasdaq.com/articles/celgene-gets-positive-chmp-recommendation-for-revlimid-analyst-blog-2014-12-22", "https://www.nasdaq.com/articles/xlv-biib-act-agn-large-inflows-detected-etf-2014-12-22", "https://www.nasdaq.com/articles/eli-lilly-adocia-strike-deal-to-develop-ultra-rapid-insulin-analyst-blog-2014-12-22", "https://www.nasdaq.com/articles/3-large-cap-biotech-stocks-could-surprise-investors-2015-2014-12-21", "https://www.nasdaq.com/articles/seattle-genetics-initiates-phase-ib-study-on-leukemia-drug-analyst-blog-2014-12-19", "https://www.nasdaq.com/articles/3-pharma-giants-growing-significantly-faster-pfizer-inc-2014-12-19", "https://www.nasdaq.com/articles/agenus-jumps-on-positive-data-from-shingles-candidate-analyst-blog-2014-12-19", "https://www.nasdaq.com/articles/integra-lifesciences-up-on-launch-of-bilayer-skin-product-analyst-blog-2014-12-19", "https://www.nasdaq.com/articles/bruker-unveils-bioafm-system-for-high-resolution-imaging-analyst-blog-2014-12-18", "https://www.nasdaq.com/articles/novo-nordisks-tresiba-favored-by-chmp-for-expanded-use-analyst-blog-2014-12-22", "https://www.nasdaq.com/articles/which-biotech-will-become-next-gilead-sciences-inc-2014-12-16", "https://www.nasdaq.com/articles/biodelivery-sciences-bdsi-in-focus%3A-stock-tanks-11-tale-of-the-tape-2014-12-16", "https://www.nasdaq.com/articles/trevena-trvn-in-focus%3A-stock-rallies-7.5-tale-of-the-tape-2014-12-16", "https://www.nasdaq.com/articles/alkermes-starts-phase-i-study-on-schizophrenia-candidate-analyst-blog-2014-12-16", "https://www.nasdaq.com/articles/acordas-ampyra-in-phase-iii-for-post-stroke-walking-deficit-analyst-blog-2014-12-16", "https://www.nasdaq.com/articles/is-illumina-ilmn-worth-adding-to-your-portfolio-analyst-blog-2014-12-16", "https://www.nasdaq.com/articles/opko-up-on-announcing-global-partnership-with-pfizer-analyst-blog-2014-12-16", "https://www.nasdaq.com/articles/ovascience-slumps%3A-ovas-tanks-12.3-in-session-tale-of-the-tape-2014-12-16", "https://www.nasdaq.com/articles/strength-seen-in-gtx-inc-gtxi%3A-stock-rises-10.6-tale-of-the-tape-2014-12-15", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-slumps%3A-aldr-falls-5.5-in-session-tale-of-the-tape-2014-12-15", "https://www.nasdaq.com/articles/alexions-soliris-receives-orphan-drug-status-in-japan-analyst-blog-2014-12-15", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-starts-defibrotide-rolling-nda-filing-analyst-blog-2014-12-15", "https://www.nasdaq.com/articles/sangamo-biosciences-sgmo-jumps%3A-stock-rises-7.2-tale-of-the-tape-2014-12-12", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-inc.-aldr-in-focus%3A-stock-soars-31.9-tale-of-the-tape-2014-12-12", "https://www.nasdaq.com/articles/celladon-corporation-cldn-falls%3A-stock-goes-down-8.6-tale-of-the-tape-2014-12-12", "https://www.nasdaq.com/articles/genomic-healths-breast-cancer-test-yields-positive-results-analyst-blog-2014-12-16", "https://www.nasdaq.com/articles/strength-seen-in-gtx-inc-gtxi%3A-stock-rises-10.6-tale-of-the-tape-2014-12-15", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-slumps%3A-aldr-falls-5.5-in-session-tale-of-the-tape-2014-12-15", "https://www.nasdaq.com/articles/alexions-soliris-receives-orphan-drug-status-in-japan-analyst-blog-2014-12-15", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-starts-defibrotide-rolling-nda-filing-analyst-blog-2014-12-15", "https://www.nasdaq.com/articles/sangamo-biosciences-sgmo-jumps%3A-stock-rises-7.2-tale-of-the-tape-2014-12-12", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-inc.-aldr-in-focus%3A-stock-soars-31.9-tale-of-the-tape-2014-12-12", "https://www.nasdaq.com/articles/celladon-corporation-cldn-falls%3A-stock-goes-down-8.6-tale-of-the-tape-2014-12-12", "https://www.nasdaq.com/articles/3-reasons-biogen-idec-inc-could-soar-2015-2014-12-12", "https://www.nasdaq.com/articles/incyte-incy-gains-on-positive-baricitinib-study-results-analyst-blog-2014-12-10", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-slips-after-dosing-issue-on-jzp-386-analyst-blog-2014-12-10", "https://www.nasdaq.com/articles/myriad-genetics-unveils-positive-cancer-study-results-analyst-blog-2014-12-10", "https://www.nasdaq.com/articles/rexahn-pharmaceuticals-inc.-rnn-rises%3A-stock-up-8.6-tale-of-the-tape-2014-12-09", "https://www.nasdaq.com/articles/acceleron-pharma-inc.-xlrn-in-focus%3A-stock-soars-13.6-tale-of-the-tape-2014-12-09", "https://www.nasdaq.com/articles/bluebird-bio-blue-in-focus%3A-stock-surges-9.4-tale-of-the-tape-2014-12-09", "https://www.nasdaq.com/articles/isis-jumps-on-positive-results-for-venous-thrombosis-drug-analyst-blog-2014-12-09", "https://www.nasdaq.com/articles/avalanche-biotechnologies-aavl-jumps%3A-stock-adds-6.1-in-session-tale-of-the-tape-2014-12", "https://www.nasdaq.com/articles/incyte-incy-gains-on-positive-baricitinib-study-results-analyst-blog-2014-12-10", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-slips-after-dosing-issue-on-jzp-386-analyst-blog-2014-12-10", "https://www.nasdaq.com/articles/myriad-genetics-unveils-positive-cancer-study-results-analyst-blog-2014-12-10", "https://www.nasdaq.com/articles/cara-therapeutics-cara-in-focus%3A-stock-rises-6.1-tale-of-the-tape-2014-12-08", "https://www.nasdaq.com/articles/compugen-cgen-worth-watching%3A-stock-moves-8.8-higher-tale-of-the-tape-2014-12-08", "https://www.nasdaq.com/articles/kindred-biosciences-inc.-kin-in-focus%3A-stock-soars-10.6-tale-of-the-tape-2014-12-08", "https://www.nasdaq.com/articles/amgen-unveils-positive-results-from-blood-cancer-studies-analyst-blog-2014-12-08", "https://www.nasdaq.com/articles/dynavax-astrazeneca-alter-agreement-for-asthma-product-analyst-blog-2014-12-09", "https://www.nasdaq.com/articles/alnylam-reports-positive-initial-phase-i-data-on-aln-at3-analyst-blog-2014-12-09", "https://www.nasdaq.com/articles/pharmacyclics-presents-imbruvica-data-at-the-ash-meeting-analyst-blog-2014-12-09", "https://www.nasdaq.com/articles/amgen-successfully-expands-xgeva-label-in-the-u.s.-analyst-blog-2014-12-09", "https://www.nasdaq.com/articles/cara-therapeutics-cara-in-focus%3A-stock-rises-6.1-tale-of-the-tape-2014-12-08", "https://www.nasdaq.com/articles/exciting-news-game-changing-alzheimers-drug-could-be-its-way-2014-12-06", "https://www.nasdaq.com/articles/bayer-files-hemophilia-a-drug-marketing-application-in-eu-analyst-blog-2014-12-05", "https://www.nasdaq.com/articles/array-biopharma-inc.-arry-in-focus%3A-stock-soars-14.3-tale-of-the-tape-2014-12-05", "https://www.nasdaq.com/articles/pharmacyclics-pcyc-launches-u.s.-based-cll-registry-analyst-blog-2014-12-08", "https://www.nasdaq.com/articles/agios-agio-reports-encouraging-data-on-leukemia-drug-analyst-blog-2014-12-08", "https://www.nasdaq.com/articles/seattle-genetics-takedas-adcetris-shows-long-term-effect-analyst-blog-2014-12-08", "https://www.nasdaq.com/articles/abbvie-reveals-phase-ii-data-on-blood-cancer-drug-at-ash-analyst-blog-2014-12-08", "https://www.nasdaq.com/articles/sequenom-inc.-sqnm-in-focus%3A-stock-surges-23.6-tale-of-the-tape-2014-12-04", "https://www.nasdaq.com/articles/amgens-blincyto-gets-fda-nod-carries-boxed-warning-analyst-blog-2014-12-04", "https://www.nasdaq.com/articles/adma-biologics-ri-002-positive-in-phase-iii-study-analyst-blog-2014-12-04", "https://www.nasdaq.com/articles/synageva-completes-bla-submission-for-sebelipase-alfa-analyst-blog-2014-12-04", "https://www.nasdaq.com/articles/walgreens-wag-up-on-4.9-y-y-rise-in-november-sales-analyst-blog-2014-12-05", "https://www.nasdaq.com/articles/celldexs-glembatumumab-vedotin-in-phase-ii-for-melanoma-analyst-blog-2014-12-05", "https://www.nasdaq.com/articles/incytes-jakafi-gets-fda-approval-for-polycythemia-vera-analyst-blog-2014-12-05", "https://www.nasdaq.com/articles/why-isis-pharmaceuticals-inc-stock-leaped-12-november-2014-12-04", "https://www.nasdaq.com/articles/sequenom-inc.-sqnm-in-focus%3A-stock-surges-23.6-tale-of-the-tape-2014-12-04", "https://www.nasdaq.com/articles/puma-biotechnology-down-on-delay-in-neratinib-nda-filing-analyst-blog-2014-12-03", "https://www.nasdaq.com/articles/actelion-submits-marketing-application-for-uptravi-in-eu-analyst-blog-2014-12-03", "https://www.nasdaq.com/articles/biogen-up-on-encouraging-interim-data-on-alzheimers-drug-analyst-blog-2014-12-03", "https://www.nasdaq.com/articles/array-biopharma-regains-binimetinib-rights-from-novartis-analyst-blog-2014-12-04", "https://www.nasdaq.com/articles/midday-update-stocks-positive-construction-spending-auto-sales-2014-12-02", "https://www.nasdaq.com/articles/sp-500-movers-nem-biib-2014-12-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-nxpi-biib-2014-12-02", "https://www.nasdaq.com/articles/stocks-resume-advance-buoyed-construction-spending-2014-12-02", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-mtum-mu-act-biib-2014-12-02", "https://www.nasdaq.com/articles/intra-cellular-therapies-itci-jumps%3A-stock-rises-6.8-tale-of-the-tape-2014-12-02", "https://www.nasdaq.com/articles/medicinova-mnov-looks-good%3A-stock-soars-19.3-tale-of-the-tape-2014-12-02", "https://www.nasdaq.com/articles/myriad-genetics-prolaris%3A-a-pocket-friendly-cancer-test-analyst-blog-2014-12-03", "https://www.nasdaq.com/articles/midday-update-stocks-positive-construction-spending-auto-sales-2014-12-02", "https://www.nasdaq.com/articles/sp-500-movers-nem-biib-2014-12-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-nxpi-biib-2014-12-02", "https://www.nasdaq.com/articles/health-care-sector-update-12022014-biib-imnp-qdel-pfe-gsk-2014-12-02", "https://www.nasdaq.com/articles/dynavax-regains-tlr-7-9-inhibitor-dv1179-rights-from-glaxo-analyst-blog-2014-12-01", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-52-week-high-driven-by-kalydeco-analyst-blog-2014-12-01", "https://www.nasdaq.com/articles/pharmacyclics-jj-seek-imbruvica-label-expansion-in-eu-analyst-blog-2014-12-02", "https://www.nasdaq.com/articles/alexions-soliris-gets-final-positive-nice-recommendation-analyst-blog-2014-11-28", "https://www.nasdaq.com/articles/avanirs-migraine-drug-gets-complete-response-letter-analyst-blog-2014-11-27", "https://www.nasdaq.com/articles/strength-seen-in-kythera-kyth%3A-stock-moves-5.5-higher-tale-of-the-tape-2014-11-26", "https://www.nasdaq.com/articles/alexions-alxn-soliris-gets-orphan-drug-status-in-japan-analyst-blog-2014-11-26", "https://www.nasdaq.com/articles/isis-pharmaceuticals-earns-milestone-on-study-initiation-analyst-blog-2014-11-26", "https://www.nasdaq.com/articles/intra-cellular-commences-phase-iii-schizophrenia-study-analyst-blog-2014-11-26", "https://www.nasdaq.com/articles/coronado-biosciences-cndo-jumps%3A-stock-rises-8.5-tale-of-the-tape-2014-11-25", "https://www.nasdaq.com/articles/oncothyreon-inc.-onty-in-focus%3A-stock-surges-10.1-tale-of-the-tape-2014-11-28", "https://www.nasdaq.com/articles/amgen-ends-gastric-cancer-drug-studies-safety-review-analyst-blog-2014-11-25", "https://www.nasdaq.com/articles/spy-ba-cop-biib-etf-outflow-alert-2014-11-24", "https://www.nasdaq.com/articles/ocera-therapeutics-ocrx-worth-watching%3A-stock-up-9.4-tale-of-the-tape-2014-11-24", "https://www.nasdaq.com/articles/enzo-biochem-enz-in-focus%3A-stock-moves-6.9-higher-tale-of-the-tape-2014-11-24", "https://www.nasdaq.com/articles/abbvies-hcv-cocktail-treatment-closer-eu-approval-analyst-blog-2014-11-24", "https://www.nasdaq.com/articles/immunomedics-veltuzumab-receives-orphan-drug-status-analyst-blog-2014-11-24", "https://www.nasdaq.com/articles/xoma-corp-worth-watching%3A-stock-moves-10.3-higher-tale-of-the-tape-2014-11-21", "https://www.nasdaq.com/articles/prosensa-soars-on-%24680m-buyout-offer-from-biomarin-analyst-blog-2014-11-25", "https://www.nasdaq.com/articles/amgen-ends-gastric-cancer-drug-studies-safety-review-analyst-blog-2014-11-25", "https://www.nasdaq.com/articles/high-yield-dividend-stock-screams-danger-2014-11-21", "https://www.nasdaq.com/articles/novavax-gains-on-fast-track-designation-for-rsv-f-vaccine-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/epizyme-gains-on-positive-phase-i-data-on-epz-6438-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/is-illumina-ilmn-worth-adding-to-your-portfolio-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/amgen-and-abbvie-strengthen-manufacturing-facilities-in-asia-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/agios-agio-shares-up-on-positive-ag-120-study-data-analyst-blog-2014-11-20", "https://www.nasdaq.com/articles/epirus-biopharmaceuticals-eprs-jumps%3A-stock-up-15.9-tale-of-the-tape-2014-11-21", "https://www.nasdaq.com/articles/compugen-cgen-worth-watching%3A-stock-adds-6-in-session-tale-of-the-tape-2014-11-21", "https://www.nasdaq.com/articles/high-yield-dividend-stock-screams-danger-2014-11-21", "https://www.nasdaq.com/articles/novavax-gains-on-fast-track-designation-for-rsv-f-vaccine-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/epizyme-gains-on-positive-phase-i-data-on-epz-6438-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/is-illumina-ilmn-worth-adding-to-your-portfolio-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/alnylam-reports-positive-initial-phase-ii-data-on-revusiran-analyst-blog-2014-11-17", "https://www.nasdaq.com/articles/is-mallinckrodt-mnk-poised-to-beat-q4-earnings-estimates-analyst-blog-2014-11-17", "https://www.nasdaq.com/articles/mallinckrodt-q4-earnings-boosted-by-acquisitions-sales-beat-analyst-blog-2014-11-19", "https://www.nasdaq.com/articles/puma-biotechnology-falls-on-disappointing-neratinib-data-analyst-blog-2014-11-17", "https://www.nasdaq.com/articles/biotech-and-yet-weve-just-begun-2014-11-14", "https://www.nasdaq.com/articles/affymetrix-affx-now-a-strong-buy-raised-guidance-positive-analyst-blog-2014-11-14", "https://www.nasdaq.com/articles/geron-collaborates-with-jj-for-imetelstat-analyst-blog-2014-11-14", "https://www.nasdaq.com/articles/isis-astrazeneca-expand-antisense-technology-collaboration-analyst-blog-2014-11-14", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-biib-2014-11-13", "https://www.nasdaq.com/articles/aegerion-to-acquire-myalept-boost-portfolio-shares-up-analyst-blog-2014-11-11", "https://www.nasdaq.com/articles/sanofis-lemtrada-gets-u.s.-approval-carries-boxed-warning-analyst-blog-2014-11-17", "https://www.nasdaq.com/articles/puma-biotechnology-falls-on-disappointing-neratinib-data-analyst-blog-2014-11-17", "https://www.nasdaq.com/articles/biotech-and-yet-weve-just-begun-2014-11-14", "https://www.nasdaq.com/articles/affymetrix-affx-now-a-strong-buy-raised-guidance-positive-analyst-blog-2014-11-14", "https://www.nasdaq.com/articles/vht-biib-celg-lly-large-inflows-detected-etf-2014-11-10", "https://www.nasdaq.com/articles/repros-soars-on-positive-fda-meeting-regarding-androxa-analyst-blog-2014-11-10", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-shares-crash-on-flint-results-analyst-blog-2014-11-10", "https://www.nasdaq.com/articles/5-prescription-drugs-selling-hot-cakes-2014-11-09", "https://www.nasdaq.com/articles/orexigen-orex-worth-watching%3A-stock-soars-33.3-tale-of-the-tape-2014-11-11", "https://www.nasdaq.com/articles/salix-q3-earnings-marred-inventory-issues-cuts-view-analyst-blog-2014-11-07", "https://www.nasdaq.com/articles/keryx-kerx-in-focus%3A-stock-adds-11.9-in-session-tale-of-the-tape-2014-11-07", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-10-2014-2014-11-07", "https://www.nasdaq.com/articles/isis-pharmaceuticals-inc-strikes-out-its-own-2014-11-07", "https://www.nasdaq.com/articles/5-things-biogen-idec-incs-management-wants-you-know-2014-11-07", "https://www.nasdaq.com/articles/alnylams-q3-loss-narrower-than-expected-pipeline-in-focus-analyst-blog-2014-11-06", "https://www.nasdaq.com/articles/perrigo-misses-on-earnings-and-sales-maintains-guidance-analyst-blog-2014-11-06", "https://www.nasdaq.com/articles/medivation-q3-earnings-revenues-lag-estimates-analyst-blog-2014-11-07", "https://www.nasdaq.com/articles/salix-q3-earnings-marred-inventory-issues-cuts-view-analyst-blog-2014-11-07", "https://www.nasdaq.com/articles/keryx-kerx-in-focus%3A-stock-adds-11.9-in-session-tale-of-the-tape-2014-11-07", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-q3-earnings-rise-y-y-lifts-guidance-analyst-blog-2014-11-05", "https://www.nasdaq.com/articles/mannkind-falls-on-missing-q3-estimates-yet-cuts-loss-y-y-analyst-blog-2014-11-04", "https://www.nasdaq.com/articles/seattle-genetics-gains-on-narrower-than-expected-q3-loss-analyst-blog-2014-11-03", "https://www.nasdaq.com/articles/amag-up-on-q3-earnings-beat-revenues-up-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/incyte-incy-looks-good%3A-stock-moves-10.9-higher-tale-of-the-tape-2014-10-31", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-seeks-approval-cf-combination-analyst-blog-2014-11-06", "https://www.nasdaq.com/articles/alkermes-incurs-wider-q3-loss-but-revenues-grow-y-y-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/affymetrix-beats-q3-earnings-revenues-raises-14-view-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/incyte-gains-on-q3-earnings-and-revenue-beat-raises-view-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/acorda-acor-beats-q3-earnings-ups-ampyra-outlook-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/oncolytics-biotech-oncy-looks-good%3A-stock-soars-26-tale-of-the-tape-2014-10-30", "https://www.nasdaq.com/articles/buy-these-top-ranked-etfs-on-solid-biotech-stock-earnings-etf-news-and-commentary-2014-10", "https://www.nasdaq.com/articles/the-medicines-company-mdco-jumps%3A-stock-gains-16.5-tale-of-the-tape-2014-10-29", "https://www.nasdaq.com/articles/bind-therapeutics-inc.-bind-surges%3A-stock-rises-14.2-higher-tale-of-the-tape-2014-10-31", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-shares-fall-on-q3-earnings-miss-analyst-blog-2014-10-29", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-posts-narrower-than-expected-loss-analyst-blog-2014-10-29", "https://www.nasdaq.com/articles/gilead-gild-posts-weak-earnings-stock-falls-4-after-hours-stocks-news-2014-10-28", "https://www.nasdaq.com/articles/amgen-beats-q3-earnings-revenues-ups-view-again-analyst-blog-2014-10-28", "https://www.nasdaq.com/articles/sarepta-slumps%3A-srpt-plunges-32.5-in-session-tale-of-the-tape-2014-10-28", "https://www.nasdaq.com/articles/pfizer-q3-earnings-top-estimates-despite-generic-pressure-analyst-blog-2014-10-28", "https://www.nasdaq.com/articles/sarepta-slumps-as-eteplirsen-nda-submission-gets-delayed-analyst-blog-2014-10-28", "https://www.nasdaq.com/articles/amgen-up-on-strategic-initiatives-and-2015-guidance-analyst-blog-2014-10-29", "https://www.nasdaq.com/articles/safe-route-biotech-sector-2014-10-27", "https://www.nasdaq.com/articles/allergan-beats-on-earnings-revenues-valeant-raises-offer-analyst-blog-2014-10-27", "https://www.nasdaq.com/articles/biogen-idec-inc-trouble-2014-10-27", "https://www.nasdaq.com/articles/3-biotech-stocks-growing-faster-gilead-sciences-inc-2014-10-27", "https://www.nasdaq.com/articles/biogen-falls-concerns-regarding-tecfidera-sales-and-pml-case-analyst-blog-2014-10-24", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-iwf-v-unp-biib-2014-10-23", "https://www.nasdaq.com/articles/why-biogen-idec-stock-shares-are-getting-pummeled-today-2014-10-22", "https://www.nasdaq.com/articles/merck-tops-q3-earnings-patent-expiries-hit-revenues-analyst-blog-2014-10-27", "https://www.nasdaq.com/articles/wednesdays-etf-unusual-volume-pwb-2014-10-22", "https://www.nasdaq.com/articles/sp-500-movers-biib-brcm-2014-10-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-brcm-2014-10-22", "https://www.nasdaq.com/articles/biogens-q3-earnings-top-estimates-view-raised-again-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/pre-market-earnings-report-october-22-2014-ba-biib-usb-abt-dow-emc-spg-tmo-gd-nsc-noc-bsx", "https://www.nasdaq.com/articles/3-stocks-could-surprise-earnings-season-2014-10-21", "https://www.nasdaq.com/articles/will-sangamo-sgmo-incur-wider-than-expected-q3-loss-analyst-blog-2014-10-20", "https://www.nasdaq.com/articles/biogen-idec-inc-earnings-were-great-heres-why-stock-tumbled-anyway-2014-10-22", "https://www.nasdaq.com/articles/drug-could-outsell-medical-marijuana-2014-10-19", "https://www.nasdaq.com/articles/us-ipo-weekly-recap-5-ipos-achieve-moderate-gains-during-market-slide-and-biotech", "https://www.nasdaq.com/articles/sustainability-pays-3-green-companies-making-money-2014-10-16", "https://www.nasdaq.com/articles/forward-pharma-goes-backward-years-largest-biotech-drops-17-ipo-2014-10-15", "https://www.nasdaq.com/articles/isis-pharmaceuticals-unveils-mid-stage-data-on-isis-smnrx-analyst-blog-2014-10-13", "https://www.nasdaq.com/articles/1-huge-risk-facing-marijuana-stock-2014-10-12", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-biib-2014-10-08", "https://www.nasdaq.com/articles/will-biogen-idec-biib-pull-a-surprise-this-earnings-season-analyst-blog-2014-10-20", "https://www.nasdaq.com/articles/5-states-expected-see-biggest-increase-alzheimers-disease-2014-10-05", "https://www.nasdaq.com/articles/next-blue-chip-stocks-biogen-idec-2014-10-04", "https://www.nasdaq.com/articles/perrigo-sells-some-assets-to-imago-pharmaceuticals-analyst-blog-2014-10-03", "https://www.nasdaq.com/articles/these-companies-are-saving-money-and-sticking-you-tax-bill-2014-09-27", "https://www.nasdaq.com/articles/etf-outlook-sp-health-care-select-spdr-etf-xlv-2014-09-25", "https://www.nasdaq.com/articles/isis-pharmaceuticals-up-on-%244m-milestone-payment-analyst-blog-2014-09-22", "https://www.nasdaq.com/articles/gileads-gild-zydelig-gets-eu-clearance-for-blood-cancer-analyst-blog-2014-09-22", "https://www.nasdaq.com/articles/xlv-amgn-bmy-biib-etf-inflow-alert-2014-10-07", "https://www.nasdaq.com/articles/5-states-expected-see-biggest-increase-alzheimers-disease-2014-10-05", "https://www.nasdaq.com/articles/next-blue-chip-stocks-biogen-idec-2014-10-04", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-thursday-tale-of-the-tape-2014-09-18", "https://www.nasdaq.com/articles/repros-therapeutics-rprx-crumbles%3A-stock-falls-by-10.5-tale-of-the-tape-2014-09-18", "https://www.nasdaq.com/articles/integra-poised-on-impressive-duraseal-product-line-solid-q2-analyst-blog-2014-09-18", "https://www.nasdaq.com/articles/sanofi-myokardia-ink-deal-to-develop-cardiomyopathies-analyst-blog-2014-09-18", "https://www.nasdaq.com/articles/alnylam-alny-to-file-clinical-trial-application-for-aln-cc5-analyst-blog-2014-09-18", "https://www.nasdaq.com/articles/arena-pharmaceuticals-inc.-arna-jumps%3A-stock-rises-9.5-tale-of-the-tape-2014-09-19", "https://www.nasdaq.com/articles/is-merck-kgaa-on-track-with-its-fit-for-2018-program-analyst-blog-2014-09-19", "https://www.nasdaq.com/articles/3-biotechs-investors-should-watch-2014-09-19", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-tuesday-tale-of-the-tape-2014-09-16", "https://www.nasdaq.com/articles/biogen-abbvie-report-positive-data-on-ms-drug-zinbryta-analyst-blog-2014-09-15", "https://www.nasdaq.com/articles/amarin-plunges-after-the-fda-denies-vascepa-spa-appeal-analyst-blog-2014-09-15", "https://www.nasdaq.com/articles/why-biogen-idec-incs-stock-17-2014-2014-09-12", "https://www.nasdaq.com/articles/sanofi-reports-data-on-multiple-sclerosis-drug-lemtrada-analyst-blog-2014-09-12", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-vug-biib-ups-ebay-2014-09-17", "https://www.nasdaq.com/articles/novartis-presents-data-on-multiple-sclerosis-drug-gilenya-analyst-blog-2014-09-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-ties-infinity-keryx-slips-fda-approval-analyst-blog-2014-09", "https://www.nasdaq.com/articles/why-receptos-inc-shares-rocketed-higher-2014-09-10", "https://www.nasdaq.com/articles/5-things-biogen-idec-incs-management-wants-you-know-2014-09-03", "https://www.nasdaq.com/articles/ibb-celg-biib-alxn-etf-outflow-alert-2014-09-02", "https://www.nasdaq.com/articles/data-on-celgenes-revlimid-published-in-oncology-journal-analyst-blog-2014-08-22", "https://www.nasdaq.com/articles/what-investors-gain-from-large-mid-small-cap-growth-funds-mutual-fund-commentary-2014-08", "https://www.nasdaq.com/articles/biogen-reports-positive-two-year-data-on-ms-drug-plegridy-analyst-blog-2014-09-12", "https://www.nasdaq.com/articles/novartis-presents-data-on-multiple-sclerosis-drug-gilenya-analyst-blog-2014-09-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-ties-infinity-keryx-slips-fda-approval-analyst-blog-2014-09", "https://www.nasdaq.com/articles/why-receptos-inc-shares-rocketed-higher-2014-09-10", "https://www.nasdaq.com/articles/5-things-biogen-idec-incs-management-wants-you-know-2014-09-03", "https://www.nasdaq.com/articles/ibb-celg-biib-alxn-etf-outflow-alert-2014-09-02", "https://www.nasdaq.com/articles/data-on-celgenes-revlimid-published-in-oncology-journal-analyst-blog-2014-08-22", "https://www.nasdaq.com/articles/what-investors-gain-from-large-mid-small-cap-growth-funds-mutual-fund-commentary-2014-08", "https://www.nasdaq.com/articles/biogen-reports-positive-two-year-data-on-ms-drug-plegridy-analyst-blog-2014-09-12", "https://www.nasdaq.com/articles/novartis-presents-data-on-multiple-sclerosis-drug-gilenya-analyst-blog-2014-09-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-ties-infinity-keryx-slips-fda-approval-analyst-blog-2014-09", "https://www.nasdaq.com/articles/why-receptos-inc-shares-rocketed-higher-2014-09-10", "https://www.nasdaq.com/articles/5-things-biogen-idec-incs-management-wants-you-know-2014-09-03", "https://www.nasdaq.com/articles/ibb-celg-biib-alxn-etf-outflow-alert-2014-09-02", "https://www.nasdaq.com/articles/data-on-celgenes-revlimid-published-in-oncology-journal-analyst-blog-2014-08-22", "https://www.nasdaq.com/articles/what-investors-gain-from-large-mid-small-cap-growth-funds-mutual-fund-commentary-2014-08", "https://www.nasdaq.com/articles/biogen-reports-positive-two-year-data-on-ms-drug-plegridy-analyst-blog-2014-09-12", "https://www.nasdaq.com/articles/novartis-presents-data-on-multiple-sclerosis-drug-gilenya-analyst-blog-2014-09-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-ties-infinity-keryx-slips-fda-approval-analyst-blog-2014-09", "https://www.nasdaq.com/articles/why-receptos-inc-shares-rocketed-higher-2014-09-10", "https://www.nasdaq.com/articles/5-things-biogen-idec-incs-management-wants-you-know-2014-09-03", "https://www.nasdaq.com/articles/ibb-celg-biib-alxn-etf-outflow-alert-2014-09-02", "https://www.nasdaq.com/articles/biotech-etf-price-swings-may-signal-need-caution-2014-07-28", "https://www.nasdaq.com/articles/abbvie-q2-earnings-top-on-humira-sales-shire-in-focus-analyst-blog-2014-07-25", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-iyh-amgn-biib-celg-2014-08-19", "https://www.nasdaq.com/articles/biogen-strengthens-ms-portfolio-plegridy-fda-approval-analyst-blog-2014-08-19", "https://www.nasdaq.com/articles/perrigo-beats-on-q4-earnings-and-sales-provides-guidance-analyst-blog-2014-08-14", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-august-12-2014-2014-08-11", "https://www.nasdaq.com/articles/sp-500-analyst-moves-biib-2014-08-11", "https://www.nasdaq.com/articles/increased-earnings-estimates-seen-for-biogen-idec-biib%3A-can-it-move-higher-tale-of-the", "https://www.nasdaq.com/articles/biotech-etf-price-swings-may-signal-need-caution-2014-07-28", "https://www.nasdaq.com/articles/abbvie-q2-earnings-top-on-humira-sales-shire-in-focus-analyst-blog-2014-07-25", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-iyh-amgn-biib-celg-2014-08-19", "https://www.nasdaq.com/articles/celsion-clsn-in-focus%3A-stock-adds-5.3-in-session-tale-of-the-tape-2014-07-25", "https://www.nasdaq.com/articles/agenus-inc.-agen-looks-strong-as-stock-surges-11.15-tale-of-the-tape-2014-07-25", "https://www.nasdaq.com/articles/celgene-beats-q2-earnings-estimates-on-strong-revlimid-sales-analyst-blog-2014-07-25", "https://www.nasdaq.com/articles/illumina-ilmn-tops-q2-earnings-revenues-ups-guidance-analyst-blog-2014-07-24", "https://www.nasdaq.com/articles/iyh-pfe-abbv-biib-large-outflows-detected-etf-2014-07-24", "https://www.nasdaq.com/articles/stock-market-news-for-july-24-2014-market-news-2014-07-24", "https://www.nasdaq.com/articles/gilead-crushes-q2-earnings-estimates-as-sovaldi-sales-soar-analyst-blog-2014-07-24", "https://www.nasdaq.com/articles/exelixis-exel-jumps%3A-stock-adds-11.4-in-session-tale-of-the-tape-2014-07-25", "https://www.nasdaq.com/articles/celsion-clsn-in-focus%3A-stock-adds-5.3-in-session-tale-of-the-tape-2014-07-25", "https://www.nasdaq.com/articles/agenus-inc.-agen-looks-strong-as-stock-surges-11.15-tale-of-the-tape-2014-07-25", "https://www.nasdaq.com/articles/celgene-beats-q2-earnings-estimates-on-strong-revlimid-sales-analyst-blog-2014-07-25", "https://www.nasdaq.com/articles/illumina-ilmn-tops-q2-earnings-revenues-ups-guidance-analyst-blog-2014-07-24", "https://www.nasdaq.com/articles/iyh-pfe-abbv-biib-large-outflows-detected-etf-2014-07-24", "https://www.nasdaq.com/articles/stock-market-news-for-july-24-2014-market-news-2014-07-24", "https://www.nasdaq.com/articles/gilead-crushes-q2-earnings-estimates-as-sovaldi-sales-soar-analyst-blog-2014-07-24", "https://www.nasdaq.com/articles/exelixis-exel-jumps%3A-stock-adds-11.4-in-session-tale-of-the-tape-2014-07-25", "https://www.nasdaq.com/articles/the-medicines-co.s-mdco-q2-earnings-decline-y-y-analyst-blog-2014-07-24", "https://www.nasdaq.com/articles/array-biopharma-inc.-arry-jumps%3A-stock-surges-10.7-higher-tale-of-the-tape-2014-07-24", "https://www.nasdaq.com/articles/biogen-idec-biib-soars%3A-stock-adds-11.2-in-session-tale-of-the-tape-2014-07-24", "https://www.nasdaq.com/articles/ucbs-brivaracetam-positive-in-phase-iii-epilepsy-study-analyst-blog-2014-07-24", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-q2-earnings-in-line-revises-view-analyst-blog-2014-07-24", "https://www.nasdaq.com/articles/actelion-beats-on-q2-earnings-and-sales-revises-view-analyst-blog-2014-07-24", "https://www.nasdaq.com/articles/midday-update-stocks-mixed-techs-biotechs-buoying-nasdaq-geo-political-tensions-dogging", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-thursday-tale-of-the-tape-2014-07-24", "https://www.nasdaq.com/articles/nasdaq-100-movers-xlnx-isrg-2014-07-23", "https://www.nasdaq.com/articles/markets-mixed-pepsico-q2-earnings-beat-street-view-2014-07-23", "https://www.nasdaq.com/articles/healthcare-spending-uptrend%3A-3-medical-stocks-for-strong-growth-analyst-blog-2014-07-23", "https://www.nasdaq.com/articles/avanir-to-conduct-phase-ii-study-on-avp-786-for-depression-analyst-blog-2014-07-23", "https://www.nasdaq.com/articles/closing-update-blue-chips-decline-broader-indices-extend-gains-mostly-positive-earnings", "https://www.nasdaq.com/articles/isis-pharma-initiates-phase-ii-study-on-isis-apoa-analyst-blog-2014-07-21", "https://www.nasdaq.com/articles/alkermes-pipeline-development-impresses-key-updates-ahead-analyst-blog-2014-07-21", "https://www.nasdaq.com/articles/biogens-q2-earnings-surpass-expectations-tecfidera-shines-analyst-blog-2014-07-23", "https://www.nasdaq.com/articles/bristol-myers-to-seek-u.s.-approval-for-immuno-oncology-drug-analyst-blog-2014-07-11", "https://www.nasdaq.com/articles/oncolytics-up-on-patient-enrolment-completion-analyst-blog-2014-07-11", "https://www.nasdaq.com/articles/celgenes-otezla-disappoints-in-ankylosing-spondylitis-study-analyst-blog-2014-07-10", "https://www.nasdaq.com/articles/lexicon-lxrx-jumps%3A-stock-moves-7.6-higher-tale-of-the-tape-2014-07-10", "https://www.nasdaq.com/articles/alexion-pharma-looks-life-beyond-its-blockbuster-2014-07-08", "https://www.nasdaq.com/articles/bind-therapeutics-bind-in-focus%3A-stock-tumbles-10.0-tale-of-the-tape-2014-07-07", "https://www.nasdaq.com/articles/ucb-dermira-sign-cimzia-dermatology-deal-analyst-blog-2014-07-07", "https://www.nasdaq.com/articles/bristol-myers-gains-japanese-approval-for-hcv-combo-drug-analyst-blog-2014-07-08", "https://www.nasdaq.com/articles/biodelivery-sciences-international-bdsi-rises%3A-stock-jumps-8.9-tale-of-the-tape-2014-07-08", "https://www.nasdaq.com/articles/oncolytics-biotech-inc.-oncy-in-focus%3A-stock-rises-9.5-tale-of-the-tape-2014-07-08", "https://www.nasdaq.com/articles/sanofi-and-curevac-ink-vaccine-deal-analyst-blog-2014-07-03", "https://www.nasdaq.com/articles/regeneron-shares-jump-as-sanofi-increases-stake-analyst-blog-2014-07-02", "https://www.nasdaq.com/articles/strength-seen-in-amicus-therapeutics-inc.-fold-as-stock-rallies-19.46-tale-of-the-tape", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-up-on-kalydeco-snda-submission-analyst-blog-2014-07-02", "https://www.nasdaq.com/articles/amgen-gets-breakthrough-therapy-status-for-leukemia-drug-analyst-blog-2014-07-02", "https://www.nasdaq.com/articles/integra-upbeat-on-duraseal-acquisition-despite-tepid-q1-analyst-blog-2014-07-07", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-jumps%3A-stock-rises-6.4-tale-of-the-tape-2014-07-01", "https://www.nasdaq.com/articles/illumina-expands-in-europe-on-3-nipt-deals-analyst-blog-2014-07-01", "https://www.nasdaq.com/articles/synagevas-sebelipase-alfa-meets-primary-endpoint-in-arise-analyst-blog-2014-07-01", "https://www.nasdaq.com/articles/ucbs-vimpat-positive-for-partial-onset-seizures-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/discovery-laboratories-inc.-dsco-in-focus%3A-stock-rises-7.83-tale-of-the-tape-2014-06-30", "https://www.nasdaq.com/articles/integra-lifesciences-down-to-sell-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/eli-lilly-boehringers-insulin-copy-gets-positive-eu-opinion-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/nps-pharmaceuticals-gattex-gets-updated-label-analyst-blog-2014-07-01", "https://www.nasdaq.com/articles/biodelivery-progresses-with-clonidine-late-stage-study-analyst-blog-2014-06-27", "https://www.nasdaq.com/articles/bristol-myers-up-on-nivolumab-news-analyst-blog-2014-06-26", "https://www.nasdaq.com/articles/prothena-corporation-prta-falls%3A-stock-goes-down-5.3-tale-of-the-tape-2014-06-26", "https://www.nasdaq.com/articles/auxilium-sobis-xiapex-filed-for-label-expansion-analyst-blog-2014-06-26", "https://www.nasdaq.com/articles/isis-pharma-gets-%241m-milestone-payment-from-glaxo-analyst-blog-2014-06-25", "https://www.nasdaq.com/articles/ligand-pharma-tg-therapeutics-collaborate-on-irak4-inhibitors-analyst-blog-2014-06-25", "https://www.nasdaq.com/articles/xenoports-xp23829-in-phase-ii-study-analyst-blog-2014-06-24", "https://www.nasdaq.com/articles/coronado-falls-on-tso-study-results-analyst-blog-2014-06-27", "https://www.nasdaq.com/articles/biotech-stock-roundup-hcv-back-focus-idenix-achillion-soar-analyst-blog-2014-06-18", "https://www.nasdaq.com/articles/merck-kgaa-ono-pharma-deal-ends-analyst-blog-2014-06-18", "https://www.nasdaq.com/articles/biogen-abbvie-presents-positive-data-on-daclizumab-analyst-blog-2014-06-18", "https://www.nasdaq.com/articles/sector-update-share-higher-pre-market-gw-pharmaceuticals-rallies-6-results-study-epilepsy", "https://www.nasdaq.com/articles/sector-update-healthcare-healthcare-2014-06-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-hemophilia-drug-approved-ariad-halozyme-clinical-hold-lifted", "https://www.nasdaq.com/articles/isis-pharma-earns-milestone-payment-on-study-initiation-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/stocks-upgraded-broker-ratings-screen-week-2014-06-24", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-adsk-2014-06-06", "https://www.nasdaq.com/articles/stock-market-news-for-june-05-2014-market-news-2014-06-05", "https://www.nasdaq.com/articles/sp-500-movers-kors-tsn-2014-05-29", "https://www.nasdaq.com/articles/nasdaq-100-movers-gmcr-biib-2014-05-29", "https://www.nasdaq.com/articles/array-biopharma-collaborates-with-biogen-analyst-blog-2014-05-29", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsla-mu-2014-05-28", "https://www.nasdaq.com/articles/chmp-still-negative-on-teva-active-biotechs-nerventra-analyst-blog-2014-05-27", "https://www.nasdaq.com/articles/biogens-eloctate-approved-in-the-u.s.-analyst-blog-2014-06-09", "https://www.nasdaq.com/articles/celgene-gains-slightly-on-management-changes-analyst-blog-2014-05-23", "https://www.nasdaq.com/articles/ishares-russell-1000-etf-experiences-big-inflow-2014-05-14", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-aveo-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/infinity-pharma-down-on-wider-than-expected-loss-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/isis-pharmas-q1-loss-widens-analyst-blog-2014-05-07", "https://www.nasdaq.com/articles/perrigo-misses-on-earnings-and-sales-outlook-slashed-analyst-blog-2014-05-07", "https://www.nasdaq.com/articles/is-perrigo-prgo-poised-to-beat-earnings-estimates-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/nasdaq-100-plays-catch-real-time-insight-2014-05-27", "https://www.nasdaq.com/articles/acorda-down-on-plumiaz-crl-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/3-biotech-beats-this-earnings-season-earnings-esp-2014-05-01", "https://www.nasdaq.com/articles/ebay-now-57-largest-company-surpassing-biogen-idec-2014-04-25", "https://www.nasdaq.com/articles/sp-500-movers-xlnx-zmh-2014-04-24", "https://www.nasdaq.com/articles/stock-market-news-for-april-24-2014-market-news-2014-04-24", "https://www.nasdaq.com/articles/spectrum-pharma-candidate-gets-positive-data-analyst-blog-2014-04-24", "https://www.nasdaq.com/articles/amgens-q1-earnings-decline-y-y-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-wynn-gild-2014-05-05", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-biogen-q1-results-fy-2014-guidance-2014-04", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-23", "https://www.nasdaq.com/articles/healthcare-stocks-snap-recent-winning-streak-biogen-idec-slips-underwater-late-after-eps", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-23-0", "https://www.nasdaq.com/articles/biogens-q1-earnings-soar-y-y-on-tecfidera-sales-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/keep-an-eye-on-these-3-biotech-stocks-earnings-esp-2014-04-22", "https://www.nasdaq.com/articles/alexion-likely-to-keep-earnings-streak-alive-analyst-blog-2014-04-22", "https://www.nasdaq.com/articles/revance-therapeutics-rvnc-soars%3A-stock-up-25.8-tale-of-the-tape-2014-04-23", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-tuesday-tale-of-the-tape-2014-04-22", "https://www.nasdaq.com/articles/ken-fishers-top-increases-first-quarter-2014-04-22", "https://www.nasdaq.com/articles/is-biogen-biib-poised-to-beat-earnings-estimates-analyst-blog-2014-04-22", "https://www.nasdaq.com/articles/sarepta-soars-on-eteplirsen-submission-plans-analyst-blog-2014-04-22", "https://www.nasdaq.com/articles/pre-market-earnings-report-april-23-2014-pg-ba-biib-dow-emc-tmo-eric-px-gd-nsc-jci-rai", "https://www.nasdaq.com/articles/will-gilead-gild-beat-q1-earnings-analyst-blog-2014-04-21", "https://www.nasdaq.com/articles/will-amgen-amgn-miss-this-earnings-season-analyst-blog-2014-04-21", "https://www.nasdaq.com/articles/cytokinetics-incorporated-cytk-jumps%3A-stock-up-13.5-tale-of-the-tape-2014-04-22", "https://www.nasdaq.com/articles/biotech-stock-roundup-mannkind-pdufa-date-pushed-out-alkermes-impresses-data-analyst-blog", "https://www.nasdaq.com/articles/will-abbott-labs-abt-disappoint-this-quarter-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/gilead-bucks-biotech-trend-thanks-to-sovaldi-news-analyst-blog-2014-04-14", "https://www.nasdaq.com/articles/will-johnson-johnson-jnj-miss-this-earnings-season-analyst-blog-2014-04-14", "https://www.nasdaq.com/articles/positive-data-on-biogen-sobis-eloctate-analyst-blog-2014-04-11", "https://www.nasdaq.com/articles/next-chapter-acorda-story-will-be-page-turner-2014-04-10", "https://www.nasdaq.com/articles/3-top-ranked-biotech-stocks-rebound-analyst-blog-2014-04-10", "https://www.nasdaq.com/articles/abbvie-candidate-in-pivotal-study-analyst-blog-2014-04-17", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ibb-amgn-biib-alxn-2014-04-03", "https://www.nasdaq.com/articles/stock-market-news-for-march-31-2014-market-news-2014-03-31", "https://www.nasdaq.com/articles/fda-nod-for-biogens-alprolix-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/ibb-biib-amgn-regn-etf-outflow-alert-2014-03-26", "https://www.nasdaq.com/articles/biotech-stock-roundup-gild-letter-triggers-major-selloff-analyst-blog-2014-03-26", "https://www.nasdaq.com/articles/stock-market-news-for-march-24-2014-market-news-2014-03-24", "https://www.nasdaq.com/articles/biogens-alprolix-approved-in-canada-analyst-blog-2014-03-24", "https://www.nasdaq.com/articles/momentum-slide-continue-netflix-facebook-analyst-blog-2014-04-07", "https://www.nasdaq.com/articles/aveo-regains-av-203-rights-from-biogen-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/healthcare-stocks-mixed-mid-day-endocyte-nearly-doubles-price-chemotherapy-test-results", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-03-21-0", "https://www.nasdaq.com/articles/biogen-entry-sp-100-puts-oef-focus-etf-news-and-commentary-2014-03-20", "https://www.nasdaq.com/articles/stock-market-news-for-march-19-2014-market-news-2014-03-19", "https://www.nasdaq.com/articles/biogen-faces-delay-in-fda-action-date-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-sp100-geron-plunges-clinical-hold-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/3-etfs-tumble-most-biotech-sell-etf-news-and-commentary-2014-03-24", "https://www.nasdaq.com/articles/aveo-regains-av-203-rights-from-biogen-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/healthcare-stocks-mixed-mid-day-endocyte-nearly-doubles-price-chemotherapy-test-results", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-03-21-0", "https://www.nasdaq.com/articles/biogen-entry-sp-100-puts-oef-focus-etf-news-and-commentary-2014-03-20", "https://www.nasdaq.com/articles/stock-market-news-for-march-19-2014-market-news-2014-03-19", "https://www.nasdaq.com/articles/biogen-faces-delay-in-fda-action-date-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/multistem-overshadows-q4-loss-at-athersys-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-novogen-soars-19-positive-outlook-anti", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-03-18-1", "https://www.nasdaq.com/articles/biogen-to-be-added-to-sp100-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/nasdaq-100-movers-ilmn-yhoo-2014-03-17", "https://www.nasdaq.com/articles/mondays-etf-movers-fbt-gdx-2014-03-17", "https://www.nasdaq.com/articles/sp-500-movers-vrsn-biib-2014-03-17", "https://www.nasdaq.com/articles/aveo-q4-loss-narrower-than-expected-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/multistem-overshadows-q4-loss-at-athersys-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-novogen-soars-19-positive-outlook-anti", "https://www.nasdaq.com/articles/wider-q4-loss-at-keryx-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-regeneron-slide-pcsk9-inhibitor-concerns-analyst-blog-2014-03", "https://www.nasdaq.com/articles/myriad-genetics-down-on-court-ruling-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/alexion-lifts-2014-view-shares-up-analyst-blog-2014-03-11", "https://www.nasdaq.com/articles/biogen-upgraded-to-strong-buy-analyst-blog-2014-03-10", "https://www.nasdaq.com/articles/ibb-biib-amgn-regn-etf-outflow-alert-2014-03-10", "https://www.nasdaq.com/articles/aegerion-pharmaceuticals-aegr-soars%3A-stock-rises-10.6-tale-of-the-tape-2014-03-10", "https://www.nasdaq.com/articles/fate-therapeutics-prohema-in-phase-ii-study-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/emergent-beats-on-earnings-revenues-shares-up-analyst-blog-2014-03-10", "https://www.nasdaq.com/articles/intermune-rises-on-takeover-rumor-analyst-blog-2014-03-10", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-intu-2014-03-07", "https://www.nasdaq.com/articles/sangamo-soars-on-positive-data-analyst-blog-2014-03-07", "https://www.nasdaq.com/articles/pipeline-setback-overshadows-xomas-q4-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-wednesday-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/sunesis-snss-jumps%3A-stock-moves-6.8-higher-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/nasdaq-100-movers-spls-bidu-2014-03-06", "https://www.nasdaq.com/articles/oncothyreon-onty-jumps%3A-stock-moves-9.9-higher-tale-of-the-tape-2014-03-06", "https://www.nasdaq.com/articles/biogen-eisai-ink-alzheimers-deal-analyst-blog-2014-03-06", "https://www.nasdaq.com/articles/update-on-alexions-soliris-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/dynavax-receives-milestone-payments-from-astrazeneca-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/pipeline-setback-overshadows-xomas-q4-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-wednesday-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/sunesis-snss-jumps%3A-stock-moves-6.8-higher-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/ovascience-ovas-in-focus%3A-stock-tanks-9.5-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/isis-pharmaceuticals-inc.-isis-in-focus%3A-stock-up-8.9-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/promising-data-on-merck-allergy-drug-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/profit-orphan-drugs-3-choices-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/dendreon-corp.-dndn-soars%3A-stock-rises-14.9-tale-of-the-tape-2014-03-04", "https://www.nasdaq.com/articles/top-mutual-funds-add-health-care-leisure-and-banks-2014-03-04", "https://www.nasdaq.com/articles/myriad-genetics-up-on-prolaris-data-aims-reimbursement-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/transition-therapeutics-tthi-jumps%3A-stock-moves-7.6-higher-tale-of-the-tape-2014-03-03", "https://www.nasdaq.com/articles/ovascience-ovas-in-focus%3A-stock-tanks-9.5-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/biogen-keeps-momentum-going-ms-drug-tecfidera-2014-03-03", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ibb-biib-gild-amgn-2014-02-28", "https://www.nasdaq.com/articles/medivation-swings-to-earnings-in-q4-analyst-blog-2014-02-28", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-friday-tale-of-the-tape-2014-02-28", "https://www.nasdaq.com/articles/synta-pharmaceuticals-snta-catches-eye%3A-stock-rises-8.9-tale-of-the-tape-2014-02-25", "https://www.nasdaq.com/articles/standard-review-for-mercks-v503-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/orphan-drug-status-for-xomas-gevokizumab-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/shares-fall-as-aegerion-posts-wider-than-expected-loss-analyst-blog-2014-02-27", "https://www.nasdaq.com/articles/oncothyreon-inc.-onty-in-focus%3A-stock-up-9.3-tale-of-the-tape-2014-02-26", "https://www.nasdaq.com/articles/intermune-soars-on-positive-esbriet-data-analyst-blog-2014-02-26", "https://www.nasdaq.com/articles/enter-biosimilars-3-stock-picks-analyst-blog-2014-02-26", "https://www.nasdaq.com/articles/endocytes-q4-loss-narrower-than-expected-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/amarins-vascepa-gets-3-year-exclusivity-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/isis-pharma-soars-on-positive-data-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/xenoports-4q-loss-narrower-than-expected-analyst-blog-2014-02-21", "https://www.nasdaq.com/articles/progenics-to-raise-funds-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-biogen-idec-biib-tale-of-the-tape-2014-02-24", "https://www.nasdaq.com/articles/stemline-therapeutics-stml-worth-watching%3A-stock-rises-8.1-tale-of-the-tape-2014-02-24", "https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-jumps%3A-stock-rises-17.3-tale-of-the-tape-2014-02-24", "https://www.nasdaq.com/articles/pipeline-progress-at-pluristem-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/discovery-laboratories-dsco-soars%3A-stock-rises-8.9-tale-of-the-tape-2014-02-19", "https://www.nasdaq.com/articles/chtps-northera-gains-fda-approval-analyst-blog-2014-02-19", "https://www.nasdaq.com/articles/oncomed-commences-study-on-omp-54f28-analyst-blog-2014-02-21", "https://www.nasdaq.com/articles/positive-opinion-on-isis-pharmas-isis-ttrrx-analyst-blog-2014-02-18", "https://www.nasdaq.com/articles/vanda-reports-wider-than-expected-loss-analyst-blog-2014-02-18", "https://www.nasdaq.com/articles/acorda-up-after-q4-earnings-analyst-blog-2014-02-18", "https://www.nasdaq.com/articles/chelsea-therapeutics-chtp-in-focus%3A-stock-tumbles-7.5-tale-of-the-tape-2014-02-14", "https://www.nasdaq.com/articles/positive-news-for-regados-reg2-analyst-blog-2014-02-14", "https://www.nasdaq.com/articles/additional-data-on-omeros-oms824-analyst-blog-2014-02-14", "https://www.nasdaq.com/articles/vical-q4-loss-narrows-analyst-blog-2014-02-13", "https://www.nasdaq.com/articles/myriad-genetics-unveils-prolaris-data-analyst-blog-2014-02-19", "https://www.nasdaq.com/articles/ibb-gild-biib-amgn-large-inflows-detected-etf-2014-02-11", "https://www.nasdaq.com/articles/newlink-genetics-nlnk-jumps%3A-stock-rises-8.3-tale-of-the-tape-2014-02-11", "https://www.nasdaq.com/articles/sunesis-pharmaceuticals-snss-falls%3A-stock-goes-down-5.4-tale-of-the-tape-2014-02-11", "https://www.nasdaq.com/articles/data-on-repros-androxal-analyst-blog-2014-02-11", "https://www.nasdaq.com/articles/three-etfs-buy-pullback-pjp-skyy-spy-2014-02-10", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-11-2014-2014-02-10", "https://www.nasdaq.com/articles/why-you-need-to-pay-attention-to-cambrex-corporation.-cbm-stock-tale-of-the-tape-2014-02", "https://www.nasdaq.com/articles/what-makes-genomic-health-ghdx-a-strong-sell-tale-of-the-tape-2014-02-13", "https://www.nasdaq.com/articles/affymetrix-slips-to-hold-analyst-blog-2014-02-10", "https://www.nasdaq.com/articles/teva-beats-on-q4-earnings-revs-affirms-view-analyst-blog-2014-02-07", "https://www.nasdaq.com/articles/fda-to-review-spectrum-pharma-beleodaq-analyst-blog-2014-02-07", "https://www.nasdaq.com/articles/affymetrix-sees-turnaround-quarter-but-earnings-miss-analyst-blog-2014-02-06", "https://www.nasdaq.com/articles/acquisition-and-earnings-beat-lift-myriad-shares-analyst-blog-2014-02-06", "https://www.nasdaq.com/articles/medicines-co.-awarded-barda-contract-analyst-blog-2014-02-06", "https://www.nasdaq.com/articles/pernix-appoints-new-ceo-shares-up-analyst-blog-2014-02-06", "https://www.nasdaq.com/articles/puma-biotech-surges-favorable-patent-ruling-analyst-blog-2014-02-10", "https://www.nasdaq.com/articles/affymetrix-slips-to-hold-analyst-blog-2014-02-10", "https://www.nasdaq.com/articles/q4-loss-narrower-than-expected-at-genomic-revs-up-y-y-analyst-blog-2014-02-05", "https://www.nasdaq.com/articles/study-on-pluristems-placental-cells-analyst-blog-2014-02-04", "https://www.nasdaq.com/articles/is-perrigo-prgo-poised-to-beat-earnings-estimates-analyst-blog-2014-02-04", "https://www.nasdaq.com/articles/safely-playing-biotech-sector-2014-02-03", "https://www.nasdaq.com/articles/biogen-idec-winner-even-if-everyone-knows-it-2014-02-03", "https://www.nasdaq.com/articles/intermune-itmn-in-focus%3A-stock-tumbles-17.9-tale-of-the-tape-2014-02-03", "https://www.nasdaq.com/articles/earnings-beat-at-perrigo-guides-up-analyst-blog-2014-02-06", "https://www.nasdaq.com/articles/3-reasons-biotech-stock-advance-continue-2014-02-03", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-friday-tale-of-the-tape-2014-01-31", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-teva-pharmaceuticals-4-fda-approval", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-01-29-1", "https://www.nasdaq.com/articles/fda-nod-for-new-formulation-of-tevas-copaxone-analyst-blog-2014-01-29", "https://www.nasdaq.com/articles/will-affymetrix-affx-surprise-this-earnings-season-analyst-blog-2014-01-29", "https://www.nasdaq.com/articles/biogen-beats-tecfidera-continues-to-shine-analyst-blog-2014-01-29", "https://www.nasdaq.com/articles/guidance-update-from-actavis-analyst-blog-2014-02-03", "https://www.nasdaq.com/articles/will-celgene-celg-miss-this-earnings-season-analyst-blog-2014-01-28", "https://www.nasdaq.com/articles/pfizer-tops-earnings-revs-guides-line-analyst-blog-2014-01-28", "https://www.nasdaq.com/articles/pre-market-earnings-report-january-29-2014-ba-biib-dow-emc-psx-px-so-vlo-hes-mpc-wlp-nvs", "https://www.nasdaq.com/articles/is-biogen-biib-poised-to-beat-earnings-estimates-analyst-blog-2014-01-28", "https://www.nasdaq.com/articles/will-amgen-amgn-miss-this-earnings-season-analyst-blog-2014-01-27", "https://www.nasdaq.com/articles/teva-falls-on-negative-chmp-opinion-analyst-blog-2014-01-27", "https://www.nasdaq.com/articles/will-pfizer-pfe-miss-this-earnings-season-analyst-blog-2014-01-27", "https://www.nasdaq.com/articles/will-alexions-alxn-earnings-streak-end-analyst-blog-2014-01-28", "https://www.nasdaq.com/articles/will-celgene-celg-miss-this-earnings-season-analyst-blog-2014-01-28", "https://www.nasdaq.com/articles/generic-unit-at-perrigo-looks-promising-analyst-blog-2014-01-17", "https://www.nasdaq.com/articles/acor-preliminary-q4-revs-look-good-analyst-blog-2014-01-14", "https://www.nasdaq.com/articles/can-biotech-repeat-2014-2014-01-14", "https://www.nasdaq.com/articles/sangamo-and-biogen-tie-up-analyst-blog-2014-01-13", "https://www.nasdaq.com/articles/biogen-idec-director-sells-15000-shares-2014-01-10", "https://www.nasdaq.com/articles/a-new-ceo-for-teva-analyst-blog-2014-01-10", "https://www.nasdaq.com/articles/will-bristol-myers-bmy-beat-q4-earnings-analyst-blog-2014-01-23", "https://www.nasdaq.com/articles/notice-of-allowance-received-by-alkermes-analyst-blog-2014-01-07", "https://www.nasdaq.com/articles/perrigo-maintained-at-neutral-analyst-blog-2014-01-03", "https://www.nasdaq.com/articles/never-ever-sell-these-stocks-2013-12-31", "https://www.nasdaq.com/articles/positive-data-on-infinity-pharma-candidate-analyst-blog-2013-12-10", "https://www.nasdaq.com/articles/biogen-idec-inc-biib-new-analyst-report-zacks-equity-research-zacks-equity-research-report", "https://www.nasdaq.com/articles/biotech-stock-roundup-cbst-hits-52-week-high-orex-lights-analyst-blog-2013-12-04", "https://www.nasdaq.com/articles/biogens-hemophilia-b-drug-approval-delayed-analyst-blog-2013-12-03", "https://www.nasdaq.com/articles/mid-day-market-update-us-stocks-turn-red-bed-bath-beyond-shares-decline-weak-q3-earnings", "https://www.nasdaq.com/articles/notice-of-allowance-received-by-alkermes-analyst-blog-2014-01-07", "https://www.nasdaq.com/articles/perrigo-maintained-at-neutral-analyst-blog-2014-01-03", "https://www.nasdaq.com/articles/never-ever-sell-these-stocks-2013-12-31", "https://www.nasdaq.com/articles/cubist-hoists-biotech-etfs-nose-bleed-levels-2013-11-25", "https://www.nasdaq.com/articles/midday-update-stocks-holding-slim-gains-intel-drops-downbeat-2014-sales-forecast-2013-11", "https://www.nasdaq.com/articles/dow-consolidating-above-16000fighting-extend-gains-seventh-straight-week-2013-11-22", "https://www.nasdaq.com/articles/safe-way-win-biotech-growth-2013-12-02", "https://www.nasdaq.com/articles/qiagen-eli-lilly-expand-partnership-analyst-blog-2013-11-19", "https://www.nasdaq.com/articles/isis-pharma-posts-lower-q3-loss-analyst-blog-2013-11-06", "https://www.nasdaq.com/articles/acorda-down-on-q3-earnings-analyst-blog-2013-11-04", "https://www.nasdaq.com/articles/tevas-earnings-overshadowed-by-ceo-exit-analyst-blog-2013-11-01", "https://www.nasdaq.com/articles/perrigo-beats-both-on-earnings-and-revs-analyst-blog-2013-10-31", "https://www.nasdaq.com/articles/teva-slumps-on-ceo-departure-analyst-blog-2013-10-31", "https://www.nasdaq.com/articles/bull-day-pharmacyclics-pcyc-bull-day-2013-10-31", "https://www.nasdaq.com/articles/biotech-stock-roundup-vanda-soars-sarepta-slumps-analyst-blog-2013-11-20", "https://www.nasdaq.com/articles/stock-downgrades-crocs-takes-walk-wild-side-2013-10-28", "https://www.nasdaq.com/articles/premarket-primer-monday-october-28-all-eyes-apple-2013-10-28", "https://www.nasdaq.com/articles/earnings-revs-beat-from-biogen-ups-view-again-analyst-blog-2013-10-28", "https://www.nasdaq.com/articles/elan-narrows-q3-loss-analyst-blog-2013-10-25", "https://www.nasdaq.com/articles/is-biogen-biib-poised-to-beat-earnings-estimates-analyst-blog-2013-10-25", "https://www.nasdaq.com/articles/trading-radar-backlogged-economic-data-catches-market-apple-facebook-earnings-way-2013-10", "https://www.nasdaq.com/articles/benzinga-weekly-preview-fomc-meeting-closely-watched-2013-10-25", "https://www.nasdaq.com/articles/company-news-for-october-29-2013-corporate-summary-2013-10-29", "https://www.nasdaq.com/articles/is-mckesson-corporation-mck-poised-to-beat-earnings-analyst-blog-2013-10-23", "https://www.nasdaq.com/articles/fda-approves-novo-nordisks-novoeight-analyst-blog-2013-10-18", "https://www.nasdaq.com/articles/another-milestone-for-isis-pharma-analyst-blog-2013-10-17", "https://www.nasdaq.com/articles/acordas-label-expansion-efforts-analyst-blog-2013-10-16", "https://www.nasdaq.com/articles/earnings-preview-will-abbott-labs-abt-disappoint-q3-analyst-blog-2013-10-15", "https://www.nasdaq.com/articles/can-johnson-johnson-jnj-keep-the-earnings-streak-alive-analyst-blog-2013-10-14", "https://www.nasdaq.com/articles/update-on-sanofis-aubagio-analyst-blog-2013-10-09", "https://www.nasdaq.com/articles/pre-market-earnings-report-october-28-2013-mrk-biib-l-rop-cna-ew-bwp-bkw-kex-ahgp-awi-ten", "https://www.nasdaq.com/articles/is-mckesson-corporation-mck-poised-to-beat-earnings-analyst-blog-2013-10-23", "https://www.nasdaq.com/articles/fda-approves-novo-nordisks-novoeight-analyst-blog-2013-10-18", "https://www.nasdaq.com/articles/another-milestone-for-isis-pharma-analyst-blog-2013-10-17", "https://www.nasdaq.com/articles/acordas-label-expansion-efforts-analyst-blog-2013-10-16", "https://www.nasdaq.com/articles/earnings-preview-will-abbott-labs-abt-disappoint-q3-analyst-blog-2013-10-15", "https://www.nasdaq.com/articles/can-johnson-johnson-jnj-keep-the-earnings-streak-alive-analyst-blog-2013-10-14", "https://www.nasdaq.com/articles/update-on-sanofis-aubagio-analyst-blog-2013-10-09", "https://www.nasdaq.com/articles/biotech-etfs-plummeting-xbi-ibb-bbh-2013-10-08", "https://www.nasdaq.com/articles/milestone-payment-for-isis-pharma-analyst-blog-2013-10-08", "https://www.nasdaq.com/articles/encouraging-data-on-novartis-gilenya-analyst-blog-2013-10-08", "https://www.nasdaq.com/articles/top-biotechnology-etf-in-focus%3A-pbe-etf-news-and-commentary-2013-10-04", "https://www.nasdaq.com/articles/pipeline-progress-at-biomarin-analyst-blog-2013-09-24", "https://www.nasdaq.com/articles/good-news-for-perrigos-generic-unit-analyst-blog-2013-09-24", "https://www.nasdaq.com/articles/strength-seen-in-isis-pharmaceuticals-isis%3A-stock-soars-14.1-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/positive-data-on-paciras-exparel-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/pipeline-progress-at-alexion-analyst-blog-2013-09-23", "https://www.nasdaq.com/articles/sarepta-therapeutics-srpt-worth-considering%3A-stock-surges-18.0-analyst-blog-2013-09-23", "https://www.nasdaq.com/articles/positive-chmp-opinion-for-nvo-candidate-analyst-blog-2013-09-23", "https://www.nasdaq.com/articles/repros-continues-to-climb-analyst-blog-2013-09-23", "https://www.nasdaq.com/articles/pipeline-progress-at-omeros-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/chmp-positive-on-gsk-thrx-candidate-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/strength-seen-in-isis-pharmaceuticals-isis%3A-stock-soars-14.1-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/actelion-acquires-ceptaris-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/relatively-small-gains-healthcare-stocks-compared-other-sectors-today-2013-09-18", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-09-18", "https://www.nasdaq.com/articles/encouraging-news-for-alexion-analyst-blog-2013-09-16", "https://www.nasdaq.com/articles/data-on-mdcos-oritavancin-analyst-blog-2013-09-16", "https://www.nasdaq.com/articles/pipeline-progress-at-gilead-analyst-blog-2013-09-16", "https://www.nasdaq.com/articles/new-phase-i-data-on-omeros-oms824-analyst-blog-2013-09-13", "https://www.nasdaq.com/articles/data-from-alexions-soliris-study-analyst-blog-2013-09-13", "https://www.nasdaq.com/articles/dendreons-provenge-cleared-in-the-eu-analyst-blog-2013-09-18", "https://www.nasdaq.com/articles/relatively-small-gains-healthcare-stocks-compared-other-sectors-today-2013-09-18", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-09-18", "https://www.nasdaq.com/articles/encouraging-news-for-alexion-analyst-blog-2013-09-16", "https://www.nasdaq.com/articles/data-on-mdcos-oritavancin-analyst-blog-2013-09-16", "https://www.nasdaq.com/articles/pipeline-progress-at-gilead-analyst-blog-2013-09-16", "https://www.nasdaq.com/articles/new-phase-i-data-on-omeros-oms824-analyst-blog-2013-09-13", "https://www.nasdaq.com/articles/data-from-alexions-soliris-study-analyst-blog-2013-09-13", "https://www.nasdaq.com/articles/dendreons-provenge-cleared-in-the-eu-analyst-blog-2013-09-18", "https://www.nasdaq.com/articles/positive-results-on-ventrus-candidate-shares-up-analyst-blog-2013-09-12", "https://www.nasdaq.com/articles/data-on-actelions-opsumit-analyst-blog-2013-09-12", "https://www.nasdaq.com/articles/company-news-for-september-10-2013-corporate-summary-2013-09-10", "https://www.nasdaq.com/articles/peregrine-reports-in-line-loss-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/sector-update-healthcare-edging-higher-pre-market-2013-09-10", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-09-10-0", "https://www.nasdaq.com/articles/rigel-pharma-trims-workforce-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/encouraging-data-on-xenoports-xp23829-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-koch-industries-acquire-molex-3850share-2013", "https://www.nasdaq.com/articles/sector-update-healthcare-flat-pre-bell-isis-pharmaceuticals-collaborates-biogen-2013-09-09", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-09-09-0", "https://www.nasdaq.com/articles/pipeline-progress-at-astrazeneca-analyst-blog-2013-09-09", "https://www.nasdaq.com/articles/bayer-looking-to-expand-in-russia-analyst-blog-2013-09-09", "https://www.nasdaq.com/articles/market-wrap-monday-september-9-nasdaq-bounces-13-year-high-2013-09-09", "https://www.nasdaq.com/articles/closing-update-stocks-pad-early-gains-after-syria-signals-possible-end-stand-over-chemical", "https://www.nasdaq.com/articles/glaxo-to-divest-lucozade-and-ribena-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-09-09", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-lead-nasdaq-various-health-names-drop-2013-09-09", "https://www.nasdaq.com/articles/healthcare-stocks-inching-higher-other-sectors-race-ahead-isis-pharma-10-biogen-co-op-pact", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-09-09-1", "https://www.nasdaq.com/articles/mid-day-market-update-dow-rises-over-100-points-apple-shares-gain-2013-09-09", "https://www.nasdaq.com/articles/setback-for-glaxos-cancer-pipeline-analyst-blog-2013-09-06", "https://www.nasdaq.com/articles/fda-licensure-for-merck-facility-analyst-blog-2013-09-06", "https://www.nasdaq.com/articles/healthcare-stocks-lagging-rest-market-oncolytics-biotech-jumps-positive-data-cancer-drug", "https://www.nasdaq.com/articles/endocyte-nihon-medi-physics-collaborate-analyst-blog-2013-09-06", "https://www.nasdaq.com/articles/myriads-decisive-test-now-available-analyst-blog-2013-09-06", "https://www.nasdaq.com/articles/amgen-cytokinetics-drug-misses-primary-endpoint-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/progress-on-ariads-iclusig-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/data-on-mdcos-cangrelor-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/good-news-for-chelsea-therapeutics-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/priority-review-for-takeda-candidate-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/bayers-stivarga-filed-in-the-eu-analyst-blog-2013-09-06", "https://www.nasdaq.com/articles/astellas-and-merck-collaborate-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/spectrum-pharma-launches-marqibo-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/pipeline-progress-at-elan-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/interim-phase-ii-data-on-isis-candidate-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/astrazeneca-reports-onglyza-data-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/new-data-on-actelions-opsumit-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/sanofis-aubagio-gets-eu-nod-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/myriad-astrazeneca-boost-alliance-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/astellas-and-merck-collaborate-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/spectrum-pharma-launches-marqibo-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/pipeline-progress-at-elan-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/simcere-to-go-private-analyst-blog-2013-08-29", "https://www.nasdaq.com/articles/orexigen-provides-contrave-update-analyst-blog-2013-08-28", "https://www.nasdaq.com/articles/bull-day-biogen-idec-biib-bull-day-2013-08-28", "https://www.nasdaq.com/articles/affymetrix-upped-to-outperform-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/data-on-actelions-opsumit-published-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/bayers-stivarga-cleared-in-the-eu-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/primecap-trims-top-biotechs-and-more-2013-08-30", "https://www.nasdaq.com/articles/actelion-inches-close-to-ceptaris-analyst-blog-2013-08-26", "https://www.nasdaq.com/articles/amgen-to-acquire-onyx-pharma-analyst-blog-2013-08-26", "https://www.nasdaq.com/articles/loss-narrows-at-immunomedics-analyst-blog-2013-08-26", "https://www.nasdaq.com/articles/amgen-to-present-data-at-esc-analyst-blog-2013-08-28", "https://www.nasdaq.com/articles/biogen-multiple-sclerosis-drug-may-become-blockbuster-2013-08-23", "https://www.nasdaq.com/articles/neutral-on-onyx-pharma-analyst-blog-2013-08-22", "https://www.nasdaq.com/articles/xoma-prices-offering-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/pipeline-setback-for-gtx-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-savient-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/repros-reports-androxal-interim-data-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/lannett-jerome-stevens-extend-contract-analyst-blog-2013-08-20", "https://www.nasdaq.com/articles/xoma-raises-funds-analyst-blog-2013-08-26", "https://www.nasdaq.com/articles/sizing-jackson-hole-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/swiss-approval-for-takeda-dainippons-latuda-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/ligand-curx-collaborate-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/beating-sp-2-1-2013-08-16", "https://www.nasdaq.com/articles/australia-approves-novartis-bexsero-analyst-blog-2013-08-16", "https://www.nasdaq.com/articles/apricus-loss-narrows-y-y-analyst-blog-2013-08-16", "https://www.nasdaq.com/articles/amgens-onyx-acquisition-could-be-delayed-analyst-blog-2013-08-16", "https://www.nasdaq.com/articles/update-on-chelseas-northera-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/sizing-jackson-hole-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/threshold-pharmas-th-302-in-melanoma-study-analyst-blog-2013-08-15", "https://www.nasdaq.com/articles/will-perrigo-company-prgo-beat-earnings-analyst-blog-2013-08-14", "https://www.nasdaq.com/articles/endp-to-offload-anatomical-pathology-unit-analyst-blog-2013-08-14", "https://www.nasdaq.com/articles/aveo-pharma-cuts-q2-loss-analyst-blog-2013-08-14", "https://www.nasdaq.com/articles/simcere-misses-earnings-estimates-in-q2-analyst-blog-2013-08-14", "https://www.nasdaq.com/articles/myriad-outstrips-q4-and-fy-earnings-estimates-analyst-blog-2013-08-14", "https://www.nasdaq.com/articles/eli-lilly-scores-with-necitumumab-analyst-blog-2013-08-15", "https://www.nasdaq.com/articles/earnings-beat-at-perrigo-in-q4-sales-dip-analyst-blog-2013-08-15", "https://www.nasdaq.com/articles/narrower-q2-loss-at-medivation-analyst-blog-2013-08-13", "https://www.nasdaq.com/articles/onyx-pharma-narrows-loss-in-q2-analyst-blog-2013-08-13", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-august-14-2013-2013-08-13", "https://www.nasdaq.com/articles/dendreon-cuts-loss-shares-fall-on-weak-guidance-analyst-blog-2013-08-12", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-nektar-analyst-blog-2013-08-12", "https://www.nasdaq.com/articles/osiris-up-on-grafix-data-analyst-blog-2013-08-14", "https://www.nasdaq.com/articles/major-setback-for-vical-analyst-blog-2013-08-13", "https://www.nasdaq.com/articles/loss-widens-at-repros-in-q2-analyst-blog-2013-08-13", "https://www.nasdaq.com/articles/narrower-q2-loss-at-medivation-analyst-blog-2013-08-13", "https://www.nasdaq.com/articles/xenoports-loss-widens-y-y-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/glaxo-seeks-votrient-label-expansion-in-eu-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-spectrum-pharma-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/affymetrix-rolls-out-advanced-assay-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/narrower-q2-loss-at-geron-analyst-blog-2013-08-12", "https://www.nasdaq.com/articles/rigel-pharma-narrows-q2-loss-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/endo-health-beats-on-earnings-revs.-in-q2-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/positive-data-on-bayer-regenerons-eye-drug-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/sanofis-vaccine-progresses-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/earnings-down-outlook-lowered-at-sanofi-analyst-blog-2013-08-06", "https://www.nasdaq.com/articles/approval-delayed-for-glaxo-drug-analyst-blog-2013-08-06", "https://www.nasdaq.com/articles/bayer-inks-oncology-deal-analyst-blog-2013-08-06", "https://www.nasdaq.com/articles/affymetrix-rise-on-turnaround-2q-earnings-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/anika-soars-on-strong-q2-results-analyst-blog-2013-08-05", "https://www.nasdaq.com/articles/affymetrix-sees-earnings-after-two-years-analyst-blog-2013-08-05", "https://www.nasdaq.com/articles/earnings-beat-at-astrazeneca-in-2q-analyst-blog-2013-08-02", "https://www.nasdaq.com/articles/earnings-beat-for-teva-analyst-blog-2013-08-02", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-optimer-analyst-blog-2013-08-02", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-amag-analyst-blog-2013-08-02", "https://www.nasdaq.com/articles/earnings-increase-at-bayer-in-2q-analyst-blog-2013-08-01", "https://www.nasdaq.com/articles/acorda-misses-on-earnings-by-a-penny-analyst-blog-2013-08-05", "https://www.nasdaq.com/articles/isis-earns-%242m-from-glaxo-analyst-blog-2013-07-31", "https://www.nasdaq.com/articles/benzinga-market-primer-friday-july-26-futures-flat-mixed-global-stocks-overnight-2013-07", "https://www.nasdaq.com/articles/breakeven-earnings-at-elan-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/benzinga-market-primer-thursday-july-25-futures-lower-after-technical-breakdown-2013-07-25", "https://www.nasdaq.com/articles/huge-earnings-beat-from-biogen-outlook-up-again-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/pre-market-earnings-report-july-25-2013-mmm-bmy-celg-cl-biib-gm-dow-pcp-pot-gg-siri-nbl", "https://www.nasdaq.com/articles/will-biogen-biib-beat-earnings-estimates-analyst-blog-2013-07-24", "https://www.nasdaq.com/articles/amgen-beats-on-earnings-revs-in-q2-analyst-blog-2013-07-31", "https://www.nasdaq.com/articles/isis-earns-%242m-from-glaxo-analyst-blog-2013-07-31", "https://www.nasdaq.com/articles/benzinga-market-primer-friday-july-26-futures-flat-mixed-global-stocks-overnight-2013-07", "https://www.nasdaq.com/articles/breakeven-earnings-at-elan-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/benzinga-market-primer-thursday-july-25-futures-lower-after-technical-breakdown-2013-07-25", "https://www.nasdaq.com/articles/huge-earnings-beat-from-biogen-outlook-up-again-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/pre-market-earnings-report-july-25-2013-mmm-bmy-celg-cl-biib-gm-dow-pcp-pot-gg-siri-nbl", "https://www.nasdaq.com/articles/will-biogen-biib-beat-earnings-estimates-analyst-blog-2013-07-24", "https://www.nasdaq.com/articles/amgen-beats-on-earnings-revs-in-q2-analyst-blog-2013-07-31", "https://www.nasdaq.com/articles/will-mckesson-corporation-mck-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-23", "https://www.nasdaq.com/articles/will-forest-labs-frx-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/will-eli-lilly-lly-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/will-alexion-alxn-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/will-amerisourcebergen-abc-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/pharmacyclics-seeks-us-approval-shares-soar-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/acorda-expands-pipeline-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/will-actavis-act-beat-earnings-estimates-analyst-blog-2013-07-24", "https://www.nasdaq.com/articles/will-mckesson-corporation-mck-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-23", "https://www.nasdaq.com/articles/will-forest-labs-frx-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/will-eli-lilly-lly-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/will-alexion-alxn-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/will-amerisourcebergen-abc-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/pharmacyclics-seeks-us-approval-shares-soar-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/acorda-expands-pipeline-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/will-actavis-act-beat-earnings-estimates-analyst-blog-2013-07-24", "https://www.nasdaq.com/articles/will-mckesson-corporation-mck-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-23", "https://www.nasdaq.com/articles/will-forest-labs-frx-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/will-eli-lilly-lly-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/will-alexion-alxn-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/will-amerisourcebergen-abc-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/pharmacyclics-seeks-us-approval-shares-soar-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/acorda-expands-pipeline-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/will-actavis-act-beat-earnings-estimates-analyst-blog-2013-07-24", "https://www.nasdaq.com/articles/australian-approval-for-vertex-kalydeco-analyst-blog-2013-07-10", "https://www.nasdaq.com/articles/bayer-initiates-phase-iii-study-analyst-blog-2013-07-09", "https://www.nasdaq.com/articles/cytokinetics-update-on-study-analyst-blog-2013-07-09", "https://www.nasdaq.com/articles/perrigo-attains-52-week-high-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/update-on-threshold-pharmas-th-302-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/biomarin-stays-neutral-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/new-data-on-biogens-eloctate-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/biogen-idec-inc-biib-todays-most-compelling-stock-buy-2013-07-11", "https://www.nasdaq.com/articles/australian-approval-for-vertex-kalydeco-analyst-blog-2013-07-10", "https://www.nasdaq.com/articles/bayer-initiates-phase-iii-study-analyst-blog-2013-07-09", "https://www.nasdaq.com/articles/cytokinetics-update-on-study-analyst-blog-2013-07-09", "https://www.nasdaq.com/articles/perrigo-attains-52-week-high-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/update-on-threshold-pharmas-th-302-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/biomarin-stays-neutral-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/new-data-on-biogens-eloctate-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/biogen-idec-inc-biib-todays-most-compelling-stock-buy-2013-07-11", "https://www.nasdaq.com/articles/australian-approval-for-vertex-kalydeco-analyst-blog-2013-07-10", "https://www.nasdaq.com/articles/bayer-initiates-phase-iii-study-analyst-blog-2013-07-09", "https://www.nasdaq.com/articles/cytokinetics-update-on-study-analyst-blog-2013-07-09", "https://www.nasdaq.com/articles/perrigo-attains-52-week-high-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/update-on-threshold-pharmas-th-302-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/biomarin-stays-neutral-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/new-data-on-biogens-eloctate-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/biogen-idec-inc-biib-todays-most-compelling-stock-buy-2013-07-11", "https://www.nasdaq.com/articles/psivida-starts-phase-iii-study-analyst-blog-2013-07-05", "https://www.nasdaq.com/articles/fda-accepts-the-medicines-co.s-nda-analyst-blog-2013-07-05", "https://www.nasdaq.com/articles/zoetis-looking-to-expand-analyst-blog-2013-07-03", "https://www.nasdaq.com/articles/isis-pharma-up-on-phase-ii-data-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/positive-data-on-infinitys-oncology-candidate-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/astrazeneca-bmy-present-forxiga-data-analyst-blog-2013-06-24", "https://www.nasdaq.com/articles/celgene-inks-oncology-deal-analyst-blog-2013-06-27", "https://www.nasdaq.com/articles/data-on-acorda-pipeline-candidate-analyst-blog-2013-06-27", "https://www.nasdaq.com/articles/integra-grows-european-portfolio-analyst-blog-2013-06-27", "https://www.nasdaq.com/articles/celgene-presents-revlimid-data-analyst-blog-2013-06-26", "https://www.nasdaq.com/articles/affymetrix-upgraded-to-neutral-analyst-blog-2013-06-26", "https://www.nasdaq.com/articles/isis-pharma-up-on-phase-ii-data-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/positive-data-on-infinitys-oncology-candidate-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/astrazeneca-bmy-present-forxiga-data-analyst-blog-2013-06-24", "https://www.nasdaq.com/articles/celgene-inks-oncology-deal-analyst-blog-2013-06-27", "https://www.nasdaq.com/articles/another-setback-for-idenix-analyst-blog-2013-06-21", "https://www.nasdaq.com/articles/draft-guidance-from-nice-for-psividas-iluvien-analyst-blog-2013-06-21", "https://www.nasdaq.com/articles/pluristem-updates-on-ic-study-analyst-blog-2013-06-20", "https://www.nasdaq.com/articles/celg-presents-positive-long-term-data-analyst-blog-2013-06-13", "https://www.nasdaq.com/articles/market-wrap-wednesday-june-12-stock-and-bond-markets-fall-mid-week-liquidity-concerns", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-344526-down-2011-points-2013-06-04", "https://www.nasdaq.com/articles/chmp-positive-on-tevas-lonquex-analyst-blog-2013-06-03", "https://www.nasdaq.com/articles/3-impressive-biotech-etfs-crushing-market-etf-news-and-commentary-2013-06-11", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-330702-2776-points-2013-04-29", "https://www.nasdaq.com/articles/benzinga-market-primer-friday-april-26-2013-04-26", "https://www.nasdaq.com/articles/biogens-earnings-surpass-expectations-analyst-blog-2013-04-25", "https://www.nasdaq.com/articles/benzinga-market-primer-thursday-april-25-2013-04-25", "https://www.nasdaq.com/articles/acorda-initiates-study-on-rhigm22-analyst-blog-2013-04-25", "https://www.nasdaq.com/articles/elan-narrows-y-y-loss-analyst-blog-2013-04-25", "https://www.nasdaq.com/articles/isis-pharmas-isis-smnrx-progresses-analyst-blog-2013-04-24", "https://www.nasdaq.com/articles/equal-weight-etf-trounces-traditional-sp-500-peers-2013-04-30", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-330702-2776-points-2013-04-29", "https://www.nasdaq.com/articles/benzinga-market-primer-friday-april-26-2013-04-26", "https://www.nasdaq.com/articles/biogens-earnings-surpass-expectations-analyst-blog-2013-04-25", "https://www.nasdaq.com/articles/benzinga-market-primer-thursday-april-25-2013-04-25", "https://www.nasdaq.com/articles/acorda-initiates-study-on-rhigm22-analyst-blog-2013-04-25", "https://www.nasdaq.com/articles/elan-narrows-y-y-loss-analyst-blog-2013-04-25", "https://www.nasdaq.com/articles/pre-market-earnings-report-april-25-2013-xom-mmm-mo-cop-bmy-oxy-ups-cl-celg-biib-dow-d", "https://www.nasdaq.com/articles/data-on-tevas-milprosa-analyst-blog-2013-04-18", "https://www.nasdaq.com/articles/elan-responds-to-royalty-pharma-offer-analyst-blog-2013-04-16", "https://www.nasdaq.com/articles/biotech-alkermes-poised-swell-pipeline-wins-2013-04-16", "https://www.nasdaq.com/articles/etf-showdown-pharma-fight-2013-04-11", "https://www.nasdaq.com/articles/snys-aubagio-gets-argentinean-nod-analyst-blog-2013-04-10", "https://www.nasdaq.com/articles/vertex-bristol-myers-collaborate-for-hcv-analyst-blog-2013-04-08", "https://www.nasdaq.com/articles/illumina-introduces-trusight-tumor-analyst-blog-2013-04-08", "https://www.nasdaq.com/articles/best-advice-managing-portfolio-risk-2013-04-19", "https://www.nasdaq.com/articles/tevas-quartette-approved-in-the-us-analyst-blog-2013-04-04", "https://www.nasdaq.com/articles/elan-gets-takeover-clarity-analyst-blog-2013-04-04", "https://www.nasdaq.com/articles/positive-data-on-repros-androxal-analyst-blog-2013-04-04", "https://www.nasdaq.com/articles/elan-sells-off-tysabri-stake-analyst-blog-2013-04-03", "https://www.nasdaq.com/articles/zacks-rank-1-addition-for-tuesday-tale-of-the-tape-2013-04-02", "https://www.nasdaq.com/articles/fda-approves-biogens-tecfidera-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-326752-11-points-2013-03-28", "https://www.nasdaq.com/articles/qlt-sells-ppds-technology-analyst-blog-2013-04-05", "https://www.nasdaq.com/articles/positive-data-on-biogens-plegridy-analyst-blog-2013-03-27", "https://www.nasdaq.com/articles/chmp-positive-on-biogens-tecfidera-analyst-blog-2013-03-25", "https://www.nasdaq.com/articles/moving-averages-indicate-these-sector-etfs-could-be-stretched-2013-03-25", "https://www.nasdaq.com/articles/chmp-in-favor-of-sanofis-aubagio-analyst-blog-2013-03-25", "https://www.nasdaq.com/articles/more-protection-for-biogens-tecfidera-analyst-blog-2013-03-22", "https://www.nasdaq.com/articles/new-data-on-biogen-elans-tysabri-analyst-blog-2013-03-19", "https://www.nasdaq.com/articles/biogen-files-hemophilia-b-application-analyst-blog-2013-03-13", "https://www.nasdaq.com/articles/biotech-breakout-boosting-etfs-2013-03-28", "https://www.nasdaq.com/articles/teva-enrolls-patients-in-ms-study-analyst-blog-2013-03-08", "https://www.nasdaq.com/articles/elan-to-share-tysabri-proceeds-analyst-blog-2013-03-07", "https://www.nasdaq.com/articles/standard-review-for-biogen-drug-analyst-blog-2013-03-05", "https://www.nasdaq.com/articles/royalty-pharma-eyes-elan-corp.-analyst-blog-2013-02-26", "https://www.nasdaq.com/articles/sppi-beats-in-4q-on-higher-sales-analyst-blog-2013-02-25", "https://www.nasdaq.com/articles/elan-updates-future-plans-analyst-blog-2013-02-25", "https://www.nasdaq.com/articles/merck-signs-biosimilars-deal-analyst-blog-2013-02-21", "https://www.nasdaq.com/articles/update-on-elans-plans-analyst-blog-2013-03-11", "https://www.nasdaq.com/articles/data-on-biogen-hemophilia-candidates-analyst-blog-2013-02-11", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-11-2013-2013-02-07", "https://www.nasdaq.com/articles/elan-beats-on-sales-loses-tysabri-analyst-blog-2013-02-07", "https://www.nasdaq.com/articles/market-wrap-wednesday-february-6-major-averages-close-near-unchanged-euro-falls-2013-02-06", "https://www.nasdaq.com/articles/closing-update-dow-sp-edge-higher-nasdaq-drifts-lower-markets-creep-back-toward-highs-2013", "https://www.nasdaq.com/articles/elan-to-sell-remaining-alks-stake-analyst-blog-2013-02-04", "https://www.nasdaq.com/articles/company-news-for-january-29-2013-corporate-summary-2013-01-29", "https://www.nasdaq.com/articles/earnings-miss-at-acorda-analyst-blog-2013-02-14", "https://www.nasdaq.com/articles/data-on-biogen-hemophilia-candidates-analyst-blog-2013-02-11", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-11-2013-2013-02-07", "https://www.nasdaq.com/articles/elan-beats-on-sales-loses-tysabri-analyst-blog-2013-02-07", "https://www.nasdaq.com/articles/benzinga-market-primer-monday-january-28-2013-01-28", "https://www.nasdaq.com/articles/pre-market-earnings-report-january-28-2013-cat-biib-rop-bbd-onb-ndz-2013-01-25", "https://www.nasdaq.com/articles/eln-biib-seek-label-expansion-analyst-blog-2013-01-17", "https://www.nasdaq.com/articles/alkermes-maintains-fiscal-2013-view-analyst-blog-2013-01-09", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-315366-down-64-points-2013-01-29", "https://www.nasdaq.com/articles/pipeline-update-from-alnylam-analyst-blog-2013-01-08", "https://www.nasdaq.com/articles/pre-market-most-active-jan-3-2013-bac-biib-f-tgt-bhp-qqq-vod-nok-siri-csco-mlnx-kep-2013", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-thursday-tale-of-the-tape-2013-01-03", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-thursday-tale-of-the-tape-2012-12-27", "https://www.nasdaq.com/articles/chmp-negative-on-isis-kynamro-analyst-blog-2012-12-17", "https://www.nasdaq.com/articles/isis-pharma-astrazeneca-ink-deal-analyst-blog-2012-12-14", "https://www.nasdaq.com/articles/these-etfs-are-awash-2013-takeover-targets-2012-12-12", "https://www.nasdaq.com/articles/biogen-submits-hemophilia-b-bla-analyst-blog-2013-01-08", "https://www.nasdaq.com/articles/sanofis-aubagio-gets-australian-nod-analyst-blog-2012-11-23", "https://www.nasdaq.com/articles/reshuffling-lineup-health-care-model-2012-11-19", "https://www.nasdaq.com/articles/alnylam-tekmira-settle-up-analyst-blog-2012-11-19", "https://www.nasdaq.com/articles/alkermes-reverts-to-neutral-analyst-blog-2012-11-16", "https://www.nasdaq.com/articles/pdlis-eps-in-line-revenue-misses-analyst-blog-2012-11-07", "https://www.nasdaq.com/articles/revenues-decline-at-alnylam-analyst-blog-2012-11-07", "https://www.nasdaq.com/articles/acorda-beats-on-all-fronts-analyst-blog-2012-11-02", "https://www.nasdaq.com/articles/pdli-guides-q4-royalty-rev-to-%2486m-analyst-blog-2012-12-07", "https://www.nasdaq.com/articles/sanofis-aubagio-gets-australian-nod-analyst-blog-2012-11-23", "https://www.nasdaq.com/articles/reshuffling-lineup-health-care-model-2012-11-19", "https://www.nasdaq.com/articles/alnylam-tekmira-settle-up-analyst-blog-2012-11-19", "https://www.nasdaq.com/articles/alkermes-reverts-to-neutral-analyst-blog-2012-11-16", "https://www.nasdaq.com/articles/pdlis-eps-in-line-revenue-misses-analyst-blog-2012-11-07", "https://www.nasdaq.com/articles/revenues-decline-at-alnylam-analyst-blog-2012-11-07", "https://www.nasdaq.com/articles/edward-owens-vanguard-health-care-fund-does-more-shedding-adding-third-quarter-2012-11-01", "https://www.nasdaq.com/articles/biibs-bg-12-review-period-extended-analyst-blog-2012-10-19", "https://www.nasdaq.com/articles/pipeline-setback-at-abbott-analyst-blog-2012-10-19", "https://www.nasdaq.com/articles/acorda-initiated-at-neutral-analyst-blog-2012-10-18", "https://www.nasdaq.com/articles/eps-beat-for-abbott-sales-miss-analyst-blog-2012-10-17", "https://www.nasdaq.com/articles/positive-data-on-novartis-gilenya-analyst-blog-2012-10-12", "https://www.nasdaq.com/articles/new-data-on-elan-biogens-tysabri-analyst-blog-2012-10-12", "https://www.nasdaq.com/articles/isis-pharma-owns-18-of-regulus-analyst-blog-2012-10-12", "https://www.nasdaq.com/articles/acordas-ampyra-patent-extended-analyst-blog-2012-10-23", "https://www.nasdaq.com/articles/biibs-bg-12-review-period-extended-analyst-blog-2012-10-19", "https://www.nasdaq.com/articles/pipeline-setback-at-abbott-analyst-blog-2012-10-19", "https://www.nasdaq.com/articles/52-week-high-guru-stocks-biib-ge-bdx-ir-pfe-2012-09-24", "https://www.nasdaq.com/articles/biogen-idec-momentum-2012-09-24", "https://www.nasdaq.com/articles/back-to-neutral-on-alkermes-analyst-blog-2012-09-18", "https://www.nasdaq.com/articles/biogen-sells-benlysta-rights-analyst-blog-2012-09-14", "https://www.nasdaq.com/articles/pdli-axogen-complete-financing-deal-analyst-blog-2012-10-10", "https://www.nasdaq.com/articles/sanofi-ms-drug-gets-approval-analyst-blog-2012-09-13", "https://www.nasdaq.com/articles/pdli-guides-q3-royalty-rev-to-%2485m-analyst-blog-2012-09-07", "https://www.nasdaq.com/articles/alnylam-presents-data-on-aln-rsv01-analyst-blog-2012-09-06", "https://www.nasdaq.com/articles/elan-starts-phase-ii-elnd005-study-analyst-blog-2012-09-06", "https://www.nasdaq.com/articles/disciplined-columbia-fund-rallies-mediocre-2011-2012-09-05", "https://www.nasdaq.com/articles/alnylam-monsanto-collaborate-analyst-blog-2012-08-29", "https://www.nasdaq.com/articles/sanofis-lemtrada-us-filing-update-analyst-blog-2012-08-28", "https://www.nasdaq.com/articles/sanofi-oncodesign-join-forces-analyst-blog-2012-09-14", "https://www.nasdaq.com/articles/tevas-quartette-filing-accepted-analyst-blog-2012-08-20", "https://www.nasdaq.com/articles/biogen-inks-deal-with-regulus-analyst-blog-2012-08-16", "https://www.nasdaq.com/articles/elan-to-split-into-two-companies-analyst-blog-2012-08-14", "https://www.nasdaq.com/articles/acorda-reports-data-on-ampyra-study-analyst-blog-2012-08-14", "https://www.nasdaq.com/articles/take-advantage-dips-market-add-market-leaders-your-portfolio-2012-08-13", "https://www.nasdaq.com/articles/update-on-tevas-laquinimod-analyst-blog-2012-08-09", "https://www.nasdaq.com/articles/isis-loss-down-on-higher-revenues-analyst-blog-2012-08-09", "https://www.nasdaq.com/articles/alnylam-isiss-regulus-to-go-public-analyst-blog-2012-08-22", "https://www.nasdaq.com/articles/pdl-biopharma-beats-zacks-estimates-analyst-blog-2012-08-06", "https://www.nasdaq.com/articles/alnylam-earns-milestone-payment-analyst-blog-2012-08-06", "https://www.nasdaq.com/articles/top-performing-funds-latch-biotech-and-discount-retail-stocks-2012-08-02", "https://www.nasdaq.com/articles/acorda-misses-on-earnings-sales-up-analyst-blog-2012-08-01", "https://www.nasdaq.com/articles/loss-at-elan-wider-than-expected-analyst-blog-2012-07-30", "https://www.nasdaq.com/articles/biotechs-motion-new-drug-pipeline-brims-2012-07-27", "https://www.nasdaq.com/articles/angiomax-drives-mdcos-results-analyst-blog-2012-07-26", "https://www.nasdaq.com/articles/weekly-top-insider-sells-goog-fis-orcl-and-biib-2012-08-06", "https://www.nasdaq.com/articles/pdl-biopharma-beats-zacks-estimates-analyst-blog-2012-08-06", "https://www.nasdaq.com/articles/alnylam-earns-milestone-payment-analyst-blog-2012-08-06", "https://www.nasdaq.com/articles/earnings-beat-for-novartis-analyst-blog-2012-07-20", "https://www.nasdaq.com/articles/abbott-beats-on-eps-affirms-view-analyst-blog-2012-07-18", "https://www.nasdaq.com/articles/better-investors-men-or-women-2012-07-13", "https://www.nasdaq.com/articles/isis-pharma-stays-neutral-analyst-blog-2012-07-11", "https://www.nasdaq.com/articles/strategy-targets-more-upside-biogen-2012-07-10", "https://www.nasdaq.com/articles/biogen-beats-on-all-fronts-analyst-blog-2012-07-24-0", "https://www.nasdaq.com/articles/isis-biogen-collaborate-again-analyst-blog-2012-07-02", "https://www.nasdaq.com/articles/novartis-presents-data-on-gilenya-analyst-blog-2012-06-15", "https://www.nasdaq.com/articles/pdl-biopharma-guides-q2-royalty-rev-to-%24125m-analyst-blog-2012-06-14", "https://www.nasdaq.com/articles/acorda-commences-patient-enrollment-analyst-blog-2012-06-14", "https://www.nasdaq.com/articles/dr.-reddys-merck-serono-team-up-analyst-blog-2012-06-08", "https://www.nasdaq.com/articles/new-lease-agreements-for-alexandria-analyst-blog-2012-06-08", "https://www.nasdaq.com/articles/positive-data-for-sanofis-aubagio-analyst-blog-2012-06-04", "https://www.nasdaq.com/articles/biogen-initiates-hemophilia-studies-analyst-blog-2012-07-06", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-teva-pharmaceutical-pfizer-novartis-and-u.s.", "https://www.nasdaq.com/articles/biogen-tysabri-canadian-label-update-analyst-blog-2012-05-25", "https://www.nasdaq.com/articles/aveos-av-203-in-phase-i-analyst-blog-2012-05-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-dr.-reddys-laboratories-bristol-myers-squibb-teva", "https://www.nasdaq.com/articles/data-on-elan-biogens-tysabri-analyst-blog-2012-05-18", "https://www.nasdaq.com/articles/zacks-bull-and-bear-of-the-day-highlights%3A-eastman-chemical-kirklands-biogen-idec-abbott", "https://www.nasdaq.com/articles/only-way-you-should-be-investing-stocks-right-now-2012-05-11", "https://www.nasdaq.com/articles/standard-review-for-isis-kynamro-analyst-blog-2012-05-30", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-teva-pharmaceutical-pfizer-novartis-and-u.s.", "https://www.nasdaq.com/articles/earnings-beat-at-pdl-biopharma-analyst-blog-2012-05-08", "https://www.nasdaq.com/articles/revenues-climb-at-acorda-analyst-blog-2012-05-04", "https://www.nasdaq.com/articles/bearish-john-hussman-sold-heavily-first-quarter-new-portfolio-update-2012-05-02", "https://www.nasdaq.com/articles/elan-misses-1q-eps-revenues-rise-analyst-blog-2012-05-01", "https://www.nasdaq.com/articles/earnings-miss-for-biogen-analyst-blog-2012-05-01", "https://www.nasdaq.com/articles/mdco-beats-ties-with-astrazeneca-analyst-blog-2012-04-26", "https://www.nasdaq.com/articles/standard-review-for-biogens-bg-12-analyst-blog-2012-05-11", "https://www.nasdaq.com/articles/isis-loss-widens-on-higher-expenses-analyst-blog-2012-05-09", "https://www.nasdaq.com/articles/earnings-beat-at-pdl-biopharma-analyst-blog-2012-05-08", "https://www.nasdaq.com/articles/biogen-inks-deal-with-makscientific-analyst-blog-2012-03-19", "https://www.nasdaq.com/articles/elan-sells-76-stake-in-alkermes-analyst-blog-2012-03-16", "https://www.nasdaq.com/articles/biogen-seeks-approval-for-bg-12-analyst-blog-2012-03-05", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-encana-enbridge-bankatlantic-bancorp-bbt-and-biogen", "https://www.nasdaq.com/articles/disappointing-results-at-novartis-analyst-blog-2012-04-25", "https://www.nasdaq.com/articles/pdl-biopharma-q4-eps-in-line-analyst-blog-2012-02-24", "https://www.nasdaq.com/articles/fourth-quarter-beat-for-mdco-analyst-blog-2012-02-23", "https://www.nasdaq.com/articles/earnings-beat-for-acorda-analyst-blog-2012-02-21", "https://www.nasdaq.com/articles/biogen-to-buy-stromedix-analyst-blog-2012-02-17", "https://www.nasdaq.com/articles/elans-4q-loss-wider-than-expected-analyst-blog-2012-02-14", "https://www.nasdaq.com/articles/3-biotechnology-stocks-short-term-traders-2012-02-09", "https://www.nasdaq.com/articles/how-many-stocks-should-you-own-investment-ideas-2012-02-03", "https://www.nasdaq.com/articles/biogen-samsung-set-up-jv-analyst-blog-2012-02-28", "https://www.nasdaq.com/articles/pdl-biopharma-q4-eps-in-line-analyst-blog-2012-02-24", "https://www.nasdaq.com/articles/fourth-quarter-beat-for-mdco-analyst-blog-2012-02-23", "https://www.nasdaq.com/articles/earnings-beat-for-acorda-analyst-blog-2012-02-21", "https://www.nasdaq.com/articles/biogen-to-buy-stromedix-analyst-blog-2012-02-17", "https://www.nasdaq.com/articles/elans-4q-loss-wider-than-expected-analyst-blog-2012-02-14", "https://www.nasdaq.com/articles/3-biotechnology-stocks-short-term-traders-2012-02-09", "https://www.nasdaq.com/articles/how-many-stocks-should-you-own-investment-ideas-2012-02-03", "https://www.nasdaq.com/articles/biogen-samsung-set-up-jv-analyst-blog-2012-02-28", "https://www.nasdaq.com/articles/eps-beat-for-biogen-outlook-weak-analyst-blog-2012-01-31", "https://www.nasdaq.com/articles/biogen-elan-announce-tysabri-trial-analyst-blog-2012-01-30", "https://www.nasdaq.com/articles/earnings-preview%3A-biogen-analyst-blog-2012-01-30", "https://www.nasdaq.com/articles/label-expansion-for-merck-kgaa-drug-analyst-blog-2012-01-27-0", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-the-boeing-lockheed-martin-abbott-labs-bristol-myers", "https://www.nasdaq.com/articles/abbott-beats-on-eps-guides-in-line-analyst-blog-2012-01-25", "https://www.nasdaq.com/articles/medicines-co.-settles-with-app-analyst-blog-2012-01-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pfizer-biogen-idec-elan-novartis-and-roche-press", "https://www.nasdaq.com/articles/eps-beat-for-biogen-outlook-weak-analyst-blog-2012-01-31", "https://www.nasdaq.com/articles/biogen-elan-announce-tysabri-trial-analyst-blog-2012-01-30", "https://www.nasdaq.com/articles/earnings-preview%3A-biogen-analyst-blog-2012-01-30", "https://www.nasdaq.com/articles/label-expansion-for-merck-kgaa-drug-analyst-blog-2012-01-27-0", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-the-boeing-lockheed-martin-abbott-labs-bristol-myers", "https://www.nasdaq.com/articles/abbott-beats-on-eps-guides-in-line-analyst-blog-2012-01-25", "https://www.nasdaq.com/articles/medicines-co.-settles-with-app-analyst-blog-2012-01-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pfizer-biogen-idec-elan-novartis-and-roche-press", "https://www.nasdaq.com/articles/eps-beat-for-biogen-outlook-weak-analyst-blog-2012-01-31", "https://www.nasdaq.com/articles/biogen-elan-announce-tysabri-trial-analyst-blog-2012-01-30", "https://www.nasdaq.com/articles/earnings-preview%3A-biogen-analyst-blog-2012-01-30", "https://www.nasdaq.com/articles/label-expansion-for-merck-kgaa-drug-analyst-blog-2012-01-27-0", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-the-boeing-lockheed-martin-abbott-labs-bristol-myers", "https://www.nasdaq.com/articles/abbott-beats-on-eps-guides-in-line-analyst-blog-2012-01-25", "https://www.nasdaq.com/articles/medicines-co.-settles-with-app-analyst-blog-2012-01-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pfizer-biogen-idec-elan-novartis-and-roche-press", "https://www.nasdaq.com/articles/eps-beat-for-biogen-outlook-weak-analyst-blog-2012-01-31", "https://www.nasdaq.com/articles/biogen-elan-announce-tysabri-trial-analyst-blog-2012-01-30", "https://www.nasdaq.com/articles/earnings-preview%3A-biogen-analyst-blog-2012-01-30", "https://www.nasdaq.com/articles/label-expansion-for-merck-kgaa-drug-analyst-blog-2012-01-27-0", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-the-boeing-lockheed-martin-abbott-labs-bristol-myers", "https://www.nasdaq.com/articles/abbott-beats-on-eps-guides-in-line-analyst-blog-2012-01-25", "https://www.nasdaq.com/articles/medicines-co.-settles-with-app-analyst-blog-2012-01-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pfizer-biogen-idec-elan-novartis-and-roche-press", "https://www.nasdaq.com/articles/eps-beat-for-biogen-outlook-weak-analyst-blog-2012-01-31", "https://www.nasdaq.com/articles/biogen-elan-announce-tysabri-trial-analyst-blog-2012-01-30", "https://www.nasdaq.com/articles/earnings-preview%3A-biogen-analyst-blog-2012-01-30", "https://www.nasdaq.com/articles/label-expansion-for-merck-kgaa-drug-analyst-blog-2012-01-27-0", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-the-boeing-lockheed-martin-abbott-labs-bristol-myers", "https://www.nasdaq.com/articles/abbott-beats-on-eps-guides-in-line-analyst-blog-2012-01-25", "https://www.nasdaq.com/articles/medicines-co.-settles-with-app-analyst-blog-2012-01-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pfizer-biogen-idec-elan-novartis-and-roche-press"], "Content": []}